VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Plasmodium spp.

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
    6. Host Protective Immunity
  2. Vaccine Related Pathogen Genes
    1. Pfs230
    2. STARP
    3. Exported protein 1 from Plasmodium falciparum (Other)
    4. LSA-1 from Plasmodium falciparum (Other)
    5. SSP2 from Plasmodium falciparum (Other)
    6. ABRA (Protective antigen)
    7. AMA-1 from P. berghei (Protective antigen)
    8. AMA-1 from P. chabaudi (Protective antigen)
    9. AMA1 from P. falciparum 3D7 (Protective antigen)
    10. AMA1 from P. knowlesi (Protective antigen)
    11. CS from P. berghei str. ANKA (Protective antigen)
    12. CS from P. falciparum (Protective antigen)
    13. CS from P. yoelii str. 17XNL (Protective antigen)
    14. CSP from P. knowlesi (Protective antigen)
    15. eba-175 (Protective antigen)
    16. EMP1 (Protective antigen)
    17. GLURP (Protective antigen)
    18. HEP17 (Protective antigen)
    19. HSP60 from P. yoelii (Protective antigen)
    20. Hsp90 (Protective antigen)
    21. Kbeta (Protective antigen)
    22. LSA-3 (Protective antigen)
    23. MSP-1 from P. falciparum (Protective antigen)
    24. MSP1 from P. berghei (Protective antigen)
    25. MSP1 from P. knowlesi (Protective antigen)
    26. MSP1 from P. vivax (Protective antigen)
    27. MSP1 from P. yoelii str. 17XNL (Protective antigen)
    28. MSP3 (Protective antigen)
    29. MSP4/5 (Protective antigen)
    30. MSP8 (Protective antigen)
    31. PF10_0155 enolase (Protective antigen)
    32. pfCelTOS (Protective antigen)
    33. Pvs25 (Protective antigen)
    34. RESA (Protective antigen)
    35. SERA-5 (Protective antigen)
    36. SSP2 (Protective antigen)
    37. SSP2 from P. knowlesi (Protective antigen)
    38. TRAP from P. falciparum (Protective antigen)
    39. FabB/FabF (Virmugen)
    40. P36p (Virmugen)
    41. PY01338 (Virmugen)
    42. Py36 (Virmugen)
    43. Py52 (Virmugen)
    44. UIS3 (Virmugen)
    45. UIS4 (Virmugen)
  3. Vaccine Information
    1. BDES-PfCSP (baculovirus dual expression system)
    2. ChAd63 -PvTRAP
    3. FMP1/AS02A
    4. MSP3-LSP with aluminium hydroxide
    5. MVA-PvTRAP
    6. NILV-Py CSP
    7. NYVAC-CSP (malaria)
    8. NYVAC-Pf7
    9. P. berghei DNA vaccine CSP-3p28
    10. P. berghei DNA vaccine encoding PbCSP
    11. P. berghei MSP1 Protein Vaccine
    12. P. chabaudi AMA1 Protein Vaccine
    13. P. falciparum CS expressed in irradiated P. berghei as Vaccine
    14. P. falciparum DNA and MVA encoding ME-TRAP
    15. P. falciparum DNA Vaccine encoding EBA-175
    16. P. falciparum Hsp90 Protein Subunit Vaccine
    17. P. falciparum LSA-3 Protein Vaccine
    18. P. falciparum MSA-2 subunit vaccine
    19. P. falciparum MSP1 from transgenic mice with Freund's adjuvant
    20. P. falciparum MSP3 Protein Subunit Vaccine
    21. P. falciparum MSP4 with AFCo1 Adjuvant
    22. P. falciparum pfCelTos protein vaccine
    23. P. falciparum Pfen Protein Subunit Vaccine
    24. P. falciparum recombinant vector vaccine MVA.ME-TRAP
    25. P. falciparum Subunit SE36 Protein Vaccine
    26. P. falciparum vaccine Combination B
    27. P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42
    28. P. vivax PVS25 with Montanide ISA-720
    29. P. yoelii DNA vaccine encoding MSP1
    30. P. yoelii DNA vaccine encoding PyHEP17 Protein
    31. P. yoelii DNA vaccine encoding PySSP2
    32. P. yoelii DNA vaccine pDIP/PyCSP. 1
    33. P. yoelii DNA vaccine pPyHsp60-VR1012
    34. P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine
    35. P. yoelii TyCS-VLP Vaccine
    36. Plasmodium berghei CS Protein Subunit Vaccine
    37. Plasmodium berghei p36p mutant vaccine
    38. Plasmodium FabB/FabF mutant vaccine
    39. Plasmodium yoelii p36/p52 mutant vaccine
    40. Plasmodium yoelii UIS3 mutant vaccine
    41. rBCGMSP1-15
    42. Recombinant ABRA protein vaccine
    43. RTS,S/AS02A
    44. SAd-ME.TRAP
  4. References
I. General Information
1. NCBI Taxonomy ID:
5820
2. Disease:
Malaria
3. Introduction
Malaria is a vector-borne infectious disease that is widespread in tropical and subtropical regions, causing disease in approximately 400 million people and killing 1-3 million, most of them young children in Sub-Saharan Africa. It is one of the most common infectious diseases, caused by protozoan parasites of the genus Plasmodium. The most serious forms of the disease are caused by P. falciparum and P. vivax, but other related species (P. ovale, P. malariae, and sometimes P. knowlesi) can also infect humans. This group of human-pathogenic Plasmodium spp. is usually referred to as malaria parasites and are transmitted by female Anopheles mosquitoes. The parasites multiply within red blood cells, causing symptoms of anemia, as well as other general symptoms such as fever, chills, nausea, flu-like illness, and in severe cases, coma and death. No vaccine is currently available for malaria; preventative drugs must be taken continuously to reduce the risk of infection. These prophylactic drug treatments are often too expensive for most people living in endemic areas. Most adults from endemic areas have a degree of long-term recurrent infection and also of partial resistance, which reduces with time and such adults may become susceptible to severe malaria if they have spent a significant amount of time in non-endemic areas (Joy et al., 2003; Escalante et al., 1998; Kaufman et al., 2005; Meis et al., 1983).
4. Microbial Pathogenesis
Malaria in humans develops via exoerythrocytic (hepatic) and erythrocytic phases. When an infected mosquito pierces a person's skin to take a blood meal, sporozoites in the mosquito's saliva enter the bloodstream and migrate to the liver. Within 30 minutes of being introduced into the human host, they infect hepatocytes, multiplying asexually and asymptomatically for a period of 6–15 d. During this "dormant" time in the liver, the sporozoites are often referred to as "hypnozoites". Once in the liver, these organisms differentiate to yield thousands of merozoites which, following rupture of their host cells, escape into the blood and infect red blood cells, thus beginning the erythrocytic stage of the life cycle. The parasite escapes from the liver undetected by wrapping itself in the cell membrane of the infected host liver cell. Within the erythrocytes, the parasites multiply further, periodically breaking out of their hosts to invade fresh erythrocytes. Several such amplification cycles occur, resulting in the classical waves of fever. Some merozoites turn into male and female gametocytes. If a mosquito pierces the skin of an infected person, it potentially picks up gametocytes within the blood. Fertilization and sexual recombination of the parasite occurs in the mosquito's gut, thereby defining the mosquito as the definitive host of the disease. New sporozoites develop and travel to the mosquito's salivary gland, completing the cycle. Pregnant women are especially attractive to the mosquitoes, and malaria in pregnant women is an important cause of stillbirths, infant mortality and low birth weight (Talman et al., 2004; Bledsoe, 2005; Sturm et al., 2006).
5. Host Ranges and Animal Models
The vast majority of malaria cases occur in children under the age of 5 years; pregnant women are also especially vulnerable. Despite efforts to reduce transmission and increase treatment, there has been little change in which areas are at risk of this disease since 1992. Precise statistics are unknown, as the majority of cases are undocumented. Although HIV/malaria co-infection produces less severe symptoms than the interaction between HIV and TB, HIV and malaria do contribute to each other's spread. This effect comes from malaria increasing viral load and HIV infection increasing a person's susceptibility to malaria infection. Malaria is presently endemic in a broad band around the equator, in areas of the Americas, many parts of Asia, and much of Africa; however, it is in sub-Saharan Africa where 85– 90% of malaria fatalities occur. The geographic distribution of malaria within large regions is complex, and malarial and malaria-free areas are often found close to each other. In drier areas, outbreaks of malaria can be predicted with reasonable accuracy by mapping rainfall (Breman, 2001; Greenwood et al., 2005; Hay et al., 2004).
6. Host Protective Immunity
Plasmodia are relatively protected from attack by the body's immune system because for most of its life cycle it resides within liver and blood cells and is relatively invisible to immune surveillance. However, circulating infected blood cells are destroyed in the spleen. To avoid this fate, P. falciparum displays adhesive proteins on the surface of the infected blood cells, causing blood cells to stick to the walls of small blood vessels, thereby sequestering the parasite from passage through the general circulation and the spleen and giving rise to hemorrhagic complications. Endothelial venules can be blocked by the attachment of masses of these infected red blood cells (RBCs). The blockage of these vessels causes placental and cerebral malaria. Although the RBC surface adhesive proteins (called PfEMP1, for Plasmodium falciparum erythrocyte membrane protein 1) are exposed to the immune system, they do not serve as good immune targets because of their extreme diversity; there are at least 60 variations of the protein within a single parasite and perhaps limitless versions within parasite populations (Chen et al., 2000; Adams et al., 2002).
1. ABRA
  • Gene Name : ABRA
  • Sequence Strain (Species/Organism) : Plasmodium falciparum Camp
  • VO ID : VO_0010926
  • NCBI Protein GI : 160047
  • Other Database IDs : swissprot:: P22620; GI:113005
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : p101/acidic basic repeat antigen
  • Protein Length : 743
  • DNA Sequence : Show Sequence
    >PFL1385c |MSP-9|Acid-Basic Repeat Antigen, ABRA, 101 kd malaria antigen, 2277.t00277, p101|Merozoite Surface Protein 9, MSP-9|Plasmodium falciparum|chr 12|STANFORD||Manual
    ATGATGAACA TGAAAATTGT TTTATTCAGT TTATTGCTCT TTGTCATAAG ATGGAATATT
    ATTAGTTGTA ATAAAAACGA CAAGAACCAA GGTGTTGATA TGAATGTTTT GAATAATTAT
    GAAAATTTAT TTAAATTTGT TAAATGTGAA TATTGTAATG AACATACTTA TGTTAAAGGT
    AAGAAAGCTC CTTCAGATCC TCAATGTGCT GATATAAAAG AAGAATGCAA AGAATTACTT
    AAGGAAAAAC AATACACAGA TTCAGTTACA TATTTAATGG ATGGTTTTAA ATCAGCAAAT
    AATTCAGCAA ATAATGGTAA AAAAAATAAC GCTGAAGAAA TGAAAAATTT AGTAAATTTC
    TTACAATCTC ATAAGAAATT AATTAAAGCA TTAAAAAAGA ATATTGAAAG TATACAAAAT
    AAGAAACACT TAATTTATAA AAACAAATCA TATAATCCAT TATTACTTTC TTGTGTTAAA
    AAAATGAATA TGTTAAAAGA AAATGTTGAC TATATTCAAA AAAATCAAAA CTTATTTAAA
    GAATTAATGA ATCAAAAAGC TACCTACTCT TTTGTTAATA CCAAAAAAAA AATTATTTCT
    TTAAAATCAC AAGGTCATAA AAAAGAAACC TCACAAAATC AAAATGAAAA TAACGACAAT
    CAAAAATATC AAGAAGTTAA TGATGAAGAT GATGTAAATG ATGAAGAAGA TACAAACGAT
    GACGAAGATA CTAACGATGA AGAAGATACA AACGATGACG AAGATACAAA TGATGACGAA
    GATACTAACG ATGAAGAAGA TACTAACGAC GAAGAAGATC ATGAAAATAA TAATGCTACA
    GCATACGAAT TAGGTATCGT CCCAGTTAAC GATGTGTTAA ATGTTAATAT GAAAAATATG
    ATAACAGGAA ATAATTTTAT GGATGTTGTT AAAAATACAT TAGCTCAATC AGGTGGATTA
    GGAAGTAATG ATTTAATAAA TTTCTTAAAT CAAGGTAAAG AAATAGGAGA AAATTTATTA
    AACATAACAA AGATGAACTT GGGAGATAAG AATAATCTTG AAAGTTTTCC TTTAGATGAA
    TTAAATATGT TAAAAGATAA TTTAATAAAC TATGAATTCA TATTAGATAA TTTGAAAACA
    AGTGTTTTAA ATAAATTAAA AGATTTATTA TTAAGATTAT TATACAAAGC ATATGTATCA
    TATAAGAAAA GAAAAGCTCA AGAAAAAGGA TTACCAGAAC CTACTGTTAC TAATGAAGAA
    TATGTTGAAG AATTAAAGAA AGGTATTCTA GATATGGGTA TCAAATTATT ATTTAGTAAA
    GTTAAAAGCC TATTAAAAAA ATTAAAAAAT AAAATATTCC CTAAGAAAAA AGAAGATAAT
    CAAGCAGTAG ATACCAAAAG TATGGAAGAA CCCAAAGTTA AAGCACAACC AGCTCTTAGA
    GGTGTTGAAC CAACGGAAGA TTCTAATATT ATGAACAGTA TTAATAATGT TATGGATGAA
    ATTGATTTCT TTGAAAAAGA ATTAATCGAA AATAATAATA CACCTAATGT TGTACCACCA
    ACTCAATCAA AAAAAAAAAA CAAAAATGAA ACTGTATCTG GTATGGATGA AAATTTTGAT
    AATCATCCTG AAAATTATTT TAAAGAAGAA TATTATTATG ATGAAAATGA TGATATGGAA
    GTAAAAGTTA AAAAAATAGG TGTCACATTA AAAAAATTTG AACCACTTAA AAATGGAAAT
    GTTAGTGAAA CCATTAAATT GATTCATTTA GGAAATAAAG ATAAAAAACA CATTGAAGCT
    ATAAACAACG ATATTCAAAT TATTAAACAA GAATTACAAG CTATTTATAA TGAACTTATG
    AATTATACAA ATGGAAACAA AAATATTCAA CAAATATTTC AACAAAATAT TCTAGAAAAT
    GATGTTCTTA ATCAAGAAAC GGAGGAAGAA ATGGAAAAAC AAGTTGAAGC AATCACCAAG
    CAAATAGAAG CTGAAGTGGA TGCCCTCGCA CCAAAAAATA AGGAAGAAGA AGAAAAAGAA
    AAGGAAAAAG AAGAAAAAGA AAAAGAAGAA AAAGAAAAAG AAAAAGAAGA AAAAGAAAAA
    GAAGAAAAAG AAAAAGAAGA AAAAGAAAAA GAAGAAAAAG AAGAAGAAAA AAAAGAAAAA
    GAAGAAGAAC AAGAAGAAGA AGAAGAAGAA GAAATAGTAC CAGAAAATTT GACAACTGAA
    GAATCAAAAT AA
  • Protein Sequence : Show Sequence
    >gi|160047|gb|AAA29462.1| p101/acidic basic repeat antigen [Plasmodium falciparum]
    MMNMKIVLFSLLLFVIRWNIISCNKNDKNQGVDMNVLNNYENLFKFVKCEYCNEHTYVKGKKAPSDPQCA
    DIKEECKELLKEKQYTDSVTYLMDGFKSANNSANNGKKNNAEEMKNLVNFLQSHKKLIKALKKNIESIQN
    KKHLIYKNKSYNPLLLSCVKKMNMLKENVDYIQKNQNLFKELMNQKATYSFVNTKKKIISLKSQGHKKET
    SQNQNENNDNQKYQEVNDEDDVNDEEDTNDDEDTNDEEDTNDDEDTNDDEDTNDEEDTNDEEDHENNNAT
    AYELGIVPVNDVLNVNMKNMITGNNFMDVVKNTLAQSGGLGSNDLINFLNQGKEIGENLLNITKMNLGDK
    NNLESFPLDELNMLKDNLINYEFILDNLKTSVLNKLKDLLLRLLYKAYVSYKKRKAQEKGLPEPTVTNEE
    YVEELKKGILDMGIKLLFSKVKSLLKKLKNKIFPKKKEDNQAVDTKSMEEPKVKAQPALRGVEPTEDSNI
    MNSINNVMDEIDFFEKELIENNNTPNVVPPTQSKKKNKNETVSGMDENFDNHPENYFKEEYYYDENDDME
    VKVKKIGVTLKKFEPLKNGNVSETIKLIHLGNKDKKHIEAINNDIQIIKQELQAIYNELMNYTNGNKNIQ
    QIFQQNILENDVLNQETEEEMEKQVEAITKQIEAEVDALAPKNKEEEEKEKEKEKEKEEKEKEEKEKEEK
    EKEKEEKEKEKEEKEEEKKEKEEEQEEEEEEIVPENLTTEESK
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Protective antigen (Kushwaha et al., 2001)
  • Related Vaccine(s): Recombinant ABRA protein vaccine
2. AMA-1 from P. berghei
  • Gene Name : AMA-1 from P. berghei
  • Sequence Strain (Species/Organism) : Plasmodium berghei
  • VO ID : VO_0011224
  • NCBI Protein GI : 1438889
  • Other Database IDs : CDD:174781
  • Taxonomy ID : 5821
  • Gene Strand (Orientation) : ?
  • Protein Name : apical membrane antigen-1
  • Protein Length : 556
  • Protein Note : Apical membrane antigen 1; cl03588
  • Protein Sequence : Show Sequence
    >gi|1438889|gb|AAC47192.1| apical membrane antigen-1 [Plasmodium berghei]
    MKEIYYILILCSIYLINLSNCSEGPNNVISENGHINYDMIQKENTERSTKLINPWEKYTEKYDIERMHGS
    GIRVDLGEDARVENRDYRIPSGKCPVIGKGITIQNSEVSFLTPVATGDQSVRSGGLALPKTDVHLSPITI
    DNLKTMYKEHTEIVKLNNMSLCAKHTSFYVPGNNANSAYRHPAVYDKSNSTCYMLYVAAQENMGPRYCSN
    NANNDNQPFCFTPEKIEKYKNLSYLTKNLRDDWETSCPNKSIKNAKFGIWVDGYCKDYQKHTVHDSDSLL
    KCNQIIFNESASDQPKQYEKHLEDTTKFRQGVAERNGKLIGEALLPIGSYKSDQIKSHGRGYNWGNYDSQ
    NKKCYIFETKPTCLINDRNFIATTALSSTEEFEEQFPCDIYKNKINEEIKVLNKNISNGNNSIEFPRIFI
    STDKNSLNCPCEPTQLTESSCNFYVCNCVEKRQYIAENNDVEIKEELEVHMKAHQTREVIVIIIFICVGI
    ILVILLVGYFFKSNKKGENYDRMGQADIYGKANSRKDGMLDPEVSFWGEDKRASHTTPVLMEKPYY
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Mice immunized with recombinant PbAMA-1 were partially protected from the challenge of P. berghei (Li et al., 2007).
3. AMA-1 from P. chabaudi
  • Gene Name : AMA-1 from P. chabaudi
  • Sequence Strain (Species/Organism) : Plasmodium chabaudi
  • VO ID : VO_0011237
  • NCBI Protein GI : 1469500
  • Other Database IDs : CDD:174781
  • Taxonomy ID : 5825
  • Gene Strand (Orientation) : ?
  • Protein Name : apical membrane antigen 1
  • Protein Length : 340
  • Protein Note : DK is a cloned line derived from 556KA
  • Protein Sequence : Show Sequence
    >gi|1469500|gb|AAB36511.1| apical membrane antigen 1 [Plasmodium chabaudi]
    DLIPKENTERSHKLINPWEKFMEKYDIEKVHGSGIRVDLGEDARVENQDYRIPSGKCPVMGKGITIQNSK
    VSFLTRVATGNQKVREGGLAFPQTDVNISPITIDNLKLMYKDHKEILALNDMSLCAKHASFYVPGTNVNT
    AYRHPAVYDKSNKTCYILYVAAQENMGPRYCSNEEDNENQPFCFTPEKKDEYKNLSYLTKNLREDWETSC
    PNKSIQNAKFGVWVDGYCSEYQKKEVHDNKTLLECNQIVFNESASDQPKQYEKHLEDTAKIRRGIVDRNG
    KLIGEALLPIGSYRADQVKSKGKGYNWANYDKKTKKCYIFNKKPTCLINDKDFVATTALS
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Mice immunized with a refolded, recombinant, Plasmodium chabaudi AMA1 fragment (AMA1B) can withstand subsequent challenge with P. chabaudi adami (Xu et al., 2000).
  • Related Vaccine(s): P. chabaudi AMA1 Protein Vaccine
4. AMA1 from P. falciparum 3D7
  • Gene Name : AMA1 from P. falciparum 3D7
  • Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
  • VO ID : VO_0010923
  • NCBI Gene ID : 810891
  • NCBI Protein GI : 124804478
  • Locus Tag : PF11_0344
  • Genbank Accession : AE014186
  • Protein Accession : XP_001348015
  • 3D structure: PDB ID : 1Z40
  • Other Database IDs : UniProt: P22621
  • Taxonomy ID : 36329
  • Chromosome No : 11
  • Gene Starting Position : 1293853
  • Gene Ending Position : 1295721
  • Gene Strand (Orientation) : +
  • Protein Name : Apical membrane antigen 1 (AMA1); PF11_0344; AMA-1, Pf83, RMA1, RMA 1, rhoptry membrane antigen
  • Protein pI : 5.23
  • Protein Weight : 69161.85
  • Protein Length : 622
  • Protein Note : This is apical membrane antigen 1 (AMA1), or designated at PF11_0344 (PF11_0344 in GeneDB).
  • DNA Sequence : Show Sequence
    >ref|NC_004315.2|:1293853-1295721 Plasmodium falciparum 3D7 chromosome 11, complete sequence
    AATGAGAAAATTATACTGCGTATTATTATTGAGCGCCTTTGAGTTTACATATATGATAAACTTTGGAAGA
    GGACAGAATTATTGGGAACATCCATATCAAAATAGTGATGTGTATCGTCCAATCAACGAACATAGGGAAC
    ATCCAAAAGAATACGAATATCCATTACACCAGGAACATACATACCAACAAGAAGATTCAGGAGAAGACGA
    AAATACATTACAACACGCATATCCAATAGACCACGAAGGTGCCGAACCCGCACCACAAGAACAAAATTTA
    TTTTCAAGCATTGAAATAGTAGAAAGAAGTAATTATATGGGTAATCCATGGACGGAATATATGGCAAAAT
    ATGATATTGAAGAAGTTCATGGTTCAGGTATAAGAGTAGATTTAGGAGAAGATGCTGAAGTAGCTGGAAC
    TCAATATAGACTTCCATCAGGGAAATGTCCAGTATTTGGTAAAGGTATAATTATTGAGAATTCAAATACT
    ACTTTTTTAACACCGGTAGCTACGGGAAATCAATATTTAAAAGATGGAGGTTTTGCTTTTCCTCCAACAG
    AACCTCTTATGTCACCAATGACATTAGATGAAATGAGACATTTTTATAAAGATAATAAATATGTAAAAAA
    TTTAGATGAATTGACTTTATGTTCAAGACATGCAGGAAATATGATTCCAGATAATGATAAAAATTCAAAT
    TATAAATATCCAGCTGTTTATGATGACAAAGATAAAAAGTGTCATATATTATATATTGCAGCTCAAGAAA
    ATAATGGTCCTAGATATTGTAATAAAGACGAAAGTAAAAGAAACAGCATGTTTTGTTTTAGACCAGCAAA
    AGATATATCATTTCAAAACTATACATATTTAAGTAAGAATGTAGTTGATAACTGGGAAAAAGTTTGCCCT
    AGAAAGAATTTACAGAATGCAAAATTCGGATTATGGGTCGATGGAAATTGTGAAGATATACCACATGTAA
    ATGAATTTCCAGCAATTGATCTTTTTGAATGTAATAAATTAGTTTTTGAATTGAGTGCTTCGGATCAACC
    TAAACAATATGAACAACATTTAACAGATTATGAAAAAATTAAAGAAGGTTTCAAAAATAAGAACGCTAGT
    ATGATCAAAAGTGCTTTTCTTCCCACTGGTGCTTTTAAAGCAGATAGATATAAAAGTCATGGTAAGGGTT
    ATAATTGGGGAAATTATAACACAGAAACACAAAAATGTGAAATTTTTAATGTCAAACCAACATGTTTAAT
    TAACAATTCATCATACATTGCTACTACTGCTTTGTCCCATCCCATCGAAGTTGAAAACAATTTTCCATGT
    TCATTATATAAAGATGAAATAATGAAAGAAATCGAAAGAGAATCAAAACGAATTAAATTAAATGATAATG
    ATGATGAAGGGAATAAAAAAATTATAGCTCCAAGAATTTTTATTTCAGATGATAAAGACAGTTTAAAATG
    CCCATGTGACCCTGAAATGGTAAGTAATAGTACATGTCGTTTCTTTGTATGTAAATGTGTAGAAAGAAGG
    GCAGAAGTAACATCAAATAATGAAGTTGTAGTTAAAGAAGAATATAAAGATGAATATGCAGATATTCCTG
    AACATAAACCAACTTATGATAAAATGAAAATTATAATTGCATCATCAGCTGCTGTCGCTGTATTAGCAAC
    TATTTTAATGGTTTATCTTTATAAAAGAAAAGGAAATGCTGAAAAATATGATAAAATGGATGAACCACAA
    GATTATGGGAAATCAAATTCAAGAAATGATGAAATGTTAGATCCTGAGGCATCTTTTTGGGGGGAAGAAA
    AAAGAGCATCACATACAACACCAGTTCTGATGGAAAAACCATACTATTA
  • Protein Sequence : Show Sequence
    >gi|124804478|ref|XP_001348015.1| apical membrane antigen 1,  AMA1 [Plasmodium falciparum 3D7]
    MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQNSDVYRPINEHREHPKEYEYPLHQEHTYQQEDSGEDE
    NTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIEEVHGSGIRVDLGEDAEVAGT
    QYRLPSGKCPVFGKGIIIENSNTTFLTPVATGNQYLKDGGFAFPPTEPLMSPMTLDEMRHFYKDNKYVKN
    LDELTLCSRHAGNMIPDNDKNSNYKYPAVYDDKDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAK
    DISFQNYTYLSKNVVDNWEKVCPRKNLQNAKFGLWVDGNCEDIPHVNEFPAIDLFECNKLVFELSASDQP
    KQYEQHLTDYEKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNTETQKCEIFNVKPTCLI
    NNSSYIATTALSHPIEVENNFPCSLYKDEIMKEIERESKRIKLNDNDDEGNKKIIAPRIFISDDKDSLKC
    PCDPEMVSNSTCRFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKPTYDKMKIIIASSAAVAVLAT
    ILMVYLYKRKGNAEKYDKMDEPQDYGKSNSRNDEMLDPEASFWGEEKRASHTTPVLMEKPYY
  • Molecule Role : Protective antigen
  • Related Vaccine(s): FMP1/AS02A
5. AMA1 from P. knowlesi
  • Gene Name : AMA1 from P. knowlesi
  • Sequence Strain (Species/Organism) : Plasmodium knowlesi strain H
  • NCBI Protein GI : 221056402
  • Other Database IDs : CDD:173341
    CDD:197890
    UniProtKB/TrEMBL: B3L5E1
  • Taxonomy ID : 5851
  • Gene Strand (Orientation) : ?
  • Protein Name : apical merozoite antigen 1
  • Protein Length : 563
  • Protein Note : apical membrane antigen 1; Provisional
  • Protein Sequence : Show Sequence
    >gi|221056402|ref|XP_002259339.1| apical merozoite antigen 1 [Plasmodium knowlesi strain H]
    MNKIYYILFLSAQCLVHMGKCERNQKTTRLTRSANNASLEKGPIIERSIRMSNPWKAFMEKYDLERAHNS
    GIRIDLGEDAEVGNSKYRIPAGKCPVFGKGIVIENSNVSFLTPVATGAQRLKEGGFAFPNADDHISPITI
    ANLKERYKENADLMKLNDIALCKTHAASFVIAEDQNTSYRHPAVYDEKNKTCYMLYLSAQENMGPRYCSP
    DSQNKDAMFCFKPDKNEKFDNLVYLSKNVSNDWENKCPRKNLGNAKFGLWVDGNCEEIPYVNEVEARSLR
    ECNRIVFEASASDQPRQYEEELTDYEKIQEGFRQNNRDMIKSAFLPVGAFNSDNFKSKGRGYNWANFDSV
    NNKCYIFNTKPTCLINDKNFFATTALSHPQEVDNEFPCSIYKDEIEREIKKQSRNMNLYSVDKERIVLPR
    IFISTDKESIKCPCEPEHISNSTCNFYVCNCVEKRAEIKENNEVIIKEEFKEDYENPDGKHKKKMLLIII
    GVTGAVCVVAVASLFYFRKKAQDDKYDKMDQAEAYGKTANTRKDEMLDPEASFWGEDKRASHTTPVLMEK
    PYY
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42
6. CS from P. berghei str. ANKA
  • Gene Name : CS from P. berghei str. ANKA
  • Sequence Strain (Species/Organism) : Plasmodium berghei str. ANKA
  • VO ID : VO_0011217
  • NCBI Gene ID : 3428738
  • NCBI Protein GI : 68076353
  • Locus Tag : PB001026.00.0
  • Genbank Accession : CAAI01007452
  • Protein Accession : XP_680096
  • Taxonomy ID : 5823
  • Gene Starting Position : 10083
  • Gene Ending Position : 10823
  • Gene Strand (Orientation) : -
  • Protein pI : 4.35
  • Protein Weight : 25535.43
  • Protein Length : 244
  • DNA Sequence : Show Sequence
    >ref|NW_674890.1|:10083-10823 Plasmodium berghei strain ANKA contig PB_RP0839, whole genome shotgun sequence
    TTTAATTAAAGAATACTAATACTAATAATATTACAAATCCTAATGAATTGCTTACAATATTAAATATACT
    TGAACATTTATCCATTTTACAAATTTCAGTATCAATTCTTCTAAGGTCAAATCTTCTGCTTTCTTATTTG
    AACCTTTTCGTTTTCTAACTCTTATACCAGAACCACATGTTACGTTACATTGAGACCATTCCTCTGTGAT
    ACTATCCCTGATCTGTTTAACAAATTCTAGTATTTTTTCCGCGCTTGGGATATAAGAATCGTCATTATTA
    TTATTTTTGTTATTGTTATTACCACCTGGCTGTGGTTGTGGCTGTGGTCGTGGCTGTGGTTGTGGCTGTG
    GCTGTGGTTGTGGCTGTGGCTGTGGTTGTGGCTGCGGCCGTGGCTGTGGTTGTGGATTGTTATTTCCTTG
    TGGTGGTGCTGGGTCATTTGGGTTTGGTGGTGGTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTTGGG
    TTTGGTGGTGGTGGGTCATTTGCGTTTGGTGGTGTTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTTG
    CGTTTGGTGGTGCTGGGTCATTTGCGTTTGGTGGTGCTGGGTCATTTGCGTTTGGTGGTGGTGGGTCATT
    TGCGTTTGGTGGTGGTGGAGTCATTTGGGTTTGGTGGTGGTGGGTCATTTGGGTTTGGTGGTGGTGGGTC
    ATTTGGGTTTGGTGGTGGTGGGTCATTTGGGTTTGGTGGTG
  • Protein Sequence : Show Sequence
    >gi|68076353|ref|XP_680096.1| circumsporozoite (CS) protein [Plasmodium berghei strain ANKA]
    PPPNPNDPPPPNPNDPPPPNPNDPPPPNPNTPPPPNANDPPPPNANDPAPPNANDPAPPNANDPAPPNAN
    DPTPPNANDPPPPNPNDPAPPNANDPPPPNPNDPAPPQGNNNPQPQPRPQPQPQPQPQPQPQPQPQPRPQ
    PQPQPGGNNNNKNNNNDDSYIPSAEKILEFVKQIRDSITEEWSQCNVTCGSGIRVRKRKGSNKKAEDLRR
    IDTEICKMDKCSSIFNIVSNSLGFVILLVLVFFN
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Researchers produced a prototypic malaria vaccine based on a highly versatile self-assembling polypeptide nanoparticle (SAPN) platform that can repetitively display antigenic epitopes. Researchers used this platform to display a tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)(2)D of the malaria parasite Plasmodium berghei circumsporozoite (CS) protein. Administered in saline, without the need for a heterologous adjuvant, the SAPN construct P4c-Mal conferred a long-lived, protective immune response to mice with a broad range of genetically distinct immune backgrounds including the H-2(b), H-2(d), and H-2(k) alleles. Mice were protected against an initial challenge of parasites up to 6 mo after the last immunization or for up to 15 mo against a second challenge after an initial challenge of parasites had successfully been cleared. (Kaba et al., 2009).
  • Related Vaccine(s): P. berghei DNA vaccine CSP-3p28 , P. berghei DNA vaccine encoding PbCSP , Plasmodium berghei CS Protein Subunit Vaccine
7. CS from P. falciparum
  • Gene Name : CS from P. falciparum
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • VO ID : VO_0011218
  • NCBI Protein GI : 552191
  • Other Database IDs : CDD:154951
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : circumsporozoite protein
  • Protein Length : 424
  • Protein Note : Thrombospondin type 1 domain; cl02514
  • Protein Sequence : Show Sequence
    >gi|552191|gb|AAA63422.1| circumsporozoite protein [Plasmodium falciparum]
    MMRKLAILSVSSFLFVEALFQEYQCYGSSSNTRVLNELNYDNAGTNLYNELEMNYYGKQENWYSLKKNSR
    SLGENDDGNNNNGDNGREGKDEDKRDGNNEDNEKLRKPKHKKLKQPGDGNPDPNANPNVDPNANPNVDPN
    ANPNVDPNANPNVDPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNAN
    PNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPN
    ANPNANPNANPNANPNANPNKNNQGNGQGHNMPNDPNRNVDENANANNAVKNNNNEEPSDKHIEQYLKKI
    QNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDYENDIEKKICKMEKCSSVFNVVNSSIGLIMVLSF
    LFLN
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : We employed a P. berghei parasite line that expresses a heterologous CSP (CS) from P. falciparum in order to assess the role of the CSP in the protection conferred by vaccination with radiation-attenuated P. berghei parasites. Our data demonstrated that sterile immunity could be obtained despite the absence of immune responses specific to the CSP expressed by the parasite used for challenge (Grüner et al., 2007).
  • Related Vaccine(s): P. falciparum CS expressed in irradiated P. berghei as Vaccine
8. CS from P. yoelii str. 17XNL
  • Gene Name : CS from P. yoelii str. 17XNL
  • Sequence Strain (Species/Organism) : Plasmodium yoelii yoelii str. 17XNL
  • VO ID : VO_0011219
  • NCBI Gene ID : 3830374
  • NCBI Protein GI : 83317409
  • Locus Tag : PY03168
  • Genbank Accession : AABL01000897
  • Protein Accession : XP_731149
  • Taxonomy ID : 352914
  • Gene Starting Position : 0
  • Gene Ending Position : 413
  • Gene Strand (Orientation) : +
  • Protein pI : 4.57
  • Protein Weight : 14411.64
  • Protein Length : 137
  • DNA Sequence : Show Sequence
    >ref|NW_865424.3|:1-413 Plasmodium yoelii yoelii str. 17XNL MALPY00900, whole genome shotgun sequence
    CCACCCCAACAACCACCCCAACAACCACCACAACAGCCACCACAACAGCCACCACAACAGCCACCACAAC
    AGCCACCACAACAACCACGCCCACAGCCAGATGGTAATAACAACAATAACAATAATAATGGTAATAATAA
    TGAAGATTCTTATGTCCCAAGCGCGGAACAAATACTAGAATTTGTTAAACAGATAAGTAGTCAACTCACA
    GAGGAATGGTCTCAATGTAGTGTAACCTGTGGTTCTGGTGTAAGAGTTAGAAAACGAAAAAATGTAAACA
    AGCAACCAGAAAATTTGACCTTAGAGGATATTGATACTGAAATTTGTAAAATGGATAAATGTTCAAGTAT
    ATTTAATATTGTAAGCAATTCATTAGGATTTGTAATATTATTAGTATTAGTATTCTTTAATTA
  • Protein Sequence : Show Sequence
    >gi|83317409|ref|XP_731149.1| circumsporozoite protein [Plasmodium yoelii yoelii str. 17XNL]
    PPQQPPQQPPQQPPQQPPQQPPQQPPQQPRPQPDGNNNNNNNNGNNNEDSYVPSAEQILEFVKQISSQLT
    EEWSQCSVTCGSGVRVRKRKNVNKQPENLTLEDIDTEICKMDKCSSIFNIVSNSLGFVILLVLVFFN
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Study showed that immunization with irradiated sporozoites (IrrSpz) of a P. berghei line whose endogenous CS was replaced by that of P. yoelii conferred sterile protection against challenge with wild type P. berghei sporozoites (Mauduit et al., 2009).
  • Related Vaccine(s): P. yoelii DNA vaccine pDIP/PyCSP. 1
9. CSP from P. knowlesi
  • Gene Name : CSP from P. knowlesi
  • Sequence Strain (Species/Organism) : Plasmodium knowlesi strain H
  • NCBI Protein GI : 221060580
  • Other Database IDs : CDD:206094
    CDD:29102
    UniProtKB/TrEMBL: B3LAV3
  • Taxonomy ID : 5851
  • Gene Strand (Orientation) : ?
  • Protein Name : circumsporozoite protein
  • Protein Length : 701
  • Protein Note : Zinc finger, C3HC4 type (RING finger); pfam13923
  • Protein Sequence : Show Sequence
    >gi|221060580|ref|XP_002260935.1| circumsporozoite protein [Plasmodium knowlesi strain H]
    MSISEHTGNEVSIAERKKKEEGSGGVINDKNVSPTDDGESMPHPMEKMKGAANDEKSVEVENCAPVGENE
    LRSSVLCVGCSGEASHIEEGSAKFVGEENPRTEVDSDKKAQPEGILNEVKNVKNEIDVEKKHKTQISNND
    TYVENAPNDNTCGEGCSNPHMNHDNKACDNGDDNDKIPNTGGTSNGGVIPNISGVLNVEDDCPLDEGNFS
    ADDRPEENADSTSSFMLEEDINLSRRAYRNFHICSIFIHGTLLLMVTLLMGILCHDFIKLSPISQKEKTM
    TYFCGLLLSMLALHLCLNLYMSLVLLRQSEVSKMLKSVEAKIHVIVLVYFSMCAYIYFFEDKYYPISSTF
    SFAIILAIIYYFMPIFLYIILRLLFIVVILVLVFVKRKSPTPKKILKKLKIMKYVEYRKYCEEEACFGSA
    YFTNWKELNGEGVSAPREATTTTAMEGGHIIATSGGDNKGEEVSSGDSTSNRNAEGKTISTATSCIRDIS
    ANGSGHPKGGDPPSSSPNDRPTRSGNSSTRSNLERHLFYDRAGVAIGRGGGSDNRGGTRPNDRGRDDPAN
    GNHQNGSDNANKHPPASYDNNCDAPNTSGEENGERNGGPNKDGKSAAVFEYFQKVLKKKNNSVQNDNVKV
    VHENNMEEHSFHINIECSDYVCSICCVEYLNEDDICILPCNYLHYYHKECIFKWLKRNNDCPLCRKPIGK
    I
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42
10. eba-175
  • Gene Name : eba-175
  • Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
  • VO ID : VO_0012382
  • NCBI Gene ID : 2654998
  • NCBI Protein GI : 296004911
  • Locus Tag : MAL7P1.176
  • Genbank Accession : AL844506
  • Protein Accession : XP_001349207
  • Taxonomy ID : 36329
  • Chromosome No : 7
  • Gene Starting Position : 1413430
  • Gene Ending Position : 1418304
  • Gene Strand (Orientation) : ?
  • Protein pI : 5.47
  • Protein Weight : 168527.84
  • Protein Length : 1502
  • Protein Note : Also known as eba 175; eba175
  • DNA Sequence : Show Sequence
    >ref|NC_004328.2|:1413430-1418304 Plasmodium falciparum 3D7 chromosome 7
    AATGAAATGTAATATTAGTATATATTTTTTTGCTTCCTTCTTTGTGTTATATTTTGCAAAAGCTAGGAAT
    GAATATGATATAAAAGAGAATGAAAAATTTTTAGACGTGTATAAAGAAAAATTTAATGAATTAGATAAAA
    AGAAATATGGAAATGTTCAAAAAACTGATAAGAAAATATTTACTTTTATAGAAAATAAATTAGATATTTT
    AAATAATTCAAAATTTAATAAAAGATGGAAGAGTTATGGAACTCCAGATAATATAGATAAAAATATGTCT
    TTAATAAATAAACATAATAATGAAGAAATGTTTAACAACAATTATCAATCATTTTTATCGACAAGTTCAT
    TAATAAAGCAAAATAAATATGTTCCTATTAACGCTGTACGTGTGTCTAGGATATTAAGTTTCCTGGATTC
    TAGAATTAATAATGGAAGAAATACTTCATCTAATAACGAAGTTTTAAGTAATTGTAGGGAAAAAAGGAAA
    GGAATGAAATGGGATTGTAAAAAGAAAAATGATAGAAGCAACTATGTATGTATTCCTGATCGTAGAATCC
    AATTATGCATTGTTAATCTTAGCATTATTAAAACATATACAAAAGAGACCATGAAGGATCATTTCATTGA
    AGCCTCTAAAAAAGAATCTCAACTTTTGCTTAAAAAAAATGATAACAAATATAATTCTAAATTTTGTAAT
    GATTTGAAGAATAGTTTTTTAGATTATGGACATCTTGCTATGGGAAATGATATGGATTTTGGAGGTTATT
    CAACTAAGGCAGAAAACAAAATTCAAGAAGTTTTTAAAGGGGCTCATGGGGAAATAAGTGAACATAAAAT
    TAAAAATTTTAGAAAAAAATGGTGGAATGAATTTAGAGAGAAACTTTGGGAAGCTATGTTATCTGAGCAT
    AAAAATAATATAAATAATTGTAAAAATATTCCCCAAGAAGAATTACAAATTACTCAATGGATAAAAGAAT
    GGCATGGAGAATTTTTGCTTGAAAGAGATAATAGATCAAAATTGCCAAAAAGTAAATGTAAAAATAATAC
    ATTATATGAAGCATGTGAGAAGGAATGTATTGATCCATGTATGAAATATAGAGATTGGATTATTAGAAGT
    AAATTTGAATGGCATACGTTATCGAAAGAATATGAAACTCAAAAAGTTCCAAAGGAAAATGCGGAAAATT
    ATTTAATCAAAATTTCAGAAAACAAGAATGATGCTAAAGTAAGTTTATTATTGAATAATTGTGATGCTGA
    ATATTCAAAATATTGTGATTGTAAACATACTACTACTCTCGTTAAAAGCGTTTTAAATGGTAACGACAAT
    ACAATTAAGGAAAAGCGTGAACATATTGATTTAGATGATTTTTCTAAATTTGGATGTGATAAAAATTCCG
    TTGATACAAACACAAAGGTGTGGGAATGTAAAAAACCTTATAAATTATCCACTAAAGATGTATGTGTACC
    TCCGAGGAGGCAAGAATTATGTCTTGGAAACATTGATAGAATATACGATAAAAACCTATTAATGATAAAA
    GAGCATATTCTTGCTATTGCAATATATGAATCAAGAATATTGAAACGAAAATATAAGAATAAAGATGATA
    AAGAAGTTTGTAAAATCATAAATAAAACTTTCGCTGATATAAGAGATATTATAGGAGGTACTGATTATTG
    GAATGATTTGAGCAATAGAAAATTAGTAGGAAAAATTAACACAAATTCAAATTATGTTCACAGGAATAAA
    CAAAATGATAAGCTTTTTCGTGATGAGTGGTGGAAAGTTATTAAAAAAGATGTATGGAATGTGATATCAT
    GGGTATTCAAGGATAAAACTGTTTGTAAAGAAGATGATATTGAAAATATACCACAATTCTTCAGATGGTT
    TAGTGAATGGGGTGATGATTATTGCCAGGATAAAACAAAAATGATAGAGACTCTGAAGGTTGAATGCAAA
    GAAAAACCTTGTGAAGATGACAATTGTAAACGTAAATGTAATTCATATAAAGAATGGATATCAAAAAAAA
    AAGAAGAGTATAATAAACAAGCCAAACAATACCAAGAATATCAAAAAGGAAATAATTACAAAATGTATTC
    TGAATTTAAATCTATAAAACCAGAAGTTTATTTAAAGAAATACTCGGAAAAATGTTCTAACCTAAATTTC
    GAAGATGAATTTAAGGAAGAATTACATTCAGATTATAAAAATAAATGTACGATGTGTCCAGAAGTAAAGG
    ATGTACCAATTTCTATAATAAGAAATAATGAACAAACTTCGCAAGAAGCAGTTCCTGAGGAAAGCACTGA
    AATAGCACACAGAACGGAAACTCGTACGGATGAACGAAAAAATCAGGAACCAGCAAATAAGGATTTAAAG
    AATCCACAACAAAGTGTAGGAGAGAACGGAACTAAAGATTTATTACAAGAAGATTTAGGAGGATCACGAA
    GTGAAGACGAAGTGACACAAGAATTTGGAGTAAATCATGGAATACCTAAGGGTGAGGATCAAACGTTAGG
    AAAATCTGACGCCATTCCAAACATAGGCGAACCCGAAACGGGAATTTCCACTACAGAAGAAAGTAGACAT
    GAAGAAGGCCACAATAAACAAGCATTGTCTACTTCAGTCGATGAGCCTGAATTATCTGATACACTTCAAT
    TGCATGAAGATACTAAAGAAAATGATAAACTACCCCTAGAATCATCTACAATCACATCTCCTACGGAAAG
    TGGAAGTTCTGATACAGAGGAAACTCCATCTATCTCTGAAGGACCAAAAGGAAATGAACAAAAAAAACGT
    GATGACGATAGTTTGAGTAAAATAAGTGTATCACCAGAAAATTCAAGACCTGAAACTGATGCTAAAGATA
    CTTCTAACTTGTTAAAATTAAAAGGAGATGTTGATATTAGTATGCCTAAAGCAGTTATTGGGAGCAGTCC
    TAATGATAATATAAATGTTACTGAACAAGGGGATAATATTTCCGGGGTGAATTCTAAACCTTTATCTGAT
    GATGTACGTCCAGATAAAAATCATGAAGAGGTGAAAGAACATACTAGTAATTCTGATAATGTTCAACAGT
    CTGGAGGAATTGTTAATATGAATGTTGAGAAAGAACTAAAAGATACTTTAGAAAATCCTTCTAGTAGCTT
    GGATGAAGGAAAAGCACATGAAGAATTATCAGAACCAAATCTAAGCAGTGACCAAGATATGTCTAATACA
    CCTGGACCTTTGGATAACACCAGTGAAGAAACTACAGAAAGAATTAGTAATAATGAATATAAAGTTAACG
    AGAGGGAAGGTGAGAGAACGCTTACTAAGGAATATGAAGATATTGTTTTGAAAAGTCATATGAATAGAGA
    ATCAGACGATGGTGAATTATATGACGAAAATTCAGACTTATCTACTGTAAATGATGAATCAGAAGACGCT
    GAAGCAAAAATGAAAGGAAATGATACATCTGAAATGTCGCATAATAGTAGTCAACATATTGAGAGTGATC
    AACAGAAAAACGATATGAAAACTGTTGGTGATTTGGGAACCACACATGTACAAAACGAAATTAGTGTTCC
    TGTTACAGGAGAAATTGATGAAAAATTAAGGGAAAGTAAAGAATCAAAAATTCATAAGGCTGAAGAGGAA
    AGATTAAGTCATACAGATATACATAAAATTAATCCTGAAGATAGAAATAGTAATACATTACATTTAAAAG
    ATATAAGAAATGAGGAAAACGAAAGACACTTAACTAATCAAAACATTAATATTAGTCAAGAAAGGGATTT
    GCAAAAACATGGATTCCATACCATGAATAATCTACATGGAGATGGAGTTTCCGAAAGAAGTCAAATTAAT
    CATAGTCATCATGGAAACAGACAAGATCGGGGGGGAAATTCTGGGAATGTTTTAAATATGAGATCTAATA
    ATAATAATTTTAATAATATTCCAAGTAGATATAATTTATATGATAAAAAATTAGATTTAGATCTTTATGA
    AAACAGAAATGATAGTACAACAAAAGAATTAATAAAGAAATTAGCAGAAATAAATAAATGTGAGAACGAA
    ATTTCTGTAAAATATTGTGACCATATGATTCATGAAGAAATCCCATTAAAAACATGCACTAAAGAAAAAA
    CAAGAAATCTGTGTTGTGCAGTATCAGATTACTGTATGAGCTATTTTACATATGATTCAGAGGAATATTA
    TAATTGTACGAAAAGGGAATTTGATGATCCATCTTATACATGTTTCAGAAAGGAGGCTTTTTCAAGTATG
    ATATTCAAATTTTTAATAACAAATAAAATATATTATTATTTTTATACTTACAAAACTGCAAAAGTAACAA
    TAAAAAAAATTAATTTCTCATTAATTTTTTTTTTCTTTTTTTCTTTTTAGGTATGCCATATTATGCAGGA
    GCAGGTGTGTTATTTATTATATTGGTTATTTTAGGTGCTTCACAAGCCAAATATCAAAGGTTAGAAAAAA
    TAAATAAAAATAAAATTGAGAAGAATGTAAATTAAATATATATATATATATATATATATATATATTGTAT
    TATATATTTTTTTTTTATAGTTCTGAAGGAGTTATGAATGAGAATAATGAGAATAATTTTTTATTTGAAG
    TTACTGATAATTTAGATAAATTATCCAATATGTGTAATACAAATATAAAAAAAAATAATAAATAAATAAA
    TAATTACAAGGAAATAAAAATGATATATATTATTACATTATGTTTGTTTACTTTTATATTATCCTATAAT
    ATTTATTTTTATTTTATGTTTTTTTTTTTTCAGTCAATCAACAAGTACAGGAAACTAATATCAACGATTT
    TTCTGAATACCATGAGGATATAAATGATATTAATTTTAAGAAATG
  • Protein Sequence : Show Sequence
    >gi|296004911|ref|XP_001349207.2| erythrocyte binding antigen 175 [Plasmodium falciparum 3D7]
    MKCNISIYFFASFFVLYFAKARNEYDIKENEKFLDVYKEKFNELDKKKYGNVQKTDKKIFTFIENKLDIL
    NNSKFNKRWKSYGTPDNIDKNMSLINKHNNEEMFNNNYQSFLSTSSLIKQNKYVPINAVRVSRILSFLDS
    RINNGRNTSSNNEVLSNCREKRKGMKWDCKKKNDRSNYVCIPDRRIQLCIVNLSIIKTYTKETMKDHFIE
    ASKKESQLLLKKNDNKYNSKFCNDLKNSFLDYGHLAMGNDMDFGGYSTKAENKIQEVFKGAHGEISEHKI
    KNFRKKWWNEFREKLWEAMLSEHKNNINNCKNIPQEELQITQWIKEWHGEFLLERDNRSKLPKSKCKNNT
    LYEACEKECIDPCMKYRDWIIRSKFEWHTLSKEYETQKVPKENAENYLIKISENKNDAKVSLLLNNCDAE
    YSKYCDCKHTTTLVKSVLNGNDNTIKEKREHIDLDDFSKFGCDKNSVDTNTKVWECKKPYKLSTKDVCVP
    PRRQELCLGNIDRIYDKNLLMIKEHILAIAIYESRILKRKYKNKDDKEVCKIINKTFADIRDIIGGTDYW
    NDLSNRKLVGKINTNSNYVHRNKQNDKLFRDEWWKVIKKDVWNVISWVFKDKTVCKEDDIENIPQFFRWF
    SEWGDDYCQDKTKMIETLKVECKEKPCEDDNCKRKCNSYKEWISKKKEEYNKQAKQYQEYQKGNNYKMYS
    EFKSIKPEVYLKKYSEKCSNLNFEDEFKEELHSDYKNKCTMCPEVKDVPISIIRNNEQTSQEAVPEESTE
    IAHRTETRTDERKNQEPANKDLKNPQQSVGENGTKDLLQEDLGGSRSEDEVTQEFGVNHGIPKGEDQTLG
    KSDAIPNIGEPETGISTTEESRHEEGHNKQALSTSVDEPELSDTLQLHEDTKENDKLPLESSTITSPTES
    GSSDTEETPSISEGPKGNEQKKRDDDSLSKISVSPENSRPETDAKDTSNLLKLKGDVDISMPKAVIGSSP
    NDNINVTEQGDNISGVNSKPLSDDVRPDKNHEEVKEHTSNSDNVQQSGGIVNMNVEKELKDTLENPSSSL
    DEGKAHEELSEPNLSSDQDMSNTPGPLDNTSEETTERISNNEYKVNEREGERTLTKEYEDIVLKSHMNRE
    SDDGELYDENSDLSTVNDESEDAEAKMKGNDTSEMSHNSSQHIESDQQKNDMKTVGDLGTTHVQNEISVP
    VTGEIDEKLRESKESKIHKAEEERLSHTDIHKINPEDRNSNTLHLKDIRNEENERHLTNQNINISQERDL
    QKHGFHTMNNLHGDGVSERSQINHSHHGNRQDRGGNSGNVLNMRSNNNNFNNIPSRYNLYDKKLDLDLYE
    NRNDSTTKELIKKLAEINKCENEISVKYCDHMIHEEIPLKTCTKEKTRNLCCAVSDYCMSYFTYDSEEYY
    NCTKREFDDPSYTCFRKEAFSSMPYYAGAGVLFIILVILGASQAKYQSSEGVMNENNENNFLFEVTDNLD
    KLSNMFNQQVQETNINDFSEYHEDINDINFKK
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : 1 of 3 Monkeys vaccinated with EBA-175 was protected from challenge of parasitized erythrocytes (Sim et al., 2001).
  • Related Vaccine(s): P. falciparum DNA Vaccine encoding EBA-175
11. EMP1
  • Gene Name : EMP1
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • VO ID : VO_0011229
  • NCBI Protein GI : 2961468
  • Other Database IDs : CDD:147552
    CDD:111855
    CDD:140204
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : erythrocyte membrane protein 1
  • Protein Length : 2228
  • Protein Note : Duffy binding domain; pfam05424
  • Protein Sequence : Show Sequence
    >gi|2961468|gb|AAC05730.1| erythrocyte membrane protein 1 [Plasmodium falciparum]
    MATSGGSGGTQDEDAKHVLDEFGQKVHDEVHGEAKNYVSELKGSLSLASILGETAFTVKSMQTESKYTEL
    IEANSKRNPCKKDGKGNDVDRFSVKEQAGYDNKKMKCSNGMTCAPFRRLHLCNKNFPNMNSNDSSKAKHD
    LLAEVCMAAKYEGESIKTHYPKYDSKYPGSDFPMCTMLARSFADIGDIIRGRDLYLGNKKKKQNGKETER
    EKLEQKLKEIFKKIHDNLKDKEAQKRYNGDEDPNFYKLREDWWTANRETVWGAMTCSKELDNSSYFRATC
    NDTGQGPSQTHNKCRCDKDKGANAGKPKAGDGDVTIVPTYFDYVPQYLRWFEEWAEDFCRKKKKKLENLE
    KQCRGKDKSDEYRYCSRNGYDCEQTISRKGKVRMGKGCTDCFFACHSYENWIDNQRKQFDKQKKYTKEIS
    DGGGRKKRAVGGTTKYEGYEKSFYEKLKNDGYGTVDAFLGLLNNEKACKDITDGGKINFKEVNSGGGVVG
    GGSGGTSGASGTNDENKGTFYRSEYCQPCPDCGVQHKGGNQWERKTKVKKMRWSKLYKPINGKMVLLLKS
    LKVVKDMMILKKNWKEFCLTQNSSDGSVGSVVTTGASGGNSEKKELYDEWKCYKHNEVQKVNVQGEVEED
    DDELKGAGGLCILPNPKKNKEVSEAKSQNNHADIQKTFHDFFYYWVAHMLKDSIHWRTKRLKSCISDGKT
    MKCRNGCNKKCDCFEKWVKQKETEWKPIKDHFKTQEGIPEGYYFTTLELILKLQFLKEDTEENTENSLDA
    EEAEELKHLQKILKLENENNLAVVNAGTEQKTLMDKLLNHELNDATKCKDCPLPEEDKSRGRSADPSPDI
    FIPRPEEKEDDENEDDDEDEVRDDEETAKETTEGSATDTTTSLDVCPIVGKVLTKDNESLQDACSLKYGG
    NNSRLGWRCVTPSGEPTTSSDKNGAICVPPRRRRLYIKKIVDWATKTESPQASGSEASSTSGSTTPPDSK
    EALLKAFVESAAIETFFLWHRYKEEKKAVAQEGAGHGLPRVEEGSPEYDPEDKLKEGKIPDGFLRQMFYT
    LGDYRDILFSGSNDTTSVSKDTPSSSNDNLKNIVLLASGSTEQEREKMNKYKEIKNFRKCSTERSAPNLV
    SHPQTWWENNGKYIWHGMVCALTSKDKIAKGVEKKPQKIENPENLWDEANKKPKPPQYQYTNVKLDENSG
    TSPRTTQTQASSDNTPTTLTHFVKRPTYFRWFEEWGESFCRERKKRLKQIKVDCKVENGDVGRCSGDGEA
    CDSISTHDYSTVPSFNCPGCGKHCSSYRKWIERKKIEFHKQSNAYGQQKTDATRNNGNTFDKEFCKTLET
    WPDAAKFLERLKNGPCKTNKEYGGDDIDFEKDSKTFQHTEYCGPCPKFKTNCQNGNCGVSGLNGNCDGKD
    SIDAKEIAKMRSSTTDVVMRVSDNDTNTFEGDDLKDACQHANIFKGIRKDVWKCGYVCGVDICEQTNINE
    RTDGKEYIQIRALFKRWVENFLEDYNKINDKISHCIKKGEGSKCINGCEKNSKCLEKWIEKKIAEWENIK
    KRFNDQYENKDQPDYNVKSILEELIPKIAVVNDQDNVIKLCVFENSKGCTLISNTQNNKENDAIDCMLKK
    LGVKAKNCPGKPSGEKQSDCKEPPPLPDEEDQNPEENTLEPPKFCPPTTQPPEEKGGETCGNKEEKKDEK
    KEESEEPAKEESGPAAEEPAPTAESEETETNFPEPPGTGPAAPPSTPAPPTPDTPPPLRPQADEPFDSTI
    LQTTIPFGVALALGSIAFLFLKKKTKASVGNLFQILQIPKSDYDIPTLKSSNRYIPYVSDRYKGKTYIYM
    EGDSDEDKYAFMSDTTDVTSSESEYEELDINDIYVPGSPKYKTLIEVVLEPSGNNTTASGKNTPSDTRND
    IQNDGIPSSKITDNEWNQLKKEFISNMLQNQPNDVPNDYTSGNSSTNTNITTTSRHNVDNNTNTTMSRDN
    MEENLLLPSIHDRNLYSGEEYSYNVNMVNSMNDIPINRDNNVYSGIDLINDSLSGGKPIDIYDEVLKRKE
    NELFGTENTKRTSTQNVAKITNSDPIHNQLELFHKWLDRHRDMCEKWKNKEDILNKLKEEWNKENINNSG
    KTYNSDNKPSHNHVLNTDVSIQIDMDNPKTKNEITNMDTNQDKSTMDTILDDLEKYNDPYYYDFYEDDII
    YHDVDVEKSSMDDIYVDHNNVTSNNMDVPTKMHIEMNIVNNKKEIFEEEYPISDIWNI
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Immunized animals were challenged in vivo with various parasite strains or clones of malaria. Immunization with the PfEMP1-DBL1 alpha domain abolished the PfEMP1-dependent sequestration of the homologous strain in immunized rats and substantially inhibited parasite adhesion in immunized monkeys. Protection against sequestration of heterologous parasite strains was also confirmed by direct or indirect challenge in the rat model (Moll et al., 2007).
12. Exported protein 1 from Plasmodium falciparum
  • Gene Name : Exported protein 1 from Plasmodium falciparum
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • NCBI Protein GI : 39843114
  • Other Database IDs : CDD:174853
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : exported protein 1
  • Protein Length : 118
  • Protein Note : Circumsporozoite-related antigen (CRA); cl05880
  • Protein Sequence : Show Sequence
    >gi|39843114|gb|AAR32120.1| exported protein 1 [Plasmodium falciparum]
    MKILSVFFLALFFIIFNKESLAEKTNKGTGSGVSSKKKNKKGSGEPLIDVHDLISDMIKKEEELVEVNKR
    KSKYKLATSVLAGLLGVVSTVLLGGVGLVLYNTEKGRHPFKLGSSDPA
  • Molecule Role : Other
13. FabB/FabF
  • Gene Name : FabB/FabF
  • Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
  • NCBI Gene ID : 3885996
  • NCBI Protein GI : 296004726
  • Locus Tag : PFF1275c
  • Genbank Accession : AL844505
  • Protein Accession : XP_966246
  • 3D structure: PDB ID : 1OB1
  • Taxonomy ID : 36329
  • Chromosome No : 6
  • Gene Starting Position : 1061115
  • Gene Ending Position : 1062891
  • Gene Strand (Orientation) : -
  • Protein pI : 9.25
  • Protein Weight : 50967.34
  • Protein Length : 473
  • DNA Sequence : Show Sequence
    >gi|86176855:1061115-1062891 Plasmodium falciparum 3D7 chromosome 6
    ATCACTTTACAATTTTTTTGAAAAGTAATGCTGTGTTATGGCCTCCAAATCCCAAATTTGTATTGAGAGA
    TATATCAATATTTTCCTTTGCATGAATATATTTATTAGGTGTATAATTTAGATCACAATCTGGGTCCTTA
    TATTCATAATTAATAGTAGGTGGTATAATATTTGTTTGCATAGTTTTAAGACATACAATAGATTCTATAG
    CTCCAGCAGCACCTATACAATGTCCTGTCATACTTTTAGTTGATGATATATATAATTTGTATGCATGATC
    TTTGAAAACATTTTTAAAAACCTTGGTTTCTATTTTATCATTTAAATTTGTTGAAGTACCATGTGCATTA
    ATATATTTAACGTCATTTATGTTTATATTTGCATTTTTTAATGCTTTATGAATAGAATTTGTTAAACCTT
    TCCCATTAGGTTCTGGTGCAGTAATATGGTATGCATCACATTCTGAAGAATATGAAATAATTTCTCCATA
    TATTGGTGCATTTCTTTTTATTGCATGTTCGTATGATTCTAGAATTAAGATGCCTGAACCTTCTCCCATA
    ACGAAACCACTTCTTTTTAAATCGAAGGGTCTACAACCTTTTTTTGGATTATCGTTATAACCTGTACATA
    AAGCCTTTAATGAATTGAATCCAGCAAAACTTATAGGAGTTATACTAGCTTCAGTTCCACCACATATCAT
    AACATCATACTCTTTATATTTTATATATCTATAGGCTTCACCTATTGTGTTACCAGACGTAGCACATGCA
    CTTAACATACCAAGAGAGATCCCTCTAATATTGTTTTCGATAGATACATATCCAGATGGAGTATTTGCTA
    TCATTGCAGGTATTAAATATGGTGTTATTCTTTTATGTCCTTTTTCATACATTGTTTTCATTTCTTTTTC
    TAAAAATCTTAGTCCACCTATGCCACTACCTATGATAGTACCTGTTTTATCTTTGTCTAATTTTTCCAAA
    TTTAGTTTTGCATCGTCTAAAGCTAAACGTGTGGCTGCGACTGCATAATGAGTACAATCATCATTACGAT
    TAACATCTTTTTTATTTGTGTAATAATCACTAGGATTAAAATCGCTTTTCTTTATTTCACTACCAATACC
    ACATGACATACCGGTTATATCAAATTTTGTAATTTTATCTATTGATGTATATCCATTTATAATATTATTC
    CAAAAATGTTCTATGCCAATCCCTAATCCAGTTACTACCCCTACACCTGTGCACACCACTCTAGAAGTCT
    AAATAAAAAATAAAAGAATTAAGAAAATTAAAATATATATAAAAATAAATGTATAGCATATTATTACTTT
    AATCATTTTTTACAATTTGTATATATCACATTTTATAAAACTATATAAATATAAATATATATATATATAT
    ATATATATATTATATATATTATATATTTTATTTAGTACTTCACAAAGATTTTTCATTTCTCTCGAATTGT
    ACAACTTGAAACCTTTAAAATAATTCTTGGATATTCCAGGTATACCCCTTTTAATGAAGGCATACCTTTT
    ACTGTTAACCTACATATGAAAATACATGGAGTATATATTATGACATGATTAATGTTTTTTTTTTTTTTTT
    TTTTTTTTTCTTTTCTACATCTAATATTCATATGGCACATGCATATGTTTGAAAGGGGAAACATATATTA
    ACTATTATGTTTGTTTTATTTTATTTTTAGAATTGTAGCATTACTTGTAGCACATAAAAGAACAGGAAAT
    AATATATTTTTATAATGTATTTTCTCA
  • Protein Sequence : Show Sequence
    >gi|296004726|ref|XP_966246.2| 3-oxoacyl-acyl-carrier protein synthase I/II [Plasmodium falciparum 3D7]
    MRKYIIKIYYFLFFYVLQVNSKRYAFIKRGIPGISKNYFKGFKLYNSREMKNLCETSRVVCTGVGVVTGL
    GIGIEHFWNNIINGYTSIDKITKFDITGMSCGIGSEIKKSDFNPSDYYTNKKDVNRNDDCTHYAVAATRL
    ALDDAKLNLEKLDKDKTGTIIGSGIGGLRFLEKEMKTMYEKGHKRITPYLIPAMIANTPSGYVSIENNIR
    GISLGMLSACATSGNTIGEAYRYIKYKEYDVMICGGTEASITPISFAGFNSLKALCTGYNDNPKKGCRPF
    DLKRSGFVMGEGSGILILESYEHAIKRNAPIYGEIISYSSECDAYHITAPEPNGKGLTNSIHKALKNANI
    NINDVKYINAHGTSTNLNDKIETKVFKNVFKDHAYKLYISSTKSMTGHCIGAAGAIESIVCLKTMQTNII
    PPTINYEYKDPDCDLNYTPNKYIHAKENIDISLNTNLGFGGHNTALLFKKIVK
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A genetically attenuated parasite (GAP) with a mutation in the FabB/FabF gene is attenuated in mice by arresting in the late liver stage. It also conferred complete protection in mice from challenge with wild type Plasmodium (Butler et al., 2011).
  • Related Vaccine(s): Plasmodium FabB/FabF mutant vaccine
14. GLURP
  • Gene Name : GLURP
  • Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
  • VO ID : VO_0011343
  • NCBI Gene ID : 810501
  • NCBI Protein GI : 124802897
  • Locus Tag : PF10_0344
  • Genbank Accession : AE014185
  • Protein Accession : XP_001347628
  • Taxonomy ID : 36329
  • Chromosome No : 10
  • Gene Starting Position : 1399191
  • Gene Ending Position : 1402892
  • Gene Strand (Orientation) : +
  • Protein Name : glutamate-rich protein
  • Protein pI : 3.98
  • Protein Weight : 130731.93
  • Protein Length : 1233
  • DNA Sequence : Show Sequence
    >ref|NC_004314.2|:1399191-1402892 Plasmodium falciparum 3D7 chromosome 10, complete sequence
    AATGAGAAACCTTTTCCATATTACCATTTGTTTAGTTACACTTAATTTATTTATATTGGAAATAAATGCA
    AAAACCAATACAAGTGAGAATAGAAATAAACGAATCGGGGGTCCTAAATTAAGGGGTAATGTTACAAGTA
    ATATAAAGTTCCCATCAGATAACAAAGGTAAAATTATAAGAGGTTCGAATGATAAACTTAATAAAAACTC
    TGAAGATGTTTTAGAACAAAGCGAAAAATCGCTTGTTTCAGAAAATGTTCCTAGTGGATTAGATATAGAT
    GATATCCCTAAAGAATCTATTTTTATTCAAGAAGATCAAGAAGGTCAAACTCATTCTGAATTAAATCCTG
    AAACATCAGAACATAGTAAAGATTTAAATAATAATGATTCAAAAAATGAATCTAGTGATATTATTTCAGT
    AAATAATAAATCAAATAAAGTACAAAATCATTTTGAATCATTATCAGATTTAGAATTACTTGAAAATTCC
    TCACAAGATAATTTAGACAAAGATACAATTTCAACAGAACCTTTTCCTAATCAAAAACATAAAGACTTAC
    AACAAGATTTAAATGATGAACCTTTAGAACCCTTTCCTACACAAATACATAAAGATTATAAAGAAAAAAA
    TTTAATAAATGAAGAAGATTCAGAACCATTTCCCAGACAAAAGCATAAAAAGGTAGACAATCATAATGAA
    GAAAAAAACGTATTTCATGAAAATGGTTCTGCAAATGGTAATCAAGGAAGTTTGAAACTTAAATCATTCG
    ATGAACATTTAAAAGATGAAAAAATAGAAAATGAACCACTTGTTCATGAAAATTTATCCATACCAAATGA
    TCCAATAGAACAAATATTAAATCAACCTGAACAAGAAACAAATATCCAGGAACAATTGTATAATGAAAAA
    CAAAATGTTGAAGAAAAACAAAATTCTCAAATACCTTCGTTAGATTTAAAAGAACCAACAAATGAAGATA
    TTTTACCAAATCATAATCCATTAGAAAATATAAAACAAAGTGAATCAGAAATAAATCATGTACAAGATCA
    TGCGCTACCAAAAGAGAATATAATAGACAAACTTGATAATCAAAAAGAACACATCGATCAATCACAACAT
    AATATAAATGTATTACAAGAAAATAACATAAACAATCACCAATTAGAACCTCAAGAGAAACCTAATATTG
    AATCGTTTGAACCTAAAAATATAGATTCAGAAATTATTCTTCCTGAAAATGTTGAAACAGAAGAAATAAT
    AGATGATGTGCCTTCCCCTAAACATTCTAACCATGAAACATTTGAAGAAGAAACAAGTGAATCTGAACAT
    GAAGAAGCCGTATCTGAAAAAAATGCCCACGAAACTGTCGAACATGAAGAAACTGTGTCTCAAGAAAGCA
    ATCCTGAAAAAGCTGATAATGATGGAAATGTATCTCAAAACAGCAACAACGAATTAAATGAAAATGAATT
    CGTTGAATCGGAAAAAAGCGAGCATGAACCAGCTGAAAATGAAGAAAGTAGTCTTGAAGAAGGTCATCAT
    GAAGAAATTGTACCTGAACAAAATAATGAAGAATCAGGTGAAAGTAAATTAGTTGATAATGATGAAGGTG
    GTTTTGAAGAAGCTCATCATGAAAATTTTTCATCTGAAGTAAGTAACTCTGAATTAAATGAAAATGAATT
    TGTTGAATCTGACAAAAGTGTAACTGAACCTGCTGAACATGAAGAAGTTGTATCTGAAGAAAGCAACCCT
    GAACCAGCTGAAAATGAAGAAAGTAGTATAGAAGAAGCTCATCAGGAAGAAATTGTACCTGAACAAAATG
    ATGAAGAATCAGGTGAAAGTGGATTAGTTGATAATGAAGAAGGTGATTTTGAAGAACCTAATCATGAAGA
    ATTTGAACCTGATCAAAATGACTCTGAATTAAGTGAAAATGAATTAGTTGAATCAGAAAAAAGTGTATCT
    GAACCAGCTGAACATGTAGAAATTGTATCAGAAAAAAGTGTATCTGAACCAGCTGAACACGTAGAAATTG
    TATCTGAAAAAAGTACATCCGAACCAGCTGAACATGTAGAAAGTGTATCTGAACAAAGTAATAACGAACC
    ATCCGAAAAGAAAGATGGACCAGTTCCTTCAAAACCATTTGAAGAAATTGAAAAAGTGGATGTTCAACCT
    AAAATTGTAGACCTTCAAATAATTGAACCTAATTTTGTTGACTCACAACCAAATCCACAAGAACCAGTTG
    AACCATCATTTGTCAAAATTGAAAAAGTTCCTTCTGAAGAAAATAAACATGCAAGTGTTGATCCTGAAGT
    AAAAGAAAAAGAAAATGTATCTGAAGTTGTTGAAGAAAAACAAAATTCACAAGAATCAGTTGAAGAAATT
    CCAGTAAATGAGGATGAATTTGAAGATGTTCACACTGAACAATTAGATTTAGATCATAAAACAGTTGATC
    CAGAAATAGTAGAAGTTGAAGAAATTCCTTCAGAACTACATGAAAATGAAGTGGCTCATCCAGAAATTGT
    TGAAATTGAGGAAGTTTTTCCTGAACCAAATCAAAATAACGAATTTCAAGAAATTAATGAAGATGATAAA
    AGTGCACATATTCAGCATGAAATAGTAGAAGTAGAAGAAATACTTCCAGAAGATGATAAAAATGAAAAAG
    TTGAACATGAAATAGTAGAAGTTGAAGAAATTCTACCAGAAGATAAAAATGAAAAAGTTCAACATGAAAT
    AGTAGAGGTTGAAGAAATTCTACCAGAAGATAAAAATGAAAAAGTTGAACATGAAATAGTAGAAGTTGAA
    GAAATTCTACCAGAAGATAAAAATGAAAAAGGTCAACATGAAATAGTAGAGGTTGAAGAAATTCTACCAG
    AAGATAAAAATGAAAAAGTTCAACATGAAATAGTAGAAGTTGAAGAAATTCTACCAGAAGATAAAAATGA
    AAAAGGTCAACATGAAATAGTAGAGGTTGAAGAAATTCTACCAGAAGATAAAAATGAAAAAGTTGAACAT
    GAAATAGTAGAAGTTGAAGAAATTCTACCAGAAGATAAAAATGAAAAAGGTCAACATGAAATAGTAGAGG
    TTGAAGAAATTCTACCAGAAGATGATAAAAATGAAAAAGGTCAACATGAAATAGTAGAGGTTGAAGAAAT
    TCTTCCAGAAATTGTTGAAATTGAAGAAGTACCATCACAAACAAATAACAATGAAAATATTGAAACTATA
    AAACCAGAAGAAAAAAAGAATGAATTTAGTGTTGTTGAAGAAAAAGCAATTCCACAAGAACCCGTGGTAC
    CTACATTAAATGAAAATGAAAACGTTACTCCCAAACCATCTGAAGGTGAATCCACTAAACCAGATATAGT
    TCAAATTAAAATAGTACAAGAAAATAAACCAAATAAAAAGGAAACACCAGTAGTAGATGGTCCAAAACAT
    GTAGAACAAAATATACAAGAAGATGATAATGATGAAGAGGATGATGATGATATAGATTTTGAAGGATTAT
    CAAGAAAAGATGATGAAAAGGATTCATCAAATAAAAATAAAAAGAAATCATCTTTTATAACATATATATC
    TACAAAGAAATTTAAAAAAGTATCTCAAACTATTGTAAGTGTTATGATTAATGCATATGATGGTGTTATT
    CAAGTTGTAAGTACAATTAAAGGAATAGCAAAGGATATAGTAATATTTTTCCAAAACATTTA
  • Protein Sequence : Show Sequence
    >gi|124802897|ref|XP_001347628.1| glutamate-rich protein [Plasmodium falciparum 3D7]
    MRNLFHITICLVTLNLFILEINAKTNTSENRNKRIGGPKLRGNVTSNIKFPSDNKGKIIRGSNDKLNKNS
    EDVLEQSEKSLVSENVPSGLDIDDIPKESIFIQEDQEGQTHSELNPETSEHSKDLNNNDSKNESSDIISV
    NNKSNKVQNHFESLSDLELLENSSQDNLDKDTISTEPFPNQKHKDLQQDLNDEPLEPFPTQIHKDYKEKN
    LINEEDSEPFPRQKHKKVDNHNEEKNVFHENGSANGNQGSLKLKSFDEHLKDEKIENEPLVHENLSIPND
    PIEQILNQPEQETNIQEQLYNEKQNVEEKQNSQIPSLDLKEPTNEDILPNHNPLENIKQSESEINHVQDH
    ALPKENIIDKLDNQKEHIDQSQHNINVLQENNINNHQLEPQEKPNIESFEPKNIDSEIILPENVETEEII
    DDVPSPKHSNHETFEEETSESEHEEAVSEKNAHETVEHEETVSQESNPEKADNDGNVSQNSNNELNENEF
    VESEKSEHEPAENEESSLEEGHHEEIVPEQNNEESGESKLVDNDEGGFEEAHHENFSSEVSNSELNENEF
    VESDKSVTEPAEHEEVVSEESNPEPAENEESSIEEAHQEEIVPEQNDEESGESGLVDNEEGDFEEPNHEE
    FEPDQNDSELSENELVESEKSVSEPAEHVEIVSEKSVSEPAEHVEIVSEKSTSEPAEHVESVSEQSNNEP
    SEKKDGPVPSKPFEEIEKVDVQPKIVDLQIIEPNFVDSQPNPQEPVEPSFVKIEKVPSEENKHASVDPEV
    KEKENVSEVVEEKQNSQESVEEIPVNEDEFEDVHTEQLDLDHKTVDPEIVEVEEIPSELHENEVAHPEIV
    EIEEVFPEPNQNNEFQEINEDDKSAHIQHEIVEVEEILPEDDKNEKVEHEIVEVEEILPEDKNEKVQHEI
    VEVEEILPEDKNEKVEHEIVEVEEILPEDKNEKGQHEIVEVEEILPEDKNEKVQHEIVEVEEILPEDKNE
    KGQHEIVEVEEILPEDKNEKVEHEIVEVEEILPEDKNEKGQHEIVEVEEILPEDDKNEKGQHEIVEVEEI
    LPEIVEIEEVPSQTNNNENIETIKPEEKKNEFSVVEEKAIPQEPVVPTLNENENVTPKPSEGESTKPDIV
    QIKIVQENKPNKKETPVVDGPKHVEQNIQEDDNDEEDDDDIDFEGLSRKDDEKDSSNKNKKKSSFITYIS
    TKKFKKVSQTIVSVMINAYDGVIQVVSTIKGIAKDIVIFFQNI
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Some of the S. sciureus monkeys immunized with MSP-3(212-380)-AS02 or GLURP(27-500)-alum were able to fully or partially control parasitaemia upon an experimental P. falciparum [Falciparum Uganda Palo Alto (FUP-SP) strain] blood-stage infection, and this protection was related to the prechallenge antibody titres induced. The data are indicative that MSP-3 and GLURP can induce protective immunity against an experimental P. falciparum infection using adjuvants that are acceptable for human use and this should trigger further studies with those new antigens (Carvalho et al., 2004).
15. HEP17
  • Gene Name : HEP17
  • Sequence Strain (Species/Organism) : Plasmodium yoelii
  • VO ID : VO_0011228
  • NCBI Protein GI : 1399353
  • Other Database IDs : CDD:174853
  • Taxonomy ID : 5861
  • Gene Strand (Orientation) : ?
  • Protein Name : hepatocyte erythrocyte protein 17 kDa
  • Protein Length : 169
  • Protein Note : Circumsporozoite-related antigen (CRA); cl05880
  • Protein Sequence : Show Sequence
    >gi|1399353|gb|AAC47199.1| hepatocyte erythrocyte protein 17 kDa [Plasmodium yoelii]
    MKINIASIIFIIFSLCLVNDAYGKNKYGKNGKYGSQNVIKKHGEPVINVQDLISDMVRKEEEIVKLTKNK
    KSLRKINVALATALSVVSAILLGGAGLVMYNTEKGRRPFQIGKSKKGGSAMARDSSFPMNEESPLGFSPE
    EMEAVASKFRESMLKDGVPAPSNTPNVQN
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Immunization of mice with subunit vaccines based on the Plasmodium yoelii 17kDa hepatocyte erythrocyte protein (PyHEP17), orthologue of Plasmodium falciparum exported protein 1 (PfExp1), induces antigen-specific immune responses and protects against sporozoite challenge (Dobaño and Doolan, 2007).
  • Related Vaccine(s): P. yoelii DNA vaccine encoding PyHEP17 Protein
16. HSP60 from P. yoelii
  • Gene Name : HSP60 from P. yoelii
  • Sequence Strain (Species/Organism) : Plasmodium yoelii strain 17X(NL)
  • NCBI Protein GI : 3885993
  • Other Database IDs : CDD:183791
    CDD:48161
  • Taxonomy ID : 5861
  • Gene Strand (Orientation) : ?
  • Protein Name : heat shock protein 60
  • Protein Length : 579
  • Protein Note : chaperonin GroEL; Reviewed; PRK12849
  • Protein Sequence : Show Sequence
    >gi|3885993|gb|AAC78150.1| heat shock protein 60 [Plasmodium yoelii]
    MLSRLCGKTIQNGNADKCVSMLNKIQKRNVAKDIRFGSDARTAMLIGCNKLADAVSVTLGPKGRNVIIEQ
    SFGSPKITKDGVTVAKSIEFNKKLANLGAQMVKQVAANTNDKAGDGTTTATILARSIFQQGCKAVDSGMN
    PMDLLRGINKGVEKVLEYLNSIKKDVTTTEEIFNVASISANGDKNIGQLIADTMKKVGKEGTITVTEGKT
    LQHELEIVEGIKFDRGYISPYFINNSKDQKVELDKPYILIHEKKISSVKSLLPVLEHVLQNQSSLLVIAE
    DVDSDALATLIVNKLRLGLKICAVKAPGFGEHRKALIHDIAVMTGSKVITEEAGLKLDDPDVISYLGKAK
    SINVSKDNTLIMEGEGKKEEISERCESIRNAIKNNTSDYEKEKLQERLAQITGGVALIKVGGISEVEVNE
    IKDRIQDALCATKAAVEEGIVPGGGSALLFASKELDSVQTDNYDQRVGVNIIKDACKAPIKQIAENAGHE
    GSVVAGNILKEKNSNMGFNAQEGKYVNMIESGIIDPTKVVKTAISDAASIASLLTTTEVAIVDSKDGKSE
    EMPSHMNSVNPMGDMGGMY
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. yoelii DNA vaccine pPyHsp60-VR1012
17. Hsp90
  • Gene Name : Hsp90
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • VO ID : VO_0011241
  • NCBI Protein GI : 1093612
  • Other Database IDs : CDD:173995
    CDD:109249
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Length : 747
  • Protein Note : Histidine kinase-like ATPases; This family includes several ATP-binding proteins for example: histidine kinase, DNA gyrase B, topoisomerases, heat shock protein HSP90, phytochrome-like ATPases and DNA mismatch repair proteins; cl00075
  • Protein Sequence : Show Sequence
    >gi|1093612|prf||2104278A heat shock protein 90
    MSTETFAFNADIRQLMSLIINTFYSNKEIFLRELISNASDALDKIRYESITDTQKLSAEPEFFIRIIPDK
    TNNTLTIEDSGIGMTKNDLINNLGTIARSGTKAFMEAIQASGDISMIGQFGVGFYSAYLVADHVVVISKN
    NDDEQYVWESAAGGSFTVTKDETNEKLGRGTKIILHLKEDQLEYLEEKRIKDLVKKHSEFISFPIKLYCE
    RQNEKEITASEEEEEGEGEGEREGEEEEEEKKKKTGEDKNADESKEENEDEEKKEDNEEDDNKTDHPKVE
    DVTEELENAEKKKKEKRKKKIHTVEHEWEELNKQKPLWMRKPEEVTNEEYASFYKSLTNDWEDHLAVKHF
    SVEGQLEFKALLFIPKRAPFDMFENRKKRNNIKLYVRRVFIMDDCEEIIPEWLNFVKGVVDSEDLPLNIS
    RESLQQNKILKVIKKNLIKKCLDMFSELAENKENYKKFYEQFSKNLKLGIHEDNANRTKITELLRFQTSK
    SGDEMIGLKEYVDRMKENQKDIYYITGESINAVSNSPFLEALTKKGFEVIYMVDPIDEYAVQQLKDFDGK
    KLKCCTKEGLDIDDSEEAKKDFETLKAEYEGLCKVIKDVLHEKVEKVVVGQRITDSPCVLVTSEFGWSAN
    MERIMKAQALRDNSMTSYMLSKKIMEINARHPIISALKQKADADKSDKTVKDLIWLLFDTSLLTSGFALE
    EPTTFSKRIHRMIKLGLSIDEEENNDIDLPPLEETVDATDSKMEEVD
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : A monkey vaccination trial using a Plasmodium falciparum protein fraction containing antigens of 90-110 kDa is reported. Three monkeys out of five resisted a heavy challenge dose of highly virulent parasites. Hsp90 was found in the immunoprecipitates obtained with SERP antisera. Interestingly, the response to hsp90 correlated with protection, high antibody titres being found only in the protected monkeys (Bonnefoy et al., 1994).
  • Related Vaccine(s): P. falciparum Hsp90 Protein Subunit Vaccine
18. Kbeta
  • Gene Name : Kbeta
  • Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
  • VO ID : VO_0011233
  • NCBI Gene ID : 813054
  • NCBI Protein GI : 124506397
  • Locus Tag : PFE1195w
  • Genbank Accession : AL844504
  • Protein Accession : XP_001351796
  • Taxonomy ID : 36329
  • Chromosome No : 5
  • Gene Starting Position : 998747
  • Gene Ending Position : 1002118
  • Gene Strand (Orientation) : ?
  • Protein pI : 4.54
  • Protein Weight : 120404.67
  • Protein Length : 1123
  • DNA Sequence : Show Sequence
    >ref|NC_004326.1|:998747-1002118 Plasmodium falciparum 3D7 chromosome 5
    AATGGATAAAATTGTAGAAGTTATTGAAGGATTAAGCAGCTCTGAGAGTCATATAAGAAATGAATGTGAA
    AATACGTTAAATTATTATAAAAAGAATGATTTAAATAATACAGTATTATCTATATTGAAATTATTAAAAA
    CCCATAAAGATAGTCAAGTTCGATTACAATGTGCTATATTAATTAGGAATATATTTCGTGTGTATATAAA
    GTCCACACATGTGGATGTGGAAGAAAAAGAAAAAAATGAGAATTCGATTGGAAATGCAGAAGAAGAGAAT
    TATTGGGTATTATTACCTGATAATTTAAAGAATATTGTAAAATCTGAATTGATTAGTAATATAGGAACTG
    AAACAGATAAGATGGTTCGAAGTAATATATGTAATAATATTATAGATTTATCATCAAAATTATTATTACA
    TAATCAATGGCCTGAGTTATTATCAGTAACATTTGAATTTTGTAATTCTAATAACGTTGATGTATTAATA
    AGTGGATATAAAATATTAGGTGGTATCTTAAGTTGTATTCCAGATGAATTAGATGGAAAACAAGAAATAA
    TATCTTCCATATGTATGAAAGGTTTAAATTCATCAAATGTACAAGTACGTGGAGAATGTATTAATTTAAT
    ATCATGTATTGTTGAAGATAATAGTTCATCCTTAGTTAAGAGTGTACATGGTTGTATCCCATTAATATTA
    CAATCATTAAGTTTGATGGCAAAGAATAGTAGTTCAGATATTGCTGTTCTAGAAGAATGTGAGAAAGTAC
    TTCAATCTATTGGTAAAATGATAGATTATAATGCTAAATTTTTTACTAAGCATATAACAAGTTTGTGTGA
    TATATTATTTAGTATTTGTATGAAAGATGAAAATGAATTGAACTATGATTTTGATAATAGCTTGAAGTCC
    CTAAGTATTGAAGCTTTAGTTACCATTCCAGAACGTCGACCAAAAATGGCTTTATCTGTACCTCATTTTG
    TAGATAAGATTATACATTTGTCTATGTTATTTATGCTTGACATTAATAATGATTGTTTTAATGAATGGAT
    GAATTCTATAAAAGAAGGTAAAGACGATAGTCAGGAGTTATATGACATAGGTGAAGAGTCCTTAGATCGT
    GTTGGTAAAGCATTTAGTGAGTTAGAAGAAGCTGAATTTATTCATATTCTTTTTAATAAAGTATCAGAAT
    TTTTAATGAAAAATACTTGGGAACATAAATATGTCGGTATTATGGCTATTGCACAAACTATAGAATATTT
    ACCAGAAGATGAAATTGAAGAACAATTAGAACATGTTATAAAAATGTTGTTACAAATATTAGTTGATCAA
    GATGTTAGAGTACGTTATGCAGCATGTCAAGCCATTGGACAAATATCTTTAGATCATCAACCATATGTAC
    AGAAAGAATTTTTTTCAGAAATTTTATCAGCATTAATTAATACCATGAACGATGTACATTTAAGAGTTCA
    ATCACATGCTACAGCAGCTTTTGTAAATTATGCAGAAGAATTAGATAAAATGGCTTTATTACCATATGCA
    GATATTATTATAGATATTTTATTACAAAAATTGAATTCTTCAAATTATTTATTAGTAAGAGAACAAGCTG
    TTACTGCTATAGCGGTTATTGCAGGTGTTATTGAAGAAGACTTTTTAAAATATTATTCTACTGTTGTACC
    TATGATGAAAGATATTATTCAAAAGGCAGTTTCTGAAGAAGAAAGAACATGCAGAGGTAAAGCCATTGAA
    TGTATTTCAATTATTGGTTTATCGGTTGGTAAAGATATTTTTATTGAAGATGCTAAAGAATGTATGAATG
    CATTATTACAAATTAGCAGTACAAAAATGGATCCTGATGATACTGTAAAAGAATATATTCAAGAAGCTAT
    TGGTCGTATATGTAGAGCATTAGGTAATGACTTTTATCCATATCTAAGTAGTATAGTACCGACCATATTA
    TCTGTACTCTCCGTTTTACCAAAACCATTAACAGATGATGAAGAAGATCTAACCATAACTATGGTATCTA
    ATGGACAATATGTAGGATTGAAAACATCCTTATTAGAAGATCAAGAAAAAGCTTTAGATTTATTAATTAT
    TATTATTGAAGTATTAAAAGAAAATTATAAGGATTATATTCAAGCAACAGCTACAGCTGTGTTGCCAATG
    TTAAATTATGAATTGTCAGATGAAATTAAACAAAAGGCATTAACAGCTGTTAGTGAATTAATTGAATCAG
    CAAGAATATTATCTGAAAAAACGGATAATGATAAATCCATGTTACTAGCCATATTAACAGCAGCAGCAGA
    AAAAGTATTAAAAAGTCTATTAGAAACAAAATTAGATGACAATTATGAATATATATTAGATGTTATGATA
    ATCGAATCCCATGGATTATATATGTGCTTACAAAAAGCGGGATCGAATGTATTGCCAGAAAATACATTAA
    AATTATTTTTTAATCAAATCTTTGCCCTATTACAATATTCAACAGATAGAAGGGTAGTATATAATCAAAA
    AAAAAATAATGATGATGTAGATGAAGATGAATTATTAATAATTGATAGAGAAGAGGAATTAGAACAGAAT
    TATCGAACAAATTTATTAGATATCTTAGGAGTATTAATTAAATATCACCCAACACAATTCTTAAATACAT
    GTTGTGAATTATGTATTGGATTTATTAATAATTATATGAATTCTCCTAATTCAGAAGATGTAGCATTAGC
    ATTATATGTATGTGATGATTTGTTAGAATTCTTACAAGAAAAGAGTGTAAACCTATGGGACTTTTTCATG
    AACCCATTATTATTAAATATTAATCATGCAGATGATAAAGTAAAACAAGCGGCATGTTATGGTGTTATAC
    AAGCAACCAAAATTGAAGCATTTGGAAAGTATGCAAATATTGCAGTAGAATATTTATTAAAATTAGTACA
    TGAAAGTACATCAAATAAAAAACCAAAAGAATATATCTCAGCTATTGATAATGCTATAGCAGCATTAGGT
    GATGTTGTTCTTATGCATACATCAAAATTTAATAATGCAGAAGATCTCATAAAAGTATGGTTAAATCATT
    TACCAATAAAAGAAGATGATGCAGAAGGTAGAAGAGTACATAAAAATCTTATAGATTTAGTTTCACAAAA
    CCATCCTCTCTTGTTCGGAAAAGATAATTCTAATACAGCAAAAATTATTGAAATATTCTTAACAATATAT
    GAAACTGATTTTTCAGATACTGACTGTAACAAAAAAATCTCAACACTTATCAATTCATTGGATAAATCAT
    ATTTAAATAATTTAGCTTCTTCAACTTTGTCACATAAGCAAGCCAAAAAATTGAACAACATTTTGAATCC
    AAACAGAAAATA
  • Protein Sequence : Show Sequence
    >gi|124506397|ref|XP_001351796.1| karyopherin beta [Plasmodium falciparum 3D7]
    MDKIVEVIEGLSSSESHIRNECENTLNYYKKNDLNNTVLSILKLLKTHKDSQVRLQCAILIRNIFRVYIK
    STHVDVEEKEKNENSIGNAEEENYWVLLPDNLKNIVKSELISNIGTETDKMVRSNICNNIIDLSSKLLLH
    NQWPELLSVTFEFCNSNNVDVLISGYKILGGILSCIPDELDGKQEIISSICMKGLNSSNVQVRGECINLI
    SCIVEDNSSSLVKSVHGCIPLILQSLSLMAKNSSSDIAVLEECEKVLQSIGKMIDYNAKFFTKHITSLCD
    ILFSICMKDENELNYDFDNSLKSLSIEALVTIPERRPKMALSVPHFVDKIIHLSMLFMLDINNDCFNEWM
    NSIKEGKDDSQELYDIGEESLDRVGKAFSELEEAEFIHILFNKVSEFLMKNTWEHKYVGIMAIAQTIEYL
    PEDEIEEQLEHVIKMLLQILVDQDVRVRYAACQAIGQISLDHQPYVQKEFFSEILSALINTMNDVHLRVQ
    SHATAAFVNYAEELDKMALLPYADIIIDILLQKLNSSNYLLVREQAVTAIAVIAGVIEEDFLKYYSTVVP
    MMKDIIQKAVSEEERTCRGKAIECISIIGLSVGKDIFIEDAKECMNALLQISSTKMDPDDTVKEYIQEAI
    GRICRALGNDFYPYLSSIVPTILSVLSVLPKPLTDDEEDLTITMVSNGQYVGLKTSLLEDQEKALDLLII
    IIEVLKENYKDYIQATATAVLPMLNYELSDEIKQKALTAVSELIESARILSEKTDNDKSMLLAILTAAAE
    KVLKSLLETKLDDNYEYILDVMIIESHGLYMCLQKAGSNVLPENTLKLFFNQIFALLQYSTDRRVVYNQK
    KNNDDVDEDELLIIDREEELEQNYRTNLLDILGVLIKYHPTQFLNTCCELCIGFINNYMNSPNSEDVALA
    LYVCDDLLEFLQEKSVNLWDFFMNPLLLNINHADDKVKQAACYGVIQATKIEAFGKYANIAVEYLLKLVH
    ESTSNKKPKEYISAIDNAIAALGDVVLMHTSKFNNAEDLIKVWLNHLPIKEDDAEGRRVHKNLIDLVSQN
    HPLLFGKDNSNTAKIIEIFLTIYETDFSDTDCNKKISTLINSLDKSYLNNLASSTLSHKQAKKLNNILNP
    NRK
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Two large fragments of PfKbeta representing the N- and C-terminal halves were expressed in E. coli. The recombinant proteins were highly immunogenic in mice, and also found to be the target for immune response in natural infections of Plasmodium spp. Immunization with recombinant PfKbeta fragments was partially protective against a heterologous challenge infection in mice (Mohmmed et al., 2005).
19. LSA-1 from Plasmodium falciparum
  • Gene Name : LSA-1 from Plasmodium falciparum
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • NCBI Protein GI : 510186
  • Other Database IDs : CDD:183692
    HSSP: 1D7M
    UniProtKB/TrEMBL: Q25887
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : liver stage antigen-1
  • Protein Length : 318
  • Protein Note : phosphodiesterase; Provisional
  • DNA Sequence : Show Sequence
    >PF10_0356 ||LSA1, LSA-1|liver stage antigen-1|Plasmodium falciparum|chr 10|TIGR||Manual
    ATGAAACATA TTTTGTACAT ATCATTTTAC TTTATCCTTG TTAATTTATT GATATTTCAT
    ATAAATGGAA AGATAATAAA GAATTCTGAA AAAGATGAAA TCATAAAATC TAACTTGAGA
    AGTGGTTCTT CAAATTCTAG GAATCGAATA AATGAGGAAA AGCACGAGAA GAAACACGTT
    TTATCTCATA ATTCATATGA GAAAACTAAA AATAATGAAA ATAATAAATT TTTCGATAAG
    GATAAAGAGT TAACGATGTC TAATGTAAAA AATGTGTCAC AAACAAATTT CAAAAGTCTT
    TTAAGAAATC TTGGTGTTTC AGAGAATATA TTCCTTAAAG AAAATAAATT AAATAAGGAA
    GGGAAATTAA TTGAACACAT AATAAATGAT GATGACGATA AAAAAAAATA TATTAAAGGG
    CAAGACGAAA ACAGACAAGA AGATCTAGAA CAAGAGAGAC TTGCTAAAGA AAAGTTGCAA
    GAACAACAAA GCGATTTAGA ACAAGAGAGA CNTGCTAAAG AAAAGTTGCA AGAACAACAA
    AGCGATTTAG AACAAGAGAG ACTTGCTAAA GAAAAGTTGC AAGAACAACA AAGCGATTTA
    GAACAAGAGA GACTTGCTAA AGAAAAGTTG CAAGAGCAAC AAAGCGATTT AGAACAAGAG
    AGACGTGCTA AAGAAAAGTT GCAAGAACAA CAAAGCGATT TAGAACGAAC GAGAGACTTG
    CTAAAGAAAA GTTGCAAGAG CAGCAAAGCG ATTTAG
  • Protein Sequence : Show Sequence
    >gi|510186|emb|CAA82974.1| liver stage antigen-1 [Plasmodium falciparum]
    MKHILYISFYFILVNLLIFHINGKIIKNSEKDEIIKSNLRSGSSNSRNRINEENHEKKHVLSHNSYEKTK
    NNENNKFFDKDKELTMSNVKNVSQTNFKSLLRNLGVSENIFLKENKLNKEGKLIEHIINDDDDKKKYIKG
    QDENRQEDLEEKAAKEKLQGQQSDSEQERRAKEKLQEQQSDLEQERLAKEKLQEQQSDLEQERRAKEKLQ
    EQQSDLEQERLAKEKLQEQQSDLEQERRAKEKLQEQQSDLEQERRAKEKLQEQQSDLEQERLAKEKLQEQ
    QSDLEQDRLAKEKLQEQQSDLEQERRAKERLQEQQSDL
  • Molecule Role : Other
20. LSA-3
  • Gene Name : LSA-3
  • Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
  • VO ID : VO_0012381
  • NCBI Gene ID : 812783
  • NCBI Protein GI : 124801463
  • Locus Tag : PFB0915w
  • Genbank Accession : AE001362
  • Protein Accession : XP_001349701
  • Taxonomy ID : 36329
  • Chromosome No : 2
  • Gene Starting Position : 796749
  • Gene Ending Position : 801583
  • Gene Strand (Orientation) : +
  • Protein Name : Liver stage antigen 3
  • Protein pI : 3.86
  • Protein Weight : 156020.34
  • Protein Length : 1558
  • DNA Sequence : Show Sequence
    >ref|NC_000910.2|:796749-801583 Plasmodium falciparum 3D7 chromosome 2, complete sequence
    AATGACAAATAGTAATTACAAATCAAATAATAAAACATATAATGAAAATAATAATGAACAAATAACTACC
    ATATTTAATAGAACAAATATGAATCCGATAAAAAAATGTCATATGAGAGAAAAAATAAATAAGTACTTTT
    TTTTGATCAAAATTTTGACATGCACCATTTTAATATGGGCTGTACAATATGCTAATAACGTAAGATAAAA
    AACTAAATAATAAATATAAATAAAAAAAAAAAAAAAAAAAAAAAAAATCAACTATATAGTATGTATAATA
    TATATATATATATATATATATATATATTTATTTTTATTTATTTATTAATTTTTTTTTTTTTTATATTATC
    TTTTTAGTCTGATATAAACAAGAGTTGGAAAAAAAATACGTATGTAGATAAGAAATTGAATAAACTATTT
    AACAGAAGTTTAGGAGAATCTCAAGTAAATGGTGAATTAGCTAGTGAAGAAGTAAAGGAAAAAATTCTTG
    ACTTATTAGAAGAAGGAAATACATTAACTGAAAGTGTAGATGATAATAAAAATTTAGAAGAAGCCGAAGA
    TATAAAGGAAAATATCTTATTAAGTAATATAGAAGAACCAAAAGAAAATATTATTGACAATTTATTAAAT
    AATATTGGACAAAATTCAGAAAAACAAGAAAGTGTATCAGAAAATGTACAAGTCAGTGATGAACTTTTTA
    ATGAATTATTAAATAGTGTAGATGTTAATGGAGAAGTAAAAGAAAATATTTTGGAGGAAAGTCAAGTTAA
    TGACGATATTTTTAATAGTTTAGTAAAAAGTGTTCAACAAGAACAACAACACAATGTTGAAGAAAAAGTT
    GAAGAAAGTGTAGAAGAAAATGACGAAGAAAGTGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATG
    ACGACGAAAGTGTAGCCTCAAGTGTTGAAGAAAGTATAGCTTCAAGTGTTGATGAAAGTATAGATTCAAG
    TATTGAAGAAAATGTAGCTCCAACTGTTGAAGAAATCGTAGCTCCAACTGTTGAAGAAATTGTAGCTCCA
    AGTGTTGTAGAAAGTGTGGCTCCAAGTGTTGAAGAAAGTGTAGAAGAAAATGTTGAAGAAAGTGTAGCTG
    AAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGC
    TGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAATCGTA
    GCTCCAACTGTTGAAGAAAGTGTAGCTCCAACTGTTGAAGAAATTGTAGCTCCAAGTGTTGAAGAAAGTG
    TAGCTCCAAGTGTTGAAGAAATTGTAGTTCCAACTGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAT
    CGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAACTGTTGAAGAA
    AGTGTAGCTCCAACTGTTGAAGAAATTGTAGCTCCAAGTGTTGAAGAAAGTGTAGCTCCAAGTGTTGAAG
    AAATTGTAGTTCCAACTGTTGAAGAAAGTGTAGCTGAAAATGTTGAAGAAAGTGTAGCTGAAAATGTTGA
    AGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTT
    GAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTG
    TTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCAAC
    AGTTGAAGAAATCGTAGCTCCAACAGTTGAAGAAATTGTAGCTCCAAGTGTTGAAGAAATCGTAGCTCCA
    ACTGTTGAAGAAAGTGTTGCTGAAAACGTTGCAACAAATTTATCAGACAATCTTTTAAGTAATTTATTAG
    GTGGTATCGAAACTGAGGAAATAAAGGACAGTATATTAAATGAGATAGAAGAAGTAAAAGAAAATGTAGT
    CACCACAATACTAGAAAACGTAGAAGAAACTACAGCTGAAAGTGTAACTACTTTTAGTAACATATTAGAG
    GAGATACAAGAAAATACTATTACTAATGATACTATAGAGGAAAAATTAGAAGAACTCCACGAAAATGTAT
    TAAGTGCCGCTTTAGAAAATACCCAAAGTGAAGAGGAAAAGAAAGAAGTAATAGATGTAATTGAAGAAGT
    AAAAGAAGAGGTCGCTACCACTTTAATAGAAACTGTGGAACAGGCAGAAGAAGAGAGCGCAAGTACAATT
    ACGGAAATATTTGAAAATTTAGAAGAAAATGCAGTAGAAAGTAATGAAAATGTTGCAGAGAATTTAGAGA
    AATTAAACGAAACTGTATTTAATACTGTATTAGATAAAGTAGAGGAAACAGTAGAAATTAGCGGAGAAAG
    TTTAGAAAACAATGAAATGGATAAAGCATTTTTTAGTGAAATATTTGATAATGTAAAAGGAATACAAGAA
    AATTTATTAACAGGTATGTTTCGAAGTATAGAAACCAGTATAGTAATCCAATCAGAAGAAAAGGTTGATT
    TGAATGAAAATGTGGTTAGTTCGATTTTAGATAATATAGAAAATATGAAAGAAGGTTTATTAAATAAATT
    AGAAAATATTTCAAGTACTGAAGGTGTTCAAGAAACTGTAACTGAACATGTAGAACAAAATGTATATGTG
    GATGTTGATGTTCCTGCTATGAAAGATCAATTTTTAGGAATATTAAATGAGGCAGGAGGGTTGAAAGAAA
    TGTTTTTTAATTTGGAAGATGTATTTAAAAGTGAAAGTGATGTAATTACTGTAGAAGAAATTAAGGATGA
    ACCGGTTCAAAAAGAGGTAGAAAAAGAAACTGTTAGTATTATTGAAGAAATGGAAGAAAATATTGTAGAT
    GTATTAGAGGAAGAAAAAGAAGATTTAACAGACAAGATGATAGATGCAGTAGAAGAATCCATAGAAATAT
    CTTCAGATTCTAAAGAAGAAACTGAATCTATTAAAGATAAAGAAAAAGATGTTTCACTAGTTGTTGAAGA
    AGTTCAAGACAATGATATGGATGAAAGTGTTGAGAAAGTTTTAGAATTGAAAAATATGGAAGAGGAGTTA
    ATGAAGGATGCTGTTGAAATAAATGACATTACTAGCAAACTTATTGAAGAAACTCAAGAGTTAAATGAAG
    TAGAAGCAGATTTAATAAAAGATATGGAAAAATTAAAAGAATTAGAGAAAGCATTATCAGAAGATTCTAA
    AGAAATAATAGATGCAAAAGATGATACATTAGAAAAAGTTATTGAAGAGGAACATGATATAACGACGACG
    TTGGATGAAGTTGTAGAATTAAAAGATGTCGAAGAAGACAAGATCGAAAAAGTATCTGATTTAAAAGATC
    TTGAAGAAGATATATTAAAAGAAGTAAAAGAAATCAAAGAACTTGAAAGTGAAATTTTAGAAGATTATAA
    AGAATTAAAAACTATTGAAACAGATATTTTAGAAGAGAAAAAAGAAATAGAAAAAGATCATTTTGAAAAA
    TTCGAAGAAGAAGCTGAAGAAATAAAAGATCTTGAAGCAGATATATTAAAAGAAGTATCTTCATTAGAAG
    TTGAAGAAGAAAAAAAATTAGAAGAAGTACACGAATTAAAAGAAGAGGTAGAACATATAATAAGTGGTGA
    TGCGCATATAAAAGGTTTGGAAGAAGATGATTTAGAAGAAGTAGATGATTTAAAAGGAAGTATATTAGAC
    ATGTTAAAGGGAGATATGGAATTAGGGGATATGGATAAGGAAAGTTTAGAAGATGTAACAGCAAAACTTG
    GAGAAAGAGTTGAATCCTTAAAAGATGTTTTATCTAGTGCATTAGGCATGGATGAAGAACAAATGAAAAC
    AAGAAAAAAAGCTCAAAGACCTAAATTGGAAGAAGTATTATTAAAAGAAGAGGTTAAAGAAGAACCAAAG
    AAAAAAATAACAAAAAAGAAAGTAAGGTTTGATATTAAGGATAAGGAACCAAAAGATGAAATAGTAGAAG
    TTGAAATGAAAGATGAAGATATAGATGAAGATATAGAAGAAGATGTAGAAGAAGATATAGAAGAAGATAA
    AGTTGAAGATATAGATGAAGATATAGATGAAGATATAGATGAAGATATAGGTGAAGACAAAGATGAAGTT
    ATAGATTTAATAGTCCAAAAAGAGAAACGCATTGAAAAGGTTAAAGAGAAAAAGAAAAAATTAGAAAAAA
    AAGTTGAAGAAGGTGTTAGTGGTCTTAAAAAACACGTAGACGAAGTAATGAAATATGTTCAAAAAATTGA
    TAAAGAAGTTGATAAAGAAGTATCTAAAGCTTTAGAATCAAAAAATGATGTTACTAATGTTTTAAAACAA
    AATCAAGATTTTTTTAGTAAAGTTAAAAACTTCGTAAAAAAATATAAAGTATTTGCTGCACCATTCATAT
    CTGCCGTTGCAGCATTTGCATCATATGTAGTTGGGTTCTTTACATTTTCTTTATTTTCATCATGTGTAAC
    AATAGCTTCTTCAACTTACTTATTATCAAAAGTTGACAAAACTATAAATAAAAATAAGGAGAGACCGTTT
    TATTCATTTGTATTTGATATCTTTAAGAATTTAAAACATTATTTACAACAAATGAAAGAAAAATTTAGTA
    AAGAAAAAAATAATAATGTAATAGAAGTAACAAACAAAGCTGAGAAAAAAGGTAATGTACAGGTAACAAA
    TAAAACCGAGAAAACAACTAAAGTTGATAAAAATAATAAAGTACCGAAAAAAAGTAGAACGCAAAAATCA
    AAATA
  • Protein Sequence : Show Sequence
    >gi|124801463|ref|XP_001349701.1| liver stage antigen 3 [Plasmodium falciparum 3D7]
    MTNSNYKSNNKTYNENNNEQITTIFNRTNMNPIKKCHMREKINKYFFLIKILTCTILIWAVQYANNSDIN
    KSWKKNTYVDKKLNKLFNRSLGESQVNGELASEEVKEKILDLLEEGNTLTESVDDNKNLEEAEDIKENIL
    LSNIEEPKENIIDNLLNNIGQNSEKQESVSENVQVSDELFNELLNSVDVNGEVKENILEESQVNDDIFNS
    LVKSVQQEQQHNVEEKVEESVEENDEESVEENVEENVEENDDESVASSVEESIASSVDESIDSSIEENVA
    PTVEEIVAPTVEEIVAPSVVESVAPSVEESVEENVEESVAENVEESVAENVEESVAENVEESVAENVEES
    VAENVEESVAENVEEIVAPTVEESVAPTVEEIVAPSVEESVAPSVEEIVVPTVEESVAENVEEIVAPSVE
    EIVAPSVEEIVAPTVEESVAPTVEEIVAPSVEESVAPSVEEIVVPTVEESVAENVEESVAENVEEIVAPS
    VEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPSVEEIVAPTVEEIVA
    PTVEEIVAPSVEEIVAPTVEESVAENVATNLSDNLLSNLLGGIETEEIKDSILNEIEEVKENVVTTILEN
    VEETTAESVTTFSNILEEIQENTITNDTIEEKLEELHENVLSAALENTQSEEEKKEVIDVIEEVKEEVAT
    TLIETVEQAEEESASTITEIFENLEENAVESNENVAENLEKLNETVFNTVLDKVEETVEISGESLENNEM
    DKAFFSEIFDNVKGIQENLLTGMFRSIETSIVIQSEEKVDLNENVVSSILDNIENMKEGLLNKLENISST
    EGVQETVTEHVEQNVYVDVDVPAMKDQFLGILNEAGGLKEMFFNLEDVFKSESDVITVEEIKDEPVQKEV
    EKETVSIIEEMEENIVDVLEEEKEDLTDKMIDAVEESIEISSDSKEETESIKDKEKDVSLVVEEVQDNDM
    DESVEKVLELKNMEEELMKDAVEINDITSKLIEETQELNEVEADLIKDMEKLKELEKALSEDSKEIIDAK
    DDTLEKVIEEEHDITTTLDEVVELKDVEEDKIEKVSDLKDLEEDILKEVKEIKELESEILEDYKELKTIE
    TDILEEKKEIEKDHFEKFEEEAEEIKDLEADILKEVSSLEVEEEKKLEEVHELKEEVEHIISGDAHIKGL
    EEDDLEEVDDLKGSILDMLKGDMELGDMDKESLEDVTAKLGERVESLKDVLSSALGMDEEQMKTRKKAQR
    PKLEEVLLKEEVKEEPKKKITKKKVRFDIKDKEPKDEIVEVEMKDEDIDEDIEEDVEEDIEEDKVEDIDE
    DIDEDIDEDIGEDKDEVIDLIVQKEKRIEKVKEKKKKLEKKVEEGVSGLKKHVDEVMKYVQKIDKEVDKE
    VSKALESKNDVTNVLKQNQDFFSKVKNFVKKYKVFAAPFISAVAAFASYVVGFFTFSLFSSCVTIASSTY
    LLSKVDKTINKNKERPFYSFVFDIFKNLKHYLQQMKEKFSKEKNNNVIEVTNKAEKKGNVQVTNKTEKTT
    KVDKNNKVPKKSRTQKSK
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites (Daubersies et al., 2000).
  • Related Vaccine(s): P. falciparum LSA-3 Protein Vaccine
21. MSP-1 from P. falciparum
  • Gene Name : MSP-1 from P. falciparum
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • VO ID : VO_0010958
  • NCBI Protein GI : 94420988
  • Other Database IDs : PlasmoDB:PFI1475w
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : merozoite surface protein 1
  • Protein Length : 116
  • Protein Note : clinical isolate
  • Protein Sequence : Show Sequence
    >gi|94420988|gb|ABF18819.1| merozoite surface protein 1 [Plasmodium falciparum]
    MLNISQHQCVKKQCPENSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNENNGGCDADATCTEEDSG
    SSRKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILMLILYSFI
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Aotus monkeys were challenged with the virulent Vietnam Oak Knoll (FVO) strain of P. falciparum. Vaccination of A. nancymai with yMSP1(19) induced protective immune responses. Both of the A. nancymai vaccinated with yMSP1(19) self-resolved an otherwise lethal infection (Kumar et al., 1995).
  • Related Vaccine(s): P. falciparum MSP1 from transgenic mice with Freund's adjuvant , P. falciparum vaccine Combination B
22. MSP1 from P. berghei
  • Gene Name : MSP1 from P. berghei
  • Sequence Strain (Species/Organism) : Plasmodium berghei
  • VO ID : VO_0011225
  • NCBI Protein GI : 1762646
  • Taxonomy ID : 5821
  • Gene Strand (Orientation) : ?
  • Protein Name : merozoite surface protein 1
  • Protein Length : 111
  • Protein Sequence : Show Sequence
    >gi|1762646|gb|AAC47502.1| merozoite surface protein 1 [Plasmodium berghei]
    SGQSSTEPASTGTPSSGEVSTGTSTGGASAGVTNTGAATTGTSTGGASAGVTNTGAATTGTTGTGAATTG
    TTGAEAVTTGNTGAEVTQVQIVPTLTPEEKKKKMDGLYAQI
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Mice vaccinated with recombinant rMSP1 (rPbMSP1), which was generated from Plasmodium berghei, in alum mounted significant protective immunity against challenge infection (P < 0.01). On day 121 after the booster, three out of ten mice immunized with rPbMSP1 in PBS survived parasite infection (P < 0.05) and eight out of ten mice vaccinated with r MSP1 in alum did (P < 0.01). Hence, immunization with MSP1 in alum obviously has conferred protective effects, which prevented death from P. berghei lethal infection in mice (P < 0.01) (Wan et al., 2007).
  • Related Vaccine(s): P. berghei MSP1 Protein Vaccine
23. MSP1 from P. knowlesi
  • Gene Name : MSP1 from P. knowlesi
  • Sequence Strain (Species/Organism) : Plasmodium knowlesi strain H
  • NCBI Protein GI : 221054886
  • Other Database IDs : CDD:116083
    CDD:193419
    CDD:205157
    UniProtKB/TrEMBL: B3L2X8
  • Taxonomy ID : 5851
  • Gene Strand (Orientation) : ?
  • Protein Name : merozoite surface protein 1, MSP-1
  • Protein Length : 1821
  • Protein Note : Merozoite surface protein 1 (MSP1) C-terminus; pfam07462
  • Protein Sequence : Show Sequence
    >gi|221054886|ref|XP_002258582.1| merozoite surface protein 1, MSP-1 [Plasmodium knowlesi strain H]
    MKALLFLFSLIFFVTKCQCETEDYKQLLVKLDKLEGLVVDGYELFHKNKISLDNIDAVQNIDGNNVNALA
    YKIRDIVGKYLELQIPGHGNLLHMIRELALDANGLKYLVENYEEFNQLMHVINFNYDLLRAKLNDMCAHE
    YCKIPEHLKISAKELDMLKKVVLGYRKPLDNIKDDIGKMEAFINKNKETINNINQLITAENAKIVGHPIN
    GVNVTGASSDAVANTGTPVAAAAGAAAAAVPGAIASPSPVESSTPENYDQKKVIFQAIYNFIFYTNQLEE
    AQKLMQVLEKRVKLLKEHKSIKALLEQIATEKNNLTTNNATTGGATTIPEEVQKKIADLEKQIVAIAKTV
    NFDMDGLFTNVEELEYYLREKAKMAGTLIGPESSQSTGTPGKAVPTLKETYPYGITYALPERTIYELIEK
    FGSEESFGDLQNPDNGRQPNKGIIINETKRKTLVDKIMSKIKLEEEKLPKLKKEYDEKMEQYKQKVQDFL
    PTLKYFYEGKLDNTLVGSKFDEFKNKREAYMKEKEELEKCTYEQSINLINKLKKQLTYLVDYTLKKDVTE
    DEINYFSDLEWKLKNEIYELAKEVRKNENKLIMENKFDFSGVLELQIHKVLMIKKIGALKNVQNLLKNAK
    LKDKLYIPKVYKTGQKPEPYYLIVLKKEIDKLKDFIPKIETMIATEKAKAPTEPVKVRAQSLRGASETAP
    SEPPTATESGSTTSASTAVQQPTQQAAQAAQAASPVTVTQPTETVTQTPAPATETAGEAAQETSPVSPTA
    PAVVSEAGTEGGEGTTEVVAQPEAASGETQTPTPGAVDASPAAPVPAGTPGTTDAAPEASVPAPAGSALP
    ATTAPAAAAPAAPAMSKLEYLEKLLEFLKSSYACHKHIFLTNSTMNPELLKQYALTTDEEKKIKESACDE
    LDLLFNVQNNLPSMYSIYDTMINDLQNLYIELYQKEMVYNIYKNKDTDTKIKAFLETLKSNAASVTPAVV
    PAAAPVVTPAPAEPVVTPAPAPGQAAPAAAPTTTNPSTTPSGTTTNAVSPTTAVTPGAQDTTQTTTQDTT
    VTEEGGVTVQASSEEEPETNIVNVEKIYEKHLSQMDKYNDYFIKFLESQKEKITSMTEEQANALGAEIEA
    LKKKVQVSLDHYGKYKLKLERFLEKKNKISNSKEHIKKLTSLKNKLERKLNFLNNPTSVLKNYIIFFNKK
    KEAEKKEVENTLKNTEILLKYYKARAKYYIGEPFPLKTLSEESLQKEDNYLNLEKFRVLSRMEGRLGNNI
    NLEKENISYLSSGLHHVFTELKEIIKNKKYTGNDHAKNTTAVKEALQAYEELLPKVATQTASLPPVAPPA
    VVPPVVPEAEAEAEAEAEAEPATSTQPATADTAAPTQTPAAPTQTPAEPATATATTGETAAAPAAPAPVE
    VQNAEVKAQEYGEDYDKVITLPLFGNDEDDVEDQEEKQIITGEAENAQPENIVPEGINEYEVVYIKPLAG
    MYKSIKKQLENHVAAFNTNITDMLDSRLKKRNYFLDVLDSELNPFKYSSSGEYIIKDPYKLLDLEQKKKL
    LGSYQYIGASVDKDLITAKDGMEYYNKMGELYKQHLEAVNAQIKEIEASVPGEQSQLNAQKEELKKYLPF
    LNSIQKEYESLVNMAHTYKENLKKFINNCQIEKKETEIIVKKLEDYTKIDENLEIYKKSKKESDVRSSGL
    LEKLKNSKLINEEESKKVLSQLLNVQTQMLNMSSAHKCIDTNVPENAACYRYLDGTEEWRCLLGFKEVGG
    KCVPASITCEENNGGCAPEAECTMDDKKEVECKCTKEGFEPLFEGVFCSSSSFLSLSFLLLILIFFLSME
    L
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42
24. MSP1 from P. vivax
  • Gene Name : MSP1 from P. vivax
  • Sequence Strain (Species/Organism) : Plasmodium vivax
  • VO ID : VO_0011230
  • NCBI Protein GI : 26985160
  • 3D structure: PDB ID : 2NPR
  • Other Database IDs : CDD:116083
  • Taxonomy ID : 5855
  • Gene Strand (Orientation) : ?
  • Protein Name : merozoite surface protein 1
  • Protein Length : 1758
  • Protein Note : Merozoite surface protein 1 (MSP1) C-terminus; pfam07462
  • Protein Sequence : Show Sequence
    >gi|26985160|gb|AAN86248.1|AF435639_1 merozoite surface protein 1 [Plasmodium vivax]
    MKALLFLFSFIFFVTKCQCETESYKQLVAKLDKLEALVVDGYELFHKKKLGESDIQVETNASANNNNNNQ
    VSVLTSKIRNFVGKFLELQIPGHTDLLHLIRELAFEPNGIKYLVESYEEFNQLMHVINFHYDLLRAKLHD
    MCAHDYCKIPEHLKISDKELDMLKKVVLGYRKPLDNIKDDIGKLETFITKNKITIKNISDLIIAENKKRS
    GHPTTTTNGAGTQPANGSIAAASSETTQISGSSNSGSTGHGSSNSGSTGHGSSNSGSSGTGSSNSGSSGT
    GSTGNGQSPPATADASSTNANYEAKKIIYQAVYNTIFYTNQLQEAQKLIAVLEKRVKVLKEHKDIKVLLE
    KIATEKGKFPNNNLNVENPTDEQKTAKSNIADLEKKIEAIAKTVNFDLDGLFTDAEELEYYLREKAKMAG
    TLIIPESTKSAGTPGKTVPTLKETYPHGISYALAENSIYELIEKIGSDETFGDLQNPDDGKQPKKGILIN
    ETKRKELLEKIMNKIKIEEDKLPDLKKEYEEKYTVYEQKVKEFQPEFNYFYEARLDNTLVGEKFGEFKKK
    REEYMKEKKKLESCSYEQNTNLINKLKKQLTYLEDYVLRKDIADDEIKHFSFMEWKLKSEIYDLAQEIRK
    NENKLTIENKFDFSGVVELQVQKVLIIKKIEALKNVQNLLKNAKVKDDLYVPKVYKTGEKPEPYYLMVLK
    REIDKLKDFIPKIESMIATEKNKPTVAAADIVAKGQSLRGASETGTTGNTVNAQTAVVQQPQHQVVNAVT
    VQPGTTGHQAQGGEAETQTNSVQAAQVQQTPAGAGGQVASTQTTSQAPAPTQASPEPAPAAPPSTPAAAV
    APAPAMSKLEYLEKLLDFLKSAYACHKHIFVTNSTMDKKLLKEYELNADEKTKINQNKCDELDLLFNVQN
    NLPAMYSIYDSMSNELQNLYIELYQKEMVYNIYKNKDTDKKIKAFLETSNNKAAAPAQSAAKPSGQAGTT
    PVTTTAPVTTTTVTPSPQTSVVTSTPPTPQAEENQRVGGNSEEKPEADTAQVEKFYEKHLSQIDKYNDYF
    KKFLESKKEEIIKMDDTKWNALGKEIEELKKKLQVSLDHYGKYKLKLERFLKKKNKISNSKDQIKKLTSL
    KNKLERRQNLLNNPTSVLKNYTAFFNKKRETEKKEVENTLKNTEILLKYYKARAKYYIGEPFPLKTLSEE
    SMQKEDNYLNLEKFRVLSRLEGRLGKNIELEKENISYLSSGLLHVLTELKEIINDKKYSGKDHAKNIAEV
    KKALQAYQELIPKVTSQESTSVAVTVPGAVVPGVPTAAAAGSGASGAVPPATGGVVPGVVESAEAQTQTQ
    AQDYAEDYDKVIALPLFGNNDDDGEEDQVTTGEAESEAPEILVPAGISDYDVVYLKPLAGMYKTIKKQLE
    NHVNAFNTNITDMLDSRLKKRNYFLEVLNSDLNPFKYSSSGEYIIKDPYKLLDLEKKKKLIGSYKYIGAS
    IDKDLATANDGVAYYNKMGELYKTHLDGVKTEIKKVEDDIKTHDEKLQKLGSEVSQNSEKTQLNAKKAEL
    EKYLPFLNSLQKEYESLVSKVNTYTDNLKKVINNCQLEKKEAEITVKKLQDYNKMDEKLEEYKKSEKKNE
    VKSSGLLEKLMKSKLIKENESKEILSQLLNVQTQLLTMSSEHTCIDTNVPDNAACYRYLDGTEEWRCLLT
    FKEEGGKCVPASNVTCKDNNGGCAPEAECKMTDSNKIVCKCTKEGSEPLFEGVFCSSSSFLSLSFLLLML
    LFLLCMEL
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Immunization of BALB/c mice and Aotus monkeys with PvMSP-1 induced IgG antibodies (titer > 10(6)) that cross-reacted with P. vivax parasites. Immunized monkeys displayed partial protection against a challenge with P. vivax blood stages (Valderrama-Aguirre et al., 2005).
25. MSP1 from P. yoelii str. 17XNL
  • Gene Name : MSP1 from P. yoelii str. 17XNL
  • Sequence Strain (Species/Organism) : Plasmodium yoelii yoelii str. 17XNL
  • VO ID : VO_0011212
  • NCBI Gene ID : 3791597
  • NCBI Protein GI : 82596427
  • Locus Tag : PY05748
  • Genbank Accession : AABL01001865
  • Protein Accession : XP_726257
  • Taxonomy ID : 352914
  • Gene Starting Position : 990
  • Gene Ending Position : 6308
  • Gene Strand (Orientation) : -
  • Protein pI : 5.05
  • Protein Weight : 188296.05
  • Protein Length : 1772
  • DNA Sequence : Show Sequence
    >ref|NW_863564.3|:990-6308 Plasmodium yoelii yoelii str. 17XNL MALPY01871, whole genome shotgun sequence
    TTTAAAATATATTAAATACAATTAATGTGATAATTAATAAAATTGATAATCCCATAAAGCTGGAAGAACT
    ACAGAATACACCTTCATAATATGCATTAGGGGTTGGTTCTTTACATGTACATATAATTTTTTTGGAATTT
    TCCGTACTTTCCGCATTTTGACAACTAGCAGTTGGATCACATCCACCATTGTTGATATCACAAGTAGGAT
    TATTATTTTCTACACATGTATTACCTTCACCTTTTTTGTAACCTAATAAACATCTCCATTCTTCAGTACC
    ATTATCATCTCTAAAACATCCAGCATTTTTAGGAATATCTCTTGTATCAACACATACATGTTTAGGGTCT
    ACACCTAATAAATCCATACCATCCATGTTAAGCATTTTTGCTAATATTTTCTTTGATTCACCTTCTCCTA
    CTAAACCAGATTTATTTAAGTTGTTTAAAGCTATTGAGGCTATGTGTTTATTATTTTCTGCATGTTCTAC
    AAATTCGTCAAGTTTTTCGTCAATTTGTATGTATTTTTCTAAATTTTTTGTTAATATTTCAAATTCAGCT
    TTTTCATTTTTATAATTATCAAGTCTATTTTGTAATTCTTCTGAATATTCTTCTGCTTGACCTATTACGG
    TTTCATATAATCCTTTAAGATCTTCAAGGATTGGAATATATTTCTTTTTTTCTTCTTTATTGGTATCGTT
    AGTTTCAGCTTCTATGGTAGCAATTTGTTCCTTTACTGCAGCTAATTGAGTGTTGTATAATTCAACCATT
    TTGTTAAAGAATTTAATTCCGTCAGTAGTTGTTTCTATATCTTCATTTATACCTTTAGTAGCATATTTTA
    AGTTTACTATTTGTTTGTCTTTTTTATCATTATCTAATAATTGATATGGATTTCTAATAACATATTTGTT
    GGTACTTAAATCTTTGAATAAATCTAATTCATGGCTTAATACTTCAAGGAAATCATTTCTTTTTTGTGAT
    TTATTATTTAATCCATTTGTCATGTCTTCTTTAATTGTTGAAAATTCTCTTAACATGTGTTTCTTTAATG
    ATTTATATGTACTACCCAACCTTTTTGTGTATACATACAAACTTTCATTTGTAAATTCGGAAAGAATATC
    TTTTTCTGGTGCATCTTCGGATTGACCACTTGCAATTTGATATATATCATCGTCTTCATTATCATCAACA
    CTGCTTCCAGCTACCCGTGTATCGGTTCCTGATCCTGGTACTGCACCTGGTACTGCTCCTGGTACTGCAC
    CTGGTACAGCTCCTGGTACTGCTCCTGGTACTGCTCCTTCTGGTGTTGCTGGTGCGTCAGCTGCTAGTGT
    CGTTGTAACTGCGACTGCTGGAGTTGAAACTGTTACTCCCTTTGGAAGCAATTCTTTATATTGTTCGAAT
    GCATTGGTAACTTCAGGGGCATTATCAGGGTTTTTTTTTCCGGTATAGTCTTTATCTTTTATAAGTTCTT
    TAAATTCTTCAAATACGTGGTGTAAACCTCCTGATACATATGAAATTCTTTCCTTTCCTAAATTAATATT
    TTTTTTTAATCTTAATTCTAATCGACTGTATGCTCTGAATTTTTCGATTTTCAAATAATTGGATTCTCTG
    TCAAGTGATGCTTTAGATAATGTTTTTAAAGGAACAGCTTCAGAAGTAAAATATTTAGTACGAGCTTTGT
    AGTATTTTAATAACATATCAGTATTTTTTAATGCATTATCTACATATTGTTTTTCAGCTTCTCTTCTCTT
    GTTAAAGAAATTTACATAACCATTTAATATATAAAATACGCCATTAAGAGTTTGTTTTCTTTTTAATAAT
    CGTGCTTTCAATATACTAAGATCTCTAATTTGTCGATTGGTTAGTTGAATTTGTTCATGTTTGTTATATA
    ATCTTTCTAATTTTAATTTATATGTAGAATAACGATCATAATAATGTTCTGATAATTCCTTTAAGTGAGC
    GATTTCAAGATATAATTGATTAACTTTTTCAGGTGTCAATGCTTTTATTAATTCTTTTTTAGATTTTATA
    AAATTTATGAATTCAGTATTATTTCCATCAATTTGTTGTAAGTAAGATTTGTATAAATTGTCTAATTCAA
    AATCATCGGCAGGCATATCCTCTTCACTTTCTGCTCGTGATCTAATACCTGAGTCAGGGTTTCCTGATTG
    AGAATTTGCTGCTGGTGGTTGTGCAGGTGCTGGTGTAGATGTTGATGGTACTGCTGCCGCTGCTGCTGGG
    GGTGTTACATCTGAGGTTGTACTTGCGTTAGATGCTGCTGATCCTGATGCTGATGTTCCTGCTGGTGTGG
    CTGCGTTAGATGCTGTTGCTCCTTCTGTTCCTGATGCTCCTGCTTCTCCTGATGGTGTACCTTCGCCAGG
    TGCTGATGATGATGCTTCTGTTGAGGTTGTTACCTCTGGTGTCGTGGATGTTACTGGTGTTTCTGGTTGT
    TGCGAGACATCTGATGGTGCTGGTGCATCTGATTGTACATCAGGTGTTGCTTGTTGTTGTTGTTGTTCTG
    TTGCTGCTGGAGTTACTGGTGTTGGTGCTGCTACTGGTTCTGGTTCAATGACGCCAGCTTTTACCAATAA
    AGATTTAATAGATGGGTTTTCATCTTTTAATTTATATATATGATACATCATTTCTTTTTCATATAATTCA
    GTATAAATGTTTTGTAAACCATCAACTATACTTTCATAAAGTGAATACATAGTAGGCATATTATTTTGAA
    TAGCTAATAATACATCTAATTCACTGCATCTTTTTAATGTTCTTATTTTATCTTCTTCAGATGTAAGAGC
    ATATTTGCTTAAAGCATCTTTGTTTATGGTAGAGTTTTGTAGTAAAACGTATTTATGGCATGAATATGAG
    AATACTAAAAATTTTTGTAATTTTTCAAGATAATATAATTTTGTCATAACTGGTTTTGCAGGTGTTGTGG
    ATGATGCAGCTTGTGATGGTTGTGTTTCTTGTGTGGTAGGGGGTATTGTTGTTTCTTCTGATGCTTCTGT
    TGATGGGGATGCTGCTTCTGCTGGTGCGGGTGCTTCTGGTAATGTGGCTGAGGAGGATTCTGCTGCTGCT
    GGGGTTGAAGATGAGGATGAGGATGAGGATGTTGAAGATTGTGTTGATCTATCTGTTGATGATTCAGCAC
    TAGGGCCAGATGGTACTTCTTCAGATTCTCCAGTAATTGCAGGTCCTTGTTCCATTCTTTCCTTCTCTTT
    AGCAATCATACTTTCGATTTTTGGAATAAATTGGGCAAGTCTGTCAACTTCTTTTTTTACAGCTATTAAA
    TAGTATGGTTCTGGTTTTCCTTCATTACCGTATGTTTTTGGAACATATAGTTTGTCTTTTAATTGAGCTT
    TGTTTAAAGATACTTCAGTTTTATTTAATTGCTCAATTTGTTTTGTTAATAAAGATTTTTGTATTTGCAA
    TTCTACAAGTGTTGAAAGTGGTACATCTTTTGATGCAACTAATACATTTTGTTTTGCTTGAACAGCTTCT
    GCTAATCTATTAATATTATATTGTAATTCTTTTTTTTTATTTGAAAAATATTCAATTTCATTACTAATTA
    TATCTTTTCTTAATGAATAATCTTGTAAATAATTAAGTTGTTTATTTAATTTATTAATTAATTCTTTAGT
    ATTTCCATATTCACAAGTGTTTAATTCGGTTTTCTTGGTCATATATTCATCTCTTTTTGTTTTGAATTTT
    TCAAAAATTTCAGAAGTCAATTTATTTCTAAATTTTGATTCATAAAATTCTTTAGCTGCTTCTTTGAATG
    GAGTTTTTTGTTGATTAAATTCTGTAAGTTTATTATCATAATTCGTTTTTAATGTTTCTAATTTTTTTTC
    TTCTGCTTTTATTTTCTTTTTAATAGCTTTTATTAGATCTTTTCTGGCTTGTTCATTTGTGGCTAAATCT
    CCTGTTAATGGTGTATTATCGGGATGTGTCAAATCACCATATGTTGTTTCAGCGGCATTATTGGCAATTT
    TATTGTAAACATCATTTTCAGGTAATGGGTAACTAATACCATTTGGATAACGTATAGTTAATGGTATTAT
    AGTTTCGGATGCTTTATTTTTTTTACAGGATGAAGTTGATAAATTGCAACTTTCTTTTTTTTTTTCTTTT
    TTGAAATATTCTAATTCGATTGGATCTACAAATATTCCTTCTAAGTTGAATTTTATAGTTTTTGCAATTT
    CTTTAATTTGAGCATAAAGTCCGGCTATTTTTTTCTGTTTTTCTTCTAATGTAAGAGTTGGAACGGGTTG
    CACTTGAGCTGTTTGTGGATTAGTTGATGCTTCACCATTTTGTCCTACACTAGGTGTTACTGTAACAGAT
    GCTACAGTGTTAGCTTGTTCTACACCTGTTCCTGCACTAGCTTGTCCTGATGAACTTGTTCCCGATGCAC
    TTGATCCACCACTACCTGGTTCTGTACTAGATTGTCCTCCTGTAACTATTTGTGTTTCGGCAGTGACGAC
    GGGGGCAGCATTGAGAACTTCAATTTGTTGCCATAATGGTTTGATGGCATCATTTTTCTTTAATGTAGAA
    ACTCGTTTTTCTAAGACTTCGACAACCTTTTGTATTTCAGCTAATTGTTTTTTGTAAAATATAACATTGT
    ACATAGCTTGGTATATTGGTTTTTTTTTATTATATTTATCGCTATCACAACTAGCGTCATTGCAATCTTC
    GTTACCTTCAGGTTGTATTTTTTTTGTTTCTTCAGCAATAAGAGCGTTTAAAGCTGCAACAGTTTCTTTA
    TTTCTTTCTATGTAAATTTCTAACTTTTCAATATCGTCTTGAATATTTTCTATTGGTTTTCTATAACCTA
    AAATTACTTTTTTAAGCATTTCTGTTTCTTCTTCACTAATTTTAAGATGTTCAGGAATTTCACAATAATT
    ATTTGCACACATATCATTTAATTTATCTCTAAGTACATCATAATAAAAATTTATTGCGTGCATTAATCCA
    TTAAATTCTTCTTTACTTTCAATTAAATATTTTACTCCATATCTATTTGGGGTTAATGCTTTTATTAAAT
    TGACTAATTCTGTTTGTTCTGTAAATCCTAATCCTTCAAATTTTGTAACAAAATCTTGTACTTGTTGTGC
    AAAGTTATGATTTGTAAATGGATCAATAGTTTCAGTTGGTTGTGTTGCATTTATAATTACTTGACTTTTT
    TGAAATAGTTCTAACCCATCCACTGACAATGATTCTAATTTTTCTAACTTTTGAATGAGATCATTATAAA
    CTTCAATTGTTTCAGATTTGCATTTTATAGCAAAAAAAACGAAAGAAAATAAAAGTCCAATCACCTTCA
  • Protein Sequence : Show Sequence
    >gi|82596427|ref|XP_726257.1| merozoite surface protein 1 precursor [Plasmodium yoelii yoelii str. 17XNL]
    MKVIGLLFSFVFFAIKCKSETIEVYNDLIQKLEKLESLSVDGLELFQKSQVIINATQPTETIDPFTNHNF
    AQQVQDFVTKFEGLGFTEQTELVNLIKALTPNRYGVKYLIESKEEFNGLMHAINFYYDVLRDKLNDMCAN
    NYCEIPEHLKISEEETEMLKKVILGYRKPIENIQDDIEKLEIYIERNKETVAALNALIAEETKKIQPEGN
    EDCNDASCDSDKYNKKKPIYQAMYNVIFYKKQLAEIQKVVEVLEKRVSTLKKNDAIKPLWQQIEVLNAAP
    VVTAETQIVTGGQSSTEPGSGGSSASGTSSSGQASAGTGVEQANTVASVTVTPSVGQNGEASTNPQTAQV
    QPVPTLTLEEKQKKIAGLYAQIKEIAKTIKFNLEGIFVDPIELEYFKKEKKKESCNLSTSSCKKNKASET
    IIPLTIRYPNGISYPLPENDVYNKIANNAAETTYGDLTHPDNTPLTGDLATNEQARKDLIKAIKKKIKAE
    EKKLETLKTNYDNKLTEFNQQKTPFKEAAKEFYESKFRNKLTSEIFEKFKTKRDEYMTKKTELNTCEYGN
    TKELINKLNKQLNYLQDYSLRKDIISNEIEYFSNKKKELQYNINRLAEAVQAKQNVLVASKDVPLSTLVE
    LQIQKSLLTKQIEQLNKTEVSLNKAQLKDKLYVPKTYGNEGKPEPYYLIAVKKEVDRLAQFIPKIESMIA
    KEKERMEQGPAITGESEEVPSGPSAESSTDRSTQSSTSSSSSSSSTPAAAESSSATLPEAPAPAEAASPS
    TEASEETTIPPTTQETQPSQAASSTTPAKPVMTKLYYLEKLQKFLVFSYSCHKYVLLQNSTINKDALSKY
    ALTSEEDKIRTLKRCSELDVLLAIQNNMPTMYSLYESIVDGLQNIYTELYEKEMMYHIYKLKDENPSIKS
    LLVKAGVIEPEPVAAPTPVTPAATEQQQQQATPDVQSDAPAPSDVSQQPETPVTSTTPEVTTSTEASSSA
    PGEGTPSGEAGASGTEGATASNAATPAGTSASGSAASNASTTSDVTPPAAAAAVPSTSTPAPAQPPAANS
    QSGNPDSGIRSRAESEEDMPADDFELDNLYKSYLQQIDGNNTEFINFIKSKKELIKALTPEKVNQLYLEI
    AHLKELSEHYYDRYSTYKLKLERLYNKHEQIQLTNRQIRDLSILKARLLKRKQTLNGVFYILNGYVNFFN
    KRREAEKQYVDNALKNTDMLLKYYKARTKYFTSEAVPLKTLSKASLDRESNYLKIEKFRAYSRLELRLKK
    NINLGKERISYVSGGLHHVFEEFKELIKDKDYTGKKNPDNAPEVTNAFEQYKELLPKGVTVSTPAVAVTT
    TLAADAPATPEGAVPGAVPGAVPGAVPGAVPGAVPGSGTDTRVAGSSVDDNEDDDIYQIASGQSEDAPEK
    DILSEFTNESLYVYTKRLGSTYKSLKKHMLREFSTIKEDMTNGLNNKSQKRNDFLEVLSHELDLFKDLST
    NKYVIRNPYQLLDNDKKDKQIVNLKYATKGINEDIETTTDGIKFFNKMVELYNTQLAAVKEQIATIEAET
    NDTNKEEKKKYIPILEDLKGLYETVIGQAEEYSEELQNRLDNYKNEKAEFEILTKNLEKYIQIDEKLDEF
    VEHAENNKHIASIALNNLNKSGLVGEGESKKILAKMLNMDGMDLLGVDPKHVCVDTRDIPKNAGCFRDDN
    GTEEWRCLLGYKKGEGNTCVENNNPTCDINNGGCDPTASCQNAESTENSKKIICTCKEPTPNAYYEGVFC
    SSSSFMGLSILLIITLIVFNIF
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Researchers found that the cysteine-rich, carboxyl-terminal region of the MSP-1 protein from the rodent malarial parasite Plasmodium yoelii yoelii can be expressed in a native configuration as a fusion protein in Escherichia coli. This recombinant polypeptide elicits antibodies in mice which recognize the native parasite MSP-1. Most significantly, both inbred and outbred mice immunized with the fusion protein in Ribi adjuvant are partially and in some cases completely protected against challenge infection with an otherwise lethal parasite strain (Daly and Long, 1993).
  • Related Vaccine(s): P. yoelii DNA vaccine encoding MSP1 , rBCGMSP1-15
26. MSP3
  • Gene Name : MSP3
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • VO ID : VO_0011220
  • NCBI Protein GI : 113207288
  • Other Database IDs : CDD:148630
    InterPro: IPR010784
    UniProtKB/TrEMBL: Q0KGB6
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : merozoite surface protein 3
  • Protein Length : 304
  • Protein Note : Merozoite surface protein (SPAM); pfam07133
  • Protein Sequence : Show Sequence
    >gi|113207288|emb|CAJ44236.1| merozoite surface protein 3 [Plasmodium falciparum]
    SKEIVKKYNLNLRNAILNNNSQIENEENVNTTITGNDFSGGEFLWPGYTEELKAKKASEDAEKAANDAEN
    ASKEAEEAAKEAVNLKESDKSYTKAKEACTAASKAKKAVETALKAKDDAEKSSKADSISTKTKEYAEKAK
    NAYEKAKNAYQKANQAVLKAKEASSYDYILGWEFGGGVPEHKKEENMLSHLYVSSKDKENISKENDDVLD
    EKEEEAEETEEEELEEKNEEETESEISEDEEEEEEEEEKEEENDKKKEQEKEQSNENNDQKKDMEAQNLI
    SKNQNNNEKNVKEAAESIMKTLAG
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Immunization with a recombinant yeast-expressed Plasmodium falciparum merozoite surface protein 3 (MSP3) protected Aotus nancymai monkeys against a virulent challenge infection (Tsai et al., 2009).
  • Related Vaccine(s): P. falciparum MSP3 Protein Subunit Vaccine
27. MSP4/5
  • Gene Name : MSP4/5
  • Sequence Strain (Species/Organism) : Plasmodium yoelii
  • VO ID : VO_0011236
  • NCBI Protein GI : 49798469
  • Taxonomy ID : 73239
  • Gene Strand (Orientation) : ?
  • Protein Name : merozoite surface protein 4/5
  • Protein Length : 171
  • Protein Sequence : Show Sequence
    >gi|49798469|gb|AAT68597.1| merozoite surface protein 4/5 [Plasmodium yoelii yoelii]
    VHEISLINTKKYQRNIFCAKRILGDPPSANPSTSLNQNEDNHNSNPDANKGNTNKSDKLNGDNIPNSQSK
    SENTNLSESPKTGTASNPPQPEPSVQPGNTNGDSQNSIHSDDEEEDDEDEDDDEEDCSVNNGGCGENLLC
    EKMESGIIKCSCPSGYKLNGTSCIELLSAHS
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection (Wang et al., 2004).
  • Related Vaccine(s): P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine
28. MSP8
  • Gene Name : MSP8
  • Sequence Strain (Species/Organism) : Plasmodium yoelii
  • VO ID : VO_0011221
  • NCBI Protein GI : 58197887
  • Taxonomy ID : 5861
  • Gene Strand (Orientation) : ?
  • Protein Name : merozoite surface protein 8
  • Protein Length : 409
  • Protein Sequence : Show Sequence
    >gi|58197887|gb|AAW65717.1| merozoite surface protein 8 [Plasmodium yoelii]
    MKKSSQIIIFLLLSLFCKFSIGNCNENGNGNINKANNNSIIRKERKRKSKSDFSKGEPENKEHEIINLYD
    DVQELLGPDEMNMLDKYSILGIDDCSNENENNKIISEYDLKAMKSVLLYKNRISRASINNLDDVKTVFKR
    CFNKDDPELSKSYEQIQNQVANEGTTIIDYLSNYISNIYIKINDEFVKNEEFQLSKYIPELEIINYVLYN
    GPKEIGNKIKNELIEINNLIISESLTSIYSSVVSGLNINCKIKDDLITILNLANGKYFKVNFSSQATMII
    PEQYSHESEHMKKISEYFIEKNRVCKNENCPINSNCYVIDSVETCRCIPGFSKNEESENLECLINESTSC
    ENNNGGCDVNANCILLEDKIMCECNNKFNGDGIYCSSAIYYGMNVFIFFLISIVCIYIM
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Immunization with Plasmodium yoelii merozoite surface protein (PyMSP)-8 protects mice from lethal malaria but does not prevent infection (Petritus and Burns, 2008).
29. P36p
  • Gene Name : P36p
  • Sequence Strain (Species/Organism) : Plasmodium berghei str. ANKA
  • NCBI Gene ID : 3424772
  • NCBI Protein GI : 68068733
  • Locus Tag : PB000799.01.0
  • Genbank Accession : CAAI01001447
  • Protein Accession : XP_676277
  • Taxonomy ID : 5823
  • Gene Starting Position : 1477
  • Gene Ending Position : 2586
  • Gene Strand (Orientation) : -
  • Protein pI : 8.96
  • Protein Weight : 24816.97
  • Protein Length : 223
  • DNA Sequence : Show Sequence
    >gi|68142845:1477-2586 Plasmodium berghei strain ANKA contig PB_RP1657, whole genome shotgun sequence
    CTTACTGCATTAATTTGATATCTTTAAAATTAAATCCTTTTTTCCCTGTCACATTAAAAGTAATATATCC
    TTCCCTTTGAGCTGAAATACAATTTTTAACATCATCATCAAAAAATATTATTTCGTTAATATTAACAGAA
    AATTCATTTCTTATCTGTAAAGAGAAACGAATAAAATAGGGAATATTTAACCATCTTACCCACACATTTA
    TATATATAATTCATATTGTGAAAATATAAAAAAAATGTTACAGTTGATTATTATTTATAAATTTTTTTAG
    AGACTATACCCTTTTTAAATGATAAGATTTGTCGTTGGACATTGGCTCTTTTAATCCAAGGGCCATATAT
    TTTTTCGGTTCCTTATAATAACTAAAAAAATATGAACATAAAAAAGTAGTTTATATTTTCGCTAGTTTAT
    GAGTTGTTTCGCTAGTTTTATGAATTTTGTGTATTTCGTATTACTAGGGGTAATATGCATAAACCCGTTC
    TATTTTGGTTTCACAATTGCTATTTTTAATACAATGCTGAATTAATTCTTCTCCTGCGATCAAAGATGGT
    GACTTTCCCTTACTATATCGAATCGTCTCGTCATCTATTCAGGCGTTAAATATGAAAATAAAAAAATGGT
    CAGGTAAAATAAGAAATGATCAGGCAAAATAAGAAATGGTCAGGTAAAATAAGAAATGAAAACATGCTCA
    CGCATTTCACCTGAAAACGTTGCAACAGTTATTTTAATATCATTTTCATAAAGCCTCTTTGATAAAATTT
    TAAAAGCATTTGTGACAGATGTTCCTATATCTTCAATATCATTGAGTTTGTCGATATATCCACCTGTACA
    ACCATGCAAAGAAAGGAGTTAAACATAAATAAGTGACAAAATATATGTGTGCGTACATATAGCCATTGCA
    TATTATGTTACAAGTACCTGAGTGTTTTCCTATTAGGGTCAAGTCAAAATCGAAAACAGCCATCTTTATG
    TTTATCTTTTTAAGGAGATCAACAAAGCCATGAATACCTTTAGATATAGAAACAAAATAAACAATTAAAT
    GAAATAAAAATATGCACGTATAAAATATTATATATATAGCAGAAAGTCCTATAATTTTCA
  • Protein Sequence : Show Sequence
    >gi|68068733|ref|XP_676277.1| P36-like protein [Plasmodium berghei strain ANKA]
    MKIIGLSAIYIIFYTCIFLFHLIVYFVSISKGIHGFVDLLKKINIKMAVFDFDLTLIGKHSGGYIDKLND
    IEDIGTSVTNAFKILSKRLYENDIKITVATFSDDETIRYSKGKSPSLIAGEELIQHCIKNSNCETKIERV
    YAYYPYYYKEPKKYMALGLKEPMSNDKSYHLKRIRNEFSVNINEIIFFDDDVKNCISAQREGYITFNVTG
    KKGFNFKDIKLMQ
  • Molecule Role : Virmugen
  • Molecule Role Annotation : Genetically attenuated P36p-deficient Plasmodium berghei sporozoites provide protection against sporozoites challenge in mice (Douradinha et al., 2007).
  • Related Vaccine(s): Plasmodium berghei p36p mutant vaccine
30. PF10_0155 enolase
  • Gene Name : PF10_0155 enolase
  • Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
  • VO ID : VO_0011223
  • NCBI Gene ID : 810313
  • NCBI Protein GI : 124802328
  • Locus Tag : PF10_0155
  • Genbank Accession : AE014185
  • Protein Accession : XP_001347440
  • Taxonomy ID : 36329
  • Chromosome No : 10
  • Gene Starting Position : 636945
  • Gene Ending Position : 639469
  • Gene Strand (Orientation) : +
  • Protein pI : 6.54
  • Protein Weight : 45501.97
  • Protein Length : 446
  • DNA Sequence : Show Sequence
    >ref|NC_004314.2|:636945-639469 Plasmodium falciparum 3D7 chromosome 10, complete sequence
    AAATTAAAAAAAATTCTATTATACTTTCCAAAATTAAAATTATTATAAATTTTATAATTCTCTCTTTTGT
    AATATTTTATTTTCTTAATATAATATTTTTTTAATATTCATTCTTATAAAAAAACTTTATATTCCTTTTA
    TATTATTTTATTTTAAATAAAATATAAACATATTATACTTACTTTAAAAAAAATGGCTCATGTAATAACT
    CGTATTAATGCCCGTGAAATTTTAGGTATAGATATTTTAATGTTATATATTTTTTCACTTTGTATATAAA
    TACCTTATTATATGTTTTTAAATAAATGTATATTCAAAGAGCTATATTCATTTTTAACTTTTTTTATTTT
    ATATTATAAGAATGAATATGATAGATAAATAAAGATATATATATTATATATATATATATATATATATATT
    TATTTATTTATTTATTTATACATTAATGTATTAATATGTTTATTTTATGAATCCACGTGATATTTCTTTA
    TGAATATGTATTCTATAGTTAACATATAATAATACATACGTATATAATAAGAATAACATAAGAATAAAAT
    TTTTTTTTATTTTTTTTTTTGTAATACAATAATTTTTTTGTGTATCATTTTATTTTATTTTATTTTTAAT
    ATCTGAACATATATAATTAAATGTGAAAATTATTTACAATATATATATATATATATATATATATATATAT
    ATGTTACATTATTACTAATATCTGTATTTTATTTATTTTCTGTTGTTATATATTTTTTTTATATATAGAT
    TCTAGAGGAAACCCAACTGTAGAAGTTGACTTAGAGACCAACTTAGGTATTTTCAGAGCTGCCGTACCAT
    CTGGTGCCTCCACTGGTATTTATGAAGCCTTAGAATTAAGAGATAATGACAAGAGCAGGTACTTAGGAAA
    GGGTGTTCAAAAAGCTATCAAGAACATTAATGAAATTATTGCTCCAAAATTGATTGGAATGAATTGTACT
    GAACAAAAGAAAATTGACAATTTAATGGTTGAAGAATTAGATGGAAGTAAAAATGAATGGGGATGGTCAA
    AAAGTAAATTAGGAGCTAATGCTATTTTAGCTATATCCATGGCTGTATGTAGAGCTGGTGCAGCTGCTAA
    TAAAGTATCTTTATACAAATATTTGGCACAATTAGCTGGAAAGAAAAGTGACCAAATGGTATTACCAGTA
    CCTTGTTTAAACGTTATCAATGGAGGATCCCATGCAGGAAACAAATTATCTTTCCAAGAATTTATGATAG
    TGCCAGTTGGTGCTCCATCATTTAAAGAAGCCTTAAGATATGGTGCTGAAGTATATCATACCTTAAAATC
    AGAAATTAAAAAGAAATATGGTATTGATGCAACCAATGTAGGTGATGAAGGTGGATTTGCTCCAAATATA
    TTAAACGCTAATGAAGCTCTTGATTTATTAGTAACTGCCATTAAATCAGCTGGTTATGAAGGAAAGGTTA
    AAATTGCTATGGATGTTGCAGCTTCTGAATTTTACAACAGTGAAAACAAAACATACGATTTAGATTTCAA
    AACTCCAAATAATGACAAATCATTAGTTAAGACTGGAGCTCAATTAGTTGACTTATACATTGATTTAGTA
    AAGAAATATCCAATTGTTTCTATTGAAGATCCATTTGATCAAGATGATTGGGAAAATTATGCTAAATTAA
    CAGCAGCTATTGGAAAGGATGTTCAAATTGTTGGTGATGATTTATTAGTTACAAACCCAACCAGAATTAC
    TAAAGCTCTTGAAAAAAATGCTTGCAATGCTTTACTTCTTAAAGTTAACCAAATCGGTTCTATTACTGAA
    GCTATTGAAGCTTGCTTATTATCTCAAAAAAATAACTGGGGTGTTATGGTTTCTCACAGATCTGGTGAAA
    CCGAAGATGTTTTTATTGCTGATTTAGTTGTTGCTTTAAGAACCGGACAAATCAAAACAGGAGCACCATG
    CAGAAGTGAAAGAAACGCCAAATATAACCAATTATTAAGAATTGAAGAATCTTTAGGAAACAATGCTGTT
    TTTGCTGGAGAAAAATTTAGATTACAATTAAATTAAAAAATATAATAAAGTAAAATTTATATATTTATAT
    ATTTATATATTTCTTTATTTTATATATATATATATAATATATATAATTTATATGTTAAAAGAGAGAATTA
    TAATATAAAATGCATATAAAAAAATATGTTCTTTTGTAATATATATATATATATATATTTATATATTTAT
    GTGTGTATTTCTTTTATGCATGTATAAATTTTAATTAAGAGAAAGTAGGTATTAATTTTATATTTTGACC
    TTTTTTTTATAAACTTATAACAAAACATATGATTAAACTGTACAAGAAAAATATAACATTTTGCACAATA
    CTTATACATTTTACGTGCATATATATATATGTATATATTATATATTTACGTATGTCGAACGTTATTTTGA
    ACAACCTTTTGTGATAAATCTTTCATTTGTTTTAATAACCTTCGGAATATTTAATACTATCATACAATTA
    AAGAG
  • Protein Sequence : Show Sequence
    >gi|124802328|ref|XP_001347440.1| enolase [Plasmodium falciparum 3D7]
    MAHVITRINAREILDSRGNPTVEVDLETNLGIFRAAVPSGASTGIYEALELRDNDKSRYLGKGVQKAIKN
    INEIIAPKLIGMNCTEQKKIDNLMVEELDGSKNEWGWSKSKLGANAILAISMAVCRAGAAANKVSLYKYL
    AQLAGKKSDQMVLPVPCLNVINGGSHAGNKLSFQEFMIVPVGAPSFKEALRYGAEVYHTLKSEIKKKYGI
    DATNVGDEGGFAPNILNANEALDLLVTAIKSAGYEGKVKIAMDVAASEFYNSENKTYDLDFKTPNNDKSL
    VKTGAQLVDLYIDLVKKYPIVSIEDPFDQDDWENYAKLTAAIGKDVQIVGDDLLVTNPTRITKALEKNAC
    NALLLKVNQIGSITEAIEACLLSQKNNWGVMVSHRSGETEDVFIADLVVALRTGQIKTGAPCRSERNAKY
    NQLLRIEESLGNNAVFAGEKFRLQLN
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Mice immunized with r-Pfen (recombinant P. falciparum enolase protein) showed protection against a challenge with the 17XL lethal strain of the mouse malarial parasite Plasmodium yoelii (Pal-Bhowmick et al., 2007).
  • Related Vaccine(s): P. falciparum Pfen Protein Subunit Vaccine
31. pfCelTOS
  • Gene Name : pfCelTOS
  • NCBI Protein GI : 62954730
  • Other Database IDs : CDD:163532
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : PF cell-traversal protein
  • Protein Length : 182
  • Protein Note : lysine-2,3-aminomutase; TIGR03820
  • Protein Sequence : Show Sequence
    >gi|62954730|dbj|BAD97684.1| PF cell-traversal protein [Plasmodium falciparum]
    MNALRRLPVICSFLVFLVFSNVLCFRGNNGHNSSSSLYNGSQFIEQLNNSFTSAFLESQSMNKIGDDLAE
    TISNELVSVLQKNSPTFLESSFDIKSEVKKHAKSMLKELIKVGLPSFENLVAENVKPPKVDPATYGIIVP
    VLTSLFNKVETAVGAKVSDEIWNYNSPDVSESEESLSDDFFD
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Immunization with PfCelTOS resulted in potent humoral and cellular immune responses and most importantly induced sterile protection against a heterologous challenge with P. berghei sporozoites in a proportion of both inbred and outbred mice (Bergmann-Leitner et al., 2010).
  • Related Vaccine(s): P. falciparum pfCelTos protein vaccine
32. Pfs230
  • Gene Name : Pfs230
  • Gene Strand (Orientation) : ?
  • Protein Name : PFB0405w, transmission-blocking target antigen s230 precursor
  • Protein Note : PlasmoDB:PFB0405w; TGAD:PFB0405w
  • DNA Sequence : Show Sequence
    >PFB0405w |||transmission-blocking target antigen s230 precursor|Plasmodium falciparum|chr 2|TIGR||Manual
    ATGAAGAAAA TTATAACGCT GAAGAATCTA TTCCTCATTA TCCTGGTATA CATATTTAGC
    GAGAAAAAAG ACCTGCGTTG TAATGTGATA AAGGGAAATA ATATTAAGGA TGATGAAGAT
    AAGAGATTCC ACTTATTTTA TTATTCCCAC AACCTTTTTA AGACACCCGA AACAAAAGAA
    AAGAAGAATA AAAAGGAGTG CTTTTATAAA AATGGTGGTA TTTATAATTT ATCTAAAGAA
    ATAAGGATGA GAAAGGATAC ATCCGTAAAA ATAAAACAAA GAACATGTCC CTTTCATAAA
    GAAGGAAGTT CATTTGAAAT GGGTTCAAAG AATATTACAT GTTTTTATCC TATCGTAGGG
    AAGAAGGAAA GGAAAACACT GGACACAATT ATTATAAAAA AGAATGTAAC AAATGATCAT
    GTTGTTAGTA GTGATATGCA TTCCAATGTA CAAGAAAAAA ATATGATATT AATAAGAAAT
    ATAGATAAAG AAAATAAAAA TGATATACAA AATGTTGAGG AAAAAATACA AAGGGATACA
    TACGAAAATA AAGATTATGA AAGTGATGAT ACACTTATAG AATGGTTTGA TGATAATACA
    AATGAAGAAA ACTTTTTACT AACTTTTTTA AAAAGGTGCT TGATGAAAAT ATTTTCTTCA
    CCCAAAAGAA AAAAAACTGT AGTACAAAAA AAACATAAGT CTAATTTTTT TATAAACAGT
    TCGTTGAAAT ATATATATAT GTATTTAACC CCCTCGGATA GCTTTAACCT AGTACGTCGA
    AACAGAAATT TGGATGAGGA AGACATGTCG CCCAGGGATA ATTTTGTAAT AGATGATGAG
    GAAGAAGAGG AGGAGGAAGA AGAAGAGGAA GAGGAAGAAG AGGAAGAAGA AGAAGAAGAG
    GAGGAGGAAG AATATGATGA TTATGTTTAT GAAGAAAGTG GGGATGAAAC AGAAGAACAA
    TTACAAGAGG AACATCAGGA AGAAGTAGGT GCTGAATCTT CAGAAGAAAG TTTTAATGAT
    GAGGATGAAG ATTCTGTAGA AGCACGGGAT GGAGATATGA TAAGAGTTGA CGAATATTAT
    GAAGACCAAG ATGGTGATAC TTATGATAGT ACAATAAAAA ATGAAGATGT AGATGAAGAG
    GTAGGTGAAG AGGTAGGTGA AGAGGTAGGT GAAGAGGTAG GTGAAGAGGT AGGTGAAGAG
    GTAGGTGAAG AGGTAGGTGA AGAGGTAGGT GAAGAGGTAG GTGAAGAAGA AGGTGAAGAG
    GTAGGTGAAG GGGTAGGTGA AGAGGTAGGT GAAGAAGAAG GTGAAGAGGT AGGTGAAGAA
    GAAGGTGAAT ATGTAGATGA AAAAGAAAGG CAAGGTGAAA TATATCCATT TGGTGATGAA
    GAAGAAAAAG ATGAAGGTGG AGAAAGTTTT ACCTATGAAA AGAGCGAGGT TGATAAAACA
    GATTTGTTTA AATTTATAGA AGGGGGTGAA GGAGATGATG TATATAAAGT GGATGGTTCC
    AAAGTTTTAT TAGATGATGA TACAATTAGT AGAGTATCTA AAAAACATAC TGCACGAGAT
    GGTGAATATG GTGAATATGG TGAAGCTGTC GAAGATGGAG AAAATGTTAT AAAAATAATT
    AGAAGTGTGT TACAAAGTGG TGCATTACCA AGTGTAGGTG TTGATGAGTT AGATAAAATC
    GATTTGTCAT ATGAAACAAC AGAAAGTGGA GATACTGCTG TATCCGAAGA TTCATATGAT
    AAATATGCAT CTAATAATAC AAATAAAGAA TACGTTTGTG ATTTTACAGA TCAATTAAAA
    CCAACAGAAA GTGGTCCTAA AGTAAAAAAA TGTGAAGTAA AAGTTAATGA GCCATTAATA
    AAAGTAAAAA TAATATGTCC ATTAAAAGGT TCTGTAGAAA AATTATATGA TAATATAGAA
    TATGTACCTA AAAAAAGCCC ATATGTTGTT TTAACAAAAG AGGAAACTAA ACTAAAGGAA
    AAACTTCTCT CGAAACTTAT TTATGGTTTA TTAATATCTC CGACGGTTAA CGAAAAGGAG
    AATAATTTTA AAGAAGGTGT TATTGAATTT ACTCTTCCCC CTGTGGTACA CAAGGCAACA
    GTGTTTTATT TTATATGTGA TAATTCAAAA ACAGAAGATG ATAACAAAAA AGGAAATAGA
    GGGATTGTAG AAGTGTATGT AGAACCATAT GGTAATAAAA TTAATGGATG TGCTTTCTTG
    GATGAAGATG AAGAAGAAGA AAAATATGGT AATCAAATTG AAGAAGATGA ACATAATGAG
    AAGATAAAAA TGAAAACATT CTTTACCCAG AATATATATA AAAAAAATAA TATATATCCA
    TGTTATATGA AATTATATAG CGGAGATATA GGTGGTATTC TATTTCCTAA GAATATAAAA
    TCAACAACGT GTTTTGAAGA GATGATACCT TATAATAAAG AAATAAAATG GAATAAAGAA
    AATAAAAGTT TAGGTAACTT AGTTAATAAT TCTGTAGTAT ATAATAAAGA GATGAATGCA
    AAATATTTTA ATGTTCAGTA TGTTCACATT CCTACAAGTT ATAAAGATAC ATTAAATTTA
    TTTTGTAGTA TTATATTAAA AGAAGAGGAA AGTAATTTAA TTTCTACTTC TTATTTAGTA
    TATGTAAGTA TTAATGAAGA ATTAAATTTT TCACTTTTCG ATTTTTATGA ATCATTTGTA
    CCTATAAAAA AAACCATACA AGTAGCTCAA AAGAATGTAA ATAATAAAGA ACATGATTAT
    ACATGTGATT TTACCGATAA ATTAGATAAA ACGGTTCCTT CTACTGCTAA TGGGAAGAAA
    TTATTTATAT GTAGAAAGCA TTTAAAAGAA TTTGATACAT TTACCTTAAA ATGTAATGTT
    AATAAAACAC AATATCCAAA TATCGAGATA TTTCCTAAAA CATTAAAAGA TAAAAAGGAA
    GTATTAAAAT TAGATCTTGA TATACAATAT CAAATGTTTA GTAAATTTTT TAAATTCAAT
    ACACAGAATG CAAAGTATTT AAATTTATAT CCATATTATT TAATTTTTCC ATTTAATCAT
    ATAGGAAAAA AAGAATTAAA AAATAATCCT ACATATAAAA ATCATAAAGA TGTGAAATAT
    TTTGAGCAAT CATCTGTATT ATCTCCCTTA TCTTCCGCAG ACAGTTTAGG GAAATTATTA
    AATTTTTTAG ATACTCAAGA GACGGTATGT CTTACGGAAA AGATAAGATA TTTAAATTTA
    AGTATCAATG AGTTAGGATC TGATAATAAT ACATTTTCTG TAACATTTCA GGTTCCACCA
    TATATAGATA TTAAGGAACC TTTTTATTTT ATGTTTGGTT GTAATAATAA TAAAGGTGAA
    GGGAATATCG GAATTGTTGA ATTATTAATA TCTAAGCAAG AAGAAAAGAT TAAAGGATGT
    AATTTCCATG AATCTAAATT AGATTATTTC AATGAAAACA TTTCTAGTGA TACACATGAA
    TGTACATTGC ATGCATATGA AAATGATATA ATTGGATTTA ATTGTTTAGA AACTACTCAT
    CCTAATGAGG TTGAGGTTGA AGTTGAAGAT GCTGAAATAT ATCTTCAACC TGAGAATTGT
    TTTAATAATG TATATAAAGG ATTGAATTCT GTTGATATTA CTACTATATT AAAAAATGCA
    CAAACATATA ATATAAATAA TAAGAAAACA CCTACCTTTT TAAAAATTCC ACCATATAAT
    TTATTAGAAG ATGTCGAAAT TAGTTGCCAA TGTACTATTA AACAAGTTGT TAAAAAAATA
    AAAGTTATTA TAACCAAAAA TGATACAGTA TTATTAAAAA GAGAAGTGCA ATCTGAGTCT
    ACATTAGATG ATAAAATATA TAAATGTGAA CATGAAAATT TTATTAATCC AAGAGTAAAT
    AAAACATTTG ATGAAAATGT AGAATATACA TGTAATATAA AAATAGAGAA TTTCTTTAAT
    TATATTCAAA TATTTTGTCC AGCCAAAGAT CTTGGTATTT ATAAAAATAT ACAAATGTAT
    TATGATATTG TAAAACCAAC AAGAGTACCA CAATTTAAAA AATTTAATAA TGAAGAATTA
    CATAAATTAA TTCCTAATTC AGAAATGTTA CATAAAACAA AAGAAATGTT AATTTTATAT
    AATGAAGAAA AAGTGGATCT ATTACATTTT TATGTATTCT TACCAATATA TATAAAAGAC
    ATATATGAAT TCAATATAGT ATGTGATAAT TCAAAAACAA TGTGGAAAAA TCAATTAGGA
    GGAAAAGTTA TATATCATAT TACTGTTTCA AAAAGAGAGC AGAAAGTAAA AGGTTGTTCA
    TTTGATAATG AACATGCACA TATGTTTAGT TATAATAAAA CTAATGTAAA AAATTGTATT
    ATAGATGCTA AACCTAAAGA TTTGATAGGT TTCGTTTGTC CCTCTGGTAC CTTAAAATTA
    ACAAATTGTT TTAAAGATGC AATAGTACAT ACAAATTTAA CAAATATTAA TGGTATACTT
    TATTTAAAAA ATAATTTGGC TAACTTTACA TATAAACATC AATTTAATTA TATGGAAATA
    CCAGCTTTAA TGGATAATGA TATATCATTT AAATGTATAT GTGTTGATTT AAAAAAAAAA
    AAATATAATG TCAAATCACC ATTAGGACCT AAAGTTTTAC GTGCTCTTTA TAAAAAATTA
    AATATAAAAT TTGATAATTA TGTTACTGGC ACTGATCAAA ATAAATATCT TATGACATAT
    ATGGATTTAC ATTTATCTCA TAAACGTAAT TATTTAAAGG AATTATTTCA TGATTTAGGT
    AAAAAAAAAC CAGCAGATAC AGATGCTAAC CCTGAATCTA TTATCGAATC TTTAAGTATT
    AATGAATCTA ATGAATCTGG ACCTTTTCCA ACCGGGGATG TAGATGCAGA ACATTTAATA
    TTAGAAGGAT ATGATACATG GGAAAGTTTA TATGATGAAC AATTAGAAGA AGTTATATAT
    AATGATATTG AATCTTTAGA ATTAAAAGAT ATTGAACAAT ATGTTTTACA AGTTAATTTA
    AAAGCTCCAA AATTAATGAT GTCTGCTCAA ATTCATAATA ATAGACATGT ATGTGATTTC
    TCAAAAAATA ATTTAATTGT ACCAGAATCA TTAAAAAAAA AAGAAGAGCT TGGTGGTAAT
    CCAGTAAATA TTCATTGTTA TGCATTATTA AAACCTTTAG ATACATTATA TGTAAAATGT
    CCTACATCAA AAGATAATTA TGAAGCTGCT AAAGTAAACA TATCTGAAAA CGACAATGAA
    TATGAGTTAC AAGTTATATC ATTAATCGAA AAAAGATTTC ATAATTTTGA GACGTTAGAA
    TCGAAGAAAC CTGGAAATGG AGATGTAGTA GTACATAATG GTGTTGTAGA TACTGGACCT
    GTATTAGATA ACAGTACATT TGAAAAATAT TTTAAAAATA TAAAAATAAA ACCAGATAAA
    TTTTTTGAGA AAGTTATAAA TGAATATGAT GATACTGAAG AAGAAAAAGA TTTAGAAAGT
    ATATTACCTG GGGCTATTGT TAGTCCTATG AAAGTTTTAA AAAAAAAGGA TCCTTTTACA
    TCATATGCTG CTTTTGTTGT TCCACCAATT GTTCCCAAAG ATTTACATTT TAAAGTAGAA
    TGTAATAATA CAGAATATAA AGATGAAAAT CAATATATAA GTGGATATAA TGGTATAATA
    CATATTGATA TATCAAATAG TAATAGGAAA ATTAATGGAT GTGATTTCTC TACGAACAAT
    AGTTCTATTT TAACATCCAG TGTAAAATTA GTAAATGGAG AAACTAAAAA TTGTGAAATA
    AATATAAATA ATAATGAAGT ATTTGGTATC ATATGTGATA ATGAAACAAA TTTAGATCCA
    GAAAAATGTT TTCATGAAAT ATATAGTAAA GATAATAAAA CTGTAAAAAA ATTTCGTGAA
    GTTATACCTA ATATAGATAT ATTCTCATTA CATAATTCTA ATAAGAAAAA AGTTGCATAT
    GCTAAAGTAC CTTTAGATTA TATTAATAAA TTATTATTTT CTTGTTCATG TAAAACATCA
    CATACTAATA CAATAGGTAC CATGAAAGTT ACTCTAAATA AAGATGAAAA AGAAGAAGAA
    GATTTTAAAA CAGCTCAAGG TATTAAACAT AATAATGTAC ATTTATGTAA TTTCTTTGAT
    AATCCTGAAT TAACATTTGA TAATAATAAA ATAGTTTTAT GTAAAATCGA TGCAGAACTG
    TTCTCAGAAG TAATTATACA ATTACCAATA TTTGGAACAA AGAATGTAGA AGAAGGAGTA
    CAAAATGAAG AATATAAAAA ATTTTCATTA AAACCATCAT TAGTTTTTGA TGATAACAAT
    AATGATATTA AAGTTATAGG AAAAGAAAAA AATGAAGTAT CTATTAGTTT AGCTTTGAAA
    GGGGTTTATG GAAATCGAAT TTTTACTTTT GATAAAAATG GAAAAAAAGG AGAAGGAATT
    AGTTTTTTTA TACCTCCAAT AAAACAAGAT ACAGATTTAA AATTTATAAT TAATGAAACA
    ATAGATAATT CAAATATTAA ACAAAGAGGA TTAATATATA TTTTTGTTAG GAAAAATGTA
    TCAGAAAATT CATTTAAATT ATGTGATTTC ACAACAGGTT CGACTTCATT AATGGAATTA
    AATAGTCAAG TAAAAGAAAA AAAGTGCACT GTTAAAATTA AAAAAGGAGA TATTTTTGGA
    TTGAAATGTC CTAAAGGTTT TGCTATATTT CCACAAGCAT GTTTTAGTAA TGTTTTATTA
    GAATATTATA AAAGTGATTA TGAAGATAGT GAACATATTA ATTATTATAT TCATAAAGAT
    AAAAAATATA ATTTAAAACC TAAAGATGTT ATTGAATTAA TGGATGAAAA TTTTAGAGAA
    TTACAAAATA TACAACAATA TACAGGAATA TCAAATATTA CAGATGTGTT ACATTTCAAA
    AATTTTAATT TAGGTAATCT ACCATTAAAT TTTAAAAATC ATTATTCTAC AGCATATGCT
    AAAGTACCAG ATACCTTTAA TTCTATTATT AACTTCTCAT GTAATTGTTA TAATCCAGAA
    AAACATGTAT ATGGTACTAT GCAAGTTGAG TCTGATAATC GAAATTTTGA TAATATTAAA
    AAAAATGAAA ATGTTATAAA AAATTTCCTT TTACCTAATA TAGAAAAATA TGCACTACTA
    TTAGATGATG AAGAAAGACA AAAAAAAATA AAACAACAAC AAGAAGAAGA ACAACAAGAA
    CAAATATTAA AAGATCAAGA TGATAGATTA AGCAGACATG ATGATTATAA TAAAAATCAT
    ACATATATAC TATATGATTC AAATGAACAT ATATGTGATT ATGAAAAAAA TGAATCACTC
    ATATCAACAT TACCTAATGA TACAAAAAAA ATACAAAAAA GTATCTGTAA AATTAATGCA
    AAAGCATTAG ATGTTGTTAC AATTAAATGT CCTCATACAA AAAATTTTAC GCCTAAAGAT
    TATTTTCCTA ATTCTTCATT AATAACTAAT GATAAAAAAA TTGTGATTAC TTTTGATAAG
    AAAAATTTTG TTACTTATAT AGATCCTACA AAAAAAACAT TTTCTTTGAA AGATATATAT
    ATACAAAGTT TTTATGGTGT TTCTCTTGAT CATCTTAATC AAATAAAAAA AATACATGAA
    GAATGGGATG ATGTACATTT ATTTTATCCT CCTCATAATG TATTACATAA TGTTGTACTT
    AATAATCATA TAGTCAACTT ATCATCTGCA TTAGAAGGAG TCTTATTTAT GAAATCAAAA
    GTTACTGGAG ATGAAACAGC TACAAAAAAA AACACTACAC TACCAACTGA TGGTGTATCA
    AGTATTTTAA TTCCACCATA TGTAAAGGAA GATATAACAT TTCATCTTTT TTGTGGGAAA
    TCTACAACAA AAAAACCAAA CAAAAAGAAC ACATCTCTTG CACTTATTCA TATACATATA
    TCATCAAACA GAAATATTAT TCATGGATGT GATTTCTTAT ATTTAGAAAA TCAAACAAAT
    GATGCTATTA GTAATAATAA TAATAATTCA TATTCTATAT TTACACATAA TAAAAATACA
    GAGAATAATC TAATATGTGA TATATCTTTA ATTCCAAAAA CTGTTATAGG AATTAAATGT
    CCTAATAAAA AATTAAATCC ACAAACATGT TTTGATGAAG TGTATTATGT TAAACAAGAA
    GATGTACCTT CGAAAACTAT AACAGCTGAT AAATATAATA CATTTAGTAA AGACAAAATA
    GGAAATATAT TAAAAAATGC AATCTCTATT AATAATCCAG ATGAAAAGGA TAATACATAT
    ACTTATTTAA TATTACCAGA AAAATTTGAA GAAGAATTAA TCGATACCAA AAAAGTTTTA
    GCTTGTACAT GTGATAATAA ATATATAATA CATATGAAAA TAGAAAAAAG TACAATGGAT
    AAAATAAAAA TAGATGAAAA AAAAACAATT GGTAAAGATA TATGTAAATA TGATGTTACT
    ACTAAAGTTG CTACTTGTGA AATTATTGAT ACAATTGATT CGTCTGTATT AAAAGAACAT
    CATACAGTAC ATTATTCTAT TACATTATCA AGATGGGATA AACTTATTAT TAAATATCCA
    ACAAATGAGA AAACACATTT CGAAAATTTT TTTGTTAATC CTTTTAATTT AAAAGATAAA
    GTTTTATATA ATTATAATAA ACCAATAAAT ATAGAACATA TCTTACCAGG AGCCATTACA
    ACAGATATAT ATGATACCAG AACAAAAATT AAACAATATA TATTAAGAAT TCCACCATAT
    GTACATAAAG ATATACATTT CTCATTAGAA TTTAACAATA GCCTAAGTTT AACAAAACAA
    AATCAAAATA TTATTTATGG AAATGTAGCC AAAATTTTTA TTCATATAAA TCAAGGATAT
    AAAGAAATTC ATGGATGTGA TTTCACAGGA AAATATTCCC ATTTATTTAC ATATTCAAAA
    AAACCTTTAC CAAATGATGA TGATATATGT AATGTAACTA TAGGTAATAA TACATTCTCA
    GGTTTTGCAT GCTTAAGCCA TTTTGAATTA AAACCAAATA ACTGCTTCTC ATCTGTTTAT
    GATTATAATG AAGCCAATAA AGTTAAAAAA TTATTCGATC TATCCACAAA AGTAGAATTA
    GACCATATCA AACAAAATAC TTCAGGATAT ACACTATCAT ATATTATTTT TAATAAAGAA
    TCCACAAAAC TTAAATTCTC ATGTACATGC TCATCCAACT ATTCAAATTA TACTATACGA
    ATCACATTTG ATCCTAATTA TATAATCCCA GAACCTCAAT CAAGAGCCAT CATTAAATAT
    GTAGATCTGC AAGATAAAAA TTTTGCAAAA TACTTGAGAA AGCTTTAA
  • Protein Sequence : Show Sequence
    >PFB0405w |||transmission-blocking target antigen s230 precursor|Plasmodium falciparum|chr 2|TIGR||Manual
    MKKIITLKNL FLIILVYIFS EKKDLRCNVI KGNNIKDDED KRFHLFYYSH NLFKTPETKE
    KKNKKECFYK NGGIYNLSKE IRMRKDTSVK IKQRTCPFHK EGSSFEMGSK NITCFYPIVG
    KKERKTLDTI IIKKNVTNDH VVSSDMHSNV QEKNMILIRN IDKENKNDIQ NVEEKIQRDT
    YENKDYESDD TLIEWFDDNT NEENFLLTFL KRCLMKIFSS PKRKKTVVQK KHKSNFFINS
    SLKYIYMYLT PSDSFNLVRR NRNLDEEDMS PRDNFVIDDE EEEEEEEEEE EEEEEEEEEE
    EEEEYDDYVY EESGDETEEQ LQEEHQEEVG AESSEESFND EDEDSVEARD GDMIRVDEYY
    EDQDGDTYDS TIKNEDVDEE VGEEVGEEVG EEVGEEVGEE VGEEVGEEVG EEVGEEEGEE
    VGEGVGEEVG EEEGEEVGEE EGEYVDEKER QGEIYPFGDE EEKDEGGESF TYEKSEVDKT
    DLFKFIEGGE GDDVYKVDGS KVLLDDDTIS RVSKKHTARD GEYGEYGEAV EDGENVIKII
    RSVLQSGALP SVGVDELDKI DLSYETTESG DTAVSEDSYD KYASNNTNKE YVCDFTDQLK
    PTESGPKVKK CEVKVNEPLI KVKIICPLKG SVEKLYDNIE YVPKKSPYVV LTKEETKLKE
    KLLSKLIYGL LISPTVNEKE NNFKEGVIEF TLPPVVHKAT VFYFICDNSK TEDDNKKGNR
    GIVEVYVEPY GNKINGCAFL DEDEEEEKYG NQIEEDEHNE KIKMKTFFTQ NIYKKNNIYP
    CYMKLYSGDI GGILFPKNIK STTCFEEMIP YNKEIKWNKE NKSLGNLVNN SVVYNKEMNA
    KYFNVQYVHI PTSYKDTLNL FCSIILKEEE SNLISTSYLV YVSINEELNF SLFDFYESFV
    PIKKTIQVAQ KNVNNKEHDY TCDFTDKLDK TVPSTANGKK LFICRKHLKE FDTFTLKCNV
    NKTQYPNIEI FPKTLKDKKE VLKLDLDIQY QMFSKFFKFN TQNAKYLNLY PYYLIFPFNH
    IGKKELKNNP TYKNHKDVKY FEQSSVLSPL SSADSLGKLL NFLDTQETVC LTEKIRYLNL
    SINELGSDNN TFSVTFQVPP YIDIKEPFYF MFGCNNNKGE GNIGIVELLI SKQEEKIKGC
    NFHESKLDYF NENISSDTHE CTLHAYENDI IGFNCLETTH PNEVEVEVED AEIYLQPENC
    FNNVYKGLNS VDITTILKNA QTYNINNKKT PTFLKIPPYN LLEDVEISCQ CTIKQVVKKI
    KVIITKNDTV LLKREVQSES TLDDKIYKCE HENFINPRVN KTFDENVEYT CNIKIENFFN
    YIQIFCPAKD LGIYKNIQMY YDIVKPTRVP QFKKFNNEEL HKLIPNSEML HKTKEMLILY
    NEEKVDLLHF YVFLPIYIKD IYEFNIVCDN SKTMWKNQLG GKVIYHITVS KREQKVKGCS
    FDNEHAHMFS YNKTNVKNCI IDAKPKDLIG FVCPSGTLKL TNCFKDAIVH TNLTNINGIL
    YLKNNLANFT YKHQFNYMEI PALMDNDISF KCICVDLKKK KYNVKSPLGP KVLRALYKKL
    NIKFDNYVTG TDQNKYLMTY MDLHLSHKRN YLKELFHDLG KKKPADTDAN PESIIESLSI
    NESNESGPFP TGDVDAEHLI LEGYDTWESL YDEQLEEVIY NDIESLELKD IEQYVLQVNL
    KAPKLMMSAQ IHNNRHVCDF SKNNLIVPES LKKKEELGGN PVNIHCYALL KPLDTLYVKC
    PTSKDNYEAA KVNISENDNE YELQVISLIE KRFHNFETLE SKKPGNGDVV VHNGVVDTGP
    VLDNSTFEKY FKNIKIKPDK FFEKVINEYD DTEEEKDLES ILPGAIVSPM KVLKKKDPFT
    SYAAFVVPPI VPKDLHFKVE CNNTEYKDEN QYISGYNGII HIDISNSNRK INGCDFSTNN
    SSILTSSVKL VNGETKNCEI NINNNEVFGI ICDNETNLDP EKCFHEIYSK DNKTVKKFRE
    VIPNIDIFSL HNSNKKKVAY AKVPLDYINK LLFSCSCKTS HTNTIGTMKV TLNKDEKEEE
    DFKTAQGIKH NNVHLCNFFD NPELTFDNNK IVLCKIDAEL FSEVIIQLPI FGTKNVEEGV
    QNEEYKKFSL KPSLVFDDNN NDIKVIGKEK NEVSISLALK GVYGNRIFTF DKNGKKGEGI
    SFFIPPIKQD TDLKFIINET IDNSNIKQRG LIYIFVRKNV SENSFKLCDF TTGSTSLMEL
    NSQVKEKKCT VKIKKGDIFG LKCPKGFAIF PQACFSNVLL EYYKSDYEDS EHINYYIHKD
    KKYNLKPKDV IELMDENFRE LQNIQQYTGI SNITDVLHFK NFNLGNLPLN FKNHYSTAYA
    KVPDTFNSII NFSCNCYNPE KHVYGTMQVE SDNRNFDNIK KNENVIKNFL LPNIEKYALL
    LDDEERQKKI KQQQEEEQQE QILKDQDDRL SRHDDYNKNH TYILYDSNEH ICDYEKNESL
    ISTLPNDTKK IQKSICKINA KALDVVTIKC PHTKNFTPKD YFPNSSLITN DKKIVITFDK
    KNFVTYIDPT KKTFSLKDIY IQSFYGVSLD HLNQIKKIHE EWDDVHLFYP PHNVLHNVVL
    NNHIVNLSSA LEGVLFMKSK VTGDETATKK NTTLPTDGVS SILIPPYVKE DITFHLFCGK
    STTKKPNKKN TSLALIHIHI SSNRNIIHGC DFLYLENQTN DAISNNNNNS YSIFTHNKNT
    ENNLICDISL IPKTVIGIKC PNKKLNPQTC FDEVYYVKQE DVPSKTITAD KYNTFSKDKI
    GNILKNAISI NNPDEKDNTY TYLILPEKFE EELIDTKKVL ACTCDNKYII HMKIEKSTMD
    KIKIDEKKTI GKDICKYDVT TKVATCEIID TIDSSVLKEH HTVHYSITLS RWDKLIIKYP
    TNEKTHFENF FVNPFNLKDK VLYNYNKPIN IEHILPGAIT TDIYDTRTKI KQYILRIPPY
    VHKDIHFSLE FNNSLSLTKQ NQNIIYGNVA KIFIHINQGY KEIHGCDFTG KYSHLFTYSK
    KPLPNDDDIC NVTIGNNTFS GFACLSHFEL KPNNCFSSVY DYNEANKVKK LFDLSTKVEL
    DHIKQNTSGY TLSYIIFNKE STKLKFSCTC SSNYSNYTIR ITFDPNYIIP EPQSRAIIKY
    VDLQDKNFAK YLRKL
33. Pvs25
  • Gene Name : Pvs25
  • Sequence Strain (Species/Organism) : P. vivax SouthernMex-62 isolate
  • VO ID : VO_0010957
  • 3D structure: PDB ID : 1Z27
  • Other Database IDs : EU024472.1; GI:154184258
  • Taxonomy ID : 5855
  • Gene Strand (Orientation) : ?
  • DNA Sequence : Show Sequence
    >gi|154184258:1-660 Plasmodium vivax isolate SouthernMex-62 ookinete surface protein (Pvs25) gene, complete cds
    ATGAACTCCTACTACAGCCTCTTCGTTTTTTTCCTCGTCCAAATTGCGCTAAAGTATAGCAAGGCAGCCG
    TCACGGTAGACACCATATGCAAAAATGGACAGCTGGTTCAAATGAGTAACCACTTTAAGTGTATGTGTAA
    CGAAGGGCTGGTGCACCTTTCCGAAAATACATGTGAAGAAAAAAATGAATGCAAGAAAGAAACCCTAGGC
    AAAGCATGCGGGGAATTTGGCCAGTGTATAGAAAACCCAGACCCAGCAAAGGTAAACATGTACAAATGTG
    GTTGCATTGAGGGCTACACTTTGAAGGAAGACACTTGTGTGCTTGATGTATGTCAATACAAAAATTGTGG
    AGAAAGTGGCGAATGCATTGTTGAGTACCTCTCGGAAACCCAAAGTGCAGGTTGCTCATGTGCTATTGGC
    AAAGTCCCCAATCCAGAAGATGAGAAAAAATGTACCAAAACGGGAGAAACTGCTTGTCAATTGAAATGTA
    ACACAGATAATGAAGTCTGCAAAAATGTTGAAGGAGTTTACAAGTGCCAGTGTATGGAAGGCTTTACGTT
    CGACAAAGAGAAAAATGTATGCCTTTCCTATTCTGTATTTAACATCCTAAACTACTCCCTCTTCTTTATC
    ATCCTGCTTGTCCTTTCGTACGTCATATAA
  • Protein Sequence : Show Sequence
    >gi|154184259|gb|ABS70957.1| ookinete surface protein [Plasmodium vivax]
    MNSYYSLFVFFLVQIALKYSKAAVTVDTICKNGQLVQMSNHFKCMCNEGLVHLSENTCEEKNECKKETLG
    KACGEFGQCIENPDPAKVNMYKCGCIEGYTLKEDTCVLDVCQYKNCGESGECIVEYLSETQSAGCSCAIG
    KVPNPEDEKKCTKTGETACQLKCNTDNEVCKNVEGVYKCQCMEGFTFDKEKNVCLSYSVFNILNYSLFFI
    ILLVLSYVI
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. vivax PVS25 with Montanide ISA-720
34. PY01338
  • Gene Name : PY01338
  • NCBI Nucleotide GI : 23485916
  • NCBI Protein GI : 23485917
  • Protein Accession : EAA20641.1
  • Taxonomy ID : 73239
  • Gene Strand (Orientation) : ?
  • Protein Name : hypothetical protein
  • DNA Sequence : Show Sequence
    >gi|23485916|gb|AABL01000353.1| Plasmodium yoelii yoelii 17XNL contig MALPY00354, whole genome shotgun sequence
    AATATATTAATTAACTATCTTAATATTTTATTATGTAAATCTGTGAAGTTGTGGCAAAAAAAAATGAAAA
    ATTATTATAGATTAATTTAAATGCATAAAGAACGTTCCCAGTTATTTTATTTTTTATATGATCCTTTACA
    ACAGATAATAAATATAATATTATTTTTGAGTCGATATTATTAGGGTTATTTAGAATACCATTTTTATTTA
    TAGTAGAATTGAATATATCTTTGATTTCTATTACAATTGAATTGGGTGCTATATTTTTAATTTTTTTATA
    AGAATAGCACTCAACCCATTCTTTGCTTGAAATATCTAATTGAGGATTTATTTTTATGATATCTTCGGCA
    TTTCGTGTTTTGTTTTCGATGTTTCGTTTTGATTGTTCATTATTATTTAGTAAATAATTTAAATTTTTAA
    TGTAATCACCCTTTTTATTATTTATTTCAATTCCCCTTTCCTTGTTCACATTTGTATTCGAAGAAATGAA
    CCAAGGATCAAAGTCATATTCATATTTTACATATATGTTTAAGAATAAGTGATACAATTTATCCTTTGAA
    TTTCTCACTGACTCTGTTTTATCCATATTGTCTATTTTTTCGACATTTTGGTCATTACTTTCATCTCTAT
    CGTTTTCAATTTTTTTAATATCTTCGTTTTCCCCTCTATAATTAAATTCCTTTTGTGTATCTATAGATTT
    CGTCATATAATTTTTGCATGATTGACTATCCAATTTTTCATGGTGAATATTTTCAGGTATGATAATTTCT
    CTATTATTCTTCGCTACATTTTTATTGATTTTTTTTTTCTTTTTTCCCCCAATTTGACTTATCTCTTCTT
    CTTGACTATCAAAATTGGAGTAATCAAAAAAGTTGTTTTTTTCGATTAAATTATTTAGGTATACAAAATA
    TTTGTTAAGAAAAGTTGAAGACACTAGATTAATCGAGTTAAATAAAAAGAAGTTCATATTTTTACATATA
    AAACCTAAATACCTAATAATACAACAAATGGCTCGATCTTTTTCTACCTTCCTATTTCCTCTTATAATTA
    ACAATAATATGTAAATATATTCAATATAAGAAATTAAATAAATGCTGGTTGAAAAATCATCATGTTTGTT
    GTCTCGAGGATTTTGAATATTTTTTAATTTGGTATCTATACATATACTCCGGGAATTTTTTTTTTGTTCT
    ATGCAACTATTGTTCTCAATCCTCTCATTTTTTGAATTAGACAAATTATATATTCTTTCAATGCCACTTT
    CATTACTAGAAAATTTTTCGGTTCCTATAAATGTGGAAATCGATGATCCAGGAATCTCCGAATATTCATT
    TTCTTCATATGTTTTTGTAGCCGATTTTGGCGACTGAATAAACTCAAGTTTGGAAGCTTGGGTATGGTGA
    TCATTTTCATTATCTGAATTATACGTTTTTTTGAGTATTTTTTTACTCTTTAATTTTTTTTCCTTTTTTT
    TGTTATTAAAATTATATAATTTTAAATCATTTACATTTGTAGATATGTTAATATTGTTTATAAAACTTAT
    AAATTCGTTAATATCTTTATTTTCTTCACTATTGTGATTACTATAATAAGAAAAGCTTTTTATATTATTT
    TGGGTAAAATAAAAAGGAATGTATGAGCTCGCGATCTCACATATACAGTTATATATATAGTATTTTAAAT
    CTACAAAAGACTCATTGTAAAATTTTATTATGTGAATAATAATATAAATATATATATAATATAATTCAAA
    TAATTTTTTTTCGTTTTTCTGTTTCCTTAACATGTAAATACTATTATTAAGTGTGTTATTGTCTTCTTTG
    GGGTTAATTTGAGAGTTTTCTAGTTTACTATTGTTATAATGGTTTTCGTTTTCTATATTGTCATTATTTT
    TTCTATCATCAGTAGATTGATGTGATATATTATCTAAACTTCCTGTGTGCTCTTTTTCGTACATTAAAAT
    ATCATTACTATGTTTTATATTAATTTTACTGATGTATTTATTTGTATTAGCTTCCATTTTTTTTAATTTA
    TCGTTTTTGAAATAATCATTGCTATTATCACTTTCTTTTTGTGATATAGTTTGATAATTATCAAATTTAA
    TAAATCTATTTGTGTTCATATTTTTAAATGAATCTTTATCACTTGTTTCTTTTTTTGTCTCATTATCTGC
    ATTAAAATCGGTAAAATATTGTTCTTCATTGTTTATATTTTCTATTTCTTGTTTTCTATTATGAACGATA
    CTATTACATATGCTAGTATCATTATTGTCATTCCTATAATTATCTACCTCGATTTGTCTATTTTTACAAA
    AAGGTTTGTCAGAAGAATGATTTCGACTACTCTTATTCATATTTTGTAAGCATTGTTGAGATTTATCAGA
    AAGAGTATTATTAAGTGTAGAAATATGATTAGACAAATTGTTTTTTTGAAAAAACTCATTAGAATTTGGT
    GAAACTAAAAATGGAGAAGCACGACTATTTTCATGAATATCTTGTTCAATTCCGTAGTACTTTTCTTGTT
    TATTTTGTGAAGAATTTAAGAAAGAACATTTTTTAAAGTTGCTTATTTGATCTGTTTTCAACATATTCAT
    ATAATTATTATTTCTACTTGTTTCATTTTGACGGGATTCATTAGTTTGTATATTAGAACCAGAAGGCGAA
    ATGGAATTTTCATCGAGTAGAATGTCAATATTGAAGTTATTTTTTGTTACGTGAAAATTATTTTGGGTAG
    AAAGAATATTATTATAATATACATTTGCTGAATTTATATGTAAGAGATTAATTTTTTTTTCATACATTTG
    TATAAATTTTTTATTAAAGGTAAATATATATTTAATAATATATTTACTGAGTGTAGTAATTATATTGCAT
    TTGATATTATTCACACAAGACGAAATTAAATTAGTTAATTTTTGTATATCTTCAATTTTTAAAACTTTAA
    AACCTTCATAACTTAGTTGAGATATACATATAATTGTATTAAAGAATACATGCTTTATTTTATTTCTTTT
    ATTAATTGTATCATTATCTATTTTATTTATGCTGTGTATATGCATTAATATATATTTTCTAAACAAATAT
    ATCATATCTCTTTCTACTAGTTTCATAAATTTGTTTTTTTGATAATTTTTGTAATTTTCTTGGCATTTCG
    AATTGTTAATATGATTGCTATTATTTTCTCTTTGTTTATTCATGTTTCCATCCTTCTCACGCTTGTCAAA
    ATGAATACCATTTTTTTTATCGTTACTATTTTTATATATTTGTTGATTTCCCCTTTTAATATTTGTAAAA
    TTGTATAAATCACTTTTTGAGGTTTTAAACTCATTTATTGTATCAGAATAATTTTTTCTTTCCTCATCCG
    GTTGTGCAGAACCATTCAAATGATTGTTTTTTATTTTTTTCATCTTTTTTCCTTCTTGTGAACTTCCACC
    GATATTAGTTTGTTCTGAAACATCACCATTGGTGAATATAGAACTGTTTTTAGCATTGTCTTTTGCTTTT
    AAAACTGAAAGTTCGGATTCATCACTATTATTATTATCAATAGTCTTATCTTCGTAGTAGGCGTTTATAA
    AAGTAAAAATATCAATCACTATTTTAATAGAAATTATTTTTATATTTATATTTTCTGATTGCAAAAAATA
    TTCCAACAAGGTTTTTACATCGTTCCAGCAATGCATGTAACAAAATAAATAATATTTCAACGTCTTTTGA
    AAAACTACAAACATATTTTTAAATATTTGCATATCATAAGGTATCAAATTATATTTATCAAATATATTTA
    CGTTTTTATTCTTGTTAAATTCTCTTTGTGTATATGATGTGATGTACTTGTTGAAAAGTTCAGTATATGA
    ATTGTTGATAGAAGTTTTTTTGTCGTTAAGGTAATTATTTTTGTTACTACAAATTTCCATATTATTGTAA
    CTCTCGATATTATTATAGATTGTTTTGTTATCAAAATTAGTATTGTAGTCATTATTTATTATCCCGTTCT
    TCTGACCCGTTTCATATTTGATATTTGTGCTAAACTGGTTATTATTTATCACACCACAATTTTTATTGTT
    ATAATCGTCCTCATTTTGAAGATTCCCTTTTATAACATGATTAAAAGTGTCATTAATATTGTAAGTTGAA
    GTATTACCTATATTGGTTATTAAATTATTCTTTACCTCATCACATGTCTGATAAAATATTTTATATAAAA
    ATATAAGCATGAAATATATCAATTGCACAAAGGAGATGTTGTACAAATAATTTTGAGTAGAATTTTCACA
    AAATATATTTCGATTGTTTAAGGTTTTATTTATATTTTTTCTGTAAATATTGGTGCATAAAAAATTATAT
    ATATCATCATTATATTCACATAACAAAACTGAAAAAATGTTTATAATAACAGTTATTGTACATATATATT
    TTGAATTCTTTGAATATTCATTGCAATATAATACTCGTATTAACAGTTCATAAGTTTTTTTGCATAAAAG
    CTTTCTATTTATTTTGTTAATATTTTTATACAAATAAGATATTTCGTTTTCATTTTTGTTCATTTGTATA
    TTTGGTTTCATTTCGTCATTTTGGAATATTTGAAAAAATTCCTTATTTTTATTTTTTCTTCTTTTTTCTG
    TTTTTTTATCAGAATATATCGAAATGATGTCTTCTTCTATATGCTCCCTTTTCATTCCACATTTACTTTC
    ATCGCTTTTATGGTCTTTGATATTGCAAATCATTTCGTCATCATTAAAATCGTTAGTATTTTGGACCCTA
    TCATAGAAACTTCTGAAATATTGGATATTCCCATTATGTGTTTCGGTATTTTCCATATTTTCAATAATAT
    CCAAATTATTGCCTTTATAAACATCATGTTTGCCGATTTTGTGATTATCTATATCGAGATGTTTTGTTTT
    TATTTTTTCATCAATTGTATTTTTCATCGATTCTTTATCTTTGAATTTGTTATTAATTTTTTCCTTTTTA
    TAATTAAAGTATGTTTCGTTTTCAATATCTTCTTGTAAAAATTGTTTTGTATCTATTTCTACATCTTTAT
    ATTTTATTTTATTTATTGTTTTATTCCCATAAGAATTATCATTATGTTCACTATTATACAAGAGACATTT
    TAAATTGTTTTTCAATTCTTTTTCATGATAAGAATATGATTTCTCAGCATCTTTTATTATATAAATGTTA
    TCTTCTTCATATCTCTCCATTTGTTTGAAACATCCTGAACTATTATTTAGCGTTTTAAATAAGTGTTCTT
    CACCTATATAATCATTTTCTACGATTTGAGCTGAGATGTCAGAAGTATTTTGAATGAATGATTGTGTTTT
    GCGAATATTTTGAGAATTGTGCTCATCTATGATATAAAGAAAATTGTTTGAAAGAGTGTGAGTTTTTTTT
    TTATTTTTTTTTATTTCTCCATTATTTATAGATTGGTCATTATTTAAAAATGTCAACTCATTATCGCTGT
    TATTATGTAATATATGTTGTTTTTTATTTTTTAAATTATTTTTATTTTGAACTACTTTTTTCCCACAAAA
    TGGTAACATATCTCCATTATTAAAATATATAAGATATTTTAATAAATAGAAAAAAGATATTTTTAAAATT
    TTCATTAATAAGTTTTTATATTTTTTTAATAACATAGATTGTGAAACTCGCAAAAAAAATCGATAAATAT
    TTAATCTGTCTATTGGTGTATAGAAATTATCTTCATTATTTAATAAGTACGTTTTATTTATTAATTTAAT
    TAAGTGAGATAATATTTTTATAATATTATCTTCTATAATTAATTTTTTATAATTTATATTGCCATTTTTG
    TAATCTGTTTCTCCATGTGTTTGTATAGAATAATCCAAATTTTTATTCCCTTTGTTCATATTTGTATGTG
    TCGATCCTTTTTTATGTATTTTATTTTGTTCATTTTGTTTTTCTAAGGATTTTTGATAATTTGAGTTAAT
    TTCTTCAATGATTTTTCCACGGGCATAAATGTCTTTATCATTTTCGTTGTCTAGTTTTTTATTTATGATA
    CATTCACTGCTCTCACTATTGTTATCATTTACAATATTTTTTAGACTTGATAAATTTTCTGGACATATAG
    CATTCCTCATTTGAGTATCAGTATAATTATATTTAATTTTCGTTTCGTTTTCTGCACATGTATATTTTCT
    TAAAGACATATCATCATTCACCATAACCATTAAGGAATATCCTTGTTTATGGGCATATGTATCATTTAAT
    GGTTGTTGATAATATTTTCCCCTATTAGTGGGGTCTATATTTTTTTCAATTTTGTTATGATCGTTACTAT
    TATTAAAACTACTATGACTGTTATTGTCTTTGGATTGATCCATAGCCATATTAGAGACACTGATTGCGCT
    TTCTTCGTCCTTTAAAGCCGATTGACCATTACTAAAGTCATTAGTGTCTGAATTATAAATATTAGTTTTT
    AATAAAAACCAATATTTGAGTTGCTTACAATCGAATAAATATTTTAAACATAAAATCGAATTAGTTCTCA
    ATTTTTGATTATGATCATTTATAATTATAGTTAAAAATATTGGAATGCGCTCATTCGTATTTTCGTTATA
    ATAATAAAGAATTTTATCCCAGTTGTTTATATAAATATGAGAAAACATCTTTATAAGTGTTTGCATAGAG
    CATAGTAAATTATTTCGCATATAAATTGACAATTCATCGTCAGTATTTTTTTTTATATGATTTTTTGCAT
    CCATAATAGAATTCTTTGAGTGAATAATATGTTCTTTATTTTGTTTGTCTAATATTTCATTGAATATTTC
    ATTACTAGTATTGTTGATATATTCAAATGTATTTTCCCTTCGATTTTTTTCAGAACACTGTAATTTATAA
    TCGATAAAATCGGAATTTTCATTATAAAATTTATTTATGTTTTCATTTTGTTGTTTCCTTTTAAGTGTTT
    GATCATAGTTATTGCCAATATTTATAAAATCCTCTATTTTTTCCATCGAATTTCCTCGTGAATGTTTATT
    CGAATAATAGCTTTCATAGTTGTTAGAACTACTGGAATCGCTTCTACTATTGCAATAACTACTGTCACAT
    GAGCTGGTTAATATTTTTGTCAGAATTTTTACCTCGTTTTTTTCATTCATTTTTGGAAAATTACTATAGT
    ATGTTGTGTTCAGAAAGAAAAATGGTTTGAGTGCTTCATACAAAGGAAACGCAATTAATTCTTCTTTTTT
    TTTATTTCTTGATATTACCCTTATTTTCCCATATTCTATAATAATTTCGTTGAAGGTATTTATAAAAGAT
    ATCAAAATTTCAAGTGATTCTTTATCCATTGGATGATTTTCATTATTATTAAAATATATTTTAAAATGTT
    CGTGTAATTTTTGAAATATATATCTGTATAAATTTAATAAAAAAAACCATGTCTTATCAATAATCGAAAT
    TGGATTCATTAAGATTAATTTAACAATACAATGTGCACATACTTTAATTATATGAAAAATATATACCCCG
    AAATTTAGTAAAAAAAATAAATTTTTTACAACAATACAAATATTATATAGTATAGATGAGTTACATTTAT
    ATATATAATTAGAATTTAGAAATGCTAGAAATGCTTCAAAATATTTATTTAAATTAAAAAAAAATTGTTC
    ATAATTATTTTCTCTTAATTTTATTAAATATAAATTAAGTTCAGTTCGTTTCTTTTTTTTTAGCAAATCA
    CTATTCACGTATAGATCGTTGAAAATTTTGTTACTGTATTGAAGAATGTTCTGTATTACATAACATATTG
    TGGTGCTGCTACTTTCTTTTATAATATTCCTGATGTTAAATTTCCCTTCAATAATGTAGTTATTCAAATT
    ATCATTTTTTTCCGTGTCTGCATTTGTTCGAATTATTGCTTCATTGTTACTAATAAATATTTCATTCTTA
    ATTTGGTTATTTGTGTTAATATAGTATTCGATTGTTTCATCATCATTTTGAACCAAAAAGTCGTTAATAT
    ATATTTTGTTGGGAGTACTAATATTTTCATATTTTGATTTTGTTCTCTCCTGATCTATATGCTTTATTTC
    ATTAAAATAAAAATTAGGATGTCTAAAATTATAATCGTTATTTTGTATCTCTGCTGTATTATTTTTTATT
    TGTAAAAAACTTTGAGGATTTACTGATTTATTTTTAAAAGTTTTTAAATTATAATCTTTTTGATATGATT
    TATATTTTCCATTTTCTGTTATATTTTTAGTATTTGCTTTATCGTTTATATTGACTGATGGAGATAAATT
    GTTCCTGTTATATTTTCCATTAACATTGTACTTCTCATTATTGATGTTCGTGTTAAGCATGTCTTTATAT
    TTTCTAAAGCAATTTATGTTTTCGTTGTTATACAGTTTGTTTTCTTCCATTTTACCATTAATATAATAAT
    ATTCACCAGTTAAATATTCAATATTTTTCTCATCTTCCAATTTTGTAATACCATCAAAAGAACTCATTTT
    AGTAGATCCTAATAAATTTTCGTCATCATTTATAATATGTGTTGGCATAAAATTTTTGTTAATATATTGA
    TTTGATAGATTAATATTTGTAGTATCATTTATATCTAATAGCTGATTATGTTTAAAGTCATTATAATTTA
    TATTATAATATTTTCTTTTATAATCTTTTACATATTCATAATTTATTGAGTTTGATTGTTGGGATAATTT
    AAAATTTGCGCTAGTAGTGTTAATACTATTATTCGAGATTAAATCTTTTCCTTGATTGTTTACCTCTTTT
    AAATTATTTGAGTATTTATTCAAGCTTTGTTCCCATTTTTTTCTACTATTTTGATCATGGAAAACGGGAT
    AATCATTAGAATGAATTTCATCAAATTTTAATTTCATATTTCTGTTGCAATTTGCATATGAATCATTTTT
    TGCAGAGCCTATATTTTCCAGTTCATCAAAATATGAAAGCTTCTTATTATAAAGTTCATTTACTTGTCTA
    TTATTGTGGTATATTATATCTTTCCCGAGTTTATTAGTATCACTATTTATTATTGGGTTTTCTGAATCCA
    TAAAAACATTTTTGATTAGTTTTATATCATTTTTCATAATTTGTCTATTATTATTTTCTGTGCTATTTTC
    TGAGCATTTTCTTGAATTTATTACCATGTCTGTATTGTTAATATTTAGATCATTATTATTTTTCTTTGGT
    TTTTCATTTTTTAAATCGTATAATTTATTCATATTACTTGACACGCTCATTTTATCAGCATTATATATAT
    CGGTGTTATCTAGATATGTTTTTTTTATCCAGTGTTTTTCTTTATTTATATTATTCATACTAGCTATGTT
    ATTGATCATGTTACTATTATTATTCCATTTCATATTGGAGGCTATTGTATTGATAATATTCCCCCCATTG
    GATGAATTTATGTCGTTGATATATGTTTCCTTTTTTACATTTTTTACATTTTCTTTTGCTTCTTCTTTAT
    TTCTATAACTTATCATTAGTTTGTTTATATTATTTGTACAATTTTTTACATGTAAATTGCTTATACCAGT
    TTTGGAGTGAAATTTTAGATCGACATTGGTATTTAGTGCGCTATTTATATTATTTGCATTATTATTTTCC
    ACATTTTTGTCATATAAACTTGTAGAAGCGTTACCATTGATTATTCTGCTACCCAAATTGGATGTTTCGT
    TTATGAATGGTCCATCCTGCGATTTGGGTGGTATGTTTTCTCGAACAATTTTATGAATGTTGGATGTGTT
    CATGTTATTTACATCGTTCTGTATATATTCTAGATTTTGATTTATATAATTGTAGCTATTGTATAATTTA
    TTATTTTTGTATATAATTGGCTTGGTATAAATTGTATGATTGTTTTTTATAAAATTATTGTTTTTCAATT
    TTTGTAGGTTAACTAAACTCGTGTTGTTTCTATTTCCATCAGTAGTAATTACCTCAATCTCATTATTATT
    TTGTTTTATGTAATTGCTTATTACATATTGATCATTGTAGTTTTCTTTTCCTCGAGTTATTTTTTGATTT
    AAACTAATATCACCTGAATAGCATTGATATGGAAAATCTTTTATATCTTGTTCAAAAATATAATTATTTT
    CACTAGATTTATTTGGAAATAAATTTTTATTATTATCTGTGTTATAATAATTGTCTATCTCTGTGTTGAA
    ATAATTTCCATTATTTCTAAATTTCTGAACATATTCCTCTTCAATTTTATTATATAAATTTTGTGGTTTA
    TAATTTATTTCGTGTAGTTTGTCCTTTATATTTTGTATTTTTTTTTCAGTTTGAATATTTTCTTTTGCAC
    TTTTAGTGAAGCTTGAAATGATGAATTTATTGTAGTTATCATTGTCTATGTCATCATTTTCACTGCTGAT
    ATTATCCTTATTAGAAATAAAATTACTTTCTTCATTTTTCATGTAATAAATGACATTTTTTTGTTCATTA
    TTTACGAATATATTATATCTGGTATTGAAATTTTCTAATTTCATATCAGAATTCCTATTCAAAATGTTTT
    GTATATCTTTAGTGGAACTTTTGAATGAATTATAATCCTCATCATTTCGATTTTCGAATGTATAATTTTT
    TTGACTGCTATTATTATTACTACTACTGTACTTTTCATAAGAATTATTAGAGAAGTAAAAAGAACCAGGA
    TTTTCTTTTTTTTCGTTTTTATTCTCGCATGTATCTAAAAATACCAATTTATTGTTAGAATCCAGGTTAT
    TTAAAATTGAATTTCCTAATTTATAAAATTGCTTTTTTTTTTTCTTTCTTTTGTCTTTTTCATTTTGTAA
    GTAGAAATATTTTGGTTCAAGATTTTCTATATTCTTTAAATTTTCATCTAATTCATTATTTATTTTTAAT
    GTACGATGTAAATCATTTTCATGCTCTGATTGCTTTTCTTGAAATTTATTTTTATTATCATTTAATATAG
    CACCATTTTTATCGTTTTTATTTCTTGCCTTTAAATTGTTCAATCCAATATTTAATTCATCTTGTGAAGT
    ATTTTGCTTTAATTCGCAAATCTTACTGTGAATATTTTTATTCATTTTTTAAAATCAGTTTTACAACAAG
    GACAATATTTCATAAAGATGCCAATTATATTCGTAAGAACAACAACAGGTGTGTTGTCTATCACTTTTAG
    AAAATGTATGTATAATTTGTATATATATATATATATATATATATAGTATTATTTTATGGGGAATGAATAG
    GAAATTATGCATAAATATATTTGTGAATGATGTAATGACACAAAAATAGGCTAATAAGTATGTATGTATA
    TATATATACTCCCCAATTTTAAGGAAATTCCAATCCAGAAGTGATTCTAAAAATGTACAACAATATTTTT
    AAATTAAAAATTATGTACTAAAAGAAACCATATAGTATATACATCCACTTGAGTATCTATTTTTTGGTCT
    GTGTTTTATAAGTGTATATATTTATCACTTCTTTAAATGCTAATAAAATAAACAACGCCAATTGACAATG
    ATACATAAGACAAATAAAAAAGGAAATAATAAAGGTTTGATATGGTTAGAAATAATTATATGTTAAAAAG
    AGAAAAAGACAACACGCATTTAGACTCTAATGTACAATGGAATACATATTGTGTAACCATTGAACTTGTT
    GTGCAAATAATAATCAAACGTAATTAAATATTTTAAAAACAAATAAAATTGCATTTTTTTTTTAAATTGC
    ACGTGCATATTTGTAAGAAAGTGTTTTTTAMCAGCCTGATCATGTTTATGTGCAAAATTATAACAAATTT
    ATAAGCGTTAATATTCACTTAATATTATTTTTTGCAATGTTTATTCCACAAATTCGATAAAGAAAGTATG
    ATTATTAATAATGAAGCTATATTATTTAAAATTTTATGTTTATAAGAATAACATTTTTTAAATAATGAAT
    GAAAGCATATATGCACAAGTCTACATAGATATGAACATATGCATAAACTTGTAATATTTCATATATATAT
    AAAGATGTATATATATTATTATATAAAAAGAAAAATTATATATTTGAATATTTTATAAACATGTGAAAAT
    GTTAATAATATGAAAAATAAATAATTAAAAATGTTGATAAATAGAACAAATTTTACAACTTGTACATATA
    TATATATTATTGACGAAATATTAAATAAATTTGTTTAAGTTTAGGGTATAAATTGATGAAAAATAACTCT
    TCTTATAATAAAGCTTAGAAAGAAATGGATAATATAATCCCTTTAAATAATATAGGTATGTATGTATATC
    CAAACATGATCAGAAATTATATGCTATATACAAAAGAGTGAAAATAGCTATGAATATTTTTCTACATATA
    GTATAGATGATAAAAAAATATATGTTTTACATATATACTCATGAAGGAAAGTAGACTAATAAATAAATAA
    ATAGCTATGTATATAAATGTGAATACTTTATAAGTCATAGAAATATATAAAAATTAGTTAATAGGACCAT
    GAACATATAAAAATTAATATTAAGTTTATGTGATCAATATTCATTTAAATATAAATGAATTATATCATGG
    ATTTAATGTGTTTTATATTTTTTGTGTTATGATTTTATTGTATATGGTGTTATATGCAACTAGATATATA
    ATCTGAATATTCATTATATGTGTGTAACAATGTACATGGGAATTTATAAACCCGTAAAATATCCACACAT
    GTATGCTTGGATAAGTCTTCGTTGTGAATAACCTATTTGGTTGTTCATAAAAAACGAAAAAAAATATTCT
    ACGTCTAATTATGATGACATCATATTAATACCAAATTAAGGAAATCAACACACTATAGATAAATATTATA
    TGTAAATATAAAAAAAGGAAAACAGTGAAAATAGGAATATAAATAATGAAAAATATAGAAATATATTACA
    GTTTTACAAAAAAGCGAAACAAAGGAATATAAAGCATACTATTATGTATATTCGAAGATTAATGTAATCA
    TAAGCAACTTGATAAAAGATTTATTCATTTATTATTATACAACAATTAGGTTATATATTCCATTAATGTT
    TTTTCTAGTTTTTTTTGTGTTTATTGTTTTATAATTAATATAAAAAATATATATTTTAAAAATTGTATTT
    GTTATTCTTTATTTGATTATTCATTTATTTTTATTTAATTTTTTACTTGGTGTGTTTTTTTATTTTTATT
    TACTATCATTTTATTTTTATTTGAATTAAATTATTTTAATTTAAAAGAAGACATAAGAATACACAAGCAT
    GCACACATATAACTAATTATAATACACACACCTAGTTTATCCACATTATATCCTTGCAGGATATACAATC
    ATGCAACTGATACTATTATCTCAATACATTAAGCCCACATTATAAACTTATGCAAATGATAACAAAATAT
    AATAAGCCCACATAATTCATCCACATATATGATACATATTTACAAAAAAATTAATAAAATAAATTAACAT
    GCATAATTTCACATTAAAAAGTTAGAATAGAAAAAACATTTATATTTTGTTTTTATTTTATGATTATGTT
    TCATGATCTTATGATAATATACCTGGGTAAACATGATGTCGTGGTGTTTATTTTAAGCTTTCTACAATGT
    GGTTTTTATAATTGTATTTATCCGCTATATATATAAATATACAAGTATATTTTATAATAATAATCAAACG
    ATTTTCATAGAGAATATGCACAAATATCAGCATACACACCAGAGGAAATACAAAAAAAACATATTTGGTT
    GCACACACATTAAAGCAAGTTATTGAGAAAACAGTTTTTATAGCATTTAAAAGGCTGATATGATATTAAA
    ATAGCAAATATGTGTCACATATATGTATACAAATGATAATAAAATAGAAAAAAAATATATATTTTTTTAT
    GCATAAGAATATTTCGATTGATAGCTCAAAATGATAGTATAAAAATAACTTGAATTAAAAAGTTATTCAA
    AATATATATGCACATGCATAAACTCGAAGTGTGCATATAAGTAAATTGGCAAATATAATCGTTAAGAATA
    ATAATTCTCATAAGATAATTTTGAAGGTCAAATTATAACGTGGAAATATTCGTGTCATCCAACAATAAAT
    ATTTGAGCATAATAGAAAATGTGTACTTTATTTATTTTAACATTTTTCCGTGTAATTAAAAATAGAGACC
    AATTATTTTGGAATATTCTTGATTTTCCTTTTATGTCGCAATTAATTTATAGTAAAAAAACACCAACAAT
    AATAGCTTTCTTATTATTTAAAAATTAAAATATGTTTTGTTGTTACTTATTAAAGTGTTGTTTCCGTTTT
    ATAATATATTTTTTGTGTGTGTGTAATTTAAACAAATATAAAAGTTCTTAAAGTTAATAATGTTAAATAT
    ATGATAAGATTATAAGTACTTTATAAAATTGTAATGAACGTTATTATATATATACTTATTAGTAGTCCGA
    TAAAATACATCTCTAGTACTCTCTATGCATTTCCTGTGTATGAATCGGCTTATTAATTTACATGCAAATA
    AATATAAAACAATGTATCCAAATTATATATTTTTATTCAATGGTGAAAAAACTTTCACGTATTAAAATTA
    TAGATTGTGGAATTTCCATGTTTATATTTATTCAGGCATTTATTTTGTTATATTTTAGAGTCTTAAATTT
    TCTCTTATTAAAGTATAACAATTTGCATTCACAAAGTTATGATTGTTTATTTTTTTAATTTTTAATTTCT
    TTATATAAAAATTAAACATTAAAAAATGTTTGTATGTTTGGAATGCCAGGATATGACATGGTTGCATGTA
    TACAGAATCGCCATGCTATGGATAGTGTAGCACATTTTTTTCAAATAGACATTTTCATCTTTGAACATAT
    AAAAATAATTTTGTTATTATTAAAAGTTTTTTACTCATTTTTCCATTTTTATTAATTTTTTTCATGGTAT
    AAAGTTGTTTATTTTTTATTTTGTTATGGAAACACCTTTTTCGTTTTTTTAATGGAAAATTATCCCAGGA
    AGGTATATTTATGTTTTCACAAAGTGACACATATTTTTAAAAACTCAACAAATTTATCACATGTTCAAAT
    TCGTGCATGTATACAAGTATATATTCATGCTTAAGAAGGTTTTCCGTCATCATTTTATATCTGTTCATAT
    AAAAAGAGGAAACTGATGAGGGATTTTGTTCTTTGAAAACTCGATATATTATGAATTGTTTAAAAAAACA
    ACTATGCATTGCAAAAATCAATTTGCAAGAAAATTTTTTTTTTCTTTGGATTCACATGTTTATGTATATA
    AATTTATAATTCTTATTTATTACTTGTATCAAATTTTACATGCTTAAAATAAAGCATACATTAGATCTTC
    TTTTGGGATAATTTGTTTAATCTGCATGTGTTGTAAAGCTTAATAGACACAAAAAATTAAGGGGCTCTCT
    TATTTTATTTATGAATATAAAATTGTTTTAAGGATTGCGAAAATTATTCCATTTTATTAAATAATTTATT
    TTTTGCTTATCACGCTCCAAATACATAAATATTTTTTCTACATTAAAGCAAAATATTGCATTTGTGGTAA
    GGCAAATCATTAAAGACACAACACATATATTGAATTATATATATTTACGATTTATTTTAATAACATTATA
    AGACATTCATATATTATGATGTCCACTATTACCGTTTGTTGTTTTTTATTTAAAAATAAATTATGCTACT
    AAGCAAGATTTATTTGTTAAAATGTTATAAATATATTACATTTTTTACATTATATTTTTTTGAAAATTAT
    AATATCACAGTAAGGAAAAAAATAAAAATTGAAGCACTTTGCAACAATTTGATTCTTGGTGTTCACAAAG
    TGTGTTTGTGCTCTTTTTTCGTCGATTTGTTCCCCCCTTCAATGTGATACATATTTTGAGAATAATAGTA
    AATGATGAAACGTCGAAGCATTTTCATGTACTACTGTTTCTGTTTCTTATTGAAATATGTAGCCTTTAGC
    AATGTGCCAAATCCTAATACGACCATAGGACACTTTGAAATTTGTGAAGTAAATACATCTTCAGGTGATG
    CCGAAGAATGTGTTTTAGAAAATGAATTTGGGAAAATGTTTTTATTTATTTGTGATATTGATTACAATGA
    GATGTCAAAAAATATAGTGCTTCCGTCAGAATGTGCTAAAAAAACATATATAGACCATGTAAACCCAAAT
    GGAACATCGCCAGAAGTTAATACTTATGATATATTTCCAGATTTGATCGCAGCAAATGAATCCCAATTTC
    GTGATAAATTTTATTTTTATGGAACCCCATATTCATCTAAAGACATTGATTTTATATGTTTATGTTTTTC
    TGAAACAAAACCAGATATAAAACATGTAATGAAAATGAGTTTTAAAAAAATGACAAAAAAAATAAAAGGA
    TGTGATTTTGGAGATAATATACCAACGAAAAAAGATTTAACAAATGGGAAAGCATTATATGAAAATTCTA
    GTTGTCATATATATGCATATCCAGGAGACGTAATTGGAATAAATTGTTATAAAAAAGACATTAATAATAT
    TTATAATAATAATTTAGAATTACAGCCAAATAATTGTTTTCATAATGTTTATTATGAAGATGATATATTA
    TTATCGTCAAAAAATTTAATACCTAATTCTAGAGTTATACCAGATCCGAGTAACGATGTTAAATTATCAA
    AAATGCATTCATATATGTCTTATATTATACTCCCTGACGAAATAAATGAAAATGTTAAAATTAGTTGTGC
    ATGCAAAAGAGATGAATATATCGGCACTATGTTTTTATATGTAAATACATCGAAAAATATTTTAACATCC
    CCTGACAACAACGTAGAAGAAATTGCTCCTTTGAATGACCACTATATTTCAATTGGAGACATGTGGGACA
    TGGGTTTACATGAAAACCCTGAGCAAATACAAGGCATTATTAGCAATCATGCAAATAAAAAATATTATGA
    ACATATGAAAATTTACAAAAGCAATAAAATGGATTCTAGTGATGATGATGAATCGAATGAGACTGAATCG
    AGTGAGAATGAATCAAATGAGCGCACACACAATGGTAATAGAGCAAATAAAGATGCTAATAATAGTGAGA
    AAATGACTGGTAATAGAAGGAAAAAAAATAATTCTATCAATAATACTAATTACTATAGTAATTATGAGGA
    TGACAATGGAATTAATATATCTACCCATGATAAATATTATGAGGACCAACATTTTGGTAACAATGGACCT
    TTGAGAAAGAAAAGAACATTTTGGCAAAATATGTTTGGTACCTCTTCTTCTTATTATGAGGTCTTTAACT
    ATTTTTCAATCGCATTTATTCTAATTATTCATATGCTCCTCTTATGATGAAGTACAATATGTGCATAGTG
    TCAATATATGCCCACTATTCGAATTTTTGGTTGATATAACATACGAAATAAAATTATTTTATTTTTGCCA
    CTACAAATTCACAGACTGTATATATGTACACATTTGCATAAACTATTCCCTTTATTTTGTTTATTCGTAT
    ATATATATCTATCTGTTTTGCCCTAACACATATTCCTCATGTTATTACGTTTATGCATTGCTACGCTTTT
    TTTCAATGCAATTATTCCTAATATATTTTTAATTCATTACACATATATCATATTTTTACATATCATTTTT
    GATACATATTGAATATGCATTTAAGTATCAAATATAATGTTTTTTTATAGCTTCATTAAATTATGTAGCC
    ACATTTATTCAACCATTTCCATACGACATGTTAATGTGTAAATAGTGTACTAAAATGTGTATATAACCAA
    CTAGCAATGATAACTTTTTTTTGCATGAATGACATTATTGAAAACCTTAATATTAAAAATATATATATAT
    AAAAGCATTAAATTCAAATAACAATGTAAGACGAGTGTATGAAAATGGAAGCATCATGCGAAAAAGAAAA
    CAATTCTGCATAAAAGACAGAAAAAAATAATAAATAAAAATAAGAGAATAAGAGAATAAGAGAAACAGGG
    TTAACATGTATATAAAATGCAAACAACTCTCAATTAATGAAACAATAAATGGCTATGCATGTATATACAC
    ACATTTTTTTAAATTATAACAAAAAAATCATATATAATAAATAAAATACAATTAAAGATAAAAATATTAA
    ATAGCATGTGTAACAATATATATATTAAAAAAAACCTTTATTATTTTAATCATGTGAAAAAAATGTTTTT
    TTTGAGGATTAATTTTAAAAACAGTACAAAAATATATAACCTTAAAAACGGTTCACCCTTTTGAGATTCA
    TCCTATGTGAAAGTTGCATGCATATCAATAAAGCGGAGAAAAGACCATTTAATAATTTAATCCTTAAATA
    ATAAAATATATTTTTTCATGGGAAATATTTAATTTATGATTTTTTTTCAAATATTATTTTAATGTTTTAT
    TCCATTAAAGAGAATTAAAAATAAAATGAATTTAAATTTGTTAATGGTATGCATTTTTTTGAAAATATAA
    GATATGCATAATATCTCAAAAACACGAAAGATAAAGAATTTAAAATATATCTTTTGAAATGAACACATTG
    TTTTATTTAATCCATATTTTGCTATAAATTTTAAAAAACTTTTAGGATTTTTGATATTTTGAAGGAATTA
    ATAAATATTGTGTGACATAAAGAGGAGGGACAAGGCAAATATACAATATATGCTTATGTCTTCACATAGC
    CAAACACATTTCGATCTGTCTCATATATAGTGATGCTTATGCGTAAACAATTCCCAATTTTTATATTGCA
    GAATGTTTTTTAGTTGCAGCAATGAATAATCATAATTGTAACAAATAAATAACGCATACTTCAGTTTTAA
    TGTAAGAATTCTTTATTACGATAACTTTTGGTTGTTTCTTTGAATCGACAGTTATCATACTTGAAGCATT
    TTTGTTGACTCTACCGTTTGAAGATTTAAAAAAATATATTATATACATATATATATATATATATATATAT
    GTGAAAAGTTTATTGACGATTGTACATATATTTATTTTTATTATTTTTGTTGATTATGAAACAATATGAG
    TTCGCACGCCATATTATATGTCATATTAACACATATTTTTCCGTAGCGCAAAATATGCTTTTTTCTATTT
    TTCTATATTATGCATTTTCGATTTTAATATTTTTATCAATTTTTGTTTTTAAGATGAGAAAAGCATTATA
    TTCTTTGTTATTTTATATGTGTATATGCTTATATATATATACCCCTGTTTTTATGGCGAATTTAAAAGAA
    ATAGAAGTTGGCAATTATTTCATATGTAACTTAAGAGACTATCCAACGGGAAACTGTAGTGTTGATCATG
    ATTATAACAAGACAATAAAATTGCTTTGCCCTATTGTCAATAATAAGAATAACAGTAATAAGACATATGA
    TCCTTCATATTGTTTTAAATATGATGGGATAAAAGATGAATTTATTATAAATAATAAACAAGCTTACATA
    CACAACACTTTACCTGGAGTTATATTAACAAATAATATAGAAAATGATACTTATAATTTGAGTATATATC
    CACCTTTTGTTGTAAAAGAAGATGTAACTATTGTTTGTATATGTGACAGTGAAAAAGGAAACGAAGGAAT
    AACGCCGTATCTTAAAATAAACATAAAAAAAACACATGGATTGAATAATGATTTAGAAGGCGATTATATA
    AAAGGGTGCGATTATGGAAACAATCAAGGGAAATATAAATTTTTAACAAAACCTGTAAAATATACTAGTA
    ATCCCATTTGTGAAATAGATGCATATCCTGGGGATGTTGTTGGAATAAATTGTAATAGTTATACTACTAA
    AATGCAAGGCGCCCGTTTAGAACCAGAAGGTTGTTTTGCTATGGTGTATTTTTCTATTTTAACAATGAAA
    TTTATAAAAACTAATGTAAATAATATAATGCCTAATGCAAAATATTATCCCGATTTAGCATCTCATCCTG
    GCAATCAAAATTCTAAAATATTCTTAACGTCATACTTATTGATACCTAATGAGGTAGATAGGGACATTTT
    AATATATTGTAATTGCTCATATAATGGGAACAAAGGATTAGCAATATATCGCATTTTCTCCACAAAAGCA
    AGTTAATATGTGATGTATGTAGAAGAGTGAGAAAGTTGAAATATAGAAGACAGCATTTCTCACGCAATTC
    ATACAATTTTGTTTATGTTTTAATGACACATAATAGTGCAATTTGTTTAACTTTTTTAAATATGTTATAT
    TCTCACTTTTTATATTTTTTATAAGTTAAATCAATATGTGTTCTTATTAGTTTTCAATTAAAGTACTTAA
    TTTGTATTTTTCCTTTTTTTTAACATTATTTTTAAATTAAAAGTAAAAATCATAATAAAAAATTATAAAT
    CGGTTGATTATTAAAAATAAGTATGCATGTGTATATTTATAAACAATAGCATCTTAATATATGCCACAAA
    TTTTAGTTTGTTACTGTTTTCTATTTGAAGTGTTTGTTTAATTATTCCATATGATCGAATATTAATTGTA
    CTATAACAAATATGCGTATGAACAAATAAATTTGTATTCATTTATAGAATAATAGTAATGTAGACATTAT
    ATTTTTTTATTAGTATGAAATAAAACAATTAACAAAATTTACGTTATTAAATGAGTTGATTGTAATAAAA
    TTATAAGCATAAATTAATTATGTAACTCGTTTTTGGTCAAATTATATTTTAAAACTTTAAAAAATTCAAT
    GTAAAGGTTATTCGTTCTGATCTTATGTTTATTTTTTTTTTACAATTCTTTCTAGAGAAATTTCAAGGTG
    AGCTTTTCACAGTAGCATCTTTTTGTTTTTATTTTATAATACTTTATTAATTTACTAATTTACTGTGATG
    TCTCTTTTGCAATAATAATAAATGTCCAATACCATAATTTATCATATCAGATTATAGCATATCGTAATGG
    TAATTCATAATATACATATAATGTTATGAAAGGAATAATCATTTTTCATTATGCTTATCTTTTCTCACGA
    CATACCCAAATATAATGATAGCAAAAAATATAGTATCAAAAACGTTCGAACTAAAAAAAATTGGTTTCCA
    ATTTTAAGTAGTAAATTGAAGAATATTTGAATTGATTGKATATATATATATTTTTTTTTTTATTTCCATT
    TGTATTGTAATTTTTCCGGTGTGCCTCAATACTTAATGAGTAAAAAAAGAGATAACGTAAAATATAACAA
    AAAGGATATAACAGACGAAAATAAAATAAATTAATATAATAATTATTTTGTATATAATTTATATAAAATA
    AATTGGATTTAATTAAAATTACGAAATTATTTGCATTATGATTACCGCTTTATGAAAAAGAATAAAATTA
    TATATTATGCATAACTGGAATAATATATAAGCGGGATAATTAAAAGATTAAACGCGAATACCCGAAAAAT
    CAATAAAAACATATAAGTAGTAATTAGGTAAAATAAATAATAATATAATGAAAAATAAAAAGTTTAAACA
    AGTAAAATAAAATTTTCATACCATCATAGGTTTGTTTATAAATCACAAATTTGATAAGCATGAGAATATA
    ATAACTAATYTAAATATATCAAATATAAACAAACCACTGTATAATAGATAAAAAATTATATGCTTGTATT
    GCATATATTTTTACACACCACTATATTTTTGTTTGCATAAGGATACAATCTTGAAAATTTTATGGACATT
    TTTTCAAAGAGGGTTAACTGTTTCTATTAATAGCTTAATAGCACTATGGTATGACAAACTTCAAAAGAGG
    AGAAAAATTTGTGGAAAAACCACAAACACAAAAACAAATAGAATAATAAAAAGGAATAATGAGAAAAAAA
    ATAGAGCATATACAATTATTACATATATGTATATGTATGGAGATAAATAACAAAAGTTGAATACATTATA
    TAAGCTTCATTATCTCTCTCTACAATGCTAAAGTATATTTATGCAATACATATATTTTTCTAATTTTATT
    TATATTTTTAATTTAGAATTTAGATTTAAATGAATCCAAGGATGGAAATTCTAAAATTCAGAATTCCAAG
    AAGTGAGTGAAAAAAATATAATGTATATATATGCAGTAAATAACCAATCTATATATTTTTTTCAATGAAC
    ATATACTTATATATATTATTAGTATTAAGCTCAATGAAATTGATATATTTTTATGGTTAATACATGAATA
    TATGACCTATATATGAGTATATTATAAAGGCAATATTTGTTTGCAAATATATGGACGTCTTTGCAACGCG
    TAGCGTGTAAAGCGATATAACGCTGTTCTAAAGCATCACCTATATATAAACTAATTTTTTGTTCGCATTT
    AGGCATAATATAGAAAAAAATGACACCCATACCAAAGTAAATACAAAAAGAAACAAAATATGAAAAGGAA
    GTAGAAAACTGCTACTAAATTTGGAAGATAAAACTAAAGTTCATATTTATATACAAATTATTTATTATAT
    ATTTTTGAACCTCTTAACAGATTGCAAAGATAGGCTCTAGTTCTCCAGATATCCACAACGAGGACATTCA
    AGGTAAATGTTAATTGAACAAGGGAATTAATAATAACAACTGATGAGTTTGTATTACATATATACGTCAT
    ACATGTTTACATTATTTATACTAACCACATTTACTTCTTTAAAAAATTAGGCGAGAACCAATCATTATAT
    GAATATCATCCTTCTAACAACGAAGGAGAAAGTGTGAATTGCGAAAAAGATGTCTTAGATTACTCAAATA
    ATAATAATAGCGAAATCGAAAGAGATAAAAATATTGTAACTGAAAATGACAATGATTATAAATATAGAGG
    CAAAAAAAAGAAAAAAAAAAAATTTAAAGAACATAAGGATGTAACTAATCATGAAAATGAAAAACCCCAA
    AAAATTAAAGAAAAGCATATTGATAAGGAGAAAAAAAATAAGATGGTTAAAAAATTTCAACAAAATAGTA
    CAAAAAATGTAGTGATAAATCCGACCGAAATGAGGAATCCTGATGGCTCTAATATTGAGAGAAAAACTGA
    TAAAGAGGAGGAAGACAATGATGATAAGAATAGGGATAATAAAGATGTCATTGAGAACAGCGACGAGGAA
    GGAGATGAAGAAGAATATGAGGAAGAAGATGAAGAAGAAGATGAAGAAGAAGATGAAGAAGATGAAGAAG
    AAGATGAAGAAGAAGATGAAGAAGATGAAGAAGAAGATGAAGAAGAAGATGAAGAAGAAGATGAAGAAGA
    AGATGAAGAAGAAGAAGAAGAAGATGATGATGAAGATAATGAAAAGGAAGAGAAGGAAGATGTAAAAGGA
    GGAGAAACTAAACCTGAAGGAGAGGAAGAAGAAAAAGAGAAAGAACACGATGATGCAAAAGATGAAGAAG
    AAGATAAAGAACATAGTGATACGCAAAATGAAGAAGAAGATAAAGAACATAGTGATGCGAAAAATGAAGA
    AGAAAATAAAGAACATAGTGATACGCAAAATGAAGAAGAAGATAAAGAACATAGTGATACAAAGGATGAA
    GACGATAAAGAAAAAATTAAATTAAACAATAAGGATAATTCATCTGAACACGATGACGATGAAAAAACCA
    GCAATAATGAAAAAAGCGTCATGGATGACGAAGATGAACAAAGCAGTGTAGCTAAAACACAAAAAAGGTA
    CAAAAAATTATATATGTGTATATTGAAATTAAAACCTATAGCTGCTAAGATGAGGGATAATTACCCGTGA
    TCTATATCATTATAATTGTTTTCATGTAATATGATTTTTCCTTTTTAATATAATTATTTTTAACTTTTTT
    TATAATAGCAATGAAAGCGTATGTAGCGAATATGGGGATATCAAAAAAAATGACCGACTTTTTGCATCAT
    TGGTAATTTAATAGAATATATTTGTGTTTTTTGTTACATTATTATTTTTTTCTCTCATTAATTTATATAC
    ATGCATTAATAATGCCAAATATGTAATCGTAAAGTAATATGAGAATGTTAAAAAAATATCTTCTTTGTCA
    AATATATTTTCATCATATATCCATATACTTTATTTTGATCTTCAGAATGATGCCAATTCACCCAATAAAC
    TATTTAGTGAATATGTAGGAACCTTAAATATATTTGGGGGAAAGGGTTTAGATTTGGAAAAATTACAGAA
    AAATATAGATAAAAAAAAAAAAGTAATAGATGAAAAAAAGGATATTAAAATGATCGAAGAAGAAAACCCA
    TTTGGTATTATCATAAAACAAACATTTGCACAAGTTTTGCATATAATATTAATAGACATGAAAACATGCA
    TTTGTAATACTTATCCACTTTGTTATGCCCCTTTTTTTGCTCAATTTTCATTATTTTTCTTCATATTTAT
    TACAATTTTTTAGAAAATGAAGAGATAATATACTCAGAAAATACTATAAAGATAAACAAATTTGTTAAGA
    AAGACGGGAAACAAGAATGGTCAGGTTATTTACCAGTAAAAATTCAAATAATGAAAAATAAAGAAAATGA
    TAAATATCGAATTTTATGTTTTCAAAAAGGAAGTGGAAGATTATTTTTGAATACGGACATTTTCGAGGGA
    TTTAAAATTATTCCCTCAAAAAAATTGTCCGCCTTATTTAATGGGCGTGATATAGGTATGTGATAGAAGT
    TGCGAAGGTGTATTAGGACAAACTCGCAAATTTCGTTACTGCATATATGTATATATATGTATGGGTGAAA
    CAAAGCCACATTTATTCTTTTTCTTTTTATTGTTAATACAGGTAATGAAAAAATAATAACCCAATATATA
    GTAACGTTTATTAGTAGTTCTTCAAGAGATGATTTTATCAGTAAAATTAATGACATTTCCAAAAAAAAAT
    AATAATTAATTAAAAATATGAAAACTTATACGAAGTGTAAACTTAAAAAAATGTTTCTCAAACACTCTTA
    AAATATTTATTTTTAATTTTTGTTGTAAAGCTATTCCATTTTATATATTTTAATCCCTCTTTCACATTTT
    TGATTTAGTTTTTCCAGTCACATAAAAAATTAAGGAAAATTTATGAAAATATTTAGCTTTCTTTTATTGT
    AATATATATAATATATTGGTGTTGTTTAAACGTTTTTTTTATTTCAATTTTTGGATTTACTGGTATCTAT
    GTGTACTACTTGTATATATATATAACCACACGTATATTGTATAAATAAAGAAATATGCATTATACATGTA
    CATAGGATCGAAAATATAATACTATACATGTATTAATTTATTCGTTCTTACAGATACATATTTCGAAAAA
    AAATATTTTTCATAAGTATACATTTCGATTTCGCTTTTTTTTTATTCATCCATTTTATATTTATCCTTTT
    TTTTGATATATTTAAAAACCTTTTGAAATTTTTAATAAAAAAATAATCATATTTACATTTTTTCATATTT
    CCAAGAATTGGCTTATAACGATTAATTGATTTATACACGTATCGAAATAAATGTATATGTGCTAGAGATG
    TGATAAATTACACATAAACATACAATAATAAAATTGAATAATTGTAGCAATATAACATGTAAGGTATTAG
    ATTTATTGCATATAGGTCGATTTATCTCGTTTAAAATATTAATAACTTAATAAAAAGGCAAAATAATAAT
    ATATACATACAAGCTATGCTTATATAGTTGTTTATACATTTTTTTAATCCGCAAAAATTGAATGAAAAAA
    GAAGTGGACGAGCGTTATGGTATATATAATTGATAAATTGTATTTTCCATACTGATATATTTTTTTTAAA
    TGTGCTAATTATATACTATTTTGTGGACTAAAAGTGAAGAATTGCTTCATTTTTTGAAATATTGATTCAT
    TATTGTGGGAAGACGAAAATGCCATAAATACGGCTATTTAAGGTTCTCCGACTGTTTATTGTAATAATAA
    TAATTGATATTGCTGATGTTATTACTTTTTTTAACGGACCTATGAATAGAGTTGTGAGAAACTTTACCAA
    TAATAGAGGGATAAACAACCCAAGCAAAATAAAAACATTTAACAATTTTTGCGATGAAAATTTGAAAAAG
    TCGTTTGAAAAAATAGCTATAGGTAACCCTCCAAGAGCCAAAATAAATAGTATTCTAAATTTTTTAATAA
    AATCAAAAATATTAAATACAGAATGGTCCAAATCACAAATTATTGATGAGATATATAAAAGGAGAGTAGA
    TAAACAGCTTTCTTTTCATTTAAATGTATTATATGGTTTAGGGTCGAAAGGAATCCATTTAAATAAAAAA
    GGAATAATATCGCCAGTATTATTTTATCCTTTAATGGATTACGACCAGTTTAAGACTATTGTACAGGTAT
    GATTGACTCACATAAAAGTATGTGAATCAATACAAATTAAATGATATTAATATGAGCATATATGTACACC
    TACATCCATATTTCCACTTTTTTGCAATAGGTAATGCAAGTTGCAGATAAAGAAAGAAAACTTGGGATAT
    ATGAAGAAAAACAATTTTTTGAAAATTTATTTAAGAAATAAACTGTGCATAAAAAATTTACTTAAAGCAA
    ATTACAAATTAAGTTATAAAATTTAAAGAGCTCATAGAAATCAATTGAATATATCCCTATTAATATATAT
    ATCTTATGATATGTGTGCGTTTTTTTGTATTATTTTATATAAGACCTTAAATTAATATGCACCGCTTTAT
    GGGCATTCGTATGCAACAATTCTAATATTATACTATTTATTATTTTTCTGAGTAAATAACATAAAATTTA
    TTTTATGAGAAAAACGAGGAAATATATATTTGTGCAAATATCTACGGATGTTTAGTGTTGCAAGTGGTCG
    ATTATGCGTAGGAATATAGGATTATTCTTATGTGTTAATATTTGGAAATGGATAATATATGTAAGTTTTA
    ATACATATTAAACATGAAAGAGAAAAAAAGACTAAAGAGTGTAGTATAGTAAAGAAAAGCTATATATTAT
    AAAGGGAGAATGATACCTACCAGTGGTAGTTTTTTTTTGCATGCACTCATTTGTTTATTTTGTATGATTA
    TTGTAATAATTTTTATACGACCTATTTTTTTGTTTCATTCTTTACGTTTTTTTTAAATGAAAATTTGCGA
    GTTTACTATTTTTTTAAGTATTAAATTATTTTGCTCATATAAATAAAACCAGTTTATCAAAAATATATCA
    TTCTTACTAAAACAAGCTATAAAAAAGAGCAAAAAAATAGTTGTAACTACTTCAACATAAGCAATAGGGA
    TGTTTGCAGTTTACATTTTGAGGTAATTATTTTTATTTATTTAATAATAGCACTTGGCTTTTTAATGCAA
    TTTTGTGAAATCAATATGTTTTATCCATATTATTCTATGCTTTCCCTTTTGTTTCCTATTTTTTTGTGTT
    ATGAAAAAATCTAAATCTTAAAAATGCACCTGTTGCATATTATATATATGTGTGTATATATTTATATATT
    GTTCAATGATTTTATAATTAATGTATAAAATAAGATACTTAAAAACAAGCCTGAATTAATATATGCACAT
    TCATGTAATAAACATACTAGTAAATACAATGTTTTATCGAAACTAAAATGTAAATGCTCAAAATAAATAA
    TATGTACATGTTTTTTTTTATATGATATTTTAGATATTTCTATAAGCTTATAACCACAAATAAATAATAT
    CCCATGATAAAATTACGATGCATATATATGCATACATGAGTATTCATTTGTTTTATTTATTTATTTTGTA
    ATTTCGATGTGCTCCTATTATTGCATAGCAATACATTGGTTGTTCTATTTATGAAGCTATAAATAGTATT
    ATATATATTAAAGTAGATAAGTGTATATAAACGAATTTTTATTATGTATAAAAATATTAATTAACGTAAT
    AAGCATTGTCTTATATAAAAATTAGAAGAATCAATAGAATGCTCGAATTTAGTAATATTATATAAGCAAC
    GTATTAAAGTAGTGAACAGTATATATAATATGCAAGAGACAGGCAGTATATAATTTGAAGAAAATAGTTA
    AGACATGGCACTAATGGTATGTTGCATCTGTATATTTTTGTTAATGTCATTATTTTTTTATTTATTTTGA
    AAATTTTCAGAATATTATATATACACCTTATACTATGCATATTTTTCCGTTTATTTTAAACTCCTATTTT
    CCGTACTTTCTCTAAAATATGTATATATCATAAGGTATTTTTTTCTTAAAACTTTTTTTTTCATATAATA
    TATTTTTTTGGATTTGATTAGATACATATTTTATCAATATTTGAATATTTTTTTTTTGTCCAAATAATAT
    ATGTACATATTTTGAAGCGATGATGCGCATATAAAAAGATATGTAAAGGAACTGGCACTATATGCATGTA
    TAAATTTGTGAATGTGCAACTGTGTCAAAAAAAAATAAGTTACATATATATGTTATTTTTATAAAAAGTT
    TAAAAATAAAATATAGACTACATGAATGAAGGTGGAATTAAAGATAAACCATTGGAAGAGGATAATTTGG
    GTCTTTTTACAGAGAACATTTCAAATATATCAAAGTTGAGGAGCAAAAATTTAAATAATGTTAAGGATGA
    TCTAAAAAAAGAGGAAGAACCCAAAGAAAAAAAATATAATGGTCATAGTAAGAAAAATGCACAAGAAAAT
    AGTTTTGACATGATTTGTTCTAACAGTAACCAAGAAAAAAGAAGATATGATCAATATAATTTATCACCAT
    ATTTTGAAAAGGAAAAATATAATAATTCGAATGTAGCAATAAGCCCATATCAATACAGTAAAAACCATTA
    CAAATGTAACCCACTGGATTATATAGAAAATAAAATAATAATGAACAAAGAAGCAAATAAAAAATTGAAT
    AATACAAGAAAAAAGAAACTATTAAAAAGCCAAAAAAGTATAATTAAATTGTATAATAGAGAGATAAAAA
    CAGGAGGAGTGGTACGTTGTAAAAATACCAAAAATGACGATATATCTCTAAATTTTGAGGAAGAAAAAAA
    CGAAGTAAAATGTAGAGAAACTAATAGTAATGATAATAAGAATCAATTGAACATAGATGTAGTAGAGAAC
    CTGTACAATTACAATGATTTTTTGTGTTTTTCCCCAAATGAAATTCATAAACATAATATTAATGGTACCA
    ATGATAATAAAATAGATACAGTTATAATAGAAGTGTGTAATAATATAAAGAAAATAGAGAAAAATAGTAA
    GATAATAAGTGAAAAAGAAAGAAGTGATAAATTGCGTAAAAAAGAGGGTTATGAAGGTATAAGAAATAAT
    GACATGACTAATACAGAGAAAGAAATAAAAAAAATACGAACGAACTTTAGTGATGATATTTCTACTAATA
    TCGGGGATAAAAAGGCTGATAGAAACAAATATCTTCCAAATATTAATAAAAAGATCAGTTGTCTAGAAAA
    TATAATAGTCAATGAAAATGATGAAAAATGGGATGCGGAAAAAATGCTCTATAATAATATACCGCAAAAA
    ATGGAGCATAATAATAGTGATATTGTGTGTGACATAGACAAATTACGTATTGATAATCTCAATATGCCAA
    AGGTAATATTACCAATAAACAGTCAAGAAAATAAAAAGGAAGCGAATAATATATCCGAAAGGACAAGCAT
    AATATATAGAGATAAGCATAATGTGTGTTTAAATAGTAAACCAAATAGTAAAATACATTTAATTAAAATT
    TTGGAAAAAAAAACGTATAAAGACAGTATGATTGTAAATCCAATTGATAAAGATAATTCTTCTGATAAAA
    CAAATGTGCTTCATATTAGATATAAAAACAACCCCCTATCAAAATGTTGTGATAAAATTAATAAACTAAA
    TCATGAGAATAATGAAAATGTGAAAAAACATAATAATATATCAAAAACTGATCTGGGTGTTAGCAGATTA
    AAAGTTGGAAATAGGACGGCATCCTCTTTAAATGAAGATGAAGAAAATGTTAATGAATATGGTAAAGGAA
    TAACTACGGGGTGCAATGTTATGAATAAAAATTCAAAAGAAGACGAAAACAACATACATATAAAAACGGA
    TAATAAGGAAAAAAAAATTAGCGACCAAAATTTTGTCGATGTATGCACTACAAATGCTAGTAAATGTGAT
    GAAGATATGAAAGATACTAAAAATAGTGATTCCATAAATAACGAAGATAATAATATCAGGGAAGAGTATG
    GATTAAAAAAAAAAAAAACATGCTTCTTAAATAAATCAACTACTACAGTTATTTGTGAAAAAAATAATGA
    CCGTGTTAATGGAAAAGAGAATAACACGTATGATAATAATGCATTATTTGGGATTGAATATGAAAGTGAA
    TTCAAAGGGGATAAACGAAAAATTTCATACAAAAATTCATTGGATATTTTGTTAAAAAGTGAAAAAGAAA
    ATAAATTAGGAGACGAAGAAAAATATGTTTTTAAGAATGAGTCTCCTTTTATAAATGACATAAAAAGTGA
    AGAAACAAATTATCCCTCAAAATGTGTGTCAACAGATGATGTAAATAATGTTTTATTAAATTATGGAAAA
    AAAAGTGTTAATAATTATGAAAACCTGAACAATTGTAATGATAATTATACTAATAATTATAAGAAGAAAA
    AAAAAAGAACAGGTATACCATTGAACGAAAGAAAATATTATAGAGTACTTGCTAAGCAAATGGTGAAGAT
    ACAAGGATTGACATTTGATCATAATCAAATTAGATGGATAGCATATTGGAAAAATGAAAACAATAAACAG
    ATTCAGAAACATTTCCCTGTGTGCAAATATGGGTTTTATAAAGCTAGACAGCTAGCTCTAGAGTTTCGGA
    ACTCGAAAATCAATGAAAAGGATGGAAATGGAAAATATGAAAAGAATAAAACTATTAATAAGAGTGAAAC
    AACATATGCAAAAGTGAACAAGAAAGAACTCTCCAAAAAAGGATCAGAGAAAATAGAATCAATTCTGAAT
    AGCGGCAAAAATGTTACGGGTGCGCATCTAAGTTATCATCCCAAGAGCATTTCATCTATGCATGGGAATG
    TGAAAAGCAAGAGTAAAATTTCAGGAAATAAAGAAAGTGTAATTTTTGACAAAGGGAATAATACTAACAA
    TGTATGCAATATAAATAGTGATAAAATTATACCTTCGAAAGAAAAAAAATATGATTTCAATTTTATAGAA
    AACGAAAACATATGGGTAAATGATGCTTCAAATTTTTTAAGAAACAATGAGCATCTTAATGTTATGTTTA
    CAAATAATGGGAAAATAAATGATATAAACTTCTCAAATATATTAAACAGTGAAGTGAACACAAAACTTTA
    TGATAACAATGGATTGATAGGTAATGTTTCATCATTTCACAAACAAAAACAGTTTTCAAATTGTGTGCCT
    ATTTCTTCAGACATAACTAATTCGGGGAATTTTCTTTGTCAATCAAAAAATGAAAATGTTAAAGATGATG
    AAATTAATATGCAACAAAATTCAATGAGCAATGAACGAATTTACCCTAATGAGGTTCCCAACAATTGTAC
    AAATAGTTATTGTGAAAATAATAATGGAAATTGTGTACATAATTATAAAAATTGCAATTCAAATGTGAAT
    ATTTGTATGAATATTTTTGAAAATACATATTATAACAAATCGAATAATCCTACTTTTTCTGGTGACCAAA
    ATAAAACGCCATTATGGGCGTATCCTCAAAATGATGTTGGATATGCTAATTACTTCAATAAATTTGAAGG
    AAGCAATAGTATTAATAATAGAGATATGAATGGTATATATACTGAAAATAAACAAATTGAGGATAAAAAA
    TTTACAGAATGGAATCCACAGCCACAATATTTAACTTGCAATAGCAAAGAGAGAAATGATTATTATTATA
    AAAATGATAATTGTACAAATTTTAGTGAAAAGGTATTTATGCACACTAATAATATAGGAACAGAGAAAGA
    AGGAGTGAATTATACTGCTGAAGTGGAACGATTAGATTGGAAGTCTCGTTATAATTTTAACTATGTTAAT
    AATATTATAAAAAATGATAATGATCTTGATGGGGTTAGCATTGAAAGGAAAAACGAAGAGCATAACAATG
    ATACAAAAAGTATACGTAATTATGATTTGACTAATAATGGGAATAATATTTTATCGAATAAAAATTGCAT
    TTATCAATATCGAACTAGTGACAATTATTTTTACGATGTGAACAATAATATTGGAAACCTTTCAAATGGT
    GATGTAATAAGTAGAGAAAAATATGAAAAAAATAACGAATTTGACAATACTTCAAGCATGACGAAAAATA
    CCATTTTACATAAAGATGTAGAAAATAGTGTAGCTTTGAATAAGAAAATAGAAATTGTGGATAGTAATAA
    ATGTAATCGTGTTATCAGAAAAAATCGAAAGGGAGATTCGAAAAGCATTTTAAATGTATTTCATGATAAT
    AGAAACAATAATTTGTATTATAATAAAGGTATGTTACACACGTACTTAAGTAATAGAAACGAAAACAATG
    AGCAAGATTTTACTACAAAATTTGGCGATAATAATAATTATTTTGAAAATGTAAGTAATATTGTAAATGT
    AAAGAAAAAAAACATTTTAAAAAATAATAGAATAAATAAAATTTCAAACTCTGAAAAAATATTGGAAAAG
    GAGAAAAATGAAATAAGTTGTAACTATAGTAGCAAAGCTGAAACACAGAATAGCACAGTTGGGAGGTCGA
    GAAAAAAGAAAAAAAAGGGAGAAGACAACACCGGAGTGGAGAAAGAAAGAAACAAAAACGATTTTAATAT
    GACAGAGAAGATTAATAATATATTGGAAGGGGACCTAAATAATAAAAACCCTGAAAAGGAAGCAATTTTA
    GATGAGATAATTTTAAAAAATAGGAACAAAGTAAAATCCTCGATAGAAAAAATAAACACAATTCATGAAT
    TTTACAAAAATGGTGAAAGAAAAGAAGATGGAGAAATCATAGGGACAAAGGGGAAAGAGAAAAAACAAAA
    ATCAAAAAATAGAAAAAAAGGAAGCACAGAAAAAATGTTTATTAGTGTAGATGAAAATCTTTCAAATCAT
    TCTACCTCTATGCTACAATTAATTGATATAAACAATCGATGTGTAAATAAAAATTATTCAGATAATACAT
    GTTTAAATTTTTTTAAAAAGGAAACGAACAATTTAATTTACCATACTAGAATTGGTGAAATAAATGATAC
    TAGTTATATTGAAAATAAATTTCCAAATTCAATTATAGACAATAAAAAAAGTGATAAAAAATATAGACCA
    TCAAAAAATGAGATAAAAAATCGAAACAATGAATTATATATAGATGAAAATAATATAAAATATGTTTACA
    ATGACGATATAGCAGGGGAACCAAAAATTGGAGACGGTATAAACGAGCCATATATAATAAGAAAAAGTGA
    AGAAAATAATTTCACCATCGAAATTGATAATATGTGTTATTCTGGAATAAATGCAAATAAGAAGAGAAAA
    AAAAAAAAAAAAAAAGGAAATGAATCAAGTGAGGTAAAAAATGATGATAACATTGACAAGGTAAGTGATG
    GTAACTTCAAAAACTGTATTGAAAACGTACGAGAAGGTGAACTAGATAAATTGGAAATATGCAGTTATAA
    ACTGAAAGGTGATAATGAGAAAAATACCAAAGAAGATAGTAACATAAATTATTACCATAAAATTATGAAG
    ATACCCAAAATGAAAGGAGTACATTTTGATATTAGACAAAAAAGATGGTGTGCATATGGATACAAAAAAA
    AAGAATGTTTTTCTGTTTATAGATATGGGTTTTTAGCAGCAAGAGAATTAGCTGTTAGAAGCAGATTAAA
    TGTTCAAAAAAGGAGAAACAATTTAAGATTAAAAAAGAAAACCAAAAATGATATTAGTGTATCAAAACGA
    AAAAGCATTCCATTGAGAAATATTCCATCTAAGAAAAAAAGGAAAAAAGAGTGTGAAGCTATTAGTAATG
    ACAACATTGATAATACTAATATAAATGGAAATATACTTTTAAAAGTGAACGGAATAGTTAGTGAAAATAA
    TAATGGGATATATGAATTACCCAATTTAAATAAGAACAACGAACTAATTAGGAATATATATTCCGTATCT
    GACTCACACCTATACGATATTCAAAATGACAATTTGATTTCTCAAAATGATTATTACAAAGGTTTGGGAA
    CTGATATATCTGGTGAAAATGCTTTTAGAAATTATCAAGCAGGGCATATTTCGATATCAAGTTATCCAAA
    AAATGATATTCTGGGGGATCGAAATTTTAAAAATGTTACAAGTGATACAAATGATATGGGTAATGCATAT
    TTGTTATGTGGTTATAACAATAATGTTGTAATTGGTAATAATAAACAAAACTATAATAGACTCGATAATG
    CACCCTATTTAGTTGGAATAAAAATGACATACGATGGAAAAATAATGGAGAATCAAAACAGTCTCACCAA
    TGAATATAATTTAAGCACAATAGACATGGACACTCAAATTAATAATAGAACTGAATTAAATAAAATAAAT
    GATGAAAATTATTTTGGAAATTATAATATTAATAGTATAAATATAAAACAAGATATTGGTACAAACAATT
    ATATAAATAGTTATTCTAATAATGAAATGTGTCTAATGGATGGAGATAGAAATAATAATTATGTTTTTAT
    GAAAAATATTGAAAAAAATTTTAATATAAATAGCTATGACAATGAATATCCCTATTTTAATCACACCAAT
    TTAAATATTCCTAATGAAGAAATATTAAGCAAATGTTTTATAGGCCCCAATACACGAATACCATTAGCAG
    ACAAATATATAAATCATGGAGAAAGGATTGAAAAATATTTTTATAAAAAAATAAACCCATATGAAATGGA
    AAATAATGAGGAGGCATACTATCATGATACATTTAATAATGTAGATACGATAAAAAAATTAAACAGGACA
    GAAAATTACACCAATAAATTTTTTGAAACAATTTTAAATAATGTTGAAAATAATAATACGGTTATTATGA
    GTGAAAATACATTTAGAAATGACGTCATTAATAGAATCAGCAGTGATAACAACATTGATAATTTGAACAA
    CTTTTGTCATGAAAACACGATGAAAGAAAACAATTTGAATGTTGAAAAAGAAAACGCAACGCTTTTGAAT
    TGGAATTGTAATACATATTCAAAATATGATGAAGGAATGTGGAATAATGGAATAGGAAAGGGTGATAATA
    TGGGTAAGCATAAAATCGAATATAGCAATAACTATAATACTTACAATGGAAATATATCTATGCCTTTTTT
    AGAATATTATAATAATAATTTTAATGACGTAGAATGTACTAAATCGTGCAATATTGTGGGTAAAGAATAT
    TTCAATAATGGAGAACATGGTATGGATAACAAATCAGAAATTAGCAATATAAATTATTGTATAGAAAATA
    AAAATTTAAATATACCAAAAATACATTTATCGCAAAATCAATATGAAATAACGAATTTTAATAAAAATAT
    GTGGATAAGTGAACATCCCAAAGAAAACGAAAATAATCAGTTCGCTATAAATGAGACAAATATTGATCAA
    AATTATTTAAATTCTAATAAAATTAATAAAAAGGACAACAACAATAATTATTATATTTTCCCTGATTGTA
    ACATTTATAATGGTGCAAATATCGAATGTCAAAATACAAGTCTATCTAATGATATGTTGACAATAAATCC
    AACTGATGTTTCTGAGTTTATGGAGCAGACAAACACTCAAAATGGGCAAAGTTTTTACCAAGATAATGTT
    AACAATGTAGGAAATTTTAGTAATATCTATTGTAATGGCACCAACAGAAGACGTAATCTTTGTGGGCAAA
    ATAAGAGTGGAATTTCTGTTGAAATGGTACAAATAAATTCACCATTTCTTCAGAAAACTTATGGGGAAAC
    TGAAGCAAAATTAATACGTTTTGGTGATAATAATACAAATACCCCTAAAATAAATAATGAAAAATTATCG
    TACAGCATAAATGATAATCAAATAAATAAAAATTTCATTAMCGATATAGAAGCAAATAATAACAATTCCG
    AATATAAACATAATAACATTTATCCTGATGTATGGAGAAACTCATTTGATTTACATTATACAGATAGAAA
    AAATATACCAATTAAAATCTCATTTTTATCACCAAACACACATAAAGTTGACAAAGTTGTTACTATTGAT
    GAAAATCTAGAAAATTTTAATAATGAAAATAATTTTTTATTTAATTCTAAAAATAATACTAATAAGGATT
    GCATTGGAAATAGAGATGACGAAAAAGAAACAACAGATTTGAGAATTACACCCAATAAATATAGTGATAT
    AAATAACTGCCAAAATAATAATATATATATGAGCAGAAATGATATATATACGGATTATCATAATTCCAAT
    AATTTTAACGAGGAAAACACAAATTTAAAGATCGAAAATGAAGATTTGTGCAACAATGGAAGTAAAATGA
    ATGAATTCACAAATAGCTTTAGTCATGAAAGCAAACAAATTTATCATGAGCAAAATAAAATAGACGATTT
    GTGGTGGGAAAATAACAATGAAAGAGTTTTTACAGATCCAACAATTTATCCTAATAATAGCATCCCATAT
    ACATGTGAACCAAATAATTTATTGAATTCATATGTTAATAATATAAGTGATAAGCATAAATTTTTATTTA
    ATTATAACAACTATGAAGATATAAATTTAAAAAAAAACGAACTGAATATAGGTACTGAATTTTCCCGTAG
    TATTTCTGCAAATGAAATAGAAATAAATATGCAATCATATGATGAAAGAAAAAACGAAAAAAAAAAAAAT
    ATATGTCATTATATTAACAACGATATGGAATATATAAGGCAAGGGTAGTAGTTTAATAAATGGAAAGGAA
    GTAAATCCTGATCAAAGCTTTATGAATATGTGTAATTTGCCTAAACGATTACAAAATGATAMCCGTGAAA
    AGAGAAATAMCAAACTAAATAAATATAATGMCAATAATAATAGCAATAGAAATGATGAAATGAATCAAAA
    CATAAATGGTGACCTAATTAGAGATTTAAATAATCTTAATAATGTAAAAATAAATAATGATTTAATTCCA
    AGGTATAATCCATACATTTTTTTCAACAATCATACAAGTAGAAATTATAATGATGGTAATAATTTTTATA
    ATGAACAAAACTGTGTTACGAAAATCAAAAACGAAAATAAGGAATACTATGATATGGAAGGATATAAAGG
    TGTATTCAATTCCGTGGAAGGGCATTTTGGCGATGTAGAACAAGTGCCAAAAAGAGGGAACGGATTTAAC
    AGAAATGAAAATATGTTCGAAAGAAGTATAGATACAATAAGTGATGAGAGTACACATCTCAATATAGGAG
    GACGACGGAACTTCATGCAGAGCAACGTTGTAAATCATTTTGTGAATGATCCAATTAAAAGTCAAAATAT
    GAATCCACTTGTTGAAAATATAAAAAATATAAAAAATATTAATAAAAGAAATGAAACTTGTACGAGTTTA
    GAGTGTGATTTAAATTGTTATGCTATAAAAAGGGATAATACGGAAAATAATTCTGAAGAAATAATCAATA
    GTAATGAAAAAAGGATAGATGATGAAGAAGAAATGCGTATAGATGTAGCGGATAATTATAACATTCTTGA
    TGATGATATAGAAAAAGGGCGAAAAAACCCAAAAATAATAAAACATATAAATAATTTCACATATACAGAT
    AATAATATTCTTAAAAATATAAAATTTTCTAGCCAAACCAACAATATCAAAAAGGGGGAAACATTTATAG
    ATAATAATAAATACATTTCAAACATTTTTGAAAAAGAAAAACATAACAAGAAAATTTTTCATCACGAAAG
    GAAATATAAATGGATGACAGATGATAGGGATATAAGCATATGTTTTCAAAAAGGGCATAATAATAATGTT
    AATGGTATTAATTCTGTTGGTAGCTCTATTCATAGAATTAATAAAAAAGGGACAATATTAAAAAATGTGC
    AAATAACGAACAAATTCAATAATAAATTTATGAAAAAATGCCTACAAATAGATATAAGCTTTGATAAGAA
    TTTAAAAAAGAAATATACACAAAATGAGAAATTAATTAATAATTACCACATATCCATATTCAAAAATATT
    AGCATTAGCAATATTTTATCGCTTCGATGCAACATTAGAAGGAAAGATACATTAATGGAATCCTATTGCG
    AATATATTTGCCTAACATTACACGTAATTTTTTTTTAACATGAAAAAATGGTGTATACTTATGAATTGTT
    TTTTTCGAAATGTTCAAGTCGCTGAATTATTCATTTTTTTTATATGCATAAATGTGCGTCATTAATATCA
    AACAGGAAGTATAGAAAATGTGATTGGTCTAATGTATATGTTTATACTTTTATTTTATTCTGCGCATATC
    TTTTATTTCGATCATATTTTATTTTTTATAACTTTTACAGGATATAAACGTGAATAGATCTAAAGATGCA
    AGCAAGACAATTTACTTTAAAAAGGTGATATACAAATTTTTAATCATTGATTTGTTTAAAAATTTAAACC
    CCATAGATTTTTCAAATAATGGGAATATAGTGGAAAATAATGATAAGCTAGGTAAACATCCATTGTTTGA
    AAATTTATTACGTGAAAAAAAAATACAAAAATATATTAATATATTAAAAAAAGTTGAAAAATATCATATC
    GATATTATAAACAACATGTATGATCTCAAATCCATACAATTGTATATAGATATTTTTGTTACATGCTTAC
    TAAAAAATATCCCATCAAGCAAGTTGTCATATGATGAACACAATATGCTCATAAGATCACTTTTGTTGTT
    TTACTTTGATAGTAATAAATAGGTAGCTATAAAGGGAGGAAATTCAGTGCTCACTTGAATTCCCCCCTTC
    AAATTAGCTAGCTACTGTGGTTAAATGGTAAAATGAAGTAACAGAAAAATTATTAATCGCTAGCATGATA
    AATGGAGCAATATGATGGTATATTGACATGATAATACAATGGTGATATATTTATCACTACATAGTTTTTA
    TTTTTTTTTTCATGGCAAACTATATTTTGTATAGTATATAAATATTTATGAGTTTTATTGTTATTTTGAT
    TTGTAATAATTAAAATTCCCAACGTTGTTTATGTATTAATTATTTGTTTTTTATGTAGCATTTATTTTTT
    TTTTTAATATTTTTTTCTCTCAAAAAAATTGCACTTTAATTCTTATTTCGTTATGGCATTACAACATTGT
    GTGCACATGAGTGTAAAACGTATACAACAATTTTTAACGATGTTTAAAAGTAAACTTGTATTTTTATACT
    AATATATTTTCGCTCATTCTTTTACAAGTCACAACTGTTATACTTATTTTTTAAAATTGATAGACAAAAT
    TAAATTAATGTATTTTTTTCAAATTACAAAATTATAAAAATAATTTTTTTTATATTAATAATATTTTTTA
    ATATTTCGTGGTGATGGTGTCTGGTATTTCTCATGATTTATTGTGGAATATTATTTTTTTTTAATACCAA
    GAAATTAATTGTAGTGTGATTTATTTATGTATTCATTATTATTGTTATATGTGTACTATTTTATATATAT
    TTTCTGTTCATTATTAACTCTGCGATATTGATATATTTTTGCATCGCCAGCAGATAAATCACTTATTCGC
    GATATTATTTTGGCTTTTTCGGTTTATATTAATTTTGTAAAATGGAACAAAAAGGAGACAGGAAAAAGAA
    AAAAAAAAAAAAGGAAAAAGAGAAGGAGCCCAGCTATTTCTCCGATACCATAACAGTAAATATAGAAAAA
    AAAATATATATGTATAAATATAATGAAATATGTGATAAAAGAAATTGTTGGCTATGATGAAAGTAGACGA
    AATGCTTTGTGTTTTATGTCGTTTCCTCGGCTTCATCACGTGTAAAAATCGTTTTATTTTATTTCATCAA
    ACTTTTCGAAAAGATTATACTACATATATATATGTTTATACGTTTTACTATATCACCACATTCGTTTGAT
    TCTCATTTGTATTAATTTTTATACATGGCTATATATTTATTCCCATTTTCTACATATAGTTTTGTGGAAC
    TTTCATGCGTGATTCTATGATAAGCGCAGCAGAAGTTGTTCAAAATAACTATTACCCCATTAAAGAATCG
    ATAATAAGTATATACGATCAGTATTTTAGTGAGAACAATCATCAAAGTAATACTCGAATTACTGGGAATG
    TCCCAATTTTTATGGTGAAGACAAGTGATACAAAGTCCAAATAAGGGTATATTCATTTGTTTAGTTTTAT
    CTCTTTTTTTAATGATAGTATGGTGATAAACATTGGTTAATTATGGATAATAAATATAAACGAAATTAAA
    ATGCTCACAAAATAAACATATTCACGTATACATATGTATATGCGAAAATATGCGGAGATTTTTGAAAATG
    GCAATTTTGCCGAAACAAAAAAAATATAATTTTAAAATATGAATTTCGTTTGCCCGAAATGATAAAGAAA
    AGAAGAGACAAAAAAATATATATGTAATGATAATAGTATAGGATGAAATCGGGTGAAGGAGCCACTATTT
    CATCTGTCAAATAAAAAGCATATATATAAAAATAAAAATTACACATATATGTCGCATGTGTGAACACATA
    CGATAATTTATATTTATGACAACATATTTTACAAGGAAATTAGCCCAATTAGGTATGAATAAAGCGGGTA
    TTAATGTATGCATCAATTTAATTAATGCTATATGATAAAGTAAAGAAAGAAGGAAATTTTGATATACAAA
    GTGATTTCCAAGTAGCATACCACAATCAATCGAGTGGTAAAATTTTGTGTCCCTTTAAACCGGTTGTGGG
    TCATAGCTTAAGCCATTCATTATCTTTAATTATTTCTCGATTTCTCTCACCATAATCGATTAGCAATTCT
    TCTCCTTTTTGTATGTCTCTAGAGGCGATGAAAAAAAGTCTGGGTAAAAAATCAACGGTTAGTACTTTAG
    GAATTAAATTTGAGTTTTTTTTTGAGTGATTTACTAATCTAGCAAAAGATCTTAAGAAATATTTTTTATT
    AGTATAATTGATAGCCGCGTCTATACTTTCTTCAGTTCCATCTATACAATATCTTTTATTTTCATGTTTA
    AAATAGAACATGTAACAACCTTTTTTTTTATTTTTAATATATATTTGCTCTCGTTCCATAGCTTCATTAT
    GTGTTAATAATTCACCAACATATTCAAAAACAAAATCAAATTTATTAATTTGTGTATCTGCATATATGCA
    TCTACCTTTTGTAGAGTCAAAAATAACTTTTATACATGCAAACATATTCATTTTAAGATTTTCTTCATAT
    ATAATATTTCTACTTTTTTCTTTTAAGTAAGATAATGGAATGGTATTAATTTCAGCTTCTTTATCAATGA
    ATAGATCAATAAGCTGTTGTTTATTTAATTTGTTTATGGTTCTATCATATTCATATTTTCCATAATATTC
    TATCCTGGATTTTTTTAATTTTTCGATTTTTCTGCTATTTATATTTTGAAGAAATTTATCAATAAAATTT
    ACACTATCTTTTAATTTCATAATTTCTATGTCTTGTTTTTTATTTTGTGACTTTCCGTAATAAGAAATAC
    AAGAATCATAAAAATCTGCAAGCCCTTGTTTTGCTTCTTTCTTCCCACCGTTTTCATTTTCTTGTTCTCT
    TTTTTCAGAAAAAAATTTATATAATTTTTCAAAACATATATCTAGATCGATGATATATTTTCTAAAATGT
    AAAGAAATGTTCCACAAGAGGTCAGGAGAATAGGTAGAAATAGTTGTTAATTTTATATTTTCAGTATTTT
    TTATCAAATAAATTAAAATTTGTATAATAATTTTTTTCGGTAATATTTTTACCTTATCATAACTATGACC
    TGTATCATTAAATTTAATATATATATAATCTCCTTGCTTTAGTTTTTTTTCTAAGGATTTATGTTTTTTG
    CTAATAAAAGCAAATATAATATCTGTATCTGTAACTAGTTCTGTGTTTTCAGATATGTCTTCTAGTTTCT
    GATCATTGCAATCTTTGTTGAATTCAGTAGGAATGCTGTTTTGGGTTAGGTGATTTGTCTCTGTTATGCC
    TTCTTTTGATAAGACATTTCCTTCCGTTTTCAATTTCTCTTTAACATCAATTCCCTCTTTGAAACTCGAA
    TAGGATTTCCCTTCTATATCAACATTTTCTGTGGTAATACGTTCATTCTGAAATGCATGATAGTTGTCTT
    GAGATTCCGAAATGAAATTTTCGACATTGGGTTCTGTTGGTATATATTTTTTAAAGTAATTAAAAATATC
    GTTATCTTCAAAATTTTGAACATCATTTTCAATTGTTTGATCTGATAATTCGTATAAATAATTTTGGTTT
    TTAAAATGCTCTTTTTTATCACATGTGTAAAAATCTTCATCATCAATTATAAATATTTTATAATTGTTTT
    TATATAAAGTTTCAATTCGCTCAAAACTTTTAGATAAAGAATTTAAATGTGGTTTCTTTTTATCCAAAAT
    ATTTTTTAATATTTTATTTATATATATATCGATGCAATCTTTATCTAATTTATTTTTTTTAAATATATGA
    CTATTAATTTTATTCTGTTGATCTTCTAAATTATTATAAAACATATTTTTAAAACAATTTACATATTCAT
    AATTCTCTAATTTATATAATTTGGATGATTCTAAAATAAGTTTTGTATTTTCGTTTAAATTTATCGGTTT
    ATTAGTGTTATTTTCCTTAATACAAATATTTTTTGTTTTTAAATTTTCTTTATTTTTTTCTTTTTGTGTT
    TCGGTATCATTTTCGATGGTAGTATCTTCTATATTGACACAATGATTTTTCATTCCTTCTAATTTTGTTG
    AGCTATTATCATTATCATTTTTATTATCTAGTTCTTTTCCGTCATTCCTACATTTTAATTTGTCTATTTC
    GTTATTTGCATCATATATATTGTTTTGGGATTGACCAATATGAGAACAATTGAAATTATTTTCTCGACAA
    TATTTATCAGTTTCAAAATATTCATTATGTTCTCCATCTTTTACACCTGTATTGACTTCATTGGTGTTTT
    CTATGTAAATTTCGTGGTTAGCAACTATAGAGTCGGGTTTTTCATCATCATCATCGGTCATATCGTTACT
    ACTACTATGACAATAATACCATGTTTTTCTTTTCTTCCTTTTTGCATTATTATTAATAGAGATATGATTA
    TCTGTGTCACTAATGATAATTGGTTTTTCTTGATTCCCATTTTTTTCATTTTTTTGAGTATTACAACTAC
    TATTATTAATGATTTGACTTTTATTTTCTGTATCTTCCATTTTTACTTTATTTTGATTAAGAAATGTTGC
    TTTTTTTTTCTGCATTTTGATTAACTTGTTCAAATTTTCATTTTCATTTTCATTAGTAAGACAAGAAAAG
    CTATTAATATTGCTGGACTTTTTTTGGTTACATTTATCAGTATTTTTATTTTTTTTTCCAGCCTCTTCTA
    TTTTTATTTTTAAGCGATACCATTTTACATCATTAATATCATTTGAATTATCTTCTAAAATATTTTTATT
    ATTTTTTAATCCATTTAAATATAAATATTTTATTTGATCGTTATTAAACATATTACCATTTTTACTATCA
    TGTTTATTAGCATTTTCATTTCTTCTTTTATTTAATTCATAACTGTTAAACTGATTGTCTGTTGTATTTT
    CATATTTGTTATAAGCGCTATTGTAAATGGATGTGTACATATCCAATTCGTCATATATATTGTATTTATT
    AATACAATCTTGGATTCCCAATTTTGTATTTATATTTAGTCTCTGTCTTTTTACCTTAGATTTTTCGAAT
    AAAAAATGAAGACTCCAGAAGTAATAACGATCGTAAATTAGGAGAGGAATATGATTATTTCGATATCCGC
    ACATAGGCTGCATTCATTGATAAAGAAAAATTAATGAATATATAGGGCACTGGATAAAGCGTAGGAATAA
    AAGCACTTATTTGTTTGGAGAAAATAATCAGCATATATAAATATTTTTTCTATTATTTTATTTTTTTGAG
    TACATACCGATATATCAAGTGCTATGTTAAAACTGTTATCATCAAACAATAGATATACCTTGGATATTAT
    AGAGGTGTCATTCCCCTGATTTATGGGATTTTTATTTAAATCATCAAAATATTTGGATAGATCTGCATAT
    AATGGTATATGAACGATCGAATCTAATTTTTCTTTTTCAATCCATATTATAGATGCTAAATCTTTGCAAG
    AAGAGTTAATATTTTCAAACGTATCATTATCAGTGTTTTTACTACTTTCAAAGGTTATATTTATTTTGTT
    TTTTTTCATTTTTCGAATTATCTAGCATGACACATGCATATATAGATATACATATATGTTTTTATTTATA
    TGGGGAAATGCGCAGAGGGTTCCTCTTTCTTTCAAACGGAATTCAGAAGAAAGAAATATATATACATATC
    GAAAATACAACCGAATTATACATTTTTATCAAAAAATTATAATAAAAAAAATGCAAAAATTCACTAGTAC
    GGGAATTTTTTTTGATCTTTTGAAATATATATATATAATGAAAATAAAAAATAAAATACAATGAGCAAAA
    AGAAGGTAATTTAAATTTTTTTTAATATTTAAAATAATAAAAAAGAAATAAGAACATCTTCAAAGAGGAC
    AAGAAATAATAAAGTTCAATGAAAATAATAAGGTTGTGTATAATAATATAAGAATTACCAATAAAATATT
    TTAATAAATTAAAAAAATATATACGTAAATAAAGATCTCTAAAATATACAAGTGAATAATCAACGTGTTA
    TATGCACGCACATATATATCCATAATAATCTAGCCAAAATATTATAAATCATTAAAATTATGTATACATA
    CAAATTTTTACTAAAATAAAATGGTGAAAAATAAGCAATAAAATGTGTAAATTCAATGGATTTTAATATA
    TCAATATTACCTTTATATGGATATTAGATTTTTTCATACAGGATAACTATCTTTTATATTTTAAAAATTA
    TAATTTCAGTTATTTTGCAAAAAAGGATGTATATAAACATAAATTTTTTAATGTTTTGCAACAATTATTT
    ATATATTATTATATGTGAAAAAGACTATATGTGGGGAAATAAAATAAGATTCTATATACTTATATGCTTT
    ATTATAAACTGGCAAATTCTTTTTTTTTAAAGAAAAACTGAATAAAAAATATTGTTTAAAAGATGAAAAT
    TAAAAAATATATTAGAATAATACATATATATATGTATGTAAAAGGTATAGTTAATTTTTTGAGTGTTGAT
    CAGCTTTGTATAATTAATAACATCTTTATAAAATAAATCATATATTCCTTTTTTAGATAGTATTTTTCGT
    TTTAATAATACATAAAAAATAGCTATTTAAATAATAATACGATTTCTTATTAAGAGAAACAAAATCATGA
    GTCTAATGAAGAAATAAAAACTGCTAATACATATATACTTACTACCATAATATGATATTATGAATAATAA
    CACCCAATTTGTATGGTTATACATATATATATGTTTAATGAACATATATGCCCATATTTTTAAAATTTAT
    ATTGAAGCTTTTATTTTTTTATGAACAAAACTATTTTCTTTAATTATATCATAGG
  • Molecule Role : Virmugen
  • Molecule Role Annotation : Deletion of P52 and P36 in Plasmodium yoelii were attenuated and provided protection against challenge in mice (Labaied et al., 2007).
35. Py36
  • Gene Name : Py36
  • Sequence Strain (Species/Organism) : Plasmodium yoelii 17XNL
  • NCBI Protein GI : 23479924
  • Other Database IDs : CDD:185624
  • Taxonomy ID : 73239
  • Gene Strand (Orientation) : ?
  • Protein Name : p36 protein
  • Protein Length : 231
  • Protein Note : p36-lilke protein; Provisional
  • Protein Sequence : Show Sequence
    >gi|23479924|gb|EAA16624.1| p36 protein [Plasmodium yoelii yoelii]
    MSENSTIEGNDIGEKVAAIKKYLEAFDHQNEAKSIHGFVDLLKKINIKMAVFDFDLTLIGKHSGTCNIMC
    GYIDKLNDIEDIGTSVTNAFKILSKRLYENNIKITVATFSDDEAIRYSKVKSPSLIAGEELIQHCIKHSN
    CETKIERVYAYYPYYYKEPKKYMALGLKEPMSNDKSYHLKRIRNEFSVNINEIIFFDDDVKNCISAKKEG
    YITFNVTGKKGFNFKDIKLMQ
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites (Labaied et al., 2007).
  • Related Vaccine(s): Plasmodium yoelii p36/p52 mutant vaccine
36. Py52
  • Gene Name : Py52
  • NCBI Nucleotide GI : 15193061
  • NCBI Protein GI : 15193062
  • Protein Accession : AAK91678.1
  • Taxonomy ID : 5861
  • Gene Strand (Orientation) : ?
  • Protein Name : Py52
  • Protein Note : member of the 6 cysteine family of Plasmodium proteins; putative membrane-bound protein; sporozoite expressed
  • DNA Sequence : Show Sequence
    >gi|15193061|gb|AF390552.1| Plasmodium yoelii Py52 mRNA, complete cds
    ATGAAACGTCGAAGCATTTTCATGTACTACTGTTTCTGTTTCTTATTGAAATATGTAGCCTTTAGCAATG
    TGCCAAATCCTAATACGACCATAGGACACTTTGAAATTTGTGAAGTAAATACATCTTCAGGTGATGCCGA
    AGAATGTGTTTTAGAAAATGAATTTGGGAAAATGTTTTTATTTATTTGTGATATTGATTACAATGAGATG
    TCAAAAAATATAGTGCTTCCGTCAGAATGTGCTAAAAAAACATATATAGACCATGTAAACCCAAATGGAA
    CATCGCCAGAAGTTAATACTTATGATATATTTCCAGATTTGATCGCAGCAAATGAATCCCAATTTCGTGA
    TAAATTTTATTTTTATGGAACCCCATATTCATCTAAAGACATTGATTTTATATGTTTATGTTTTTCTGAA
    ACAAAACCAGATATAAAACATGTAATGAAAATGAGTTTTAAAAAAATGACAAAAAAAATAAAAGGATGTG
    ATTTTGGAGATAATATACCAACGAAAAAAGATTTAACAAATGGGAAAGCATTATATGAAAATTCTAGTTG
    TCATATATATGCATATCCAGGAGACGTAATTGGAATAAATTGTTATAAAAAAGACATTAATAATATTTAT
    AATAATAATTTAGAATTACAGCCAAATAATTGTTTTCATAATGTTTATTATGAAGATGATATATTATTAT
    CGTCAAAAAATTTAATACCTAATTCTAGAGTTATACCAGATCCGAGTAACGATGTTAAATTATCAAAAAT
    GCATTCATATATGTCTTATATTATACTCCCTGACGAAATAAATGAAAATGTTAAAATTAGTTGTGCATGC
    AAAAGAGATGAATATATCGGCACTATGTTTTTATATGTAAATACATCGAAAAATATTTTAACATCCCCTG
    ACAACAACGTAGAAGAAATTGCTCCTTTGAATGACCACTATATTTCAATTGGAGACATGTGGGACATGGG
    TTTACATGAAAACCCTGAGCAAATACAAGGCATTATTAGCAATCATGCAAATAAAAAATATTATGAACAT
    ATGAAAATTTACAAAAGCAATAAAATGGATTCTAGTGATGATGATGAATCGAATGAGACTGAATCGAGTG
    AGAATGAATCAAATGAGCGCACACACAATGGTAATAGAGCAAATAAAGATGCTAATAATAGTGAGAAAAT
    GACTGGTAATAGAAGGAAAAAAAATAATTCTATCAATAATACTAATTACTATAGTAATTATGAGGATGAC
    AATGGAATTAATATATCTACCCATGATAAATATTATGAGGACCAACATTTTGGTAACAATGGACCTTTGA
    GAAAGAAAAGAACATTTTGGCAAAATATGTTTGGTACCTCTTCTTCTTATTATGAGGTCTTTAACTATTT
    TTCAATCGCATTTATTCTAATTATTCATATGCTCCTCTTATGA
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A genetically attenuated parasite (GAP) with deletions in p52 and p36 are attenuated in mice. Mice immunized with the mutant were completely protected against challenge with wild type Plasmodium sporozoites (Labaied et al., 2007).
  • Related Vaccine(s): Plasmodium yoelii p36/p52 mutant vaccine
37. RESA
  • Gene Name : RESA
  • Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
  • VO ID : VO_0010959
  • NCBI Gene ID : 813159
  • NCBI Protein GI : 124505681
  • Locus Tag : PFA_0110w
  • Genbank Accession : AL844501
  • Protein Accession : XP_001350954
  • Taxonomy ID : 36329
  • Chromosome No : 1
  • Gene Starting Position : 99051
  • Gene Ending Position : 102514
  • Gene Strand (Orientation) : ?
  • Protein Name : RESA, ring-infected erythrocyte surface antigen, Pf155, MAL1P1.13
  • Protein pI : 4.13
  • Protein Weight : 117293.03
  • Protein Length : 1085
  • Protein Note : Also known as Pf155
  • DNA Sequence : Show Sequence
    >ref|NC_004325.1|:99051-102514 Plasmodium falciparum strain 3D7, chromosome 1
    TATGAGACCTTTTCATGCATATAGTTGGATTTTTTCTCAACAATATATGGATACAAAAAATGTTAAGGAA
    AAAAATCCCACCATATATTCATTTGATGATGAAGAAAAAAGAAATGAAAATAAGAGCTTTTTAAAGGTGT
    TGTGTTCTAAACGTGGTGTTCTTCCAATTATTGGAATACTATATATCATTTTAAATGTAAGTTTTTTTTT
    TTTTTTTTTTTTTTGAAATAAAATACATATTTTTTATATTTAATTTTTTATGTTAATGCTTATTTTATTT
    TATTCTATTCTTTTTTATATGTCATGCATATTTTATATATTATAATACCGTTTTTAATAATATATAATAT
    ATCTTTGTTATTATATATAATTTTTTTTTTTTTTTTTTTTTTTTTTTCATAGGGTAATCTTGGATATAAT
    GGAAGTTCATCTTCTGGCGTACAATTTACTGATAGATGTTCAAGAAATTTATACGGGGAAACATTGCCAG
    TAAACCCATATGCTGATTCTGAAAACCCAATAGTTGTAAGTCAGGTATTTGGTTTACCCTTCGAAAAACC
    TACGTTTACCTTAGAAAGTCCTCCTGATATTGATCATACAAATATTTTGGGTTTTAATGAGAAGTTCATG
    ACTGATGTAAATAGATATCGATATTCTAATAACTATGAAGCCATTCCTCATATAAGTGAGTTCAATCCAC
    TTATTGTAGATAAAGTTCTTTTCGACTATAACGAAAAGGTTGATAACTTAGGAAGAAGTGGAGGAGACAT
    TATAAAAAAAATGCAAACTTTATGGGATGAAATAATGGATATTAATAAAAGAAAATATGATTCTTTAAAA
    GAAAAATTACAGAAAACTTACAGTCAGTACAAGGTTCAATATGATATGCCAAAAGAAGCATATGAGAGCA
    AATGGACACAATGCATAAAACTTATTGATCAAGGAGGAGAGAACCTTGAAGAAAGATTGAACTCACAATT
    TAAAAACTGGTACAGGCAGAAATATTTAAATCTTGAAGAATATAGAAGATTGACTGTGTTGAACCAAATC
    GCTTGGAAAGCTTTATCCAACCAAATTCAATATTCATGCAGAAAAATTATGAATAGTGACATTTCTTCCT
    TTAAACATATAAATGAATTGAAAAGTTTAGAACACAGAGCCGCAAAAGCTGCAGAAGCAGAAATGAAGAA
    AAGAGCTCAAAAACCGAAGAAGAAAAAAAGTAGAAGAGGATGGTTATGTTGTGGGGGGGGAGATATCGAA
    ACAGTTGAACCACAACAAGAAGAACCAGTCCAAACCGTTCAAGAACAACAAGTAAATGAATATGGTGATA
    TATTACCATCATTAAGGGCCAGTATTACTAATTCAGCTATTAATTATTATGATACCGTAAAAGATGGTGT
    ATACTTAGACCATGAAACATCAGATGCTCTTTATACAGATGAAGATTTGTTATTTGATTTGGAAAAACAA
    AAATATATGGATATGTTAGATACATCTGAAGAAGAATCTGTTAAAGAAAATGAAGAAGAACACACTGTTG
    ATGATGAACATGTAGAAGAACACACTGCTGATGACGAACATGTAGAAGAACCAACTGTTGCTGATGATGA
    ACATGTAGAAGAACCAACTGTTGCTGATGAACACGTAGAAGAACCAACTGTTGCTGAAGAACATGTAGAA
    GAACCAACTGTTGCTGAAGAACACGTAGAAGAACCAGCTAGTGATGTTCAACAAACTTCAGAAGCAGCTC
    CAACAATTGAAATCCCCGATACATTATATTACGATATATTAGGTGTTGGTGTTAATGCTGATATGAACGA
    AATTACTGAACGTTATTTTAAGTTAGCTGAAAATTACTATCCATACCAAAGATCAGGTTCTACTGTTTTC
    CACAACTTTAGGAAAGTCAACGAAGCCTACCAAGTTTTAGGAGATATTGATAAAAAAAGATGGTACAATA
    AATACGGATATGATGGAATAAAACAAGTCAACTTTATGAATCCATCCATCTTTTATTTATTATCTAGTTT
    AGAAAAATTTAAAGATTTTACCGGAACACCCCAAATAGTAACTCTTTTGAGATTCTTTTTTGAAAAGAGA
    TTATCTATGAATGATTTAGAGAATAAAAGTGAACATTTATTAAAATTTATGGAACAATATCAAAAAGAAA
    GAGAAGCACATGTATCTGAATATTTATTAAATATATTACAACCATGTATAGCTGGTGATTCAAAATGGAA
    TGTACCAATTATAACAAAACTTGAAGGTTTAAAAGGATCTCGCTTTGATATACCAATATTAGAATCTTTA
    AGATGGATATTCAAACATGTCGCTAAAACACATTTGAAAAAATCCTCAAAATCAGCTAAGAAACTTCAAC
    AGAGAACCCAGGCTAATAAACAAGAATTAGCAAATATAAATAATAACCTAATGAGTACATTGAAAGAATA
    TGTAGGAAGTAGTGAACAAATGAATTCAATAACATACAATTTCGAAAACATCAATTCCAATGTTGATAAC
    GGAAACCAATCAAAAAATATTTCAGATTTAAGTTATACAGATCAGAAGGAAATATTAGAAAAAATTGTTA
    GTTATATAGTAGATATTTCCCTTTATGATATAGAGAACACAGCTTTAAATGCCGCTGAACAATTGTTGTC
    AGATAATTCAGTAGATGAAAAAACTCTTAAAAAGAGAGCTCAATCATTAAAAAAATTATCATCCATTATG
    GAGAGATATGCAGGTGGTAAAAGAAACGATAAAAAAGCAAAAAAATATGATACCCAAGATGTTGTAGGAT
    ATATTATGCATGGAATTAGCACAATTAATAAAGAAATGAAAAACCAAAATGAAAATGTACCCGAACATGT
    ACAACATAATGCTGAAGCAAATGTAGAACATGATGCTGAAGAAAATGTAGAACATGATGCTGAAGAAAAT
    GTTGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAA
    ATGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAAATGTTGAAGAAAATGTAGAAGAAAATGTTGAAGA
    AAATGTAGAAGAAAATGTAGAAGAAAATGTTGAAGAATATGATGAAGAAAATGTTGAAGAAGTAGAAGAA
    AATGTTGAAGAATATGATGAAGAAAATGTTGAAGAAGTAGAAGAAAATGTAGAAGAAAATGTAGAAGAAA
    ATGTAGAAGAAAATGTTGAAGAATATGATGAAGAAAATGTTGAAGAAGTAGAAGAAAATGTAGAAGAAAA
    TGTAGAAGAAAATGTTGAAGAAAATGTAGAAGAAAATGTTGAAGAAGTAGAAGAAAATGTAGAAGAAAAT
    GTAGAAGAAAATGTAGAAGAGAATGTTGAAGAGAATGTTGAAGAGAATGTTGAAGAATATGATGAAGAAA
    ATGTTGAAGAACACAATGAAGAATATGATGAATA
  • Protein Sequence : Show Sequence
    >gi|124505681|ref|XP_001350954.1| DNAJ protein, putative [Plasmodium falciparum 3D7]
    MRPFHAYSWIFSQQYMDTKNVKEKNPTIYSFDDEEKRNENKSFLKVLCSKRGVLPIIGILYIILNGNLGY
    NGSSSSGVQFTDRCSRNLYGETLPVNPYADSENPIVVSQVFGLPFEKPTFTLESPPDIDHTNILGFNEKF
    MTDVNRYRYSNNYEAIPHISEFNPLIVDKVLFDYNEKVDNLGRSGGDIIKKMQTLWDEIMDINKRKYDSL
    KEKLQKTYSQYKVQYDMPKEAYESKWTQCIKLIDQGGENLEERLNSQFKNWYRQKYLNLEEYRRLTVLNQ
    IAWKALSNQIQYSCRKIMNSDISSFKHINELKSLEHRAAKAAEAEMKKRAQKPKKKKSRRGWLCCGGGDI
    ETVEPQQEEPVQTVQEQQVNEYGDILPSLRASITNSAINYYDTVKDGVYLDHETSDALYTDEDLLFDLEK
    QKYMDMLDTSEEESVKENEEEHTVDDEHVEEHTADDEHVEEPTVADDEHVEEPTVADEHVEEPTVAEEHV
    EEPTVAEEHVEEPASDVQQTSEAAPTIEIPDTLYYDILGVGVNADMNEITERYFKLAENYYPYQRSGSTV
    FHNFRKVNEAYQVLGDIDKKRWYNKYGYDGIKQVNFMNPSIFYLLSSLEKFKDFTGTPQIVTLLRFFFEK
    RLSMNDLENKSEHLLKFMEQYQKEREAHVSEYLLNILQPCIAGDSKWNVPIITKLEGLKGSRFDIPILES
    LRWIFKHVAKTHLKKSSKSAKKLQQRTQANKQELANINNNLMSTLKEYVGSSEQMNSITYNFENINSNVD
    NGNQSKNISDLSYTDQKEILEKIVSYIVDISLYDIENTALNAAEQLLSDNSVDEKTLKKRAQSLKKLSSI
    MERYAGGKRNDKKAKKYDTQDVVGYIMHGISTINKEMKNQNENVPEHVQHNAEANVEHDAEENVEHDAEE
    NVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEENVEEYDEENVEEVE
    ENVEEYDEENVEEVEENVEENVEENVEENVEEYDEENVEEVEENVEENVEENVEENVEENVEEVEENVEE
    NVEENVEENVEENVEENVEEYDEENVEEHNEEYDE
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. falciparum vaccine Combination B
38. SERA-5
  • Gene Name : SERA-5
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • VO ID : VO_0011210
  • NCBI Protein GI : 238629807
  • 3D structure: PDB ID : 3CH2
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : serine repeat antigen 5
  • Protein Length : 287
  • Protein Sequence : Show Sequence
    >gi|238629807|gb|ACR49652.1| serine repeat antigen 5 [Plasmodium falciparum]
    TGGGQAGNTGGGQAGNTGGGQAGNTVGDQAGSTGGSPQGSTGASQPGSSEPSNPVSSGHSVSTVSVSQTS
    TSSEKQDTIQVKSALLKDYMGLKVTGPCNENFIMFLVPHIYIDVDTEDTNIELRTTLKKTNNAISFESNS
    GSLEKKKYVKLPSNGTTGEQGSSTGTVRGDTEPISDSSSSSSSSSSSSSSSSSSSSSSSESLPANGPDSP
    TVKPPRNLQNICETGKNFKLVVYIKENTLILKWKVYGETKDTTENNKVDVRKYLINEKETPFTNILIHAY
    KEHNEQT
  • Molecule Role : Protective antigen
  • Molecule Role Annotation : Researchers constructed a new recombinant molecule of SERA5, namely SE36. Vaccination of Squirrel monkeys with SE36 protein and aluminium hydroxyl gel (SE36/AHG) conferred protection against high parasitemia and boosted serum anti-SE36 IgG after P. falciparum parasite challenge (Horii et al., 2010).
  • Related Vaccine(s): P. falciparum Subunit SE36 Protein Vaccine
39. SSP2
  • Gene Name : SSP2
  • Sequence Strain (Species/Organism) : Plasmodium yoelii yoelii
  • NCBI Protein GI : 45645179
  • Other Database IDs : CDD:29244
    CDD:197574
  • Taxonomy ID : 73239
  • Gene Strand (Orientation) : ?
  • Protein Name : Sporozoite surface protein 2
  • Protein Length : 827
  • Protein Note : Potential.
  • Protein Sequence : Show Sequence
    >gi|45645179|sp|Q01443.2|SSP2_PLAYO RecName: Full=Sporozoite surface protein 2; Flags: Precursor
    MKLLGNSKYIFVVLLLCISVFLNGQETLDEIKYSEEVCTEQIDIHILLDGSGSIGYSNWKAHVIPMLNTL
    VDNLNISNDEINVSLTLFSTNSRELIKLKGYGSTSKDSLRFILAHLQNNYSPNGNTNLTSALLVVDTLIN
    ERMYRPDAIQLAIILTDGIPNDLPRSTAVVHQLKRKHVNVAIIGVGAGVNNEYNRILVGCDRYAPCPYYS
    SGSWNEAQNMIKPFLTKVCQEVERIAHCGKWEEWSECSTTCDEGRKIRRRQILHPGCVSEMTTPCKVRDC
    PQIPIPPVIPNKIPEKPSNPEEPVNPNDPNDPNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNN
    PNNPNNPNNPNNPNNPNNPNNPNNPNNPNNPNDPSNPNNPNPKKRNPKRRNPNKPKPNKPNPNKPNPNEP
    SNPNKPNPNEPSNPNKPNPNEPSNPNKPNPNEPSNPNKPNPNEPLNPNEPSNPNEPSNPNAPSNPNEPSN
    PNEPSNPNEPSNPNEPSNPNEPSNPKKPSNPNEPSNPNEPLNPNEPSNPNEPSNPNEPSNPEEPSNPKEP
    SNPNEPSNPEEPNPEEPSNPKEPSNPEEPINPEELNPKEPSNPEESNPKEPINPEESNPKEPINPEDNEN
    PLIIQDEPIEPRNDSNVIPILPIIPQKGNNIPSNLPENPSDSEVEYPRPNDNGENSNNTMKSKKNIPNEP
    IPSPGDNPYKGHEERIPKPHRSNDDYVYDNNVNKNNKDEPEIPNNEYEEDKNKNQSKSNNGYKIAGGIIG
    GLAILGCAGVGYNFIAGSSAAGLAGAEPAPFEDVIPDDDKDIVENEQFKLPEDNDWN
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. yoelii DNA vaccine encoding PySSP2
40. SSP2 from P. knowlesi
  • Gene Name : SSP2 from P. knowlesi
  • Sequence Strain (Species/Organism) : Plasmodium knowlesi strain H
  • NCBI Protein GI : 221058683
  • Other Database IDs : CDD:185620
    CDD:29244
    CDD:197574
    UniProtKB/TrEMBL: B3L8N1
  • Taxonomy ID : 5851
  • Gene Strand (Orientation) : ?
  • Protein Name : sporozoite surface protein 2
  • Protein Length : 579
  • Protein Note : sporozoite surface protein 2 (SSP2); Provisional
  • Protein Sequence : Show Sequence
    >gi|221058683|ref|XP_002259987.1| sporozoite surface protein 2 [Plasmodium knowlesi strain H]
    MKLLQNKSYLLVVFLLYVSIFARGDQKIVDEVKYNEEVCNEKVDLYLLVDGSGSIGYANWITRVIPMLTG
    LIENLNLSKDSINLYMSLFASHTTELIRLGSGPSMDKKQALNVVRDLRKGYEPYGNTSMSSALSEVEMHL
    KDRVNRPNAIQLVILMTDGIPNNKYRALELSRALKERNVKLAVIGIGQGINHQYNKLMAGCRPRERSCKF
    YSSADWSEAISLIKPFIAKVCTEVERIAKCGPWDDWTPCSVTCGKGTHSRSRPLLHAGCTTHMVKECEMD
    ECPVEPEPVPVPAPVPPTPEDENPRTTDEEDDHPNFHQGLDVPDVENDVPPENDGGDGNPFEENFFPPGD
    DTVPDESNVIPVPPTVPGGSNSEFSSDVENAAQYPENPENPENPENSENPENPENQNNPEDFPMEPDMSA
    DNKINEPTNPSDSGQGIPENVIPTPINNEKDIINKNKAVYPNGSNQSHDRYPKPHRNAGGYDNNPNANSD
    IPEGPFSSEEEQPEDKGKKSSNNGYKIAGGVIAGLALVGCVGFAYNFVSSGGAAGMAGEPAPFDEAMAED
    EKDAGEADQFKLPEDNDWN
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42
41. SSP2 from Plasmodium falciparum
  • Gene Name : SSP2 from Plasmodium falciparum
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • NCBI Protein GI : 160691
  • Other Database IDs : CDD:185620
    CDD:29244
    CDD:199489
  • Taxonomy ID : 5833
  • Gene Strand (Orientation) : ?
  • Protein Name : sporozoite surface protein 2
  • Protein Length : 574
  • Protein Note : sporozoite surface protein 2 (SSP2); Provisional
  • Protein Sequence : Show Sequence
    >gi|160691|gb|AAA29767.1| sporozoite surface protein 2 [Plasmodium falciparum]
    MNHLGNVKYLVIVFLIFFDLFLVNGRDVQNNIVDEIKYREEVCNDEVDLYLLMDCSGSIRRHNWVNHAVP
    LAMKLIQQLNLNDNAIHLYASVFSNNAREIIRLHSDASKNKEKALIIIKSLLSTNLPYGKTNLTDALLQV
    RKHLNDRINRENANQLVVILTDGIPDSIQDSLKESRKLSDRGVKIAVFGIGQGINVAFNRFLVGCHPSDG
    KCNLYADSAWENVKNVIGPFMKAVCVEVEKTASCGVWDEWSPCSVTCGKGTRSRKREILHEGCTSELQEQ
    CEEERCLPKREPLDVPDEPEDDQPRPRGDNFAVEKPNENIIDNNPQEPSPNPEEGKGENPNGFDLDENPE
    NPPNPPNPPNPPNPPNPPNPDIPEQEPNIPEDSEKEVPSDVPKNPEDDREENFDIPKKPENKHDNQNNLP
    NDKSDRYIPYSPLSPKVLDNERKQSDPQSQDNNGNRHVPNSEDRETRPHGRNNENRSYNRKHNNTPKHPE
    REEHEKPDNNKKKAGSDNKYKIAGGIAGGLALLACAGLAYKFVVPGAATPYAGEPAPFDETLGEEDKDLD
    EPEQFRLPEENEWN
  • Molecule Role : Other
42. STARP
  • Gene Name : STARP
  • Sequence Strain (Species/Organism) : Plasmodium falciparum
  • Other Database IDs : PlasmoDB:PF07_0006
  • Chromosome No : 7
  • Gene Starting Position : 152127
  • Gene Ending Position : 154096
  • Gene Strand (Orientation) : ?
  • Protein Name : starp antigen
  • DNA Sequence : Show Sequence
    >PF07_0006 |||starp antigen|Plasmodium falciparum|chr 7|SANGER| unspliced DNA
    ATGATACATA TTTTTTATAG GACAGCCATA TTTACTCTCT CAATCTGGAC AACACTGTTA
    TATTCTAATA AAGTAAGATA AAAAGAATTA GAATTAAAAA TTGAAAATTA AAATTTAAAA
    ATGATATATA TGCAAATAAT TTTAATTATA TATATATATA TATATATATA TATATATATG
    TATCTTTTTA TTTTTCCAAT ACATATTTAA TATATAATTA TTTATATTTT TTTTTTTTTT
    TTAATATTAC TTTTTAGAAT TTAAAATGTA ATTTTTATTA TAATAACAAC AACTTATCAA
    CATACGTTAT AAAGCATAAC AGATTTTTAT CAGAATATCA ATCGAACTTT CTTGGTGGGG
    GATATAGTGC AGCTTTAAAA TTAGTAAATA GTAAAAAATC CGGAACAAAT GTAAATACAA
    AGTATAATTC AGAAAATACC AATACAAATA ATAATATACC AGAAAGTAGT AGTACATATA
    CAAATACAAG GTTAGCAGCA AATAACAGTA CAACTACAAG CACTACAAAA GTAACAGATA
    ATAATAAAAC AAATATTAAA TTAACAGGAA ACAATAGTAC AACTATAAAT ACAAATTCAA
    CAGAAAATAC TAGTGCTACC AAAAAAGTAA CCGAAAATGT TATTACAAAT CAAATATTAA
    CAGGAAATAA CAATACAACC ACAAATACAT CCACGACAGA ACATAATAAT AATATTAACA
    CAAATACAAA TTCAACAGAA AATACTAGTG CTACCAAAAA AGTAACCGAA AATGTTATTA
    CAAATCAAAT ATTAACAGGA AATAACAATA CAACCACAAA TACATCCACG ACAGAACATA
    ATAATAATAT TAACACAAAT ACAAATTCAA CAGATAATAG TAATACTAAT ACAAATTTAA
    CCGATAATAC TTCTACAACT AAAAAGTTGA CTGATAATAT AAACACAACA CAAAATTTAA
    CAACAAGTAC TAATACAACT ACAGTATCAA CCGATAATAA TAATATAAAT ACAAAACCCA
    TTGATAATAA TAACACAGAT ATAAAATCGA CAGATAATTA TAACACAGGC ACAAAGGAAA
    CAGATAATAA GAACACAGAC ATAAAAGCAA CAGACAATAA TAATATTACA ACAACCACGG
    ATAATACTAA TACAAATGTA ATATCAACAG ATAATAGTAA AACAAATGTA ATATCAACAG
    ATAATAGTAA AACAAATACA ATATCAACAG ATAATGATAA TGCAGATACA ATATTAACAG
    ATAATGATAA TAATACAGAT ATAATATTAA CAGATAATAA TAATACAGAT ACAATATCAA
    CAGATAATGA TAATGCAGAT ACAAAAGCAA CAGATAATAA TAATAATACA AATACAAAAG
    CAACAGATAA TAATAATACA AAAATAATAT CACCAGATAA TAATAATACA AAAACAACAT
    CAACAGATAA TAATAATAAT ACAAATACAA AAGCAACAGA TAATAATAAT ACAAAAACAA
    TATCAAACGA TAATAATAAT ACAAAAACAA TATCAACAGA TAATAATAAT ACAAAAACAA
    TATCAAACGA TAATAATAAT ACAAATACAA TATCAACAGA TAATAATAAT AATAATACAA
    ACCAATATGT CTTTGCTAAC AATTATAATG AAACAACTTC TGATGATGAA CTAAATAAAG
    ATTCCTGTGA TTATTCAGAA GAAAAAGAAA ATATAAAATC AATGATTAAC GCTTATTTAG
    ACAAGTTAGA TTTAGAAACT GTTCGTAAAA TACATTCAGA TATAAGTACA TGTATTGAAA
    AAAAAAATAA TCCTAGGAAT CAAATAACAC ATTTAAACAA TTTAAAAAAT ATGTATAATA
    TAATTAAATT TATAGTGGTT ATATATATTG CTTTTAATTG GAGTGAAGTA ATATATAAAT
    ATGTAGGAAA ATTAATTTTA GCTTTTGCTT TATATATGTT AATTAATTAA
    
    >PF07_0006 |||starp antigen|Plasmodium falciparum|chr 7|SANGER|Spliced DNA
    ATGATACATA TTTTTTATAG GACAGCCATA TTTACTCTCT CAATCTGGAC AACACTGTTA
    TATTCTAATA AAAATTTAAA ATGTAATTTT TATTATAATA ACAACAACTT ATCAACATAC
    GTTATAAAGC ATAACAGATT TTTATCAGAA TATCAATCGA ACTTTCTTGG TGGGGGATAT
    AGTGCAGCTT TAAAATTAGT AAATAGTAAA AAATCCGGAA CAAATGTAAA TACAAAGTAT
    AATTCAGAAA ATACCAATAC AAATAATAAT ATACCAGAAA GTAGTAGTAC ATATACAAAT
    ACAAGGTTAG CAGCAAATAA CAGTACAACT ACAAGCACTA CAAAAGTAAC AGATAATAAT
    AAAACAAATA TTAAATTAAC AGGAAACAAT AGTACAACTA TAAATACAAA TTCAACAGAA
    AATACTAGTG CTACCAAAAA AGTAACCGAA AATGTTATTA CAAATCAAAT ATTAACAGGA
    AATAACAATA CAACCACAAA TACATCCACG ACAGAACATA ATAATAATAT TAACACAAAT
    ACAAATTCAA CAGAAAATAC TAGTGCTACC AAAAAAGTAA CCGAAAATGT TATTACAAAT
    CAAATATTAA CAGGAAATAA CAATACAACC ACAAATACAT CCACGACAGA ACATAATAAT
    AATATTAACA CAAATACAAA TTCAACAGAT AATAGTAATA CTAATACAAA TTTAACCGAT
    AATACTTCTA CAACTAAAAA GTTGACTGAT AATATAAACA CAACACAAAA TTTAACAACA
    AGTACTAATA CAACTACAGT ATCAACCGAT AATAATAATA TAAATACAAA ACCCATTGAT
    AATAATAACA CAGATATAAA ATCGACAGAT AATTATAACA CAGGCACAAA GGAAACAGAT
    AATAAGAACA CAGACATAAA AGCAACAGAC AATAATAATA TTACAACAAC CACGGATAAT
    ACTAATACAA ATGTAATATC AACAGATAAT AGTAAAACAA ATGTAATATC AACAGATAAT
    AGTAAAACAA ATACAATATC AACAGATAAT GATAATGCAG ATACAATATT AACAGATAAT
    GATAATAATA CAGATATAAT ATTAACAGAT AATAATAATA CAGATACAAT ATCAACAGAT
    AATGATAATG CAGATACAAA AGCAACAGAT AATAATAATA ATACAAATAC AAAAGCAACA
    GATAATAATA ATACAAAAAT AATATCACCA GATAATAATA ATACAAAAAC AACATCAACA
    GATAATAATA ATAATACAAA TACAAAAGCA ACAGATAATA ATAATACAAA AACAATATCA
    AACGATAATA ATAATACAAA AACAATATCA ACAGATAATA ATAATACAAA AACAATATCA
    AACGATAATA ATAATACAAA TACAATATCA ACAGATAATA ATAATAATAA TACAAACCAA
    TATGTCTTTG CTAACAATTA TAATGAAACA ACTTCTGATG ATGAACTAAA TAAAGATTCC
    TGTGATTATT CAGAAGAAAA AGAAAATATA AAATCAATGA TTAACGCTTA TTTAGACAAG
    TTAGATTTAG AAACTGTTCG TAAAATACAT TCAGATATAA GTACATGTAT TGAAAAAAAA
    AATAATCCTA GGAATCAAAT AACACATTTA AACAATTTAA AAAATATGTA TAATATAATT
    AAATTTATAG TGGTTATATA TATTGCTTTT AATTGGAGTG AAGTAATATA TAAATATGTA
    GGAAAATTAA TTTTAGCTTT TGCTTTATAT ATGTTAATTA ATTAA
  • Protein Sequence : Show Sequence
    >PF07_0006 |||starp antigen|Plasmodium falciparum|chr 7|SANGER||Manual
    MIHIFYRTAI FTLSIWTTLL YSNKNLKCNF YYNNNNLSTY VIKHNRFLSE YQSNFLGGGY
    SAALKLVNSK KSGTNVNTKY NSENTNTNNN IPESSSTYTN TRLAANNSTT TSTTKVTDNN
    KTNIKLTGNN STTINTNSTE NTSATKKVTE NVITNQILTG NNNTTTNTST TEHNNNINTN
    TNSTENTSAT KKVTENVITN QILTGNNNTT TNTSTTEHNN NINTNTNSTD NSNTNTNLTD
    NTSTTKKLTD NINTTQNLTT STNTTTVSTD NNNINTKPID NNNTDIKSTD NYNTGTKETD
    NKNTDIKATD NNNITTTTDN TNTNVISTDN SKTNVISTDN SKTNTISTDN DNADTILTDN
    DNNTDIILTD NNNTDTISTD NDNADTKATD NNNNTNTKAT DNNNTKIISP DNNNTKTTST
    DNNNNTNTKA TDNNNTKTIS NDNNNTKTIS TDNNNTKTIS NDNNNTNTIS TDNNNNNTNQ
    YVFANNYNET TSDDELNKDS CDYSEEKENI KSMINAYLDK LDLETVRKIH SDISTCIEKK
    NNPRNQITHL NNLKNMYNII KFIVVIYIAF NWSEVIYKYV GKLILAFALY MLIN
43. TRAP from P. falciparum
  • Gene Name : TRAP from P. falciparum
  • Sequence Strain (Species/Organism) : Plasmodium falciparum 3D7
  • VO ID : VO_0010920
  • NCBI Gene ID : 814170
  • NCBI Protein GI : 124513464
  • Locus Tag : PF13_0201
  • Genbank Accession : AL844509
  • Protein Accession : XP_001350088
  • Taxonomy ID : 36329
  • Chromosome No : 13
  • Gene Starting Position : 1465092
  • Gene Ending Position : 1466816
  • Gene Strand (Orientation) : -
  • Protein Name : Thrombospondin-related anonymous protein (TRAP), SSP-2, SSP2, Sporozoite specific protein 2, Sporozoite surface protein 2
  • Protein pI : 4.7
  • Protein Weight : 61465.35
  • Protein Length : 574
  • DNA Sequence : Show Sequence
    >ref|NC_004331.2|:1465092-1466816 Plasmodium falciparum 3D7 chromosome 13
    TTTAATTCCACTCGTTTTCTTCAGGTAATCTGAATTGTTCAGGTTCGTCCAAATCTTTATCTTCTTCACC
    TAATGTTTCATCAAAAGGTGCAGGTTCTCCGGCATAGGGTGTTGCTGCTCCTGGTACTACGAATTTATAA
    GCAAGTCCAGCACATGCGAGTAAAGCTAATCCTCCAGCTATTCCACCTGCAATTTTATATTTATTATCTG
    ATCCTGCTTTTTTTTTATTATTATCTGGCTTTTCATGTTCTTCCCTTTCAGGATGTTTTGGAGTATTGTT
    ATGTTTTCTATTGTATGATCTATTTTCATTATTTCTACCATGTGGACGTGTTTCTCTATCTTCACTATTA
    GGTACGTGCCTATTTCCATTATTATCTTGACTTTGGGGGTCACTTTGTTTCCTTTCATTATCCAAAACTT
    TTGGAGATAATGGTGAATATGGAATATATCTATCACTTTTATCATTTGGTAAATTATTTTGATTATCGTG
    CTTATTTTCGGGTTTCTTTGGAATATCAAAGTTTTCTTCTCGATCGTCTTCTGGATTTTTTGGAACATCA
    GAAGGTACTTCTTTTTCTGAATCTTCAGGTATATTTGGTTCTTGTTCAGGAATATCTGGATTTGGTGGAT
    TTGGTGGATTTGGTGGATTTGGTGGATTTGGTGGATTTGGTGGATTTTCTGGATTTTCATCTAAATCAAA
    TCCGTTTGGATTTTCACCCTTTCCTTCTTCTGGATTTGGTGAAGGTTCTTGTGGATTATTATCTATTATA
    TTTTCGTTTGGTTTTTCGACAGCAAAATTATCTCCTCTTGGTCTAGGTTGATCATCTTCGGGTTCATCTG
    GAACATCTAATGGTTCCCGTTTTGGAAGACATCTTTCTTCTTCACATTGTTCTTGTAATTCACTTGTACA
    TCCTTCGTGTAAGATTTCTCTTTTTCTTGACCTGGTACCTTTACCACAAGTTACACTACATGGAGACCAT
    TCGTCCCAAACACCACAACTTGCTGTTTTTTCTACTTCAACACAAACAGCCTTCATAAAGGGTCCGATAA
    CATTTTTTACATTTTCCCATGCAGAATCAGCATACAAGTTACATTTACCATCTGATGGATGACAACCTAC
    AAGAAATCTGTTGAAAGCTACATTAATACCTTGTCCAATACCAAAAACAGCTATTTTAACACCACGATCA
    CTTAATTTTCTTGATTCTTTTAATGAATCTTGAATACTATCTGGAATTCCATCTGTTAATATAACAACTA
    ATTGATTAGCATTCTCTCTATTGATTCGGTCATTTAAATGTTTTCTTACTTGTAACAGTGCATCAGTTAA
    GTTTGTTTTACCATATGGAAGATTTGTACTTAAGAGTGACTTTATAATAATTAAAGCCTTCTCTTTGTTT
    TTAGATGCATCACTATGTAATCTAATAATTTCTCTTGCATTGTTTGAAAAAACACTAGCATATAAGTGAA
    TTGCATTATCATTAAGATTTAATTGTTGTATCAATTTCATAGCTAGAGGTACTGCATGGTTCACCCAATT
    ATGACGACGTATACTTCCAGAACAATCCATTAGAAGGTAAAGATCTACCTCATCATTACATACTTCTTCA
    CGATATTTTATTTCATCCACTATATTGTTTTGCACATCTCTACCATTAACTAGAAACAAATCAAAGAAAA
    TCAAAAACACAATGACTAAATATTTAACATTCCCAAGATGATTCA
  • Protein Sequence : Show Sequence
    >gi|124513464|ref|XP_001350088.1| Thrombospondin-related anonymous protein, TRAP [Plasmodium falciparum 3D7]
    MNHLGNVKYLVIVFLIFFDLFLVNGRDVQNNIVDEIKYREEVCNDEVDLYLLMDCSGSIRRHNWVNHAVP
    LAMKLIQQLNLNDNAIHLYASVFSNNAREIIRLHSDASKNKEKALIIIKSLLSTNLPYGKTNLTDALLQV
    RKHLNDRINRENANQLVVILTDGIPDSIQDSLKESRKLSDRGVKIAVFGIGQGINVAFNRFLVGCHPSDG
    KCNLYADSAWENVKNVIGPFMKAVCVEVEKTASCGVWDEWSPCSVTCGKGTRSRKREILHEGCTSELQEQ
    CEEERCLPKREPLDVPDEPEDDQPRPRGDNFAVEKPNENIIDNNPQEPSPNPEEGKGENPNGFDLDENPE
    NPPNPPNPPNPPNPPNPPNPDIPEQEPNIPEDSEKEVPSDVPKNPEDDREENFDIPKKPENKHDNQNNLP
    NDKSDRYIPYSPLSPKVLDNERKQSDPQSQDNNGNRHVPNSEDRETRPHGRNNENRSYNRKHNNTPKHPE
    REEHEKPDNNKKKAGSDNKYKIAGGIAGGLALLACAGLAYKFVVPGAATPYAGEPAPFDETLGEEDKDLD
    EPEQFRLPEENEWN
  • Molecule Role : Protective antigen
  • Related Vaccine(s): P. falciparum DNA and MVA encoding ME-TRAP
44. UIS3
  • Gene Name : UIS3
  • Sequence Strain (Species/Organism) : Plasmodium yoelii yoelii str. 17XNL
  • NCBI Gene ID : 3830198
  • NCBI Protein GI : 83315853
  • Locus Tag : PY03011
  • Genbank Accession : AABL01000850
  • Protein Accession : XP_730972
  • 3D structure: PDB ID : 2VWA
  • Taxonomy ID : 352914
  • Gene Starting Position : 1385
  • Gene Ending Position : 2296
  • Gene Strand (Orientation) : -
  • Protein pI : 9.63
  • Protein Weight : 26806.7
  • Protein Length : 241
  • DNA Sequence : Show Sequence
    >gi|221228555:1385-2296 Plasmodium yoelii yoelii str. 17XNL MALPY00853, whole genome shotgun sequence
    TTCATTTTGGTTGATATTGTTCTTTAAGAAAATGCTCCACGCCTAAAACTGCGATATCTTCTTGGGCTCT
    TGAAATATTAACATCCTTATTTTCATCTAAAGTCTGGACAATTTTCCTTAAGTAATCATAATCCTTGATT
    AAATATTTCTGTTGTTCATTTGATAAATTGCTGAAATGGTGTTTAGCAGCTAGTTTCACATTATCCATAA
    ATGTATTAAACCTTTTCAAAGGAACATCAATATCATTATTGTTTTCTTTTAATTTTCCTTTTATATTTAC
    TTTATTTACTCCTAATGGTTCTTCATATTTTGTACTAGTGCTTGGTTTTTCACCATCAGGTTGTTTATAT
    TCTGTTTGTTTATTAAAGGGGAAAAAATTAAAACCTTTATTCCAATCATGTCTTCCTTTATTATGAGATT
    TATACATATAATAAAGTACCCCAATAACACTTGCCACTAATCCTGATGATAACAAAGCAATTGCAACTGA
    TTTCCTCTTCTTTTTTTTTTTTATAGCAGTATCAATGCTATCTAATGCCCCATCATCTATTTCTGAATAA
    TAATCTGCATCCTCACAAAAGCAAGGGTTAAAAAAAAATGTAGTAATATATAACACATAAAAAACGAAAA
    AAACTTTGAGAGTGTTCATTTTATACACTTTCATATATTTTTTATTTGTCTAAGTAATAAAAAAAATTAA
    ATTACTATAAAGATCAAATAATTATGTACAAATTTTTATCATTATTATTGTTAATATTATATTTTTTTTT
    TATGTGTCAACAAAAAATTATTAAGCAAAGAATAATCTTTGAGTCACAATGATAAATGTGATGCTATTAT
    AAATAATATTTCCTGTCAATCATACTCTAAAATATTTATTAATATAAATTATGCATGTGAAAAATTGAGG
    CA
  • Protein Sequence : Show Sequence
    >gi|83315853|ref|XP_730972.1| early transcribed membrane protein [Plasmodium yoelii yoelii str. 17XNL]
    MPQFFTCIIYINKYFRTNKKYMKVYKMNTLKVFFVFYVLYITTFFFNPCFCEDADYYSEIDDGALDSIDT
    AIKKKKKRKSVAIALLSSGLVASVIGVLYYMYKSHNKGRHDWNKGFNFFPFNKQTEYKQPDGEKPSTSTK
    YEEPLGVNKVNIKGKLKENNNDIDVPLKRFNTFMDNVKLAAKHHFSNLSNEQQKYLIKDYDYLRKIVQTL
    DENKDVNISRAQEDIAVLGVEHFLKEQYQPK
  • Molecule Role : Virmugen
  • Molecule Role Annotation : Deletion of UIS3 in Plasmodium yoelii provided attenuation and full protection in mice by Pyuis3(-) sporozoites required at least 2 immunizations against challenges with infectious sporozoites (Tarun et al., 2007).
  • Related Vaccine(s): Plasmodium yoelii UIS3 mutant vaccine
45. UIS4
  • Gene Name : UIS4
  • Sequence Strain (Species/Organism) : Plasmodium yoelii yoelii str. 17XNL
  • NCBI Gene ID : 3853948
  • NCBI Protein GI : 82753006
  • Locus Tag : PY00876
  • Genbank Accession : AABL01000235
  • Protein Accession : XP_727503
  • Other Database IDs : CDD:158776
    CDD:152003
  • Taxonomy ID : 352914
  • Gene Starting Position : 896
  • Gene Ending Position : 1580
  • Gene Strand (Orientation) : +
  • Protein Name : upregulated in infective sporozoites 3
  • Protein pI : 9.56
  • Protein Weight : 20676.82
  • Protein Length : 184
  • Protein Note : Malarial early transcribed membrane protein (ETRAMP); cl09917
  • DNA Sequence : Show Sequence
    >gi|221227283:896-1580 Plasmodium yoelii yoelii str. 17XNL MALPY00236, whole genome shotgun sequence
    AATGAATAAAAGGATATTTAGTTTAGTTTGCATTGCCTTGTATACCCTTTTGACTGTACCAGCACATTGC
    TCCGAACAGGAAGTAAGTTGTCAAAACAAAATATAAACTAATATATAGAAAATTATATAATAATCGTTAT
    TTACATGTGGTGATGTATATATTAACGCATATATATATATATTAGTATATTCCCTTGTATGATCGATCTA
    AGGTATCTGATGTAGGAAACAAAAGTGACGAAAAAAATGATATAGAATATAAACGTGAAACACAATTAAA
    GAATACAAATTCTAAAGATGATAGAGGATTCAATTGTTTTAATATATTTAAAAAAAATAAAAGAACACAA
    TCACATTCATATAGTAAAGTACCCTTAACTCATCCATATAATAAAATAACCGAAACATCTTCAAATAACA
    ATGACTCTATTCATAAGATAGAATTGTTGATGGAAAAGATTGCCCGTTACTTTCTTGCAAACCATTCAGA
    AATTTTAAAGTTTTTATCAAATAATAAAATAACCGAAGCATCTTCAAATAACAATGACGCTATTCATAAG
    GTATCATTAGAGATGCGAAAAATTATGCGTGAACTTCTTGAAAAAAGTCCAGAAGGTTTAAAGTTATTGT
    CACGATTAGCTGAAAAATTAGAAAAACGTCCTTCAAATGATAAACCAAGTGAATA
  • Protein Sequence : Show Sequence
    >gi|82753006|ref|XP_727503.1| hypothetical protein [Plasmodium yoelii yoelii str. 17XNL]
    MNKRIFSLVCIALYTLLTVPAHCSEQEVSDVGNKSDEKNDIEYKRETQLKNTNSKDDRGFNCFNIFKKNK
    RTQSHSYSKVPLTHPYNKITETSSNNNDSIHKIELLMEKIARYFLANHSEILKFLSNNKITEASSNNNDA
    IHKVSLEMRKIMRELLEKSPEGLKLLSRLAEKLEKRPSNDKPSE
  • Molecule Role : Virmugen
  • Molecule Role Annotation : A UIS4 mutant of Plasmodium yoelii is attenuated and a single dose of Pyuis4(-) sporozoites conferred complete protection against challenges with infectious sporozoites (Tarun et al., 2007).
III. Vaccine Information
1. BDES-PfCSP (baculovirus dual expression system)
a. Vaccine Ontology ID:
VO_0004801
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Mouse
e. Preparation
(Iyori et al., 2013)
f. Immunization Route
Intramuscular injection (i.m.)
2. ChAd63 -PvTRAP
a. Vaccine Ontology ID:
VO_0004797
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Mouse
e. Preparation
(Bauza et al., 2014) the recombinant ChAd63 vectors expressing P. vivax TRAP (PvTRAP).
f. Immunization Route
Intramuscular injection (i.m.)
3. FMP1/AS02A
a. Vaccine Ontology ID:
VO_0000777
b. Type:
Subunit vaccine
c. Antigen
Apical membrane antigen 1 (AMA-1) is an asexual blood stage antigen. AMA-1 is considered to be an important candidate malaria vaccine antigen (Morais et al., 2006; Polhemus et al., 2007).
d. Gene Engineering of AMA1 from P. falciparum 3D7
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
e. Adjuvant: AS02 vaccine adjuvant
  • VO ID: VO_0001264
  • Description: The Plasmodium falciparum vaccine candidate FMP2.1/AS02A , a recombinant E coli-expressed protein based upon the apical membrane antigen-1 (AMA-1 ) of the 3D7 clone formulated with the AS02A adjuvant(Polhemus et al., 2007)
f. Preparation
FMP2.1 antigen represents amino acids #83-531 of the P. falciparum (clone 3D7) AMA-1 protein. Just prior to immunization, the lyophilized FMP2.1 protein was mixed with AS02A such that approximately 8, 20 or 40 μg of FMP2.1 was delivered in a final volume of 0.5 mL of AS02A (Polhemus et al., 2007).
g. Human Response
  • Vaccination Protocol: An open-label, staggered-start, dose-escalating Phase I trial was conducted in 23 malaria-naïve volunteers who received 8, 20 or 40 μg of FMP2.1 in a fixed volume of 0.5 mL of AS02A on a 0, 1, and 2 month schedule. Nineteen of 23 volunteers received all three scheduled immunizations (Polhemus et al., 2007).
  • Immune Response: All volunteers seroconverted after second immunization as determined by ELISA. Immune sera recognized sporozoites and merozoites by immunofluorescence assay (IFA), and exhibited both growth inhibition and processing inhibition activity against homologous (3D7) asexual stage parasites. Post-immunization, peripheral blood mononuculear cells exhibited FMP2.1-specific lymphoproliferation and IFN-γ and IL-5 ELISPOT assay responses (Polhemus et al., 2007).
  • Side Effects: The most frequent solicited local and systemic adverse events associated with immunization were injection site pain (68%) and headache (29%). There were no significant laboratory abnormalities or vaccine-related serious adverse events.
4. MSP3-LSP with aluminium hydroxide
a. Vaccine Ontology ID:
VO_0000773
b. Type:
Subunit vaccine
c. Antigen
The merozoite surface protein-3 long synthetic peptide (MSP3-LSP) comprises the amino acid sequence 186-276 of the Plasmodium falciparum protein MSP3 (Sirima et al., 2007). The C-terminal conserved region of Plasmodium falciparum merozoite surface protein 3 (MSP3) is the trigger antigen of a protective immune response mediated by cytophilic antibodies (Audran et al., 2005).
d. Adjuvant: aluminum hydroxide vaccine adjuvant
  • VO ID: VO_0000127
  • Description: aluminium hydroxide (Sirima et al., 2007). In another phase I clinical trial study using MSP3-LSP, two adjuvants were used, including Montanide ISA 720 and aluminum hydroxide (Audran et al., 2005). However, it showed that it was unacceptably reactogenic when it was combined with Montanide (Audran et al., 2005).
e. Virulence
No.
f. Human Response
  • Host Strain: healthy male adults Africans
  • Vaccination Protocol: A Phase 1b single-blind controlled trial was performed in the village of Balonghin in Burkina Faso. Thirty male volunteers aged 18-40 years were randomised to receive either three doses of 30 microg MSP3-LSP or 0.5 ml of tetanus toxoid vaccine . The second and third vaccine doses were given 28 and 112 days after the first dose . Participants for 1 year were followed for one year (Sirima et al., 2007).
  • Persistence: Immune response did not wane appreciably up to 365 days post-vaccination (Sirima et al., 2007).
  • Immune Response: Humoral immune responses (IgG, IgG subclasses, IgM) to MSP3-LSP peptide were similar in the two groups following vaccination. Some cell-mediated immune responses appeared to differ between the two vaccine groups. After the second dose of MSP3-LSP, there appeared to be a marked increase in the lymphocyte proliferation index and IFN-gamma in response to stimulation with MSP3-LSP (Sirima et al., 2007).
  • Side Effects: There were no serious adverse events in either vaccine group. In both groups participants reported local reactions at the site of injection when compared to an earlier trial in European volunteers. Only one systemic adverse event ( tachycardia ) was identified which occurred immediately after the first vaccination in one individual receiving MSP3-LSP. No clinically significant biological abnormalities following vaccination were observed (Sirima et al., 2007).
  • Description: In summary, this Phase 1b single-blind controlled trial showed that three doses of 30 microg MSP3-LSP when administered subcutaneously on days 0 , 28 and 112 are well-tolerated by adult males previously exposed to natural P falciparum infection. MSP3-LSP is able to stimulate an enhanced cell-mediated immune response in individuals with some degree of preexisting immunity (Sirima et al., 2007).
5. MVA-PvTRAP
a. Vaccine Ontology ID:
VO_0004796
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Mouse
e. Preparation
(Bauza et al., 2014) the recombinant MVA vectors expressing P. vivax TRAP (PvTRAP) .
f. Immunization Route
Intramuscular injection (i.m.)
6. NILV-Py CSP
a. Vaccine Ontology ID:
VO_0004798
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
(Coutant et al., 2012) nonintegrative lentiviral vectors (NILV) encoding Plasmodium yoelii Circumsporozoite Protein (Py CSP), and challenged with sporozoites one month later. 50% (37.5-62.5) of the animals were fully protected. Moreover, protection was long-lasting with 42.8% sterile protection six months after the last immunization.
f. Immunization Route
Intramuscular injection (i.m.)
7. NYVAC-CSP (malaria)
a. Vaccine Ontology ID:
VO_0004800
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Baboon
e. Preparation
(Lanar et al., 1996) NYVAC-based vaccinia virus recombinants expressing the circumsporozoite protein (CSP) were evaluated in the Plasmodium berghei rodent malaria model system. Immunization of mice with a NYVAC-based CSP recombinant elicited a high level of protection (60 to 100%).
f. Immunization Route
Intramuscular injection (i.m.)
8. NYVAC-Pf7
a. Vaccine Ontology ID:
VO_0004794
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Human
e. Preparation
(Ockenhouse et al., 1998)
f. Immunization Route
Intramuscular injection (i.m.)
9. P. berghei DNA vaccine CSP-3p28
a. Vaccine Ontology ID:
VO_0004594
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Antigen
CSP and 3 copies of the p28 fragment of C3d (Bergmann-Leitner et al., 2007)
f. Gene Engineering of CS from P. berghei str. ANKA
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Vector:
pBLUESCRIPT (Bergmann-Leitner et al., 2007)
h. Immunization Route
Gene gun
i. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Vaccination with CSP-3p28 resulted in better (100%) protection than CSP alone (60%) against P. berghei sporozoites at the 6-week challenge (p = 0.043) suggesting that the addition of 3 copies of the p28 peptide to CSP results in the generation of a better vaccine (Bergmann-Leitner et al., 2007).
10. P. berghei DNA vaccine encoding PbCSP
a. Vaccine Ontology ID:
VO_0004591
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of CS from P. berghei str. ANKA
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
pcDNA3.1 (Yoshida et al., 2000)
g. Immunization Route
Gene gun
h. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Protection obtained by gene gun delivery into the liver once (73%) was significantly higher than that by the material into the skin twice (31%) (Yoshida et al., 2000).
11. P. berghei MSP1 Protein Vaccine
a. Vaccine Ontology ID:
VO_0004065
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
Recombinant MSP1 (rPbMSP1)
e. Gene Engineering of MSP1 from P. berghei
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
f. Adjuvant: aluminum vaccine adjuvant
g. Immunization Route
Intraperitoneal injection (i.p.)
h. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Lyophilized rPbMSP1 was mixed with alum on the day of injection. Each vaccine formulation, containing 10 ug was administered through IP route to mice .
  • Challenge Protocol: For challenge study, mice were intraperitoneally inoculated with parasitized erythrocytes at a density of either 106 or 105 parasitized
    erythrocytes per mouse (Wan et al., 2007).
  • Efficacy: Eight out of ten mice vaccinated with rMSP1 in alum survived challenge with P. berghei (Wan et al., 2007).
12. P. chabaudi AMA1 Protein Vaccine
a. Vaccine Ontology ID:
VO_0004194
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
Recombinant ectodomain of P. chabaudi adami (DS stain) AMA1 (denoted rAMA1B)
e. Gene Engineering of AMA-1 from P. chabaudi
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
f. Adjuvant: Montanide ISA 720
g. Immunization Route
Intraperitoneal injection (i.p.)
h. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Groups of three to five mice were immunized i.p. with 15 µg of rAMA1B emulsified in Montanide ISA720. Four weeks later, a booster immunization was given using the same amount of rAMA1B emulsified with Montanide ISA720. Controls were immunized with PBS emulsified in Montanide ISA720 (Xu et al., 2000).
  • Challenge Protocol: Ten days after being given a booster immunization the mice were challenged i.v. with 1 x 105 P. chabaudi adami parasitized erythrocytes (Xu et al., 2000).
  • Efficacy: Immunized mice demonstrated significantly lower peak parasitemias compared with PBS-immunized mice, showing that rAMA1B immunization confers protection against challenge with P. chabaudi (Xu et al., 2000).
13. P. falciparum CS expressed in irradiated P. berghei as Vaccine
a. Vaccine Ontology ID:
VO_0004195
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Antigen
CSP from P. falciparum
e. Gene Engineering of CS from P. falciparum
  • Type: Recombinant vector construction
  • Description: P. berghei ANKA cloned lines were transfected with the P. falciparum CSP gene (Grüner et al., 2007).
  • Detailed Gene Information: Click here.
f. Immunization Route
non-specified injection
g. Mouse Response
  • Host Strain: BALB/cJ
  • Vaccination Protocol: In order to induce sterile immunity in all the animals, BALB/cJ mice were immunized with 12,000 rad-irradiated P. berghei sporozoites as follows: one dose of 75,000 sporozoites followed by two booster doses of 25,00 of P. berghei sporozoites on days 15 and 21. In [BALB/c×C57BL/6] F1 mice immunisation was made with 3 injections of 10,000 P. berghei irradiated sporozoites at days 0, 15 and 21 (Grüner et al., 2007).
  • Challenge Protocol: Control mice and mice immunized with irradiated sporozoites (transfected with P. falciparum CS) were challenged intravenously with 5,000 P. berghei or P. berghei [PfCS] sporozoites (Grüner et al., 2007).
  • Efficacy: Mice immunized with irradiated sporozoites were protected from challenge (Grüner et al., 2007).
14. P. falciparum DNA and MVA encoding ME-TRAP
a. Vaccine Ontology ID:
VO_0000747
b. Type:
DNA vaccine
c. Antigen
Multiple epitope-thrombospondin-related adhesion protein (ME-TRAP)
d. Gene Engineering of TRAP from P. falciparum
  • Type: Epitope construction used for delivery vector
  • Description: Multiple epitopes from the thrombospondin-related adhesion protein were prepared. The ME-TRAP were then introduced into three delivery vectors: DNA and modified vaccinia virus Ankara (MVA) (Dunachie et al., 2006).
  • Detailed Gene Information: Click here.
e. Vector:
pSG2 and MVA (Dunachie et al., 2006)
f. Preparation
DNA and modified vaccinia virus Ankara (MVA) prime-boost regimes were assessed by using either thrombospondin-related adhesion protein (TRAP) with a multiple-epitope string ME (ME-TRAP) (Dunachie et al., 2006).
g. Description
The T-cell responses induced by this prime-boost regime , in animals and humans, are substantially greater than the sum of the responses induced by DNA or MVA vaccines used alone, leading to the term introduced here of "synergistic" prime-boost immunisation.
h. Human Response
  • Vaccination Protocol: Sixteen healthy subjects who never had malaria (malaria-naive subjects) received two priming vaccinations with DNA, followed by one boosting immunization with MVA, with ME-TRAP (Dunachie et al., 2006).
  • Immune Response: The vaccines were well tolerated and immunogenic, with the DDM-ME TRAP regimen producing strong ex vivo IFN-gamma ELISPOT responses
  • Challenge Protocol: Two weeks after the final vaccination, the subjects underwent P. falciparum sporozoite challenge, with six unvaccinated controls.
  • Efficacy: One of eight subjects receiving the DDM-ME TRAP regimen was completely protected against malaria challenge, with this group as a whole showing significant delay to parasitemia compared to controls (P = 0.045). The peak ex vivo IFN-gamma ELISPOT response in this group correlated strongly with the number of days to parasitemia (P = 0.033). Therefore, prime-boost vaccination with DNA and MVA encoding ME-TRAP resulted in partial protection against P. falciparum sporozoite challenge in the present study (Dunachie et al., 2006).
15. P. falciparum DNA Vaccine encoding EBA-175
a. Vaccine Ontology ID:
VO_0004196
b. Type:
DNA vaccine
c. Status:
Research
d. Antigen
P. falciparum EBA-175 RII
e. Gene Engineering of eba-175
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
expression plasmid vector VR1020
g. Immunization Route
Intradermal injection (i.d.)
h. Monkey Response
  • Host Strain: Aotus lemurinus lemurinus
  • Vaccination Protocol: Intradermal delivery of DNA vaccines was performed under light sedation with Ketamine at 20 mg/kg intramuscularly, using a 1 mL insulin syringe with a fused 29-gauge 0.5-inch needle. Monkeys received a total of 500 &mu;g of plasmid DNA in saline in a series of four immunizations at weeks 0, 3, 6, and 47 on the lower back on six different sites. The maximal volume administered in any one site was 100 &mu;l (Sim et al., 2001).
  • Challenge Protocol: Aotus monkeys were challenged with 1 X 104 P. falciparum (FVO) infected erythrocytes (Sim et al., 2001).
  • Efficacy: One of three monkeys vaccinated with EBA-175 was protected from challenge of parasitized erythrocytes (Sim et al., 2001).
16. P. falciparum Hsp90 Protein Subunit Vaccine
a. Vaccine Ontology ID:
VO_0011396
b. Type:
Subunit vaccine
c. Status:
Research
d. Gene Engineering of Hsp90
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
e. Adjuvant: complete Freunds adjuvant
f. Immunization Route
Subcutaneous injection
g. Monkey Response
  • Host Strain: S. sciureus
  • Vaccination Protocol: Monkeys were immunized on days 0, 21, and 42 with 120/~g of protein in PBS/0.1% SDS. Each dose consisted of 1.5ml
    emulsified with Freund's complete adjuvant for the first immunization and Freund's incomplete adjuvant for the others, injected subcutaneously on multiple sites in the back. Control monkeys received the same treatment but without parasite proteins (Bonnefoy et al., 1994).
  • Challenge Protocol: All monkeys were challenged on day 56 by intravenous injection of 5 x 107 FUP/SP-infected monkey erythrocytes (Bonnefoy et al., 1994).
  • Efficacy: The three control monkeys showed a rapid rise of parasitaemia with a prepatent period of 2 days and required drug treatment within 7 days to prevent fatal outcome. Three immunized monkeys developed a reduced parasitaemia with a prepatent period of 2 to 6 days with a maximum peak of parasitaemia of 5-11.6% that dropped spontaneously. The two other immunized monkeys developed parasitaemia similar to the controls and were drug-cured at day 7 (Bonnefoy et al., 1994).
17. P. falciparum LSA-3 Protein Vaccine
a. Vaccine Ontology ID:
VO_0004193
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
Recombinant proteins GST-DG729, GST-NN and GST-PC were designed to cover 95% of the LSA-3 antigen and were used as a mixture (called LSA-3 GST-rec) (Daubersies et al., 2000).
e. Gene Engineering of LSA-3
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
f. Adjuvant: Montanide ISA51
g. Immunization Route
subcutaneous injection
h. Chimpanzee Response
  • Vaccination Protocol: 50 μg of recombinant LSA-3 peptides were emulsified in Montanide ISA51 and were injected subcutaneously into chimpanzees (Daubersies et al., 2000).
  • Challenge Protocol: All chimpanzees were immunized at weeks 0, 4 and 8 and were challenged with 2 x 104 sporozoites at week 13 (Daubersies et al., 2000).
  • Efficacy: Immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites (Daubersies et al., 2000).
18. P. falciparum MSA-2 subunit vaccine
a. Vaccine Ontology ID:
VO_0004269
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
merozoite antigen, MSA-2 (Pye et al., 1997).
e. Adjuvant: SAF-1 vaccine adjuvant
f. Immunization Route
Intramuscular injection (i.m.)
g. Sheep Response
  • Vaccination Protocol: Sheep were immunized intramuscularly (i.m.) in the left rear leg, with a second immunization in the right rear leg 4 weeks later. A 100 μg antigen dose was delivered in 1.0 ml. Serum was prepared from bleeds taken prior to the first immunization, 3 or 4 weeks later (i.e. prior to the second dose), and a final bleed 2 weeks after the second immunization (Pye et al., 1997).
  • Immune Response: Sheep immunized with MSA-2 and SAF-1 had higher antibody response than sheep immunized with MSA-2 and alhydrogel (Pye et al., 1997).
19. P. falciparum MSP1 from transgenic mice with Freund's adjuvant
a. Vaccine Ontology ID:
VO_0000775
b. Type:
Subunit vaccine
c. Antigen
the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1) (Stowers et al., 2002).
d. Gene Engineering of MSP-1 from P. falciparum
e. Adjuvant: complete Freunds adjuvant
  • VO ID: VO_0000139
  • Description: The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).
f. Adjuvant: incomplete Freunds adjuvant
  • VO ID: VO_0000142
  • Description: The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).
g. Preparation
Two strains of transgenic mice were generated that secrete into their milk a malaria vaccine candidate, the 42-kDa C-terminal portion of Plasmodium falciparum merozoite surface protein 1 (MSP1-42). One strain secretes an MSP1-42 with an amino acid sequence homologous to that of the FVO parasite line. In the other strain, an MSP1-42 where two putative N-linked glycosylation sites in the FVO sequence have been removed. Both forms of MSP142 were purified from whole milk to greater than 91% homogeneity at high yields (Stowers et al., 2002).
h. Virulence
None.
i. Description
It is likely for producing efficacious malarial vaccines in transgenic animals (Stowers et al., 2002).
j. Monkey Response
  • Host Strain: owl monkey (Aotus nancymai)
  • Vaccination Protocol: In total 28 monkeys were randomly assigned to groups of seven. The three vaccine groups received bvMSP1-42, TgMSP1-42 NG, and TgMSP1-42 G, respectively, and the fourth group placebo. Monkeys received three vaccinations of 100 µg of the respective recombinant protein 3 wk apart, following our established protocol. The initial vaccinations were emulsified with complete Freund's adjuvant (Sigma), and the next two with incomplete Freund's adjuvant (Sigma) (Stowers et al., 2002).
  • Immune Response: There was a significant difference in the Endpoint ELISA titers to bvMSP142 between those animals vaccinated with bvMSP142 and TgMSP142 G (P = 0.008), and between those vaccinated with TgMSP142 NG and TgMSP142 G (P = 0.05). No differences in titers were observed between the bvMSP142 and TgMSP142 NG groups. No significant differences were seen in ELISA titers to other antigens (TgMSP142 NG, TgMSP142 G, or MSP119), nor were any significant differences seen in IFA titers against P. falciparum FVO parasites. Overall, antibody titers to none of the four antigens used as ELISA capture antigens (bvMSP142, TgMSP142 NG, TgMSP142 G, or MSP119) correlated with the primary outcome of protection as defined above (cumulative parasitemia until first monkey treated for anemia). However, antibody titers to bvMSP142 did correlate with days until treatment (r2 = 0.6241, P = 0.005) and inversely with parasitemia at time of treatment (r2 = -0.4206, P = 0.05) (Stowers et al., 2002).
  • Side Effects: During vaccination, three animals died (two in the TgMSP142 NG group and one in the TgMSP142 G group), unfortunately not a rare occurrence with these fragile monkeys. No animals died during the second study. When partially protected from P. falciparum malaria, it is a characteristic of Aotus monkeys that some protected animals will suffer from anemia (Stowers et al., 2002).
  • Challenge Protocol: Vaccinated monkeys were challenged 15 days after the third vaccination by i.v. infusion of a freshly passaged preparation of 104 infected RBC of the highly virulent P. falciparum FVO strain. Monkeys were treated when parasitemia reached 5%, or their hematocrit fell below 20%. All monkeys not treated previously were treated on day 30. The treatment consisted of mefloquine administered in a single dose of 25 mg/kg of body mass by intubation. The second Aotus challenge trial followed the protocol outlined above, with the exceptions that only two groups (TgMSP142 NG and placebo) and a larger challenge inoculum were used (1 ml of 5 × 104 pRBCs/ml) (Stowers et al., 2002).
  • Efficacy: Vaccination with the glycosylated version of milk-derived MSP1(42) conferred no protection compared with an adjuvant control. Vaccination with the nonglycosylated, milk-derived MSP1(42) successfully protected the monkeys, with 4/5 animals able to control an otherwise lethal infection with P falciparum compared with 1/7 control animals (Stowers et al., 2002).
  • Description: Analysis of the different vaccines used suggested that the differing nature of the glycosylation patterns may have played a critical role in determining efficacy (Stowers et al., 2002).
20. P. falciparum MSP3 Protein Subunit Vaccine
a. Vaccine Ontology ID:
VO_0011440
b. Type:
Subunit vaccine
c. Status:
Research
d. Gene Engineering of MSP3
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
e. Adjuvant: complete Freunds adjuvant
f. Immunization Route
Intramuscular injection (i.m.)
g. Monkey Response
  • Host Strain: Aotus nancymai
  • Vaccination Protocol: Seven monkeys were vaccinated with 100 μg of EcMSP3, seven with 100 μg of control protein Pfs25, a parasite protein expressed during the mosquito stage of the life cycle. Each monkey received 0.125 mL of antigen emulsified in complete Freund's adjuvant at four sites, for a total of 0.5 mL, followed by two booster vaccinations with the same dose of antigen in a Montanide ISA51 (SEPPIC) formulation at 3-week intervals (Tsai et al., 2009).
  • Challenge Protocol: Seventeen days after the third vaccination, the monkeys were challenged by intravenous infusion of 5 × 104 P. falciparum FVO strain parasitized RBCs collected from a naïve donor monkey (Tsai et al., 2009).
  • Efficacy: By day 11 post-challenge, the parasitemia in all but one monkey in the control group had reached the predetermined upper limit and were treated In contrast, no animals in the EcMSP3-vaccinated group required treatment by this time (Tsai et al., 2009).
21. P. falciparum MSP4 with AFCo1 Adjuvant
a. Vaccine Ontology ID:
VO_0004243
b. Type:
Subunit vaccine
c. Status:
Research
d. Adjuvant: protein cochleates
e. Immunization Route
Not specified
f. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: MIce were immunized at 14-day intervals with three doses of 10 μg MSPs (Bracho et al., 2009).
  • Immune Response: AFCo1 significantly enhanced the IgG and T-cell response against MSP4, with a potency equivalent to CFA, with the response being characterized by both IgG1 and IgG2a isotypes, increased interferon gamma production and a strong DTH response, consistent with the ability of AFCo1 to induce Th1-like immune responses (Bracho et al., 2009).
22. P. falciparum pfCelTos protein vaccine
a. Vaccine Ontology ID:
VO_0004204
b. Type:
Subunit vaccine
c. Status:
Research
d. Gene Engineering of pfCelTOS
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
e. Adjuvant: Montanide ISA 720
  • VO ID: VO_0001268
  • Description: Montanide ISA 720
f. Immunization Route
subcutaneous injection
g. Mouse Response
  • Host Strain: Balb/c-J
  • Vaccination Protocol: Mice were immunized subcutaneously in the scruff of the neck three times with 25 or 10 or 1 µg/dose of recombinant PfCelTOS or saline emulsified in Montanide ISA 720 (Bergmann-Leitner et al., 2010).
  • Challenge Protocol: Fourteen days after the final immunization, mice were challenged by subcutaneous inoculation (into the inguinal region) with 4,000 P. berghei sporozoites for Balb/c and 15,000 P. berghei sporozoites for CD-1 mice, dissected from infected mosquito salivary glands. The challenge dose was determined by titration studies in each mouse strain and compared to the different challenge routes. Infection was determined by the presence of blood stage parasites in Giemsa stained thin blood smears on day 6 and day 8 after challenge. Animals that were not infected at that time were tested again on day 14. Mice that remained un-infected by day 14 were classified as sterilely protected. We used this evaluation schedule because animals that are infected with P. berghei ANKA strain malaria parasites do not self-cure.
  • Efficacy Detail
    No. Efficacy method Result Description Group Efficacy Detail
    1 CFU Immunization with PfCelTOS resulted in potent humoral and cellular immune responses and most importantly induced sterile protection against a heterologous challenge with P. berghei sporozoites in a proportion of both inbred and outbred mice (Bergmann-Leitner et al., 2010).
23. P. falciparum Pfen Protein Subunit Vaccine
a. Vaccine Ontology ID:
VO_0011418
b. Type:
Subunit vaccine
c. Status:
Research
d. Gene Engineering of PF10_0155 enolase
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
e. Adjuvant: Freunds emulsified oil adjuvant
f. Immunization Route
Intraperitoneal injection (i.p.)
g. Mouse Response
  • Host Strain: Swiss
  • Vaccination Protocol: Mice were injected intraperitoneally with r-Pfen emulsified in Freund's adjuvant at 21-day intervals (the first injection was 100 μg of r-Pfen in complete Freund's adjuvant, followed by 50 μg for the two boosters in incomplete Freund's adjuvant). In one control group, mice were injected in parallel with a recombinant Drosophila odorant binding protein OSF (as an irrelevant His-tagged protein control) emulsified in complete Freund's adjuvant. The other control group received no injections. After three immunizations, the antibody titers against r-Pfen were monitored (Pal-Bhowmick et al., 2007).
  • Challenge Protocol: Mice having anti-r-Pfen antibody titers greater than 1:300,000 were then challenged with the lethal strain of P. yoelii (strain 17XL; 106 parasites per mouse), and parasitemia was monitored daily (Pal-Bhowmick et al., 2007).
  • Efficacy: All the control mice and the mice immunized with the irrelevant His-tagged protein developed a high degree of parasitemia (>17% on average) by day 4 postchallenge, whereas r-Pfen-immunized mice showed <1% parasitemia at that time point. The highest average parasitemia values were 70% and 40% for nonimmunized mice and mice injected with irrelevant His-tagged protein, respectively. However, among the mice immunized with r-Pfen, there was significant delay in the increase in parasitemia, and the highest average parasitemia was about 20% on day 8 postchallenge. The averages of these groups were compared using one-way analysis of variance, which showed that the mice immunized with enolase were significantly protected (Pal-Bhowmick et al., 2007).
24. P. falciparum recombinant vector vaccine MVA.ME-TRAP
a. Vaccine Ontology ID:
VO_0004399
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Human
e. Vector:
Recombinant fowlpox strain FP9 and recombinant MVA (Webster et al., 2005)
f. Immunization Route
Intramuscular injection (i.m.)
g. Human Response
  • Vaccination Protocol: FFM Regime: FP9 priming, either once or twice, followed by MVA boosting (Webster et al., 2005).
  • Vaccine Immune Response Type: VO_0000286
  • Immune Response: Vaccine regimes with FP9 as the priming agent induced significantly more CD8+ T cells in addition to the CD4+ T cells. This finding suggests that induced CD8+ T cell responses may be of particular value in vaccination against liver-stage malaria (Webster et al., 2005).
  • Efficacy: Two of five subjects who went on to a malaria challenge conducted 14 days after their final vaccination were completely protected. These two subjects were entered, without further vaccinations, into a second malaria challenge 6 months later in which one subject (137) remained completely protected. In addition, all 17 subjects immunized with this FFM regime (FP9 priming, once or twice, followed by MVA boosting) who underwent challenge, overall, compared with nonvaccinees, had a significant delay in time to onset of parasitemia (Webster et al., 2005).
25. P. falciparum Subunit SE36 Protein Vaccine
a. Vaccine Ontology ID:
VO_0011415
b. Type:
Subunit vaccine
c. Status:
Clinical trial
d. Gene Engineering of SERA-5
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
e. Adjuvant: aluminum hydroxide vaccine adjuvant
f. Immunization Route
Intramuscular injection (i.m.)
g. Monkey Response
  • Host Strain: squirrel monkey (Saimiri sciureus)
  • Vaccination Protocol: The monkeys, weighing between 680 and 760 g at the beginning of the experiment, were divided into two groups. Group1 monkeys (R57, R59, and R61) received SE36/AHG and Group2 monkeys (R60 and R62) received PBS as a control by intra-muscular injection in their left thigh 5 and 3 weeks before challenge infection. Monkey R61 received a third injection on the 2 weeks before challenge infection. The dose used was 50 μg SE36 protein with 500 μg aluminum hydroxide gel (50/500) in 0.5 ml of PBS. Group2 monkeys (R60 and R62) received the same volume of PBS (Horii et al., 2010).
  • Challenge Protocol: Two weeks after the last immunization, all monkeys were challenged with P. falciparum-infected red blood cells. Each of the five squirrel monkeys received 1 × 109 parasitized red blood cells. Parasitemia was monitored daily by counting 5000 RBCs in Giemsa-stained thin blood smears (Horii et al., 2010).
  • Efficacy: Whereas two control monkeys developed 10–20% peak parasitemia, the parasitemia in the two immunized monkeys with higher antibody titers stayed at low values below 3% (Fig. 3B). One vaccinated monkey (Monkey R61), with the lowest antibody titer, developed 5% peak parasitemia but was able to control parasitemia by Day 7 onwards. Importantly, control monkeys did not raise anti-SE36 IgG titer even after the onset of parasitemia which parallels the less immunogenicity of SERA5 N-terminal domain observed in endemic areas. Thus, although the observed protection was not able to prevent infection, vaccinated monkeys had lower parasitemia and booster effects on antibody titers were observed after infection for all vaccinated monkeys (Horii et al., 2010).
h. Chimpanzee Response
  • Vaccination Protocol: Three chimpanzees, named Satoru (7 years old male, 45 kg), Arare (10 years old female, 51 kg) and Mizuo (11 years old male, 60 kg) were born in Japan, and thus have no prior exposure to P. falciparum. Satoru, Arare and Mizuo received 10/100, 50/500 and 450/4500 SE36/AHG, respectively by subcutaneous injection on their backs after anesthetization with Ketamine hydrochloride (5 mg/kg) at Weeks 0, 4 and 8 (Horii et al., 2010).
  • Immune Response: Chimpanzee immunization experiment, likewise, indicated the immunogenicity of SE36/AHG and a long duration of antibody production over 1-year with only a gradual decrease. Three chimpanzees were immunized with GMP-grade SE36/AHG of either 10/100, 50/500 or 450/4500 dose. Throughout the study, all blood biochemistry results were normal according to human standards and no signs of systemic aberrations were observed, except for the commonly observed swelling at the administration sites (Horii et al., 2010).
26. P. falciparum vaccine Combination B
a. Tradename:
Combination B
b. Vaccine Ontology ID:
VO_0000740
c. Type:
Subunit vaccine
d. Antigen
The vaccine Combination B contains three recombinant asexual blood-stage Plasmodium falciparum proteins: merozoite surface protein (MSP) 1, MSP2 and ring-infected erythrocyte surface antigen (RESA) (Genton et al., 2003).
e. Gene Engineering of RESA
  • Type: Recombinant protein preparation
  • Description: The vaccine Combination B contains peptides from the ring-infected erythrocyte surface antigen (RESA) (Genton et al., 2003).
  • Detailed Gene Information: Click here.
f. Gene Engineering of MSP-1 from P. falciparum
  • Type: Recombinant protein preparation
  • Description: The vaccine Combination B contains MSP1 peptides (Genton et al., 2003).
  • Detailed Gene Information: Click here.
g. Adjuvant: Montanide ISA 720
  • VO ID: VO_0001268
  • Description: Montanide ISA 720. It is an oil composition containing a natural metabolizable oil and a highly refined emulsifier from the mannide mono-oleate family (Genton et al., 2003).
h. Preparation
Combination B is a malaria vaccine that comprises recombinant P falciparum blood-stage proteins MSP1, MSP2 and RESA, formulated with the adjuvant Montanide ISA 720 (Genton et al., 2003a). The three vaccine candidate antigens were produced by recombinant DNA technology. All three antigens were expressed in Escherichia coli with histidine tags to facilitate purification by nickel chelate chromatography. Two of the antigens, 190LCS.T3 (Ro 45-2067) and Ag1624 (Ro 46-2924), corresponded to parts of the well-characterized merozoite surface proteins MSP1 and MSP2, respectively. The MSP1 antigen was the 190L fragment from the K1 parasite line, comprising the relatively conserved blocks 3 & 4 of MSP1 fused with a universal T cell epitope derived from the circumsporozoite protein of P. falciparum. The MSP2 antigen corresponded to the near full-length MSP2 sequence of the 3D7 cloned line. Ag1505H (Ro 45-2164) consisted of the C-terminal 70% of RESA of the FCQ-27/PNG parasite line. All three antigens were supplied in separate vials at a concentration of 160 μg/ml of saline-Montanide ISA720 emulsion. Prior to use the three formulations were mixed and diluted with additional emulsion to give a dose of 15 μg of each antigen in a total volume of 0.55 ml (Genton et al., 2003).
i. Description
The "Combination B" vaccine resulted from a collaborative effort by the Papua New Guinea Institute for Medical Research along with the Australian Cooperative Research Center for Vaccine Technology in Queensland, The Walter and Eliza Hall Research Institute and the Swiss Tropical Institute (Girard et al., 2007). This vaccine has led to a considerable reduction of parasite density in the immunized children.
j. Human Response
  • Host Strain: Papua New Guinean children
  • Vaccination Protocol: To insure safety, the enrolment and immunisations were done sequentially, with 10 days observation between each sub-cohort. It was started with one block (3 No SP+vaccine, 3 No SP+placebo, 3 SP+vaccine, 3 SP+placebo) of the older age group, then the remaining four blocks (12 No SP+vaccine, 12 No SP+placebo, 12 SP+vaccine, 12 SP+placebo) of this stratum, then one block of the younger age group, and then the remaining four blocks of this stratum. Children were given either SP or a sugar tablet (indistinguishable tablets provided by Hoffman La-Roche). During Week 0 they were injected i.m. in the left lateral thigh with the vaccine or placebo. Four weeks after the first injection, they received a second injection i.m. in the right lateral thigh (Genton et al., 2003).
  • Immune Response: The vaccine induced significant antibody responses to all three antigens but triggered an IFN-γ response to MSP1 only. At Week 12, the IFN-γ response to MSP1 was substantially higher in the vaccine group where No SP had been given (Genton et al., 2003)
  • Side Effects: No serious or severe AEs occurred. Moderate AEs were seen in 3% of the vaccine and 3% of the placebo recipients after first injection and in 12 and 10% after second injection (Genton et al., 2003).
  • Description: This is a phase I-IIb double-blind randomised placebo-controlled trial was undertaken in 120 children aged 5-9 years.
27. P. knowlesi DNA vaccine encoding PkCSP, PkSSP2, PkAMA1, and PkMSP1p42
a. Vaccine Ontology ID:
VO_0004595
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Rhesus monkeys
e. Gene Engineering of AMA1 from P. knowlesi
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Gene Engineering of CSP from P. knowlesi
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
g. Gene Engineering of MSP1 from P. knowlesi
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
h. Gene Engineering of SSP2 from P. knowlesi
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
i. Vector:
VR1020 prime, recombinant canarypox viruses boost (Rogers et al., 2001)
j. Immunization Route
Intramuscular injection (i.m.)
k. Monkey Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Following challenge with 100 P. knowlesi sporozoites, 1 of 12 experimental monkeys was completely protected and the mean parasitemia in the remaining monkeys was significantly lower than that in 4 control monkeys (Rogers et al., 2001).
28. P. vivax PVS25 with Montanide ISA-720
a. Vaccine Ontology ID:
VO_0000776
b. Type:
Subunit vaccine
c. Antigen
P. vivax protein Pvs25 is the vaccine antigen. It is a protein composed of four cysteine-rich epidermal growth factor–like domains expressed on the surface of zygotes and ookinetes of P. vivax (Arevalo-Herrera et al., 2005).
d. Gene Engineering of Pvs25
e. Adjuvant: Montanide ISA 720
  • VO ID: VO_0001268
  • Description: Montanide ISA-720 an adjuvant suitable for human vaccination trials (Arevalo-Herrera et al., 2005).
f. Preparation
To produce a recombinant protein, Pvs25 was expressed in S. cerevisiae in a secreted form. Briefly, P. vivax genomic DNA from the Salvador I strain was used to amplify the gene fragment encoding the Pvs25 regions (Ala23-Leu195), which was inserted into the yeast episomal plasmid YEpRPEU-3 that encodes a secretory {alpha} factor containing a 6-His tail.12 Supernatants of fermentation were recovered by tangential microfiltration, concentrated by ultrafiltration, and extensively dialyzed. The retentate was incubated overnight at 4°C with Ni-nitrilotriacetic acid agarose. Proteins were purified by chromatography (Arevalo-Herrera et al., 2005).
g. Virulence
Not virulent.
h. Monkey Response
  • Host Strain: owl monkey (Aotus lemurinus griseimembra)
  • Vaccination Protocol: Male and female adult, malaria-naive Aotus monkeys were randomly allocated into two groups. An experimental group of six animals (group A) were immunized with the recombinant Pvs25 vaccine. A control group of three animals (group B) were immunized with adjuvant alone. Both groups were immunized on days 0, 60, and 120. Group A was inoculated with a total volume of 500 µL of vaccine formulated as 100 µg of the Pvs25 recombinant protein in Montanide ISA-720 in a 7:3 antigen:adjuvant ratio. Group B was injected with distilled water containing no protein and mixed in the same adjuvant following the same procedure. The immunization was performed by the subcutaneous route distributed in five different sites of the thorax and abdomen of each animal (Arevalo-Herrera et al., 2005).
  • Immune Response: Antigen-specific antibody responses to the Pvs25 protein as determined by ELISA were evident by day 30 after the first immunization at low levels (61–478 units of anti-Pvs25). By day 60, at the time of the first boosting dose, responses of most animals were similar and by day 90, antibodies were boosted in all but two animals. Only one monkey had an apparent boost with the third antigen injection given on day 120. All animals had maximum antibody levels by day 150. These levels started to decrease by day 180, but were still detectable 10 months after the first immunization (Arevalo-Herrera et al., 2005).
  • Side Effects: No adverse side effects were encountered here (Arevalo-Herrera et al., 2005).
  • Challenge Protocol: Approximately 10 months after the last immunization (day 440) when specific antibodies to Pvs25 are no longer detected by ELISA, all monkeys were challenged with the P. vivax Salvador I strain by intravenous injection of 105 parasitized red blood cells. Total parasitemia and gametocytemia were followed every other day using thick and thin blood smears stained with Giemsa. Parasite concentrations were expressed as the number of gametocytes per microliter and the percentage of red blood cells parasitized by asexual parasite forms.19 Monkeys were bled post-challenge (days 447–503) to evaluate the presence of antibodies to Pvs25 by ELISA. In addition, the infectivity of circulating gametocytes was tested by feeding of An. albimanus mosquitoes with parasitized monkey red blood cells mixed with normal AB human sera using the MFA on days 460 (Arevalo-Herrera et al., 2005).
  • Efficacy: All monkeys developed patent parasitemia by day 453, approximately two weeks after intravenous challenge. The peak of parasitemia for most of the monkeys was observed between days 462 and 464 with parasitemias and ranged from 0.1% to 1.3% as determined by thin blood smear. Gametocytes were first evident between days 458 and 460 and remained at detectable levels in all animals until day 468. Plasma samples obtained on days 447, 462, 482, and 503 after parasite challenge were negative for antibodies directed to the Pvs25 recombinant protein by ELISA. Gametocytes that developed in both groups were infectious to mosquitoes as determined in an MFA conducted with monkey blood drawn on day 460 in which plasma from AB human control sera was replaced by sera from infected monkeys. This result supports the viability and functionality of the circulating gametocytes from both the Pvs25-immunized and the control animals.

    Mosquitoes fed with P. vivax gametocyte-carrying human blood in the presence of either normal monkey plasma or normal AB human sera (negative controls) produced positive infections with an arithmetic mean of oocysts per midgut ranging between 0.3 and 3.8 and 0.2 and 1.0 oocysts, respectively. However, plasma from the Pvs25-immunized Aotus tested individually were highly inhibitory and completely blocked the development of oocysts, in all assays (reduction of the oocysts number > 98%) using three different P. vivax human isolates. Plasma from monkeys in the Montanide ISA-720 control group showed similar inhibition to the normal monkey plasma (negative control). Therefore, boosting of antibodies to Pvs25 is not caused by the parasite infection, this Pvs25 vaccine can be used as a malaria transmission-blocking vaccine (Arevalo-Herrera et al., 2005).
29. P. yoelii DNA vaccine encoding MSP1
a. Vaccine Ontology ID:
VO_0004593
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of MSP1 from P. yoelii str. 17XNL
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
pJW4304 (Sakai et al., 2003)
g. Immunization Route
Gene gun
h. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: MSP1 vaccine alone conferred partial protection. Vaccination with MSP1 + IL-12 conferred the strongest protective immunity against the infection. Only two of the six mice immunized with MSP1 alone survived, while five of the six mice immunized with MSP1 + IL-12 survived (Sakai et al., 2003).
30. P. yoelii DNA vaccine encoding PyHEP17 Protein
a. Vaccine Ontology ID:
VO_0004162
b. Type:
DNA vaccine
c. Status:
Research
d. Gene Engineering of HEP17
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
e. Vector:
nkCMVintpolyli (Doolan et al., 1996)
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Host Strain: BALB/cByJ, A/J, B10.BR, B10.Q and C57BL/6
  • Vaccination Protocol: Female 6- to 8-wk-old mice were immunized three times at 3-wk intervals intramuscularly in each tibialis anterior muscle with 50 μg of PyHEP17 DNA in 50 μl of saline or unmodified nkCMVintpolyli plasmid. 2 wk after the third immunization, mice were challenged by tail-vein injection with 100 infectious sporozoites or 200 infected erythrocytes (Doolan et al., 1996).
  • Challenge Detail
    No. Pathogen Name Dose Route Age Interval
    1 Plasmodium yoelii 100 CFU in volume ml Tail vein injection day 14 day
  • Efficacy Detail
    No. Efficacy method Result Description Group Efficacy Detail
    1 In vivo protection study CFU Immunization with PyHEP17 DNA partially protected three of the five strains >20% against challenge with 100 infectious sporozoites. A 2 to 6 day delay in the onset of parasitemia in some nonprotected mice was consistent with partial immunity, which eliminated up to 90% of infected hepatocytes (Doolan et al., 1996).
31. P. yoelii DNA vaccine encoding PySSP2
a. Vaccine Ontology ID:
VO_0004590
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of SSP2
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
nkCMVint or VR1012 (Hoffman et al., 1997)
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: The full-length gene of PySSP2 in the nkCMVint vector induced specific antibodies and protected 50% of immunized mice. Subsequently, outbred CD-l mice were immunized with nkCMVint and VR1012 vector based PySSP2 DNA vaccines and as many as 33% were protected (Hoffman et al., 1997).
32. P. yoelii DNA vaccine pDIP/PyCSP. 1
a. Vaccine Ontology ID:
VO_0004589
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of CS from P. yoelii str. 17XNL
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
pBC12/CMV/IL-2 (Hoffman et al., 1994)
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: Mice immunized with three doses of pDIP/PyCSP.1 and challenged with 5 × 105 P. yoelii sporozoites had a significant reduction in liver stage infection compared with mice immunized with the empty plasmid. Most importantly, 9 of 16 mice were protected against challenge (Hoffman et al., 1994).
33. P. yoelii DNA vaccine pPyHsp60-VR1012
a. Vaccine Ontology ID:
VO_0004592
b. Type:
DNA vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of HSP60 from P. yoelii
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click here.
f. Vector:
VR1012 (Sanchez et al., 2001)
g. Immunization Route
Intramuscular injection (i.m.)
h. Mouse Response
  • Vaccine Immune Response Type: VO_0003057
  • Efficacy: In experiment 1, 40% of mice immunized with the combination of pPyHsp60-VR1012 and pmurGM-CSF did not develop parasitemia during the 14 days postchallenge. Only this group had statistically significant protection on day 14 as compared with the pooled controls (two-tailed Fisher's exact test: P = 0.031 , group 1.B versus group 1.H + group 1.I). However, in experiment 2 (identical immunization schedule), immunized mice only experienced delayed parasitemia, rather than protection from parasitemia (Sanchez et al., 2001).
34. P. yoelii MSP1 and MSP4/5 Proteins Subunit Vaccine
a. Vaccine Ontology ID:
VO_0011439
b. Type:
Subunit vaccine
c. Status:
Research
d. Gene Engineering of MSP4/5
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
e. Immunization Route
Orally
f. Mouse Response
  • Vaccination Protocol: One group of mice was treated by gavage with 25 μg of EcMSP4/5, and the other group was treated by gavage with 25 μg of EcMSP4/5 plus an amount of GST-PyMSP119 equivalent to 25 μg of PyMSP119 (Wang et al., 2004).
  • Challenge Protocol: In order to examine the protective efficacy of the induced antibodies, the immunized mice were challenged at 2 weeks after the sixth immunization with a lethal dose of 105 P. yoelii YM parasites (Wang et al., 2004).
  • Efficacy: Oral immunization of mice with Escherichia coli-expressed Plasmodium yoelii merozoite surface protein 4/5 or the C-terminal 19-kDa fragment of merozoite surface protein 1 induced systemic antibody responses and protected mice against lethal malaria infection. All of the eight immunized mice survived the challenge, with peak parasitemia levels between 0.2 and 55.2% (Wang et al., 2004).
35. P. yoelii TyCS-VLP Vaccine
a. Vaccine Ontology ID:
VO_0004271
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
CD8+ T cell epitope (SYVPSAEQI) of the circumsporozoite (CS) protein of Plasmodium yoelii (Oliveira-Ferreira et al., 2000).
e. Adjuvant: ty particles vaccine adjuvant
f. Immunization Route
Intramuscular injection (i.m.)
g. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: All the immunizations with TyCS-VLP carrying the CTL epitope of the P. yoelii circumsporozoite protein (SYVPSAEQI), except the dose response and the route of immunization experiments, consisted of 50 mg per mouse injected intramuscularly (i.m.) in the leg quadriceps (Oliveira-Ferreira et al., 2000).
  • Challenge Protocol: Mice were challenged with 75 sporozoites per mice administered i.v. (Oliveira-Ferreira et al., 2000).
  • Efficacy: 2/8 mice immunized with the TyCs-VLP vaccine were protected from challenge with P. yoelii sporozoites (Oliveira-Ferreira et al., 2000).
36. Plasmodium berghei CS Protein Subunit Vaccine
a. Vaccine Ontology ID:
VO_0011549
b. Type:
Subunit vaccine
c. Status:
Research
d. Antigen
A tandem repeat of the B cell immunodominant repeat epitope (DPPPPNPN)2D of the malaria parasite Plasmodium berghei circumsporozoite protein (P4c-Mal) (Kaba et al., 2009).
e. Gene Engineering of CS from P. berghei str. ANKA
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
f. Immunization Route
Intraperitoneal injection (i.p.)
g. Mouse Response
  • Host Strain: BALB/c, C57BL/6
  • Vaccination Protocol: Mice were randomly divided into groups of 5 or 10 and immunized i.p. three times at 14-day intervals. Where indicated, a positive control group was immunized with irradiated P. berghei sporozoites (Kaba et al., 2009).
  • Challenge Protocol: P. berghei sporozoites (ANKA strain), maintained by cyclical transmission in mice and Anopheles stephensi, were dissected from mosquitoes 21–23 days after their infectious blood meal and used within 6 h. Fourteen days after the final immunization or at other specific times on long-term memory experiments, mice were challenged with a lethal dose of live P. berghei sporozoites by i.v. inoculation. C57BL/6, MHC KO, and nude mice were injected with 1000 sporozoites and BALB/c mice were injected with 4000 sporozoites per mouse (Kaba et al., 2009).
  • Efficacy: More than 95% of mice immunized with P4c-Mal, both with and without Montanide ISA-720, or R-PbCSP in Montanide ISA-720 did not develop any parasitemia and thus showed complete protection against challenge with viable sporozoites (Fig. 2B). This ability to prevent parasitemia and thus prevent malaria following sporozoite challenge is equivalent to what is only achieved with the whole, irradiated sporozoite immunization regime. In contrast, as few as 5% of animals administered saline, saline and Montanide ISA-720, or R-PbCSP in saline did not develop parasites and survived until 11 days post challenge. No animal was observed with blood stage parasites that did not die naturally or was killed according to protocol. These results show that immunization with P4c-Mal had a significant ability to induce a protective immune response in the presence as well as in the absence of adjuvant (Kaba et al., 2009).
37. Plasmodium berghei p36p mutant vaccine
a. Vaccine Ontology ID:
VO_0003008
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of P36p
f. Immunization Route
Intravenous injection (i.v.)
g. Mouse Response
38. Plasmodium FabB/FabF mutant vaccine
a. Vaccine Ontology ID:
VO_0003007
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of FabB/FabF
f. Immunization Route
Intravenous injection (i.v.)
g. Mouse Response
  • Persistence: A FabB/FabF genetically attenuated parasite is attenuated in mice (Butler et al., 2011).
  • Efficacy: A FabB/FabF genetically attenuated parasite induces complete protection in mice from challenge with wild type Plasmodium (Butler et al., 2011).
39. Plasmodium yoelii p36/p52 mutant vaccine
a. Type:
Live, attenuated vaccine
b. Status:
Research
c. Host Species as Laboratory Animal Model:
Mouse
d. Gene Engineering of Py36
e. Gene Engineering of Py52
f. Immunization Route
Intravenous injection (i.v.)
g. Mouse Response
40. Plasmodium yoelii UIS3 mutant vaccine
a. Vaccine Ontology ID:
VO_0003011
b. Type:
Live, attenuated vaccine
c. Status:
Research
d. Host Species as Laboratory Animal Model:
Mouse
e. Gene Engineering of UIS3
f. Immunization Route
Intravenous injection (i.v.)
g. Mouse Response
  • Persistence: A UIS3 mutant is attenuated in mice (Tarun et al., 2007).
  • Efficacy: A UIS3 mutant provided complete protection in mice after two doses from challenge with wild type Plasmodium yoelii (Tarun et al., 2007).
41. rBCGMSP1-15
a. Vaccine Ontology ID:
VO_0004791
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Mouse
e. Antigen
MSP1-15 as a fusion protein with the α antigen of Mycobacterium kansasii (α-k), which is secreted from the rBCG vaccine vector (Matsumoto et al., 1998).
f. Gene Engineering of MSP1 from P. yoelii str. 17XNL
  • Type: Recombinant vector construction
  • Description: A 2.4-kbp fragment containing an α-k–MSP1-15 hybrid gene was subcloned into pSO246. The final construct (designated pSOMSP1-15) was transformed into BCG Tokyo by electroporation (Matsumoto et al., 1998).
  • Detailed Gene Information: Click here.
g. Immunization Route
Intravenous injection (i.v.)
h. Mouse Response
  • Host Strain: C57BL/6, C3H/He, A/J
  • Vaccination Protocol: C3H/He mice were immunized intravenously with 106 CFU of rBCGMSP1-15 in 200 μl of PBS containing 0.1% PBS-T80. A control group of mice was injected with 106 CFU of BCG in 200 μl of PBS-T80 or PBS-T80 only. 30 days later, the same amount of each sample was injected intraperitoneally to boost the immune response (Matsumoto et al., 1998).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: Mice were challenged with 104 P. yoelii 17XL-parasitized erythrocytes intravenously or intraperitoneally 1 month after the final immunization (Matsumoto et al., 1998).
  • Efficacy: 3 out of 7 mice immunized with GST-MSP1-15 in RAS and 2 out of 8 mice immunized with GST-MSP1-15 in IFA survived the infection. 6 out of 7 mice immunized with rBCGMSP1-15 survived the infection. Data showed the three adjuvants examined are effective for vaccination with MSP1-15, while their efficacy levels differ. The rBCG system was the most effective for vaccination (Matsumoto et al., 1998).
42. Recombinant ABRA protein vaccine
a. Vaccine Ontology ID:
VO_0000778
b. Type:
Subunit vaccine
c. Antigen
The acidic basic repeat antigen (ABRA) of Plasmodium falciparum is a vaccine candidate against erythrocytic stages of malaria (Kushwaha et al., 2001).
d. Gene Engineering of ABRA
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click here.
e. Adjuvant: complete Freunds adjuvant
  • VO ID: VO_0000139
  • Description: Complete Freund's adjuvant (CFA) was used as the first adjuvant. Boosters of the same amount of protein were given in incomplete Freund's adjuvant (IFA) (Kushwaha et al., 2001).
f. Preparation
The four fragments of ABRA, including N-terminal [ABRA (N); aa 24–369], middle [ABRA (M); aa 370–507], N-terminal + middle [ABRA (P); aa 24–507] and the C-terminal [ABRA (C); aa 508–743], were expressed as fusions with either maltose binding protein (MBP) or 6X histidine tag at their amino terminii using pMALc-2 vector from NEB (New England Biolabs, Beverly, MA, USA) or pQE30 vector (Qiagen GmbH, Germany), respectively. These recombinant proteins were purified to near homogeneity by affinity chromatography of the soluble fraction, concentrated, and the purity of the protein judged by SDS-PAGE.
g. Mouse Response
  • Host Strain: BALB/c
  • Vaccination Protocol: Groups of BALB/c mice were immunized by i.p. injection with ABRA protein/MBP emulsified in complete Freund's adjuvant (CFA). Control mice received only PBS in the adjuvant. Boosters of the same amount of protein were given in incomplete Freund's adjuvant (IFA). Sera were collected from each group and treated as described earlier (Kushwaha et al., 2001).
  • Persistence: Humoral and cell-mediated response was still robust up to 70 days post-immunization (Kushwaha et al., 2001).
  • Immune Response: Results showed that ABRA (M), ABRA (C) and ABRA (P) were highly immunogenic in these animals; end point titres greater than 105 were observed in these constructs. Mice were immunized using standard methods. Relative concentrations of the antibodies elicited by them in mice at different intervals of immunization were measured at a dilution of 1 : 3000. ABRA (N) and ABRA (C) did not show a boostable antibody response; two secondary immunizations did not result in any increase in the antibody titre. Immunogenicity studies with these constructs in rabbits and mice indicated that the N-terminal region is the least immunogenic part of ABRA. T-cell proliferation experiments in mice immunized with these constructs revealed that the T-cell epitopes were localized in the middle portion of the protein (Kushwaha et al., 2001).
  • Efficacy: The purified immunoglobulin G specific to middle and C-terminal fragments prevented parasite growth at levels approaching 80-90% (Kushwaha et al., 2001).
  • Description: This antibody response was the focus of intense interest when it was found that mice could be rendered resistant to sporozoite challenge by passive immunisation with monoclonal antibodies against circumsporozoite protein (Kwiatkowski et al., 1997).
43. RTS,S/AS02A
a. Vaccine Ontology ID:
VO_0000774
b. Type:
Subunit vaccine
c. Antigen
RTS,S is the pre-erythrocyte sporozoite-stage Plasmodium falciparum antigen. It is a circumsporozoite surface protein (Alonso et al., 2004).
d. Adjuvant: AS02 vaccine adjuvant
e. Preparation
RTS,S/AS02 is a pre-erythrocyte sporozoite-stage malaria vaccine based on the circumsporozoite surface protein of Plasmodium falciparum RTS,S fused to HBsAg , incorporating a new adjuvant (AS02) (Bojang et al., 2001; Alonso et al., 2004).
f. Human Response
  • Host Strain: Mozambique children
  • Vaccination Protocol: A double-blind, phase IIb, randomised controlled trial was performed in Mozambique in 2022 children aged 1–4 years. The study included two cohorts of children living in two separate areas which underwent different follow-up schemes. Participants were randomly allocated three doses of either RTS,S/AS02A candidate malaria vaccine or control vaccines. The primary endpoint, determined in cohort 1 (n=1605), was time to first clinical episode of P falciparum malaria (axillary temperature ≥37·5°C and P falciparum asexual parasitaemia >2500 per μL) over a 6-month surveillance period. Efficacy for prevention of new infections was determined in cohort 2 (n=417) (Alonso et al., 2004).
  • Persistence: Vaccine efficacy in extending time to first infection was determined in cohort 2. 323 children had first episodes of asexual P falciparum parasitaemia (157 in the RTS,S/AS02A group and 166 in the control group), yielding a vaccine efficacy estimate of 45.0% (95% CI 31.4–55.9; p<0.0001). The mean density of asexual-stage parasites at the time of first infection was similar for the control and RTS,S/AS02A groups (3950 vs 3016 per μL, p=0.354). With the same methods as those used to assess persistence of efficacy for cohort 1, the model with the best fit suggested waning efficacy of the vaccine over time, which stabilised at about 40%. The prevalence of asexual P falciparum parasitaemia at the end of follow-up was lower in the RTS,S/AS02A group than in the control group (52.3% vs 65.8%; p=0.019), and prevalence of anaemia at month 8·5 was 2.7% in the control group and 0% in the RTS,S/AS02A group (p=0.056) (Alonso et al., 2004).
  • Immune Response: Prevaccination anti-circumsporozoite antibody titres were low in the study children. The vaccine was immunogenic, inducing specific antibody levels after dose three, decaying over 6 months to about a quarter of the initial level, but remaining well above baseline values. Antibody levels in the control group remained low over the follow-up period. The vaccine also induced high levels of antibodies against HBsAg (>97% seroprotection). For both circumsporozoite and HBsAg, immunogenicity of the vaccine was greater in children younger than 24 months of age (Alonso et al., 2004).
  • Side Effects: RTS,S/AS02A and control vaccines were safe and well tolerated. More than 92% of children in both groups received all three doses. Local and general solicited adverse events were of short duration and were mostly mild or moderate in intensity. Grade 3 local or general adverse events were uncommon and of short duration. Local injection-site pain that limited arm motion arose after seven (0.2%) doses in the RTS,S/AS02A group and after one (0.03%) dose in the control vaccine group, and injection-site swelling of more than 20 mm happened after 224 (7.7%) and 14 (0.5%) doses, respectively. General solicited adverse events (fever, irritability, drowsiness, anorexia) that prevented normal activities arose after 55 (1.9%) doses in the RTS,S/AS02A group and 23 (0.8%) doses in the control group. At least one unsolicited adverse event was reported by 653 (64.5%) children in the RTS,S/AS02A group and 597 (59.1%) in the control group. 429 serious adverse events were reported: 180 (17.8%) in the RTS,S/AS02A group and 249 (24.7%) in the control group. 15 children died during the study, five (0.6%) in the RTS,S/AS02A group and ten (1.2%) in the control group. Four of those who died had malaria as a significant contributing factor and all four were in the control group. No serious adverse event or death was judged to be related to vaccination (Alonso et al., 2004).
  • Challenge Protocol: Children were not challenged (Alonso et al., 2004)
  • Efficacy: Vaccine efficacy for the first clinical episodes was 29.9% (95% CI 11.0-44.8; p=0.004). At the end of the 6-month observation period, prevalence of P falciparum infection was 37% lower in the RTS,S/AS02A group compared with the control group (11.9% vs 18.9%; p=0.0003). Vaccine efficacy for severe malaria was 57.7% (95% CI 16.2-80.6; p=0.019). In cohort 2, vaccine efficacy for extending time to first infection was 45.0% (31.4-55.9; p<0.0001) (Alonso et al., 2004).
  • Description: Development of an effective malaria vaccine could greatly contribute to disease control. RTS,S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium falciparum circumsporozoite surface antigen. The RTS,S/AS02A vaccine was safe, well tolerated, and immunogenic (Alonso et al., 2004).
44. SAd-ME.TRAP
a. Vaccine Ontology ID:
VO_0004799
b. Type:
Recombinant vector vaccine
c. Status:
Research
d. Host Species for Licensed Use:
Mouse
e. Preparation
(Reyes-Sandoval et al., 2008) AdC7 and AdC9 elicited strong immunogenicity ( approximately 20% of CD8(+) T cells in spleen), equivalent to or outperforming AdH5 and inducing sterile protection in 92% (C9), 83% (H5 and C7) and 67% (C6) of the mice, providing the first evidence of single-dose protection to Plasmodium berghei.
f. Immunization Route
Intramuscular injection (i.m.)
IV. References
1. Adams et al., 2002: Adams S, Brown H, Turner G. Breaking down the blood-brain barrier: signaling a path to cerebral malaria?. Trends in parasitology. 2002 Aug; 18(8); 360-6. [PubMed: 12377286].
2. Aidoo et al., 2000: Aidoo M, Lalvani A, Gilbert SC, Hu JT, Daubersies P, Hurt N, Whittle HC, Druihle P, Hill AV. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infection and immunity. 2000 Jan; 68(1); 227-32. [PubMed: 10603392].
3. Alonso et al., 2004: Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, Mandomando I, Spiessens B, Guinovart C, Espasa M, Bassat Q, Aide P, Ofori-Anyinam O, Navia MM, Corachan S, Ceuppens M, Dubois MC, Demoitie MA, Dubovsky F, Menendez C, Tornieporth N, Ballou WR, Thompson R, Cohen J. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet. 2004 Oct 16-22; 364(9443); 1411-20. [PubMed: 15488216].
4. Arevalo-Herrera et al., 2005: Arevalo-Herrera M, Solarte Y, Yasnot MF, Castellanos A, Rincon A, Saul A, Mu J, Long C, Miller L, Herrera S. Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein. The American journal of tropical medicine and hygiene. 2005 Nov; 73(5 Suppl); 32-7. [PubMed: 16291764].
5. Audran et al., 2005: Audran R, Cachat M, Lurati F, Soe S, Leroy O, Corradin G, Druilhe P, Spertini F. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infection and immunity. 2005 Dec; 73(12); 8017-26. [PubMed: 16299295].
6. Bauza et al., 2014: Bauza K, Malinauskas T, Pfander C, Anar B, Jones EY, Billker O, Hill AV, Reyes-Sandoval A. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia Ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infection and immunity. 2014; 82(3); 1277-1286. [PubMed: 24379295].
7. BenMohamed et al., 2004: BenMohamed L, Thomas A, Druilhe P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infection and immunity. 2004 Aug; 72(8); 4376-84. [PubMed: 15271893].
8. Bergmann-Leitner et al., 2007: Bergmann-Leitner ES, Duncan EH, Leitner WW, Neutzner A, Savranskaya T, Angov E, Tsokos GC. C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine. 2007; 25(45); 7732-7736. [PubMed: 17931754].
9. Bergmann-Leitner et al., 2010: Bergmann-Leitner ES, Mease RM, De La Vega P, Savranskaya T, Polhemus M, Ockenhouse C, Angov E. Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PloS one. 2010; 5(8); e12294. [PubMed: 20808868].
10. Bledsoe, 2005: Bledsoe GH. Malaria primer for clinicians in the United States. Southern medical journal. 2005 Dec; 98(12); 1197-204; quiz 1205, 1230. [PubMed: 16440920].
11. Bojang et al., 2001: Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L, Delchambre M, Voss G, Greenwood BM, Hill A, McAdam KP, Tornieporth N, Cohen JD, Doherty T. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet. 2001 Dec 8; 358(9297); 1927-34. [PubMed: 11747915].
12. Bonnefoy et al., 1994: Bonnefoy S, Gysin J, Blisnick T, Guillotte M, Carcy B, Pereira da Silva L, Mercereau-Puijalon O. Immunogenicity and antigenicity of a Plasmodium falciparum protein fraction (90-110 kDa) able to protect squirrel monkeys against asexual blood stages. Vaccine. 1994; 12(1); 32-40. [PubMed: 8303938].
13. Bracho et al., 2009: Bracho G, Zayas C, Wang L, Coppel R, Pérez O, Petrovsky N. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5. Malaria journal. 2009; 8; 35. [PubMed: 19250541].
14. Breman, 2001: Breman JG. The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. The American journal of tropical medicine and hygiene. 2001 Jan-Feb; 64(1-2 Suppl); 1-11. [PubMed: 11425172].
15. Bruna-Romero et al., 2004: Bruna-Romero O, Rocha CD, Tsuji M, Gazzinelli RT. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine. 2004 Sep 9; 22(27-28); 3575-84. [PubMed: 15315836].
16. Burgess et al., 2005: Burgess BR, Schuck P, Garboczi DN. Dissection of merozoite surface protein 3, a representative of a family of Plasmodium falciparum surface proteins, reveals an oligomeric and highly elongated molecule. The Journal of biological chemistry. 2005 Nov 4; 280(44); 37236-45. [PubMed: 16135515].
17. Butler et al., 2011: Butler NS, Schmidt NW, Vaughan AM, Aly AS, Kappe SH, Harty JT. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell host & microbe. 2011; 9(6); 451-462. [PubMed: 21669394].
18. Carter et al., 1995: Carter R, Coulson A, Bhatti S, Taylor BJ, Elliott JF. Predicted disulfide-bonded structures for three uniquely related proteins of Plasmodium falciparum, Pfs230, Pfs48/45 and Pf12. Molecular and biochemical parasitology. 1995 May; 71(2); 203-10. [PubMed: 7477102].
19. Carvalho et al., 2004: Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MC, Zanini GM, Brígido MC, Oeuvray C, Póvoa MM, Muniz JA, Druilhe P, Daniel-Ribeiro CT. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scandinavian journal of immunology. 2004; 59(4); 363-372. [PubMed: 15049780].
20. Castellanos et al., 2007: Castellanos A, Arevalo-Herrera M, Restrepo N, Gulloso L, Corradin G, Herrera S. Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Memorias do Instituto Oswaldo Cruz. 2007 Jun; 102(3); 411-6. [PubMed: 17568948].
21. Chen et al., 2000: Chen Q, Schlichtherle M, Wahlgren M. Molecular aspects of severe malaria. Clinical microbiology reviews. 2000 Jul; 13(3); 439-50. [PubMed: 10885986].
22. Coutant et al., 2012: Coutant F, Sanchez David RY, Félix T, Boulay A, Caleechurn L, Souque P, Thouvenot C, Bourgouin C, Beignon AS, Charneau P. A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria. PloS one. 2012; 7(11); e48644. [PubMed: 23133649].
23. Daly and Long, 1993: Daly TM, Long CA. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infection and immunity. 1993; 61(6); 2462-2467. [PubMed: 8363656].
24. Daubersies et al., 2000: Daubersies P, Thomas AW, Millet P, Brahimi K, Langermans JA, Ollomo B, BenMohamed L, Slierendregt B, Eling W, Van Belkum A, Dubreuil G, Meis JF, Guérin-Marchand C, Cayphas S, Cohen J, Gras-Masse H, Druilhe P. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nature medicine. 2000; 6(11); 1258-1263. [PubMed: 11062538].
25. Dobaño and Doolan, 2007: Dobaño C, Doolan DL. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa. Molecular immunology. 2007; 44(11); 3037-3048. [PubMed: 17303242].
26. Doolan et al., 1996: Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman SL. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. The Journal of experimental medicine. 1996; 183(4); 1739-1746. [PubMed: 8666931].
27. Douradinha et al., 2007: Douradinha B, van Dijk MR, Ataide R, van Gemert GJ, Thompson J, Franetich JF, Mazier D, Luty AJ, Sauerwein R, Janse CJ, Waters AP, Mota MM. Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection. International journal for parasitology. 2007; 37(13); 1511-1519. [PubMed: 17604034].
28. Dunachie et al., 2006: Dunachie SJ, Walther M, Epstein JE, Keating S, Berthoud T, Andrews L, Andersen RF, Bejon P, Goonetilleke N, Poulton I, Webster DP, Butcher G, Watkins K, Sinden RE, Levine GL, Richie TL, Schneider J, Kaslow D, Gilbert SC, Carucci DJ, Hill AV. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infection and immunity. 2006; 74(10); 5933-5942. [PubMed: 16988273].
29. Eksi et al., 2006: Eksi S, Czesny B, van Gemert GJ, Sauerwein RW, Eling W, Williamson KC. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. Molecular microbiology. 2006 Aug; 61(4); 991-8. [PubMed: 16879650].
30. El et al., 2010: El Sahly HM, Patel SM, Atmar RL, Lanford TA, Dube T, Thompson D, Lee Sim BK, Long C, Keitel WA. The Safety and Immunogenicity of Recombinant EBA 175-RII NG Malaria Vaccine in Healthy Adults Living in a Non-Endemic Area. Clinical and vaccine immunology : CVI. 2010; ; . [PubMed: 20702657].
31. Escalante et al., 1998: Escalante AA, Freeland DE, Collins WE, Lal AA. The evolution of primate malaria parasites based on the gene encoding cytochrome b from the linear mitochondrial genome. Proceedings of the National Academy of Sciences of the United States of America. 1998 Jul 7; 95(14); 8124-9. [PubMed: 9653151].
32. Eslava et al., 2010: Eslava I, Payares G, Pernia BM, Holder AA, Spencer LM. Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii. Malaria journal. 2010; 9; 46. [PubMed: 20146804].
33. Etlinger et al., 1991: Etlinger HM, Caspers P, Matile H, Schoenfeld HJ, Stueber D, Takacs B. Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infection and immunity. 1991; 59(10); 3498-3503. [PubMed: 1894356].
34. Fanning et al., 2003: Fanning SL, Czesny B, Sedegah M, Carucci DJ, van Gemert GJ, Eling W, Williamson KC. A glycosylphosphatidylinositol anchor signal sequence enhances the immunogenicity of a DNA vaccine encoding Plasmodium falciparum sexual-stage antigen, Pfs230. Vaccine. 2003 Jul 4; 21(23); 3228-35. [PubMed: 12804852].
35. Flanagan et al., 2003: Flanagan KL, Mwangi T, Plebanski M, Odhiambo K, Ross A, Sheu E, Kortok M, Lowe B, Marsh K, Hill AV. Ex vivo interferon-gamma immune response to thrombospondin-related adhesive protein in coastal Kenyans: longevity and risk of Plasmodium falciparum infection. The American journal of tropical medicine and hygiene. 2003 Apr; 68(4); 421-30. [PubMed: 12875291].
36. Flanagan et al., 2006: Flanagan KL, Plebanski M, Odhiambo K, Sheu E, Mwangi T, Gelder C, Hart K, Kortok M, Lowe B, Robson KJ, Marsh K, Hill AV. Cellular reactivity to the p. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. The American journal of tropical medicine and hygiene. 2006 Mar; 74(3); 367-75. [PubMed: 16525093].
37. Gantt et al., 2000: Gantt S, Persson C, Rose K, Birkett AJ, Abagyan R, Nussenzweig V. Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo. Infection and immunity. 2000 Jun; 68(6); 3667-73. [PubMed: 10816526].
38. Garcia et al., 2006: Garcia JE, Puentes A, Patarroyo ME. Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design. Clinical microbiology reviews. 2006 Oct; 19(4); 686-707. [PubMed: 17041140].
39. Genton et al., 2003: Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine. 2003 Dec 8; 22(1); 30-41. [PubMed: 14604568].
40. Genton et al., 2003a: Genton B, Anders RF, Alpers MP, Reeder JC. The malaria vaccine development program in Papua New Guinea. Trends in parasitology. 2003 Jun; 19(6); 264-70. [PubMed: 12798084].
41. Gilbert et al., 2006: Gilbert SC, Moorthy VS, Andrews L, Pathan AA, McConkey SJ, Vuola JM, Keating SM, Berthoud T, Webster D, McShane H, Hill AV. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine. 2006 May 22; 24(21); 4554-61. [PubMed: 16150517].
42. Girard et al., 2007: Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. Vaccine. 2007 Feb 19; 25(9); 1567-80. [PubMed: 17045367].
43. Grüner et al., 2007: Grüner AC, Mauduit M, Tewari R, Romero JF, Depinay N, Kayibanda M, Lallemand E, Chavatte JM, Crisanti A, Sinnis P, Mazier D, Corradin G, Snounou G, Rénia L. Sterile protection against malaria is independent of immune responses to the circumsporozoite protein. PloS one. 2007; 2(12); e1371. [PubMed: 18159254].
44. Greenwood et al., 2005: Greenwood BM, Bojang K, Whitty CJ, Targett GA. Malaria. Lancet. 2005 Apr 23-29; 365(9469); 1487-98. [PubMed: 15850634].
45. Hay et al., 2004: Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. The Lancet infectious diseases. 2004 Jun; 4(6); 327-36. [PubMed: 15172341].
46. Heal et al., 1999: Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Vaccine. 1999 Sep; 18(3-4); 251-8. [PubMed: 10506649].
47. Healer et al., 1997: Healer J, McGuinness D, Hopcroft P, Haley S, Carter R, Riley E. Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infection and immunity. 1997 Aug; 65(8); 3017-23. [PubMed: 9234748].
48. Heppner et al., 2005: Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine. 2005 Mar 18; 23(17-18); 2243-50. [PubMed: 15755604].
49. Hillier et al., 2005: Hillier CJ, Ware LA, Barbosa A, Angov E, Lyon JA, Heppner DG, Lanar DE. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infection and immunity. 2005 Apr; 73(4); 2109-15. [PubMed: 15784552].
50. Hoffman et al., 1994: Hoffman SL, Sedegah M, Hedstrom RC. Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. Vaccine. 1994; 12(16); 1529-1533. [PubMed: 7879419].
51. Hoffman et al., 1997: Hoffman SL, Doolan DL, Sedegah M, Aguiar JC, Wang R, Malik A, Gramzinski RA, Weiss WR, Hobart P, Norman JA, Margalith M, Hedstrom RC. Strategy for development of a pre-erythrocytic Plasmodium falciparum DNA vaccine for human use. Vaccine. 1997; 15(8); 842-845. [PubMed: 9234529].
52. Horii et al., 2010: Horii T, Shirai H, Jie L, Ishii KJ, Palacpac NQ, Tougan T, Hato M, Ohta N, Bobogare A, Arakaki N, Matsumoto Y, Namazue J, Ishikawa T, Ueda S, Takahashi M. Evidences of Protection Against Blood-stage Infection of Plasmodium falciparum by the Novel Protein Vaccine SE36. Parasitology international. 2010; ; . [PubMed: 20493274].
53. Iyori et al., 2013: Iyori M, Nakaya H, Inagaki K, Pichyangkul S, Yamamoto DS, Kawasaki M, Kwak K, Mizukoshi M, Goto Y, Matsuoka H, Matsumoto M, Yoshida S. Protective efficacy of baculovirus dual expression system vaccine expressing Plasmodium falciparum circumsporozoite protein. PloS one. 2013; 8(8); e70819. [PubMed: 23951015].
54. Joy et al., 2003: Joy DA, Feng X, Mu J, Furuya T, Chotivanich K, Krettli AU, Ho M, Wang A, White NJ, Suh E, Beerli P, Su XZ. Early origin and recent expansion of Plasmodium falciparum. Science (New York, N.Y.). 2003 Apr 11; 300(5617); 318-21. [PubMed: 12690197].
55. Kaba et al., 2009: Kaba SA, Brando C, Guo Q, Mittelholzer C, Raman S, Tropel D, Aebi U, Burkhard P, Lanar DE. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. Journal of immunology (Baltimore, Md. : 1950). 2009; 183(11); 7268-7277. [PubMed: 19915055].
56. Kaufman et al., 2005: Kaufman TS, Ruveda EA. The quest for quinine: those who won the battles and those who won the war. Angewandte Chemie (International ed. in English). 2005 Jan 28; 44(6); 854-85. [PubMed: 15669029].
57. Kester et al., 2007: Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG Jr, Hall T, Wellde BT, White K, Sun P, Schwenk R, Krzych U, Delchambre M, Voss G, Dubois MC, Gasser RA Jr, Dowler MG, O'Brien M, Wittes J, Wirtz R, Cohen J, Ballou WR. A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults. Vaccine. 2007 Jul 20; 25(29); 5359-66. [PubMed: 17574311].
58. Kocken et al., 2002: Kocken CH, Withers-Martinez C, Dubbeld MA, van der Wel A, Hackett F, Valderrama A, Blackman MJ, Thomas AW. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infection and immunity. 2002 Aug; 70(8); 4471-6. [PubMed: 12117958].
59. Komisar, 2007: Komisar JL. Malaria vaccines. Frontiers in bioscience : a journal and virtual library. 2007 May 1; 12; 3928-55. [PubMed: 17485348].
60. Kristoff, 2007: Kristoff J. Malaria stage-specific vaccine candidates. Current pharmaceutical design. 2007; 13(19); 1989-99. [PubMed: 17627532].
61. Kumar et al., 1995: Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow DC. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Molecular medicine (Cambridge, Mass.). 1995; 1(3); 325-332. [PubMed: 8529111].
62. Kushwaha et al., 2001: Kushwaha A, Rao PP, Suresh RP, Chauhan VS. Immunogenicity of recombinant fragments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite immunology. 2001 Aug; 23(8); 435-44. [PubMed: 11489167].
63. Kwiatkowski et al., 1997: Kwiatkowski D, Marsh K. Development of a malaria vaccine. Lancet. 1997 Dec 6; 350(9092); 1696-701. [PubMed: 9400530].
64. Kwon et al., 2005: Kwon YU, Soucy RL, Snyder DA, Seeberger PH. Assembly of a series of malarial glycosylphosphatidylinositol anchor oligosaccharides. Chemistry (Weinheim an der Bergstrasse, Germany). 2005 Apr 8; 11(8); 2493-504. [PubMed: 15729674].
65. Labaied et al., 2007: Labaied M, Harupa A, Dumpit RF, Coppens I, Mikolajczak SA, Kappe SH. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infection and immunity. 2007; 75(8); 3758-3768. [PubMed: 17517871].
66. Lal et al., 1996: Lal AA, Hughes MA, Oliveira DA, Nelson C, Bloland PB, Oloo AJ, Hawley WE, Hightower AW, Nahlen BL, Udhayakumar V. Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria. Infection and immunity. 1996 Mar; 64(3); 1054-9. [PubMed: 8641760].
67. Lanar et al., 1996: Lanar DE, Tine JA, de Taisne C, Seguin MC, Cox WI, Winslow JP, Ware LA, Kauffman EB, Gordon D, Ballou WR, Paoletti E, Sadoff JC. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infection and immunity. 1996; 64(5); 1666-1671. [PubMed: 8613376].
68. Langermans et al., 2006: Langermans JA, Hensmann M, van Gijlswiik M, Zhang D, Pan W, Giersing BK, Locke E, Dubovsk F, Wittes J, Thomas AW. Preclinical evaluation of a chimeric malaria vaccine candidate in Montanide ISA 720: immunogenicity and safety in rhesus macaques. Human vaccines. 2006 Sep-Oct; 2(5); 222-6. [PubMed: 17035731].
69. Le et al., 2000: Le TP, Coonan KM, Hedstrom RC, Charoenvit Y, Sedegah M, Epstein JE, Kumar S, Wang R, Doolan DL, Maguire JD, Parker SE, Hobart P, Norman J, Hoffman SL. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine. 2000; 18(18); 1893-1901. [PubMed: 10699338].
70. Li et al., 2007: Li SL, Zhang DM, Cao Y, Pan WQ. [Expression and immunogenicity evaluation of ectodomain and subdomains of Plasmodium berghei apical membrane antigen 1]. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases. 2007; 25(1); 1-5. [PubMed: 17639690].
71. Matsumoto et al., 1998: Matsumoto S, Yukitake H, Kanbara H, Yamada T. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. The Journal of experimental medicine. 1998; 188(5); 845-854. [PubMed: 9730886].
72. Mauduit et al., 2009: Mauduit M, Grüner AC, Tewari R, Depinay N, Kayibanda M, Chavatte JM, Franetich JF, Crisanti A, Mazier D, Snounou G, Rénia L. A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PloS one. 2009; 4(11); e7717. [PubMed: 19890387].
73. McConkey et al., 2003: McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, Vuola JM, Blanchard TJ, Gothard P, Watkins K, Hannan CM, Everaere S, Brown K, Kester KE, Cummings J, Williams J, Heppner DG, Pathan A, Flanagan K, Arulanantham N, Roberts MT, Roy M, Smith GL, Schneider J, Peto T, Sinden RE, Gilbert SC, Hill AV. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature medicine. 2003; 9(6); 729-735. [PubMed: 12766765].
74. Meis et al., 1983: Meis JF, Verhave JP, Jap PH, Sinden RE, Meuwissen JH. Malaria parasites--discovery of the early liver form. Nature. 1983 Mar 31-Apr 6; 302(5907); 424-6. [PubMed: 6339945].
75. Mohmmed et al., 2005: Mohmmed A, Kishore S, Patra KP, Dasaradhi PV, Malhotra P, Chauhan VS. Identification of karyopherin beta as an immunogenic antigen of the malaria parasite using immune mice and human sera. Parasite immunology. 2005; 27(5); 197-203. [PubMed: 15987343].
76. Moll et al., 2007: Moll K, Pettersson F, Vogt AM, Jonsson C, Rasti N, Ahuja S, Spångberg M, Mercereau-Puijalon O, Arnot DE, Wahlgren M, Chen Q. Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain. Infection and immunity. 2007; 75(1); 211-219. [PubMed: 17074852].
77. Moore et al., 2004: Moore AC, Hill AV. Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunological reviews. 2004 Jun; 199; 126-43. [PubMed: 15233731].
78. Moore et al., 2005: Moore AC, Gallimore A, Draper SJ, Watkins KR, Gilbert SC, Hill AV. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. Journal of immunology (Baltimore, Md. : 1950). 2005 Dec 1; 175(11); 7264-73. [PubMed: 16301631].
79. Moormann et al., 2006: Moormann AM, John CC, Sumba PO, Tisch D, Embury P, Kazura JW. Stability of interferon-gamma and interleukin-10 responses to Plasmodium falciparum liver stage antigen-1 and thrombospondin-related adhesive protein in residents of a malaria holoendemic area. The American journal of tropical medicine and hygiene. 2006 Apr; 74(4); 585-90. [PubMed: 16606988].
80. Morais et al., 2006: Morais CG, Soares IS, Carvalho LH, Fontes CJ, Krettli AU, Braga EM. Antibodies to Plasmodium vivax apical membrane antigen 1: persistence and correlation with malaria transmission intensity. The American journal of tropical medicine and hygiene. 2006 Oct; 75(4); 582-7. [PubMed: 17038677].
81. Mueller et al., 2005: Mueller AK, Labaied M, Kappe SH, Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature. 2005; 433(7022); 164-167. [PubMed: 15580261].
82. Ockenhouse et al., 1998: Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LW, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AV, Tine JA, Guito KP, de Taisne C, Anders R, Ballou WR. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. The Journal of infectious diseases. 1998; 177(6); 1664-1673. [PubMed: 9607847].
83. Oliveira-Ferreira et al., 2000: Oliveira-Ferreira J, Miyahira Y, Layton GT, Savage N, Esteban M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Zavala F. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus. Vaccine. 2000; 18(17); 1863-1869. [PubMed: 10699335].
84. Ong'echa et al., 2003: Ong'echa JM, Lal AA, Terlouw DJ, Ter Kuile FO, Kariuki SK, Udhayakumar V, Orago AS, Hightower AW, Nahlen BL, Shi YP. Association of interferon-gamma responses to pre-erythrocytic stage vaccine candidate antigens of Plasmodium falciparum in young Kenyan children with improved hemoglobin levels: XV. Asembo Bay Cohort Project. The American journal of tropical medicine and hygiene. 2003 May; 68(5); 590-7. [PubMed: 12812352].
85. Pal-Bhowmick et al., 2007: Pal-Bhowmick I, Mehta M, Coppens I, Sharma S, Jarori GK. Protective properties and surface localization of Plasmodium falciparum enolase. Infection and immunity. 2007; 75(11); 5500-5508. [PubMed: 17785475].
86. Parker et al., 2001: Parker SE, Monteith D, Horton H, Hof R, Hernandez P, Vilalta A, Hartikka J, Hobart P, Bentley CE, Chang A, Hedstrom R, Rogers WO, Kumar S, Hoffman SL, Norman JA. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene therapy. 2001; 8(13); 1011-1023. [PubMed: 11438836].
87. Pasquetto et al., 1997: Pasquetto V, Fidock DA, Gras H, Badell E, Eling W, Ballou WR, Belghiti J, Tartar A, Druilhe P. Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen. European journal of immunology. 1997; 27(10); 2502-2513. [PubMed: 9368603].
88. Pearce et al., 2004: Pearce JA, Hodder AN, Anders RF. The alanine-rich heptad repeats are intact in the processed form of Plasmodium falciparum MSP3. Experimental parasitology. 2004 Nov-Dec; 108(3-4); 186-9. [PubMed: 15582517].
89. Petritus and Burns, 2008: Petritus PM, Burns JM Jr. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection. Journal of immunology (Baltimore, Md. : 1950). 2008; 180(1); 444-453. [PubMed: 18097046].
90. PF11_0344 in GeneDB: PF11_0344 in GeneDB [http://www.genedb.org/genedb/Dispatcher?formType=navBar&organism=malaria&desc=yes&wildcard=yes&name=PF11_0344&ohmr=.&ohmr2=.]
91. PF13_0201 in GeneDB: PF13_0201 in GeneDB [http://www.genedb.org/genedb/Search?organism=malaria&name=PF13_0201&isid=true]
92. PFL1385c in GeneDB: PFL1385c in GeneDB [http://www.genedb.org/genedb/Search?organism=malaria&name=PFL1385c&isid=true]
93. Pichyangkul et al., 2004: Pichyangkul S, Gettayacamin M, Miller RS, Lyon JA, Angov E, Tongtawe P, Ruble DL, Heppner DG Jr, Kester KE, Ballou WR, Diggs CL, Voss G, Cohen JD, Walsh DS. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine. 2004 Sep 28; 22(29-30); 3831-40. [PubMed: 15364429].
94. Polhemus et al., 2007: Polhemus ME, Magill AJ, Cummings JF, Kester KE, Ockenhouse CF, Lanar DE, Dutta S, Barbosa A, Soisson L, Diggs CL, Robinson SA, Haynes JD, Stewart VA, Ware LA, Brando C, Krzych U, Bowden RA, Cohen JD, Dubois MC, Ofori-Anyinam O, De-Kock E, Ballou WR, Heppner DG Jr. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine. 2007 May 22; 25(21); 4203-12. [PubMed: 17442466].
95. Pye et al., 1997: Pye D, Vandenberg KL, Dyer SL, Irving DO, Goss NH, Woodrow GC, Saul A, Alving CR, Richards RL, Ballou WR, Wu MJ, Skoff K, Anders RF. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine. 1997; 15(9); 1017-1023. [PubMed: 9261951].
96. Reyes-Sandoval et al., 2008: Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, Gilbert SC, Gao G, Ertl HC, Wilson JC, Hill AV. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. European journal of immunology. 2008; 38(3); 732-741. [PubMed: 18266272].
97. Robson et al., 1998: Robson KJ, Dolo A, Hackford IR, Doumbo O, Richards MB, Keita MM, Sidibe T, Bosman A, Modiano D, Crisanti A. Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. The American journal of tropical medicine and hygiene. 1998 Jan; 58(1); 81-9. [PubMed: 9452297].
98. Rogers et al., 2001: Rogers WO, Baird JK, Kumar A, Tine JA, Weiss W, Aguiar JC, Gowda K, Gwadz R, Kumar S, Gold M, Hoffman SL. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infection and immunity. 2001; 69(9); 5565-5572. [PubMed: 11500430].
99. Rosa et al., 2004: Rosa DS, Tzelepis F, Cunha MG, Soares IS, Rodrigues MM. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunology letters. 2004 Apr 15; 92(3); 259-68. [PubMed: 15081621].
100. Sakai et al., 2003: Sakai T, Hisaeda H, Nakano Y, Zhang M, Takashima M, Ishii K, Maekawa Y, Matsumoto S, Nitta Y, Miyazaki Ji, Yamamoto S, Himeno K. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice. Vaccine. 2003; 21(13-14); 1432-1444. [PubMed: 12615440].
101. Sanchez et al., 2001: Sanchez GI, Sedegah M, Rogers WO, Jones TR, Sacci J, Witney A, Carucci DJ, Kumar N, Hoffman SL. Immunogenicity and protective efficacy of a Plasmodium yoelii Hsp60 DNA vaccine in BALB/c mice. Infection and immunity. 2001; 69(6); 3897-3905. [PubMed: 11349057].
102. Saul et al., 1992: Saul A, Lord R, Jones GL, Spencer L. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2. Journal of immunology (Baltimore, Md. : 1950). 1992; 148(1); 208-211. [PubMed: 1727867].
103. Schneider et al., 1998: Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AV. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature medicine. 1998; 4(4); 397-402. [PubMed: 9546783].
104. Seeberger et al., 2004: Seeberger PH, Soucy RL, Kwon YU, Snyder DA, Kanemitsu T. A convergent, versatile route to two synthetic conjugate anti-toxin malaria vaccines. Chemical communications (Cambridge, England). 2004 Aug 7; (15); 1706-7. [PubMed: 15278147].
105. Sim et al., 2001: Sim BK, Narum DL, Liang H, Fuhrmann SR, Obaldia N 3rd, Gramzinski R, Aguiar J, Haynes JD, Moch JK, Hoffman SL. Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Molecular medicine (Cambridge, Mass.). 2001; 7(4); 247-254. [PubMed: 11471569].
106. Singh et al., 2003: Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infection and immunity. 2003 Dec; 71(12); 6766-74. [PubMed: 14638762].
107. Sirima et al., 2007: Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, Gansane A, Derme AI, Diarra A, Ouedraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine. 2007 Mar 30; 25(14); 2723-32. [PubMed: 17280744].
108. Stewart et al., 2007: Stewart VA, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infection and immunity. 2007 May; 75(5); 2283-90. [PubMed: 17307942].
109. Stoute et al., 2006: Stoute JA, Heppner DG Jr, Mason CJ, Siangla J, Opollo MO, Kester KE, Vigneron L, Voss G, Walter MJ, Tornieporth N, Cohen JD, Ballou WR. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. The American journal of tropical medicine and hygiene. 2006 Jul; 75(1); 166-70. [PubMed: 16837726].
110. Stowers et al., 2002: Stowers AW, Chen Lh LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ, Kaslow DC, Saul A, Long CA, Meade H, Miller LH. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America. 2002 Jan 8; 99(1); 339-44. [PubMed: 11752405].
111. Sturm et al., 2006: Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, Rennenberg A, Krueger A, Pollok JM, Menard R, Heussler VT. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science (New York, N.Y.). 2006 Sep 1; 313(5791); 1287-90. [PubMed: 16888102].
112. Talman et al., 2004: Talman AM, Domarle O, McKenzie FE, Ariey F, Robert V. Gametocytogenesis: the puberty of Plasmodium falciparum. Malaria journal. 2004 Jul 14; 3; 24. [PubMed: 15253774].
113. Tarun et al., 2007: Tarun AS, Dumpit RF, Camargo N, Labaied M, Liu P, Takagi A, Wang R, Kappe SH. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. The Journal of infectious diseases. 2007; 196(4); 608-616. [PubMed: 17624848].
114. Thera et al., 2006: Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV. Safety and allele-specific immunogenicity of a malaria vaccine in malian adults: results of a phase I randomized trial. PLoS clinical trials. 2006 Nov 24; 1(7); e34. [PubMed: 17124530].
115. Tsai et al., 2009: Tsai CW, Duggan PF, Jin AJ, Macdonald NJ, Kotova S, Lebowitz J, Hurt DE, Shimp RL Jr, Lambert L, Miller LH, Long CA, Saul A, Narum DL. Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure. Molecular and biochemical parasitology. 2009; 164(1); 45-56. [PubMed: 19073223].
116. Valderrama-Aguirre et al., 2005: Valderrama-Aguirre A, Quintero G, Gómez A, Castellanos A, Pérez Y, Méndez F, Arévalo-Herrera M, Herrera S. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. The American journal of tropical medicine and hygiene. 2005; 73(5 Suppl); 16-24. [PubMed: 16291762].
117. Vincent et al., 1999: Vincent AA, Fanning S, Caira FC, Williamson KC. Immunogenicity of malaria transmission-blocking vaccine candidate, y230.CA14 following crosslinking in the presence of tetanus toxoid. Parasite immunology. 1999 Nov; 21(11); 573-81. [PubMed: 10583858].
118. Wan et al., 2007: Wan Omar A, Roslaini AM, Ngah ZU, Azahari AA, Zahedi M, Baharudin O. A recombinant 19 kDa Plasmodium berghei merozoite surface protein 1 formulated with alum induces protective immune response in mice. Tropical biomedicine. 2007; 24(1); 119-126. [PubMed: 17568385].
119. Wang et al., 2004: Wang L, Goschnick MW, Coppel RL. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge. Infection and immunity. 2004; 72(10); 6172-6175. [PubMed: 15385527].
120. Wang et al., 2005: Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, Charoenvit Y, Epstein JE, Luke T, Freilich DA, Norman J, Hoffman SL. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infection and immunity. 2005; 73(5); 2863-2872. [PubMed: 15845492].
121. Webster et al., 2005: Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(13); 4836-4841. [PubMed: 15781866].
122. Xu et al., 2000: Xu H, Hodder AN, Yan H, Crewther PE, Anders RF, Good MF. CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. Journal of immunology (Baltimore, Md. : 1950). 2000; 165(1); 389-396. [PubMed: 10861076].
123. Yoshida et al., 2000: Yoshida S, Kashiwamura SI, Hosoya Y, Luo E, Matsuoka H, Ishii A, Fujimura A, Kobayashi E. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite. Biochemical and biophysical research communications. 2000; 271(1); 107-115. [PubMed: 10777689].
124. Yuen et al., 2007: Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development. Vaccine. 2007 Jan 5; 25(3); 490-9. [PubMed: 16949181].
125. Zhou et al., 2006: Zhou Z, Todd CW, Wohlhueter RM, Price A, Xiao L, Schnake P, Bonner PC, Martin AM, Goldman IF, De La Vega P, Udhayakumar V, Lal AA. Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli. Human vaccines. 2006 Jan-Feb; 2(1); 14-23. [PubMed: 17012909].